[go: up one dir, main page]

WO2025224168A1 - Aryl sulfone and sulfanone derivatives as orexin receptor modulators - Google Patents

Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Info

Publication number
WO2025224168A1
WO2025224168A1 PCT/EP2025/061059 EP2025061059W WO2025224168A1 WO 2025224168 A1 WO2025224168 A1 WO 2025224168A1 EP 2025061059 W EP2025061059 W EP 2025061059W WO 2025224168 A1 WO2025224168 A1 WO 2025224168A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
sulfonyl
pyrrolidine
amide
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/061059
Other languages
French (fr)
Inventor
Olivier Bezencon
Bibia Heidmann
Andreas MUEHLEMANN
Davide Pozzi
Sylvia Richard-Bildstein
Romain Siegrist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of WO2025224168A1 publication Critical patent/WO2025224168A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/08—Diarylmethoxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • the present invention relates to novel aryl sulfone and sulfanone derivatives of Formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor (hereinafter also referred to as OX2R), and particularly as agonists of the human orexin-2 receptor (hereinafter also referred to as hOX2R).
  • the orexin system (also known as hypocretin system) was discovered in 1998 by two independent research groups and is composed of 2 neuropeptides and 2 receptors (de Lecea L et al.; The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity; Proc Natl Acad Sci U S A. 1998, 95(1 ):322-7; Sakurai T et al.; Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior; Cell. 1998, 92(5): 1 page following 696).
  • Orexin A and orexin B are neuropeptides specifically expressed in a small population of neurons of the lateral, dorsomedial and perifornical hypothalamus. They are proteolytically derived from a single precursor prepro-orexin peptide. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide. Orexins bind to two G-protein-coupled receptors (orexin- 1 receptor (OX1R) and orexin-2 receptor (OX2R)) widely expressed throughout the brain. While OX-A binds to both receptors with similar affinity, OX-B binds preferentially to OX2R. The wide distribution of orexin fibers and receptors in many parts of the brain suggests that orexins have multiple functions.
  • the orexin system is recognized as being crucial for the stability of wakefulness and the regulation of vigilance in accordance with various physiological processes (de Lecea L; Hypocretins and the neurobiology of sleep-wake mechanisms; Prog Brain Res. 2012, 198: 15-24; Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci. 2007, 8(3): 171 -81 ; Scammell TE et al.; Neural Circuitry of Wakefulness and Sleep; Neuron. 2017, 93(4):747-765). Orexin neurons are primarily active during wakefulness (Lee MG et al.; Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle; J Neurosci.
  • wake-promoting neuronal populations such as the histaminergic neurons of the tuberomammillary nucleus, noradrenergic neurons of the locus coeruleus, serotoninergic neurons of the dorsal raphe, dopaminergic neurons in the ventral tegmental area and cholinergic neurons in the basal forebrain and the pedunculopontine and laterodorsal tegmental nuclei.
  • wake-promoting regions of the brain predominantly express OX1R or OX2R, or both (for review see (Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci.
  • orexin neurons integrate a variety of signals related to internal or external environment (e.g. emotion, light/dark cycles, sleep pressure, energy balance) and send information to a variety of neuronal systems to adjust the arousal level to the one necessary for an appropriate behavioral response (Inutsuka A et al.; The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions; Front Endocrinol (Lausanne). 2013, 4: 18).
  • signals related to internal or external environment e.g. emotion, light/dark cycles, sleep pressure, energy balance
  • narcolepsy type 1 a chronic sleep disorder characterized by excessive daytime sleepiness (EDS), sleep attacks and cataplexy (loss of muscle tone in full consciousness often triggered by positive emotions), is linked to a deficiency in the orexin system (Chemelli RM et al.; Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation; Cell. 1999, 98(4):437-51 ; Lin L et al.; The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene; Cell.
  • narcolepsy type 1 has been shown to be caused by the loss of orexin-producing neurons (Peyron C et al.; A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains; Nat Med. 2000, 6(9):991 -7) and low OX-A level in the CSF can be used as specific biological measure for the diagnosis (Dauvarri Y et al.; Narcolepsy and Other Central Hypersomnias; Continuum (Minneap Minn). 2017, 23(4, Sleep Neurology):989-1004).
  • intracerebroventricular (i.c.v.) injections of OX-A in rats or mice increased wakefulness and markedly reduced both non-rapid eye movement (NREM) and REM sleep (Piper DC et al.; The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats; Eur J Neurosci. 2000, 12(2)726-30; Huang ZL et al.; Arousal effect of orexin A depends on activation of the histaminergic system; Proc Natl Acad Sci U S A. 2001 , 98(17):9965- 70).
  • orexin receptors activation of orexin receptors is a promising therapeutic approach for disease associated with difficulties maintaining wakefulness with patients complaining of: feelings of excessive sleepiness; episodes of inadvertently falling asleep, including sleep attacks (episodes of falling asleep without prodromal symptoms of drowsiness); a prolonged main sleep episode that is unrefreshing; recurrent naps in the same day; and sleep inertia (prolonged difficulty waking up, with irritability, automatic behavior, or confusion).
  • sleep disorders such as the disorders of hypersomnolence.
  • ICSD-3 3 rd edition
  • idiopathic hypersomnia Kleine-Levin syndrome
  • hypersomnia due to a medical disorder hypersomnia due to a medication or substance
  • hypersomnia associated with psychiatric disorder and insufficient sleep syndrome.
  • Narcolepsy is supposed to be the result of an autoimmune disorder which specifically destroy orexin-producing neurons.
  • symptoms of narcolepsy can occur during the course of other neurologic disorders and be caused by the underlying condition, e.g. inherited disorders (such as Prader-Willi syndrome, Niemann-Pick C disease, or myotonic dystrophy), tumors or head trauma (particularly when the hypothalamus area is involved) (Kanbayashi T et al.; The pathophysiologic basis of secondary narcolepsy and hypersomnia; Curr Neurol Neurosci Rep.
  • orexin deficiency in the CSF and narcolepsy-like symptoms have been observed in patients with neuromyelitis optica, multiple sclerosis (Kanbayashi T et al.; The pathophysiologic basis of secondary narcolepsy and hypersomnia; Curr Neurol Neurosci Rep. 2011, 11 (2):235-41 ; Kanbayashi T et al.; Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications; Arch Neurol.
  • Guillain- Barre syndrome (Nishino S et al.; CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies; Neurology. 2003, 61 (6):823-5), or anti-Ma2 encephalitis (Overeem S et al.; Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis; Neurology. 2004, 62(1): 138-40).
  • EDS can also be observed in circadian rhythm sleep-wake disorders such as for example delayed sleep-wake phase disorder, shift work or jet lag disorder and result from a misalignment between the body clock and social requirements (Sateia MJ; International classification of sleep disorders-third edition: highlights and modifications; Chest. 2014, 146(5): 1387-1394; Vogel KD et al.; Excessive Daytime Sleepiness: A Clinical Review; Mayo Clin Proc. 2021 , 96(5): 1288-1301 ). It is specially the case when the patient needs to be awake but their alertness level secondary to their internal body clock is at its nadir.
  • EDS is accompanying disorders such as obesity, diabetes, depression and objective sleep disturbances such as sleep apnea (Fernandez-Mendoza J et al.; Natural history of excessive daytime sleepiness: role of obesity, weight loss, depression, and sleep propensity; Sleep. 2015, 38(3):351-60).
  • sleep apnea apnea
  • OSA obstructive sleep apnea
  • dysregulation of the orexin system could play a role in the pathogenesis of this disorder (Wang W et al.; Orexin: a potential role in the process of obstructive sleep apnea; Peptides. 2013, 42:48-54).
  • fatigue is a lack of energy ("an overwhelming sense of tiredness, a feeling of exhaustion") with a reduced ability to perform physical activities that would have previously been easily accomplished. It may be accompanied by mental fatigue with poor concentration and memory, but it is not generally associated with inappropriate episodes of sleep during the day. It is observed in a number of disorders including infections, chronic inflammatory diseases, cancer and neurodegeneration. It is suggested that a dysregulation of the orexin system could contribute to fatigue.
  • Traumatic brain injury can induce disorders of consciousness (DOC) such as syndromes of coma, vegetative state, and minimally conscious state (O'Donnell JO et al.; Challenges and demand for modeling disorders of consciousness following traumatic brain injury; Neurosci Biobehav Rev. 2019, 98:336-346).
  • Consciousness is a complex state including arousal and awareness and the ascending reticular activating system (ARAS) is known to play an essential role in maintaining consciousness (Edlow BL et al.; Neuroanatomic connectivity of the human ascending arousal system critical to consciousness and its disorders; J Neuropathol Exp Neurol. 2012, 71 (6):531- 46).
  • the ARAS is a complex and diffuse network of neuronal fibers that connects the brainstem reticular formation (such as the nuclei containing serotoninergic, noradrenergic, dopaminergic, cholinergic and glutamatergic neurons) with nonspecific thalamic nuclei, the basal forebrain, hypothalamus, and the cerebral cortex. Impairment of the ARAS can cause loss of consciousness following TBI (Jang SH et al.; The Relation Between Loss of Consciousness, Severity of Traumatic Brain Injury, and Injury of Ascending Reticular Activating System in Patients With Traumatic Brain Injury; Am J Phys Med Rehabil. 2019, 98(12): 1067-1071).
  • Monoaminergic drugs acting by increasing for instance dopaminergic levels, norepinephrine levels and acetylcholine levels could have some beneficial impacts on DOC.
  • the orexin system Given its projections to the wake-promoting system and its contribution to the stabilization of wakefulness/arousal, the orexin system is well placed to support and regulate consciousness.
  • abnormally low level of OX-A in the CSF was reported (Baumann CR et al.; Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury; Neurology. 2005, 65(1 ): 147- 9).
  • OX-A facilitated the recovery of arousal in a cardiac arrest- induced coma rat model
  • a cardiac arrest- induced coma rat model Koenig MA et al.; Intraventricular orexin-A improves arousal and early EEG entropy in rats after cardiac arrest; Brain Res. 2009, 1255:153-61; Modi HR et al.; Intranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation; PLoS One. 2017, 12(9):e0182707).
  • Orexin agonists could then provide beneficial effects following cardiac failure.
  • OX-A did not only accelerate arousal and behavior recovery, but it also had some anti-inflammatory effects.
  • OX-A improved the neurofunctional outcomes and mitigated brain edema (Li T et al.; Orexin A alleviates neuroinflammation via OXR2/CaMKKbeta/AMPK signaling pathway after ICH in mice; J Neuroinflammation. 2020, 17(1):187). It is suggested that OX-A was beneficial because of its anti-inflammatory effects.
  • orexins facilitate the emergence from anesthetic-induced unconsciousness with anesthesia being either intraperitoneal or gas anesthesia and that inhibiting the orexin signaling delays the emergence (Zhang LN et al.; Orexin-A facilitates emergence from propofol anesthesia in the rat; Anesth Analg. 2012, 115(4)789-96; Kelz MB et al.; An essential role for orexins in emergence from general anesthesia; Proc Natl Acad Sci U S A.
  • Orexins Besides stabilizing wakefulness, the orexins system seems to play a role in the regulation of many other functions such as energy homeostasis, learning and memory, stress/emotion, reward, and pain.
  • the orexin system is involved in the regulation of feeding behaviors and energy homeostasis.
  • Orexin neurons are sensitive to glucose, leptin and ghrelin with high concentrations of glucose and leptin inhibiting orexinergic neurons, while low concentrations of glucose and ghrelin exciting them (Diano S et al.; Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets; Endocrinology.
  • mice exhibit obesity despite a significant lower calorie consumption which can be explained, to some extent, by a lower energy expenditure (Zhang S et al.; Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy; J Physiol. 2007, 581 (Pt 2):649-63).
  • the prevalence of obesity is also increased in narcoleptic patients (Mohammad! S et al.; Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis; Sleep Med. 2021 , 81 :268-284).
  • the orexin system seems to play a role in learning and memory processes.
  • On one hand given its recognized role for the stability of wakefulness and the regulation of vigilance in accordance with various physiological processes (de Lecea L; Hypocretins and the neurobiology of sleep-wake mechanisms; Prog Brain Res. 2012, 198:15-24; Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci. 2007, 8(3): 171 -81 ; Scammell TE et al.; Neural Circuitry of Wakefulness and Sleep; Neuron. 2017, 93(4)747-765), it will contribute to the sustained arousal level necessary to learn.
  • mice showed that OX-A could contribute to the increase hippocampal plasticity associated with the consolidation of social recognition memory (Yang L et al.; Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice; J Neurosci.
  • Cognitive impairment is a common feature of several neuropsychiatric/neurological disorders and of age/age- related dementias. Age is also affecting the orexin system. Indeed in both human and animals, loss of orexin neurons is reported (for review (Nixon JP et al.; Sleep disorders, obesity, and aging: the role of orexin; Ageing Res Rev. 2015, 20:63-73)). Interestingly, age-related impairments in attentional performance could be improved in rats via intranasal administration of OX-A (Galva CB et al.; Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction; Brain Res.
  • the orexin system plays a role in behaviours needing motivation (Mahler SV et al.; Motivational activation: a unifying hypothesis of orexin/hypocretin function; Nat Neurosci. 2014, 17(10): 1298-303). And motivation (the psychological drive underlying goal-directed behaviour) is important to organize psychological and physiological processes leading to adaptive behaviours. Motivated behaviours support, for example, food seeking, coordinated stress response and the development of coping strategy. Dysregulation of those processes can lead to neuropsychiatric disorders in which orexin receptor agonists could provide beneficial effects.
  • stimulation of OX2R promoted coping responses in a decision-making test during social stress in mice (in this test: promotion of escape behaviour)
  • Staton CD et al. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression; Neuropharmacology. 2018, 143:79-94
  • Stimulation of OX2R also increased resilience to social stress (i.e. social novelty seeking)
  • Staton CD et al.; Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression; Neuropharmacology. 2018, 143:79-94).
  • Anhedonia one of the key symptoms of depression, can be described as the failure to experience pleasure or pursue gratification and encompasses reward-associated disorders such as perturbation in decision-making and motivational drive.
  • Anhedonia symptoms evoke a dysregulation of brain reward processing in which an alteration of the orexin system function could play a role (Coccurello R; Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing; Behav Brain Res. 2019, 372: 112041).
  • Several preclinical and clinical studies have shown a link between dysregulation of the orexin system and depression (Khairuddin S et al.; Dysregulation of the orexinergic system: A potential neuropeptide target in depression; Neurosci Biobehav Rev.
  • Wistar-Kyoto rats which demonstrate depressive-like behaviours, OX-A immunoreactivity and prepro-orexin mRNA levels were reduced in the hypothalamus compared to Wistar rats (Taheri S et al.; Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats; Neuroreport. 2001 , 12(3):459- 64).
  • animals models of depression induced by chronic, inescapable stressors such as the social defeat model of chronic stress, downregulation of orexin neurotransmission was observed (Lutter M et al.; Orexin signaling mediates the antidepressant-like effect of calorie restriction; J Neurosci.
  • Orexin neurons project to many brain regions involved in the regulation of pain, including the spinal dorsal horn, the ventrolateral periaqueductal gray, the rostral ventromedial medulla or the trigeminal caudate nucleus (Peyron C et al.; Neurons containing hypocretin (orexin) project to multiple neuronal systems; J Neurosci. 1998, 18(23):9996-10015).
  • Administration of orexin into the spinal cord or centrally in brain areas associated with the descending pain regulatory circuits reduces nociceptive responses in animal models of inflammatory pain and in chronic neuropathic pain models.
  • intrathecal injections or local injections in pain-regulating brain areas of orexin receptor antagonists modulate pain responses (for review see: (Kang X et al.; Research progress on the mechanism of orexin in pain regulation in different brain regions; Open Life Sci. 2021 , 16(1):46-52)).
  • pain threshold is lower in orexin knockout mice following peripheral local inflammation (Watanabe S et al.; Persistent pain and stress activate pain-inhibitory orexin pathways; Neuroreport. 2005, 16(1):5-8).
  • lower CSF orexin levels were reported in patients suffering from cluster headache (Barloese M et al.; Reduced CSF hypocretin-1 levels are associated with cluster headache; Cephalalgia.
  • US 2014/0051700 discloses cyclic guanidinyl OX2R agonists useful for enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
  • WO 2014/198880 discloses 2-(2-aminophenoxy)-3-chloronaphthalene-1, 4-dione compounds having orexin 2 receptor agonist activities, and their use therapeutic active substances for the treatment of conditions mediated by agonizing the orexin 2 receptor.
  • WO 2017/135306 discloses substituted piperidine compounds having an orexin type 2 receptor agonist activity, and their use as prophylactic or therapeutic agents for narcolepsy.
  • WO 2018/164191 discloses substituted pyrrolidine compounds having an orexin type 2 receptor agonist activity.
  • WO 2019/117148 discloses sulfonamide derivatives showing an orexin receptor agonist activity.
  • WO 2019/027003, WO 2019/027058, WO 2020/004537/US 2021/198240, WO 2020/122092 and WO 2020/122093 disclose heterocyclic compounds having orexin type 2 receptor agonist activity.
  • WO 2020/167706 discloses 5-alkyl pyrrolidine orexin receptor agonists.
  • Orexin receptor agonists are further reported in WO 2018/164192, WO 2021/106975, WO 2020/158958, US 2021/0155636, WO 2020/167701 , WO 2021/026047, WO 2021/107023, WO 2016/133160, WO 2021/065893, and WO 2019/191327.
  • Selected indolyl and pyrrolyl aryl sulfones are disclosed as anti-HIV agents (Silvestri R et al., Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations: Synthesis and SAR Studies, J. Med. Chem. 2003, 46:2482-2493; Ragno R et al., Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones.
  • Certain benzene sulfonamide derivatives are disclosed as selective potassium channel activators (Mattmann M et al., Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1- tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K v 7.1 (KCNQ1) potassium channel activator, 2012, 22(18):5936-5941).
  • WO 2005/097162 describes selected aryl sulfonyl derivatives as steroid sparing agents.
  • WO 00/04892 discloses certain hydroxamic acid-comprising benzene sulfonyl derivatives as MMP inhibitors.
  • US 2001/0056184 describes pipecolinic acid derivatives as MMP inhibitors.
  • WO 97/18194 and US6225311 discloses certain hydroxamic acidcomprising benzene sulfonamide derivatives as MMP and TACE inhibitors, respectively.
  • WO 2005/030728 describes selected aryl sulfonamide derivatives as MMP inhibitors.
  • WO 2013/020440 discloses certain aryl sulfonamide derivatives as 11-p hydroxy steroid dehydrogenase type I inhibitors.
  • EP0469984 refers to N-sulfonyl- indoline derivatives as binding to vasopressin and oxytocin receptors.
  • WO 2014/098098 describes selected aryl sulfonamide antagonists of TRPA1.
  • JP 2006124387 referring to MCH receptor antagonists, discloses certain sulfone-comprising pyridine derivatives.
  • WO 2012/025877 discloses certain proline sulfonamide derivatives as orexin receptor antagonists.
  • WO 2008/038251 describes selected non-peptide antagonists of orexin receptors. Further orexin receptor antagonists are described in: WO 2002/051838, WO 2004/004733, WO 2004/085403, WO 2005/118548, WO 2008/020405, WO 2008/026149, WO 2008/065626, WO 2008/078291, WO 2008/081399, WO 2008/087611, WO 2008/117241,
  • WO 2010/131191 WO 2010/131192, WO 2012/063207, and WO 2012/110986.
  • the following compounds are known as chemical library compounds: 1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-piperidinecarboxamide (CAS no. 2174271-82-8); 1 -([1,1'-biphenyl]-2-ylsulfonyl)-N-methyl-2-piperidinecarboxamide (CAS no. 2421462-12-4); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-pyrrolidinecarboxamide (CAS no.
  • a first aspect of the invention relates to compounds of the Formula (I) wherein
  • Ring B is a 6-membered aromatic ring, wherein independently:
  • X 1 represents N or CR B2 , wherein R B2 represents hydrogen, halogen (especially fluoro), or (Ci-3)alkyl (especially methyl), and X 2 represents CH; [notably such X 1 represents CH, C-CH3, or N]; or X 1 represents CH and X 2 represents N; and
  • R B3 represents: OR 01 , wherein R 01 represents (C2-s)alkyl (especially ethyl, propyl, isopropyl, sec-butyl, or isobutyl) that is substituted with zero, one or two (Ci)fluoroalkyl (especially difluoromethyl or trifluoromethyl); wherein R 01 contains a total of at least 3 carbon atoms; [notably OR 01 represents propoxy, isopropoxy, sec-butoxy, isobutoxy, (1 , 1 -d if I uoropropan-2-y l)-oxy , (3, 3-d ifl uoro-2, 2-d I methy l-propy l)-oxy , (1 ,1 ,1 -trifl uoropropan-2- yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1 ,1 , 1 ,3, 3, 3- hexafluoropropan-2-
  • ⁇ R N1 represents:
  • (C2-5)alkyl especially propyl, isopropyl, sec-butyl, or fert-butyl); wherein said (C2-5)alkyl is unsubstituted, or mono- or di-substituted (especially unsubstituted or monosubstituted); wherein the substituents are independently selected from the group consisting of: (Ci)fluoroalkyl (especially trifluoromethyl), (C ⁇ cycloalkyl (especially cyclopropyl), and (Ci-3)alkoxy (especially methoxy); or
  • NR N1 R N2 represents isopropyl-amino, sec-butyl-amino, terf-butyl-amino, (l-methyl-cyclopropyl)-amino, (l-cyclopropyl-ethyl)-amino, (1 -methoxy propan-2-yl)-ami no, (1, 1 ,1 -tr if I uoropropan-2-y l)-ami no, (1 , 1 ,1 -trifl uorobu tan-2 -y I )-am I no, (1 -cy clopropy I-2, 2, 2- trifluoroethyl)-amino, (isopropyl)-(methyl)-amino, (ferf-butyl)-(methyl)-amino, (cyclopropyl)- (methyl)-amino, diethyl-amino, (ethyl)-(isopropy
  • R N1 and R N2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), (Ci.
  • R N2 represents pyrrolidin-1 -yl, piperidin-1 - yl, 2-methylpyrrolidin-1-yl, 2-(trifluoromethyl)pyrrolidin-1-yl, 2-methylpiperidin-1-yl, 3- fluoropiperidin-1-yl, 4-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2- (methoxymethyl)piperidin-l-yl, 2,5-dimethylpyrrolidin-1-yl, 2,3-dimethylpyrrolidin-1-yl, 2-ethyl-5- methylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1 -yl, azepan-1-yl, 3-methylmorpholin-4-y
  • R N1 and R N2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom;
  • group NR N1 R N2 represents 2-azabicyclo[2.2.1]heptan-2-yl, 7- azabicyclo[2.2.1 heptan-7-yl, 2-oxa-5-azabicyclo[2.2.2]octan-5-yl, or 3-oxa-8- azabicyclo[3.2.1]octan-8-yl)]; or a saturated or mono-unsaturated monocyclic (C5-z)cycloalkyl (notably cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1 -yl, cycloheptyl, or cyclohept-1-en-1-yl); wherein said (C4-6)cycloal
  • X 3 represents 0 or NR N3 , wherein R N3 represents hydrogen, (Ci-s)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom (especially oxetanyl or tetrahydrofuranyl), a 5-membered saturated bridged bicyclic cycloalkyl (especially bicyclo[1.1.1]pentanyl), phenyl, or pyridinyl; [notably X 3 represents 0, N-methyl, NH, or N-cyclopropyl]; and
  • X 4 represents CH or N such that: when X 4 represents CH, Ring A represents a monocyclic (C5-6)cycloalkan-diyl; or when X 4 represents N, Ring A represents: • a 4- to 7-membered (notably 5- to 7-membered) saturated monocyclic heterocycloalkan-diyl comprising X 4 , and zero or one further ring heteroatom selected from 0 or S (especially azetidin-diyl, pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl; in particular pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl); wherein said saturated heterocycloalkan-diyl is unsubstituted, or mono- or di-substituted; wherein the substituents
  • a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X 4 , and zero or one ring oxygen atom (notably hexahydrocyclopenta[b]pyrrol-1 (2/7),2-diy I, hexahydro-4/-/- furo[3,2-b]pyrrol-4,5-diyl, azabicyclo[2.1.1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, or azaspiro[2.4]heptan-diyl; in particular azabi cyclo [2.1 .1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, azaspiro[2.4]heptan-diyl,
  • R 1 represents: hydrogen; or (Ci-3)alkyl (especially methyl or ethyl); wherein said (Ci-3)alkyl is unsubstituted, or mono-substituted with (Ci-3)alkoxy (especially methoxy); and
  • R 2 represents: (Ci-6)alkyl (especially linear (C2-e)alkyl or branched (C3-e)alkyl); wherein said (Ci-e)alkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently halogen (especially fluoro or chloro) or (Ci-3)alkoxy (especially methoxy); or -(CH2) q -Cy 1 ; wherein q is 0 or 1 (especially 0) and Cy 1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl
  • a 5- or 6-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S
  • said 5- or 6-membered heterocycle is pyrrolidine, piperidine, thiazolidine, thiomorpholine, or morpholine
  • said 5- or 6-membered heterocycle is unsubstituted, or mono-, di- or tri-substituted
  • the substituents are independently selected from the group consisting of: hydroxy, (Ci-3)fluoroalkyl (especially trifluoromethyl), halogen (especially fluoro), (Ci ⁇ alkyl (especially methyl), (Ci-3)alkyl-(Ci-3)alkoxy (especially methoxymethyl or ethoxymethyl), ethynyl, and (Ci-3)alkoxy (especially methoxy or ethoxy);
  • such heterocycle represents 2-(methoxymethyl)pyrrolidin-1 -yl, 2-(ethoxymethyl
  • a 7- to 11-membered (especially 8-membered) saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms (notably said heterocycle is 2- azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan-
  • 6-yl 2-oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan- 2-yl, 1-oxa-6-azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8- azaspiro[5.5]undecan-8-yl, 3-oxa-9-azaspiro[5.5]undecan-9-yl, 1 ,4-dioxa-8-azaspiro[4.6]undecan-8- yl, 8-oxa-2-azaspiro[4.5]decan-2-yl, or 8-azaspiro[4.5]decan-8-yl; in particular said heterocycle is 6- azaspiro[2.5]octan-6-yl); wherein said heterocycle is unsubstitute
  • an 8- to 10-membered saturated or mono-unsaturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom
  • said heterocycle is hexahydrocyclopenta[c]pyrrol-2(1 /-/)-yl, octahy d roq ui nol I n-1 (2/7)-y I , hexahy d rofu ro[3, 2-c] py rid I n- 5(4/-/)-yl, or 1 ,3,3a, 4,7, 7a-hexahydro-2/-/-isoindol-2-yl); or
  • a 7- to 9-membered (especially 7- to 8-membered) saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom
  • said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3- oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; in particular said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl or 8
  • a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms (notably 2-azaadamantan-2-yl or 2-oxa-6-azaadamantan-6-yl); with the exception of the following compounds: 1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-piperidinecarboxamide (CAS no. 2174271-82-8); 1 -([1 ,1 '-biphenyl]-2-ylsulfonyl)-N-methyl-2-piperidinecarboxamide (CAS no.
  • N-cyclopropyl-1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-2-pyrrolidinecarboxamide (CAS no. 1957026-44-6); 1-([1 J T-biphenyl]-2-ylsulfonyl)-N-propyl-2-pyrrolidinecarboxamide (CAS no. 1101182-03-9); 1-[(4-ethoxy-3-pyridinyl)sulfonyl]-2-(methoxymethyl)-N-methyl-2-pyrrolidinecarboxamide (CAS no.
  • N,N-diethyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 1444098-57-0); N-(1 , 1-dimethylethyl)-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 2175321- 07-8); N-cyclopropyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-4-thiazolidinecarboxamide (CAS no.
  • the compounds of Formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, which may be present in (R)- or (S)-configuration.
  • the compounds of Formula (I) may further encompass compounds with one or more double bonds which may be present in Z- or E-configuration and/or compounds with substituents at a ring system which may be present, relative to each other, in cis- or transconfiguration.
  • the compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • a particular compound (or generic structure) contains one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, which may be present in (R)- or (S)-configuration, but where one (or more) of said stereogenic or asymmetric centers is not explicitly designated as (R)- or (S)-, it is understood that said stereogenic or asymmetric center may be in (R)- or (S)-configuration.
  • stereogenic or asymmetric center may be in (R)- or (S)-configuration.
  • Such compound name or generic structure is understood to encompass the compound I generic structure where such center is in (R)- or (S)- configuration, or any mixture of epimers with regard to such center.
  • stereogenic or asymmetric center in (RS)-configuration
  • this means that such stereogenic or asymmetric center in such compound may be present in (R)-configuration, in (S)-configuration, or in any mixture of epimers with regard to such center.
  • two or more such stereogenic or asymmetric centers in undesignated or designated (RS)-configuration) are present in one molecule, it is understood that the order of absolute configuration does not indicate any defined relative configuration with regard to the two or more centers.
  • any defined relative configuration with regard to the two or more centers is present, such centers are denominated with (R*,R*) or (R*,S*) nomenclature indicating in the first instance that the respective centers are either (R,R) or (S,S), and in the second instance that the respective centers are either (R,S) or (S,R), in each case encompassing any mixture of these stereoisomers including the racemate. It is understood that explicitly designated (R)- or (S)-configuration, undesignated or designated (RS)-configuration, and relative (R*,R*)- or (R*,S*)- configuration can co-exist in one and the same molecule and are to be interpreted accordingly.
  • the compound (2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide encompasses enantiomerically enriched (2R,4R)-1-[2-(Ethyl- isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide, (2S,4S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide,
  • a particular compound (or generic structure) is designated as Sa- or Ra-stereoisomer (i.e., designating an conformational isomer, or atropisomer, arising from a hindered rotation around a single bond), such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, stereoisomeric form.
  • enriched when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a ratio of at least 70:30, especially of at least 90: 10 (i.e., in a purity of at least 70% by weight, especially of at least 90% by weight), with regard to the respective other stereoisomer I the entirety of the respective other stereoisomers.
  • essentially pure when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a purity of at least 95% by weight, especially of at least 99% by weight, with regard to the respective other stereoisomer I the entirety of the respective other stereoisomers.
  • the present invention also includes isotopically labelled, especially 2H (deuterium) labelled compounds of Formula (I) according to embodiments 1) to 27), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotopically labelled, especially 2H (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g.
  • the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • a bond drawn as a dotted line shows the point of attachment of the radical drawn.
  • the radical drawn below is the 4,4-difluorocyclohexyl group.
  • the compounds of Formula (I) may contain tautomeric forms. Such tautomeric forms are encompassed in the scope of the present invention. In case tautomeric forms exist of a certain residue, and only one form of such residue is disclosed or defined, the other tautomeric form(s) are understood to be encompassed in such disclosed residue.
  • salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
  • Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
  • Definitions provided herein are intended to apply uniformly to the compounds of Formula (I), as defined in any one of embodiments 1) to 27), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein.
  • substituent Whenever a substituent is denoted as optional, it is understood that such substituent may be absent, in which case all positions having a free valency (to which such optional substituent could have been attached to; such as for example in an aromatic ring the ring carbon atoms and I or the ring nitrogen atoms having a free valency) are substituted with hydrogen where appropriate.
  • halogen means fluorine, chlorine, bromine, or iodine; especially fluorine, chlorine, or bromine; preferably fluorine or chlorine.
  • alkyl used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated straight or branched chain hydrocarbon group containing one to six carbon atoms.
  • (Cx-y)alkyl (x and y each being an integer), refers to an alkyl group as defined before, containing x to y carbon atoms.
  • a (Ci-e)alkyl group contains from one to six carbon atoms.
  • alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, fert-butyl, 3-methyl-butyl, 2,2-dimethyl-propyl, and 3,3-dimethyl-butyl.
  • a group is referred to as e.g. propyl or butyl, it is meant to be n-propyl, respectively n-butyl.
  • Preferred are methyl and ethyl. Most preferred is methyl.
  • R B1 representing (Ci-3)alkyl are methyl, ethyl, and isopropyl.
  • An example of R B2 representing (Ci-3)alkyl is methyl.
  • R 01 representing (C2-5)alkyl are ethyl, propyl, isopropyl, sec-butyl, and isobutyl; such R 01 representing (C ⁇ alkyl may be unsubstituted or substituted as explicitly defined.
  • R N1 representing (Ci-s)alkyl are methyl, ethyl, and isopropyl.
  • R N2 representing (C ⁇ alkyl are propyl, isopropyl, sec-butyl, and fert-butyl; such R N2 representing (C2-5)alkyl may be unsubstituted or substituted as explicitly defined.
  • Examples of (Ci-s)alkyl as substituent of a group R B3 are methyl and ethyl, and especially methyl.
  • Examples of R N3 representing (Ci-s)alkyl are methyl and ethyl.
  • An example of (Ci-s)alkyl as substituent of Ring A is methyl.
  • Examples of R 1 representing (Ci-3)alkyl are methyl and ethyl; such R 1 representing (Ci-3)alkyl may be unsubstituted or substituted as explicitly defined.
  • R 2 representing (Ci-e)alkyl are methyl, ethyl, propyl, isopropyl, 2,2-dimethyl-propyl, n-butyl, 3- methyl-butyl, 3,3-dimethyl-butyl, and fert-butyl; such R 2 representing (Ci ⁇ alkyl may be unsubstituted or substituted as explicitly defined.
  • Examples of (Ci-s)alkyl as substituent of a group Cy 1 are methyl and isopropyl.
  • An example of (Ci-3)alkyl as substituent of a group Cy 2 or Cy 3 is methyl.
  • (Ci ⁇ )alkyl as substituent of a 5- or 6- membered saturated monocyclic heterocycle formed by R 1 and R 2 , together with the nitrogen to which they are attached, is methyl.
  • alkoxy used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl-O- group wherein the alkyl group is as defined before.
  • (C x -y)alkoxy (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (Ci-4)alkoxy group means a group of the formula (Ci-4)alkyl-O- in which the term “(Ci-4)alkyl” has the previously given significance.
  • alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, secbutoxy, and tert-butoxy. Preferred is methoxy.
  • An example of R B1 representing (Ci -3)alkoxy is methoxy.
  • An example of (Ci-3)alkoxy as substituent of R B3 is methoxy.
  • An example of (Ci-3)alkoxy as substituent of Ring A is methoxy.
  • An example of (Ci-3)alkoxy as substituent of a group R 1 is methoxy.
  • An example of (Ci-3)alkoxy as substituent of a group R 2 is methoxy.
  • Examples of (Ci-3)alkoxy as substituent of a 5- to 6-membered saturated monocyclic heterocycle formed by R 1 and R 2 , together with the nitrogen to which they are attached, are methoxy and ethoxy.
  • Examples of (Ci-3)al koxy as substituent of a 7- to 9-membered saturated bridged bicyclic heterocycle formed by R 1 and R 2 , together with the nitrogen to which they are attached, are methoxy and ethoxy.
  • (Ci-4)alkoxy-(C2-4)alkyl is methoxy methyl.
  • fluoroalkyl used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x.y fluoroalkyl” (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms.
  • a (Ci-3)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • fluoroalkyl groups include trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, and 2,2,2- trifluoroethyl; especially trifluoromethyl.
  • Preferred are (Ci-3)fluoroalkyl groups such as trifluoromethyl.
  • An example of R B1 representing (Ci-3)fluoroalkyl is trifluoromethyl.
  • Examples of (Ci)fluoroalkyl as substituent of R 01 are difluoromethyl and trifluoromethyl.
  • An example of (Ci)fluoroalkyl as substituent of R N2 representing a (C ⁇ alkyl is trifluoromethyl.
  • Examples of (Ci-2)fl uoroalky I as substituent of a 5- to 7-membered saturated monocyclic heterocycle formed by R N1 and R N2 , together with the nitrogen to which they are attached, are trifluoromethyl and 2,2,2- trifluoroethyl.
  • An example of (Ci-3)fluoroalkyl as substituent of R B3 representing phenyl or a 5- or 6-membered heteroaryl is trifluoromethyl.
  • Examples of (Ci-3)fluoroalkyl as substituent of Cy 1 are difluoromethyl and trifluoromethyl.
  • An example of (Ci ⁇ fluoroalkyl as substituent of Cy 2 is difluoromethyl.
  • fluoroalkoxy used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x -y)fluoroalkoxy refers to a fluoroalkoxy group as defined before containing x to y carbon atoms.
  • a (Ci-3)fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2 -fluoroethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy.
  • R B3 representing OR 01 , wherein R 01 represents (C2- s)alkyl substituted with one or two (Ci)fluoroalkyl, and wherein R 01 contains a total of at least 3 carbon atoms; are (1, 1-difluoropropan-2-yl)oxy, 3,3-difluoro-2,2-dimethyl-propoxy, (1 ,1, 1-trifluoropropan-2-yl)oxy, (4,4,4- trifluorobutan-2-yl)oxy, (1 ,1 , 1 ,3, 3, 3- hexafluoropropan-2-yl)oxy.
  • An example of (Ci-3)fluoroalkyl as substituent of R B3 representing phenyl or 5- or 6-membered heteroaryl is trifluoromethoxy.
  • hydroxy refers to a group -OH.
  • cyano refers to a group -ON.
  • (Cx-Y)alkylidene (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before, containing x to y carbon atoms, wherein said alkyl group is linked to the rest of the molecule via a double bond.
  • (Cx-Y)alkenyl (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before, containing x to y carbon atoms, wherein said alkyl group contains a double bond and wherein said alkyl group is linked to the rest of the molecule via a single bond.
  • An example of a (C2-4)alkenyl is vinyl group -CHOH2.
  • ethynyl refers to a group -C CH.
  • cycloalkyl used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated monocyclic hydrocarbon ring containing three to eight carbon atoms.
  • (C x-y )cycloalky I (x and y each being an integer), refers to a cycloalkyl containing x to y carbon atoms.
  • a (Cs ejcycloalky I group contains from three to six carbon atoms.
  • (C x.y )cycloalkyl refers to a saturated monocyclic cycloalkyl group as defined before, containing x to y carbon atoms.
  • monocyclic cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • R B1 representing a monocyclic (C3-4)cycloalkyl are cyclopropyl and cyclobutyl.
  • R N2 representing a monocyclic (C ⁇ cycloalkyl is cyclopropyl; such R N2 representing a monocyclic (C ⁇ cycloalkyl may be unsubstituted or substituted as explicitly defined.
  • An example of (C ⁇ cycloalkyl as substituent of R N2 representing (C ⁇ alkyl is cyclopropyl.
  • Examples of R B3 representing a saturated monocyclic (C4-6)cycloalkyl are cyclopentyl, cyclohexyl, and cycloheptyl; such R B3 representing a saturated monocyclic (C4-6)cycloalkyl may be unsubstituted or substituted as explicitly defined.
  • R B3 represents phenyl or a 5- or 6-membered heteroaryl
  • R N3 representing a monocyclic (C3-6)cycloalkyl are cyclopropyl, cyclopentyl and cyclohexyl.
  • Cx-y mono-unsaturated monocyclic (Cx-y)cycloalkyl
  • x and y each being an integer
  • R B3 representing a mono-unsaturated monocyclic (C5-
  • cycloalkyl are cyclopent-1 -en-1-yl, cyclohex-1 -en-1-yl, and cyclohept-1-en-1-yl; such R B3 representing a monounsaturated monocyclic (Cs-zjcycloalkyl may be unsubstituted or substituted as explicitly defined.
  • (C x -y)cycloalkan-diyl or "monocyclic (C x -y)cycloalkan-diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to bivalently bound cycloalkyl group, as defined before, containing x to y carbon atoms.
  • Ring A represents a monocyclic (Cs-ejcycloalkan-diyl
  • the points of attachment of said (C5-6)cycloalkan-diy I in Formula (I) are on X 4 and on a carbon atom neighboring X 4 ; examples are cyclopentane-1 ,2-diyl and cyclohexane-1 ,2-diyl; such monocyclic (C5-6)cycloalkan-diyl may be unsubstituted or substituted as explicitly defined.
  • saturated bicyclic (C x-y )spirocycloalkyl or "saturated spiro bicyclic (C x.y ) cycloalkyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated spiro-bicyclic hydrocarbon ring containing x to y carbon atoms.
  • R 1 representing a saturated bicyclic (C6-8)spirocycloalkyl are spiro[2.3]hexanyl, spiro[3.3]heptanyl, spiro[2.4]heptanyl, and spiro[2.5]octanyl (especially spiro[2.3]hexanyl and spiro[2.5]octanyl); such saturated bicyclic (Ce-sjspirocycloalkyl may be unsubstituted or substituted as explicitly defined. Examples of Cy 3 representing a saturated spiro bicyclic (C5-
  • Cy 3 is spiro[2.3]hexanyl, spiro[3.3]heptanyl, spiro[2.4]heptanyl, and spiro[2.5]octanyl; such Cy 3 may be unsubstituted or substituted as explicitly defined.
  • saturated fused or bridged bicyclic (C x-y )cycloalkyl (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated fused or bridged bicyclic hydrocarbon ring containing x to y carbon atoms.
  • R N3 representing a 5-membered saturated bridged bicyclic cycloalkyl is bicyclo[1.1.1]pentanyl.
  • R B3 representing a saturated bridged bicyclic (C6-8)cycloalkyl is bicyclo[2.2.1]heptanyl.
  • Cy 3 representing a saturated fused or bridged bicyclic (C5- 8)cycloalkyl are bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, bicyclo[4.1.0]heptanyl, and bicyclo[2.2.1]heptanyl; such Cy 3 may be unsubstituted or substituted as explicitly defined.
  • di-unsaturated bridged bicyclic (C x -y)cycloalkyl (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a mono-unsaturated bridged bicyclic hydrocarbon ring containing x to y carbon atoms (i.e., said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds).
  • R B3 representing a mono-unsaturated bridged bicyclic (C6-8)cycloalkyl is bicyclo[2.2.1 ]hept-2-en-2-yl.
  • heterocycle or “saturated monocyclic heterocycle”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated monocyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups).
  • x- to y-membered heterocycle or "x- to y-membered saturated monocyclic heterocycle” refers to such a heterocycle containing x to y ring atoms. Such heterocycles are unsubstituted or substituted as explicitly defined.
  • NR N1 R N2 wherein R N1 and R N2 together with the nitrogen to which they are attached form a 5- to 7- membered saturated monocyclic heterocycle are pyrrolidinyl, piperidinyl, azepanyl, and morpholinyl; such 5- to 7- membered saturated monocyclic heterocycle may be unsubstituted or substituted as explicitly defined.
  • R N3 representing a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom
  • Cy 2 representing a 4- to 7-membered saturated monocyclic heterocycle comprising one ring heteroatomic group selected from -0-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- are oxetanyl, tetrahydrofuranyl, tetrahydro-2/7-pyranyl, tetrahydro-2/7-thiopyran-1,1 -dioxide, 1-imino-1- oxidohexahydro-1 -A 6 -thiopyranyl, and 1 -methylimino-1-oxidohexahydro-1 -A 6 -thiopyranyl; such Cy 2 are substituted or unsubstituted as explicitly defined.
  • R 1 and R 2 together with the nitrogen to which they are attached, forming a 5- or 6-membered saturated monocyclic heterocycle (comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S) are pyrrolidine, piperidine, thiazolidine, thiomorpholine, and morpholine; such 5- or 6-membered saturated monocyclic heterocycle may be unsubstituted or substituted as explicitly defined.
  • mono-unsaturated monocyclic heterocycle refers to a mono-unsaturated monocyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups), said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds.
  • x- to y-membered heterocycle or "x- to y-membered saturated monocyclic heterocycle” refers to such a heterocycle containing x to y ring atoms. Such heterocycles are unsubstituted or substituted as explicitly defined.
  • An example of Cy 2 representing a 4- to 7-membered mono-unsaturated monocyclic heterocycle comprising one ring heteroatomic group selected from -O-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- is 3,6-dihydro-2/-/-pyranyl.
  • saturated spiro bicyclic heterocycle refers to a saturated spiro bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e. , such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups).
  • x- to y-membered saturated spiro bicyclic heterocycle refers to such a heterocycle containing x to y ring atoms.
  • R 2 representing a 7-membered saturated spiro bicyclic heterocycle comprising one ring oxygen atom is 2-oxaspiro[3.3]heptanyl.
  • R 1 and R 2 together with the nitrogen to which they are attached, forming a 7- to 11 -membered saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms, are 2-azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan-6-yl, 2- oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan-2-yl, 1-oxa-6- azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8-azaspiro[5.5]unde
  • saturated fused bicyclic heterocycle used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated fused bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups).
  • x- to y-membered saturated fused bicyclic heterocycle refers to such a heterocycle containing x to y ring atoms.
  • R 1 and R 2 together with the nitrogen to which they are attached, forming an 8- to 10-membered saturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom, are hexahydrocyclopenta[c]pyrrol-2(1 H)-yl, octahydroqui nol in- 1 (2H)-yl, and hexahydrofuro[3,2-c]py ridi n-5(4H)-yl .
  • fused bicyclic heterocycle used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a fused bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups), and wherein said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds.
  • x- to y-membered mono-unsaturated fused bicyclic heterocycle refers to such a heterocycle containing x to y ring atoms.
  • saturated bridged bicyclic heterocycle used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated bridged bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups).
  • x- to y-membered saturated bridged bicyclic heterocycle refers to such a heterocycle containing x to y ring atoms.
  • R 2 representing a 7-membered saturated bridged bicyclic heterocycle comprising one ring oxygen atom is 7-oxabicyclo[2.2.1]heptanyl.
  • NR N1 R N2 wherein R N1 and R N2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom (and zero or one additional ring oxygen atom) are 2-azabicyclo[2.2.1]heptan-2-yl, 7-azabicyclo[2.2.1 heptan-7-yl, 2-oxa- 5-azabicyclo[2.2.2]octan-5-yl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl.
  • Examples of 7- to 9-membered saturated bridged bicyclic heterocycles formed by R 1 and R 2 together with the nitrogen to which they are attached are 7-azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, and 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; such 7- to 9-membered saturated bridged bicyclic heterocycle may be unsubstituted or substituted as explicitly defined.
  • saturated bridged tricyclic heterocycle refers to a saturated bridged tricyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups).
  • x- to y-membered saturated bridged tricyclic heterocycle refers to such a heterocycle containing x to y ring atoms.
  • R 1 and R 2 together with the nitrogen to which they are attached, forming a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms, are 2- azaadamantan-2-yl and 2-oxa-6-azaadamantan-6-yl.
  • x- to y-membered heterocycloalkan-diyl or "x- to y-membered saturated monocyclic heterocycloalkan- diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a bivalently bound heterocycloalkyl as defined before; wherein in each instance, the number and nature of ring heteroatoms or heteroatomic groups are explicitly defined.
  • Ring A represents a 4- to 7-membered saturated monocyclic heterocycloalkan-diyl comprising X 4 and zero or one further ring heteroatoms selected from 0 or S
  • the points of attachment of said heterocycloalkan-diyl in Formula (I) are on X 4 and on the carbon atom attached to the group -CO-N(R 1 )(R 2 );
  • examples of such Ring A are azetidin-diyl, pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, and oxazolidin-diyl; such Ring A is unsubstituted, or substituted as explicitly defined.
  • the carbon atom of Ring A attached to the group -CO-N(R 1 )(R 2 ) is not further substituted.
  • x- to y-membered mono-unsaturated monocyclic heterocycloalkan-diyl refers to a bivalently bound monocyclic hydrocarbon ring containing x to y ring atoms of which one or two (especially one) ring atoms are heteroatoms independently selected from N, 0, or S, and wherein said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds.
  • Ring A represents a 4- to 6- membered mono-unsaturated monocyclic heterocycloalkan-diyl comprising X 4 and zero or one further ring N atom, and no further ring heteroatoms
  • the points of attachment of said mono-unsaturated heterocycloalkan-diyl in Formula (I) are on X 4 and on the carbon atom attached to the group -CO-N(R 1 )(R 2 ); the unsaturated (double) bond of said mono-unsaturated heterocycloalkan-diyl does not contain X 4 .
  • Ring A examples include 2, 5-dihy d ro- 1 H- pyrrol-1 ,2-diyl, 2,3-dihydro-1 H-pyrrol-1 ,5-diyl, 3,6-dihydropyridin-1 (2H)-1 ,2-diyl, and 4,5-dihydro-1 H-pyrazol-1,5- diyl); such Ring A may be unsubstituted or substituted as explicitly defined. In a particular embodiment, the carbon atom of Ring A attached to the group -CO-N(R 1 )(R 2 ) is not further substituted.
  • x- to y-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl refers to a bivalently bound saturated spiro, fused or bridged bicyclic hydrocarbon ring containing x to y ring atoms of which one or two (especially one) ring atoms are heteroatoms independently selected from N, 0, or S.
  • Ring A represents a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X 4 , and zero or one ring oxygen atom
  • the points of attachment of said bicyclic heterocycloalkan-diyl in Formula (I) are on X 4 and on the carbon atom attached to the group -C0-N(R 1 )(R 2 ).
  • Ring A examples include hexahydrocyclopenta[b]pyrrol-1 (2/-/),2-diyl, hexahydro-4H-furo[3,2-b]pyrrol-4,5-diyl, 2-azabicyclo[2.1.1]hexan-1 ,2- diyl, 2-azabicyclo[3.1.0]hexan-2,3-diyl, 3-azabicyclo[3.1.0]hexan-2,3-diyl, 2-azabicyclo[2.2.1]heptan-1 ,2-diyl, 5- azaspiro[2.4]heptan-4,5-diyl, 5-azaspiro[2.4]heptan-5,6-diyl, and 6-azaspiro[2.5]octan-5,6-diyl); such Ring A is unsubstituted, or substituted as explicitly defined.
  • aryl used alone or in combination, means phenyl or naphthyl, especially phenyl.
  • R B3 represents phenyl
  • such phenyl may be unsubstituted or substituted as explicitly defined.
  • R B3 represents a mono-, di- or tri-substituted (especially mono- or di-substituted) phenyl, especially at least one of the substituent(s) is attached in para position with regard to the point of attachment of the rest of the molecule.
  • substituent(s) in para position is/are (Ci-3)alkyl (notably methyl), halogen (notably fluoro), or (Ci-3)alkoxy (especially methoxy).
  • heteroaryl used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing one to a maximum of four heteroatoms (especially one to a maximum three), each independently selected from N, 0, or S.
  • heteroaryl groups are 5-membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, and tetrazolyl; 6-membered heteroaryl groups such as pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl; and 8- to 10-membered bicyclic heteroaryl groups such as indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, furopyridinyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazo
  • R B3 represents a 5- or 6- membered heteroaryl
  • such heteroaryl comprises one to three ring heteroatoms independently selected from N, 0, or S, wherein said heteroaryl is especially linked to the rest of the molecule via a ring carbon atom.
  • R B3 is notably isothiazolyl, oxazolyl, pyrazolyl, triazolyl, pyridinyl, or pyrazinyl; such 5- or 6-membered heteroaryl may be unsubstituted or substituted as explicitly defined.
  • the term "about” placed before a numerical value "X” refers in the current application to an interval extending from X minus (10% of X) to X plus (10% of X), and preferably to an interval extending from X minus (5% of X) to X plus (5% of X).
  • the term “about” placed before a numerical range "X to Y” refers in the current application to an interval extending from X minus (10% of X) to Y plus (10% of Y), and preferably to an interval extending from X minus (5% of X) to Y plus (5% of Y).
  • the term "about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
  • room temperature refers to a temperature of about 25°C.
  • X 1 represents N or CR B2 , wherein R B2 represents hydrogen, halogen (especially fluoro), or (Ci-3)alkyl (especially methyl), and X 2 represents CH [in particular X 1 represents CH, C-CH3, or N, and X 2 represents CH],
  • Another embodiment relates to compounds according to embodiment 1), wherein X 1 represents CH and X 2 represents N.
  • R B1 represents (Ci-3)alkyl (especially methyl, ethyl, or isopropyl) or (Ci)fluoroalkyl (especially trifluoromethyl) [in particular R B1 represents methyl or trifluoromethyl].
  • R B3 represents: OR 01 , wherein R 01 represents (C ⁇ alkyl (especially propyl, isopropyl, sec-butyl, or isobutyl) that is substituted with zero, one or two (Ci)fluoroal ky I (especially difluoromethyl or trifluoromethyl); [notably OR 01 represents propoxy, isopropoxy, sec-butoxy, isobutoxy, (1,1-difluoropropan-2-yl)-oxy, (3,3-difluoro-2,2- dimethyl-propyl)-oxy, (1,1 , 1-trifluoropropan-2-yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1, 1 ,1 , 3,3,3— hexafl uoropropan-2-yl)-oxy; in particular OR 01 represents sec-butoxy]; or NR N1 R N
  • ⁇ R N1 represents:
  • ⁇ R N2 represents:
  • (C2-5)alkyl especially propyl, isopropyl, sec-butyl, or fert-butyl); wherein said (C2-5)alkyl is unsubstituted, or mono- or di-substituted (especially unsubstituted or monosubstituted); wherein the substituents are independently selected from the group consisting of: (Ci)fluoroalkyl (especially trifluoromethyl), (C ⁇ cycloalkyl (especially cyclopropyl), and (Ci-3)alkoxy (especially methoxy); or
  • NR N1 R N2 represents isopropyl-amino, sec-butyl-amino, terf-butyl-amino, (l-methyl-cyclopropyl)-amino, (l-cyclopropyl-ethyl)-amino, (1 -methoxy propan-2-yl)-ami no, (1, 1 ,1 -tr if I uoropropan-2-y l)-ami no, (1 , 1 ,1 -trifl uorobu tan-2 -y I )-am i no, (1 -cy clopropy I-2, 2, 2- trifluoroethyl)-amino, (isopropyl)-(methyl)-amino, (ferf-butyl)-(methyl)-amino, (cyclopropyl)- (methyl)-amino, diethyl-amino, (ethyl)-(isopropyl-
  • R N1 and R N2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), (Ci.
  • R N2 represents pyrrolidin-1 -yl, piperidin-1 - yl, 2-methylpyrrolidin-1-yl, 2-(trifluoromethyl)pyrrolidin-1-yl, 2-methylpiperidin-1-yl, 3- fluoropiperidin-1-yl, 4-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2- (methoxymethyl)piperidin-l-yl, 2,5-dimethylpyrrolidin-1-yl, 2,3-dimethylpyrrolidin-1-yl, 2-ethyl-5- methylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1 -yl, azepan-1-yl, 3-methylmorpholin-4-y
  • R N1 and R N2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom;
  • group NR N1 R N2 represents 2-azabicyclo[2.2.1]heptan-2-yl, 7- azabicyclo[2.2.1 heptan-7-yl, 2-oxa-5-azabicyclo[2.2.2]octan-5-yl, or 3-oxa-8- azabicyclo[3.2.1]octan-8-yl)]; or a saturated or mono-unsaturated monocyclic (Cs-zjcycloalkyl (notably cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1 -yl, cycloheptyl, or cyclohept-1-en-1-yl); wherein said (C4-6)cycloal
  • R B3 represents: propoxy, isopropoxy, sec-butoxy, isobutoxy, (1 ,1-difluoropropan-2-yl)-oxy, (3,3-difluoro-2,2-dimethyl- propyl)-oxy, (1 ,1 ,1-trifluoropropan-2-yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1 , 1 ,1 , 3,3,3- hexafluoropropan-2-yl)-oxy [in particular R B3 represents sec-butoxy]; or NR N1 R N2 , wherein independently:
  • ⁇ R N1 represents:
  • ⁇ R N2 represents:
  • R N1 and R N2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl) and (Ci.
  • NR N1 R N2 represents piperidin-1-yl, 2-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2,5- dimethylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1-yl, azepan-1-yl, or 3,5-dimethylmorpholin-4-yl]; or a saturated monocyclic (C4-e)cycloalkyl (notably cyclohexyl); wherein said saturated (C4-6)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently (Ci-s)al ky I (especially methyl); or a mono-unsaturated monocyclic (Ce-zjcycloalkyl (notably cyclohex-1 -en-1-yl, or cyclohept-1
  • R B3 represents: NR N1 R N2 , wherein independently:
  • ⁇ R N1 represents (Ci-3)alkyl (especially methyl, ethyl, or isopropyl);
  • ⁇ R N2 represents (C ⁇ alkyl (especially isopropyl);
  • NR N1 R N2 represents (ethyl)-(isopropyl)-amino, diisopropyl-amino, or (isopropyl)-(methyl)-amino]; or
  • R N1 and R N2 together with the nitrogen to which they are attached form a heterocycle selected from pyrrolidinyl, piperidinyl, or morpholinyl; wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl) and (Ci-2)fluoroalkyl (especially trifluoromethyl or 2,2,2- trifluoroethyl); [in particular such group NR N1 R N2 represents piperidin-1-yl, 2-methylpiperidin-1 -yl, 2-(trifluoromethyl)piperidin-1 -yl, 2,5-dimethylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1-yl, or 3,5- dimethylmorpholin-4-yl]; or a mono-unsaturated monocyclic (C6-z)cycloalkyl (notably cyclohex- 1-
  • Ring B represents 2- isopropoxy-6-methylpyridin-3-yl, 6-methyl-2-propoxypyridin-3-yl, 2-(sec-butoxy)-6-methylpiridin-3-yl, 2-isobutoxy- 6-methylpyridin-3-yl, 2-((1,1-difluoropropan-2-yl)oxy)-4-methylphenyl, 2-(3,3-difluoro-2,2-dimethyl-propoxy)-4- methy I phenyl , 4-methy l-2-((1 , 1 ,1 -trifl uoropropan-2-yl)oxy) phenyl , 6-methy l-2-(1 ,1 , 1 -trifl uoropropan-2- yl)oxy)pyridin-3-yl, 4-methyl-2-((4,4,4-trifluorobutan-2-yl)oxy)phenyl, 2-(((4,4,4-trifluorobutan-2-y
  • Ring B represents 2-(sec- butoxy)-6-methylpiridin-3-yl, 2-(isopropylamino)-6-methylpyridin-3-yl, 2-(fert-butylamino)-6-methylpyridin-3-yl, 2- (isopropyl(methyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl, 2- (ethyl(isopropyl)amino)-6-(trifluoromethyl)pyridin-3-yl, 2-(ethyl(isopropyl)amino)-4-methylphenyl, 2- (diisopropylamino)-6-methylpyridin-3-yl, 4-methyl-2-(piperidin-1-yl)phenyl, 6-methyl-2-(piperidin-1-yl)pyridin-3-yl, 4-methyl-2-(piperidin-1-yl)phenyl, 6-
  • Ring B represents 2- (isopropyl(methyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl, 2- (ethyl(isopropyl)amino)-6-(trifluoromethyl)pyridin-3-yl, 2-(ethyl(isopropyl)amino)-4-methylphenyl, 2- (diisopropylamino)-6-methylpyridin-3-yl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)pheny
  • Another embodiment relates to compounds according to any one of embodiments 1) to 9), wherein X 3 represents 0.
  • X 3 represents NR N3 , wherein R N3 represents hydrogen, (Ci-3)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom (especially oxetanyl or tetrahydrofuranyl), a 5-membered saturated bridged bicyclic cycloalkyl (especially bicyclo[1.1.1]pentanyl), phenyl, or pyridinyl.
  • R N3 represents hydrogen, (Ci-3)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom (especially oxetanyl or tetrahydrofuranyl), a 5-membered saturated bridged bicyclic cycloalkyl (especially bicyclo[1.
  • Another embodiment relates to compounds according to any one of embodiments 1) to 9), wherein X 3 represents NR N3 , wherein R N3 represents hydrogen, (Ci-3)alkyl (especially methyl), or (C3-6)cycloalkyl (especially cyclopropyl).
  • Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X 4 represents N and Ring A represents:
  • Ring A represents 2,5-dihydro-1 H-pyrrol-1 ,2-diyl or 3-methyl-4,5-dihydro-1 H-pyrazol-1 ,5-diyl];
  • a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X 4 , and zero or one ring oxygen atom (notably hexahydrocyclopenta[b]pyrrol-1 (2/7),2-diy I, hexahydro-4/-/- furo[3,2-b]pyrrol-4,5-diyl, azabicyclo[2.1.1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, or azaspiro[2.4]heptan-diyl; in particular azabi cyclo [2.1 .1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, azaspiro[2.4]heptan-diyl,
  • Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X 4 represents N and Ring A represents:
  • Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X 4 represents N and Ring A represents hexahydrocyclopenta[b]pyrrol-1 (2/-/),2-diyl, hexahydro-4/-/-furo[3,2-b]pyrrol- 4,5-diyl, 4-methyl-2-azabicyclo[2.1 ,1]hexan-1 ,2-diyl, 2-azabicyclo[3.1.0]hexan-2,3-diyl, 3-azabicyclo[3.1.0]hexan- 2,3-diyl, 2-azabicyclo[2.2.1]heptan-1,2-diyl, 5-azaspiro[2.4]heptan-4,5-diyl, 5-azaspiro[2.4]heptan-5,6-diyl, 1,1- difluoro-5-azaspiro[2.4]heptan-5,6-diyl, or 6-azaspiro[2.5]octan-5
  • FIG. 16 Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X 4 represents N and Ring A represents 4-methyl-2-azabicyclo[2.1 .1]hexan-1 ,2-diyl, 2-azabicyclo[3.1 .0] hexan-2, 3-diy I , 3-azabicyclo[3.1.0]hexan-2,3-diyl, 2-azabicyclo[2.2.1]heptan-1 ,2-diyl, or 5-azaspiro[2.4]heptane-4,5-diyl, 5- azaspiro[2.4]heptan-5,6-diyl [notably 4-methyl-2-azabicyclo[2.1.1]hexan-1,2-diyl, 3-azabicyclo[3.1.0]hexan-2,3- diyl, or 2-azabicyclo[2.2.1]heptan-1 ,2-diyl],
  • Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X 4 represents CH and Ring A represents a monocyclic (Cs-ejcycloalkan-diyl .
  • a compound of Formula (I) represents either a compound of Formula (II), or a compound of Formula (III), or any mixture thereof (especially enantiomerically-enriched compound of Formula (II)):
  • R 1 represents hydrogen; methyl or ethyl.
  • R 2 represents: -(CH2) q -Cy 1 ; wherein q is 0 or 1 (especially 0) and Cy 1 represents a saturated monocyclic (CsjJcycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl or isopropyl), (Ci-3)alkoxy (especially methoxy), cyano, and hydroxy; [notably such R 2 represents (cyclopropyl)methyl, 2- iso
  • R 2 represents 2- isopropylcyclopropyl, 3-(trifluoromethyl)cyclobutyl, 3-(difluoromethyl)cyclobutyl, 3,3-dimethylcyclobutyl, 3,3-difluorocyclobutyl, (3,3-difluorocyclobutyl)methyl, (cyclopentyl)methyl, 2-methoxycyclopentyl, 2- cyanocyclopentyl, 3-fluorocyclopentyl, 3-cyanocyclopentyl, 3-cyanocyclopentyl, 3,3-dimethylcyclopentyl, 3,3- difluorocyclopentyl, cyclohex
  • R 2 represents: -(CH2) q -Cy 1 ; wherein q is 0 or 1 (especially 0) and Cy 1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl or isopropyl), (Ci-3)alkoxy (especially methoxy), cyano, and hydroxy; [notably such R 2 represents 2-isopropylcyclopropyl,
  • R 2 represents: -(CH2) q -Cy 1 ; wherein q is 0 and Cy 1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (Cs-zjcycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro), (Ci-s)alkyl (especially methyl), (Ci-3)alkoxy (especially methoxy), and cyano; [notably such R 2 represents 3,3-dimethylcyclobutyl,
  • Another embodiment relates to compounds according to any one of embodiments 1 ) to 18), wherein R 1 and R 2 together with the nitrogen to which they are attached form:
  • a 7- to 11-membered (especially 8-membered) saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms (notably said heterocycle is 2- azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan- 6-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan- 2-yl, 1-oxa-6-azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8- azaspiro[5.5]undecan-8-yl, 3-ox
  • a 7- to 9-membered (especially 7- to 8-membered) saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom
  • said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3- oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; in particular said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl or 8
  • Another embodiment relates to compounds according to any one of embodiments 1 ) to 18), wherein R 1 and R 2 together with the nitrogen to which they are attached form:
  • an 8-membered saturated spiro bicyclic heterocycle comprising said nitrogen atom (notably said heterocycle is 6-azaspiro[2.5]octan-6-yl); or
  • R 1 and R 2 together with the nitrogen to which they are attached represent: (4,4-difluorocyclohexyl)-(methyl)-amino, (4,4- difluorocyclohexyl)-amino, (3-cyanocyclopentyl)-amino, (1,1-difluorospiro[2.5]octan-6-yl)-(methyl)-amino, (1 ,1- difluorospiro[2.5]octan-6-yl)-amino, (3-fluorocyclopentyl)-amino, (bicyclo[4.1.0]heptan-3-yl)-amino,
  • Another embodiment relates to compounds according to embodiment 1) which are selected from the following compounds:
  • (2S)-N-((3R,6s)-1 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)- ⁇ 1- ⁇ (R)-N-(methyl)-(2-cyclohexyl-6-methyl-pyridin-3- yl)-sulfonimidoyl ⁇ -pyrrolidine ⁇ -2-carboxamide;
  • the compounds of Formula (I) according to embodiments 1) to 27) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral e.g. in form of a tablet or a capsule) or parenteral administration (including topical application or inhalation).
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a method for the prevention I prophylaxis or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I) according to embodiments 1) to 27).
  • compounds are described as useful for the prevention I prophylaxis or treatment of certain diseases, such compounds are likewise suitable for use in the preparation of a medicament for the prevention I prophylaxis or treatment of said diseases. Likewise, such compounds are also suitable in a method for the prevention I prophylaxis or treatment of such diseases, comprising administering to a subject (mammal, especially human) in need thereof, an effective amount of such compound.
  • the compounds of Formula (I) according to any one of embodiments 1 ) to 27) are useful for the prevention I prophylaxis or treatment of diseases or disorders relating to the OX2R receptor, and notably in disease and disorders in which agonism of OX2R plays a role.
  • Disease and disorders in which agonism of OX2R plays a role are particularly disease and disorders associated with difficulties maintaining wakefulness.
  • Subjects presenting disease and disorders associated with difficulties maintaining wakefulness complain of: feelings of excessive sleepiness; episodes of inadvertently falling asleep, including sleep attacks (episodes of falling asleep without prodromal symptoms of drowsiness); a prolonged main sleep episode that is unrefreshing; recurrent naps in the same day; or sleep inertia (prolonged difficulty waking up, with irritability, automatic behavior or confusion).
  • the compounds of Formula (I) according to embodiments 1) to 27) are useful for improving wakefulness in a subject (especially in a subject having hypersomnia or narcolepsy, or presenting excessive daytime sleepiness (EDS)).
  • the term "improving wakefulness in a subject” refers to improving symptoms of, or to the prevention I prophylaxis or treatment of: hypersomnia, particularly prevention I prophylaxis or treatment of:
  • narcolepsy including especially narcolepsy type 1 and narcolepsy type 2;
  • secondary narcolepsy associated with inherited disorders such as Prader-Willi syndrome, Niemann- Pick C disease, or myotonic dystrophy
  • EDS excessive daytime sleepiness
  • said medical disorder is especially an objective sleep disturbance, obesity, diabetes, a neurodegenerative disorder, an auto-immune disorder, a psychiatric disorder, or insufficient sleep syndrome; in particular:
  • ⁇ improving symptoms of EDS associated with a neurodegenerative disorder notably associated with: Alzheimer's, Parkinson's, Lewy body dementia, Perry syndrome, multiple system atrophy, or Huntington's disease;
  • narcolepsy ⁇ improving symptoms pronounced of narcolepsy in subjects having an auto-immune disorder (especially neuromyelitis optica, multiple sclerosis, Guillain-Barre syndrome, or anti-Ma2 encephalitis);
  • neuropsy type 1 describes a chronic sleep disorder characterized by excessive daytime sleepiness (EDS), sleep attacks and cataplexy (loss of muscle tone in full consciousness often triggered by positive emotions).
  • Fatigue is characterized by a lack of energy ("an overwhelming sense of tiredness, a feeling of exhaustion").
  • neuropsychiatric disorders notably mood disorders, particularly depression (such as major depressive disorder (MDD)); • pain, particularly inflammatory pain, or chronic neuropathic pain;
  • mood disorders particularly depression (such as major depressive disorder (MDD)
  • pain particularly inflammatory pain, or chronic neuropathic pain
  • agonism of OX2R plays a role in:
  • the term “subject” refers to a mammal, especially a human; in the context of a certain diagnosis or disease, the term “subject” and “patient” are to be understood as being interchangeable.
  • the compounds of Formula (I) according to any one of embodiments 1) to 27) are in particular useful as therapeutic agents for the prevention I prophylaxis or treatment of a disease and disorders associated with difficulties maintaining wakefulness. They can be used as single therapeutic agents or in combination with one or more additional therapeutic agents.
  • therapeutic agents include modafinil, pitolisant, sodium oxybate, solriamfetol, armodafinil, dextroamphetamine, methylphenidate, clarithromycin, venlafaxine, clomipramine and lithium (see for example Mask! K. et al. J Clin Sleep Med. 2021 , 17(9), 1881-1893; Bassett! C. et al. Eur J Neurol. 2021 , 00, 1-16).
  • the invention thus, also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and one or more additional therapeutic agents.
  • the invention thus, further relates to a kit comprising a pharmaceutical composition, said composition comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and instructions how to use said pharmaceutical composition for improving wakefulness in a subject presenting excessive daytime sleepiness (EDS).
  • a kit comprising a pharmaceutical composition, said composition comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and instructions how to use said pharmaceutical composition for improving wakefulness in a subject presenting excessive daytime sleepiness (EDS).
  • a kit comprising a pharmaceutical composition, said composition comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and instructions how to use said pharmaceutical composition for improving wakefulness in a subject presenting excessive daytime sleepiness (EDS).
  • EDS daytime sleepiness
  • any preferences and (sub-)embodiments indicated for the compounds of Formula (I) (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, or uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of Formula (II), Formula (III) and Formula (IV).
  • Compounds of the present invention may be further characterized with regard to their general pharmacokinetic and pharmacological properties using conventional assays well known in the art; for example relating to their bioavailablility in different species (such as rat or dog) including metabolic stability potentially affecting (human) bioavailability and/or dosage requirements, or relating to their ability to cross the blood-brain barrier, using for example a human P-glycoprotein 1 (MDR 1) substrate assay, or an in vivo assay to determine drug concentrations in the brain, e.g.
  • MDR 1 human P-glycoprotein 1
  • a further aspect of the invention is a process for the preparation of compounds of Formula (I).
  • Compounds according to Formula (I) of the present invention can be prepared from commercially available or well known starting materials according to the methods described in the experimental part, by analogous methods, or according to the general sequence of reactions outlined below, wherein R 1 , R 2 , R B1 , R B3 , X 1 , X 2 , X 3 , X 4 , Ring A, and Ring B are as defined for Formula (I).
  • R 1 , R 2 , R B1 , R B3 , X 1 , X 2 , X 3 , X 4 , Ring A, and Ring B are as defined for Formula (I).
  • Other abbreviations used herein are explicitly defined, or are as defined in the experimental section.
  • the generic groups R 1 , R 2 , R B1 , R B3 , X 1 , X 2 , X 3 and X 4 might be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG).
  • protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T. W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place.
  • the compounds obtained may also be converted into salts, especially pharmaceutically acceptable salts thereof in a manner known perse.
  • Amines 3 are either commercially available, prepared following procedures described in the literature, or prepared as described in the experimental part.
  • Compound 4 can be deprotected using standard deprotection methods known in the literature and familiar to the person skilled in the art to give 5 (or the corresponding salt, like HCI or TFA salts).
  • Amine 5 is condensed with a sulfonyl chloride 6 (where Hal is a halogen such as I, Br, Cl, or F) in solvent such as DCM, DMF, MeCN and in presence of a base such as TEA or DIPEA to give 7.
  • amine 5 can also be condensed with a sulfonyl chloride of general formula 10 in solvent such as DCM, DMF, MeCN and in presence of a base such as TEA or DIPEA to give 9.
  • Sulfonyl chlorides 6 and 10 and amines 3 may be commercially available, prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
  • Scheme 1 Synthesis of sulfonamide compound 9 by variation of sulfonamide part in the last step.
  • variation in the amide functional group can be introduced at the very last step following the procedures described in Scheme 2.
  • An appropriate aminoester 11 (or the corresponding salt, like HCI or TFA salts) can be reacted with sulfonyl chloride 6 (where Hal is a halogen such as I, Br, Cl, or F) in solvent such as DCM, DMF, MeCN, and in presence of a base such as TEA or DIPEA to yield intermediate 12.
  • sulfonyl chloride 6 where Hal is a halogen such as I, Br, Cl, or F
  • solvent such as DCM, DMF, MeCN
  • a base such as TEA or DIPEA
  • Intermediate 13 can also be synthesized starting from aminoester 11 (or the corresponding salt, like HCI or TFA salts) by condensation with a sulfonyl chloride 10 comprising R B3 .
  • Ester 13 can then be hydrolysed into the corresponding acid (14) using a base such as LiOH or NaOH in a mixture of solvents such as THF/water.
  • Amide formation between carboxylic acid 14 and amine 3 in a solvent such as THF, DMF, DCM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDC or similar and a base such as DIPEA, TEA or N-methylmorpholine yields compound with formula 9.
  • Scheme 2 Synthesis of sulfonamide 9 by variation of the amide substituent in the last step.
  • Step I Sulfonamide formation, ii) Cross-coupling, ill) Hydrolysis, iv) Amide formation, v) Hydrolysis vi) SNAP reaction.
  • An arylthiol (16) can be oxidized into its corresponding sulfinate ester 17 by reaction with NBS and MeOH in a solvent such as DCM.
  • Sulfinate ester 17 can be converted into sulfinamide with general structure 19 by reaction with primary amine 18 (or the corresponding salt, like HCI or TFA salts) using a base such as n-BuLi in a solvent like THF.
  • Compound 19 can then be condensed with 5 in presence of a chlorinating agent such as fert-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2- dichloroethane to give SIA derivative 20.
  • a chlorinating agent such as fert-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2- dichloroethane to give SIA derivative 20.
  • arylthiols 16 are prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
  • Sulfinate ester 17 can be converted into sulfinamide 21 by reaction with lithium hexamethyldisilazide (LHMDS) in a solvent like THF and hydrolysis with sat. aq. NH4CI.
  • Intermediate 21 can be protected with an appropriate protecting group (PG) to yield 22 using standard protection methods known in the literature and familiar to the person skilled in the art.
  • Compound 22 can be condensed with 5 in presence of a chlorinating agent such as ferf-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2-dichloroethane to give SIA intermediate 23.
  • Compound 24 can then be produced by subjecting intermediate 23 to standard deprotection methods known in the literature and familiar to the person skilled in the art.
  • 20 and 24 can be obtained via a late-stage R B3 functionalization as described in Scheme 5.
  • An arylthiol (25) can be oxidised into its corresponding sulfinate ester (26) and converted into sulfinamide 27 in a similar way as described herein before for the preparation of intermediates 17 and 21.
  • Sulfinamide 28 can be protected with an appropriate protecting group (PG) to yield 28 using standard protection methods known in the literature and familiar to the person skilled in the art.
  • SIA 29 can be obtained by reacting intermediate 28 with 5 in presence of a chlorinating agent such as ferf-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2- dichloroethane.
  • the PG can be cleaved using standard deprotection methods known in the literature and familiar to the person skilled in the art to yield 24.
  • SIA 20 can be obtained by subjecting 24 to alkylation using a base such as NaH or KOfBu and an alkylating agent such as an alkyl halide, or an alkyl sulfonates, in a solvent such as DMF.
  • arylthiols 25 can be prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
  • Intermediate 32 is subjected to a Suzuki-Miyaura cross-coupling reaction with the appropriate arylboronic acid or ester in a solvent such as THF or DME and in presence of a base such as K2CO3, NaHCOa or K3PO4 and a Pd catalyst such as Pd (PPhs)4 to give 33.
  • Thioether 33 can be oxidized in presence of an oxidant such as MCPBA and in a solvent such as DOM to lead to sulfone 34.
  • Derivative 34 can be hydrolysed using standard methods as described herein before into its corresponding carboxylic acid 35 with frans-relative configuration.
  • 36 can be produced by a R B3 late-stage functionalization as described in the sequence in Scheme 7.
  • an oxidant such as MCPBA and in a solvent such as DCM.
  • Hydrolysis of the ester using a base such as LiOH or NaOH in a mixture of solvents such as THF/Water gives carboxylic acid 38 with frans-relative stereochemistry.
  • Amide 40 can be subjected to hydrosulfonylation in presence of an iridium catalyst as tris(2-phenylpyridine)iridium and a radical reducing agent such as (TMS ⁇ SIH in a solvent such as MeCN and under blue LED irradiation (Angew.Chem.lnt.Ed. 2020,59,11620-11626).
  • an iridium catalyst as tris(2-phenylpyridine)iridium and a radical reducing agent such as (TMS ⁇ SIH in a solvent such as MeCN and under blue LED irradiation (Angew.Chem.lnt.Ed. 2020,59,11620-11626).
  • Intermediate 43 can be oxidised into 44 using an oxidant such as MCPBA and in a solvent such as DCM.
  • Carboxylic acid 44 can be activated using a coupling reagent such as TBTU, HBTU, HATU, EDC, pyCloP (or similar) and be subjected to amide coupling with amine 3 (or the corresponding salt, like HCI or TFA salts) in presence of a base such as DIPEA, TEA, or N-methylmorpholine, in a solvent such as THF, DMF, DCM or MeCN, to give 39.
  • a coupling reagent such as TBTU, HBTU, HATU, EDC, pyCloP (or similar) and be subjected to amide coupling with amine 3 (or the corresponding salt, like HCI or TFA salts) in presence of a base such as DIPEA, TEA, or N-methylmorpholine, in a solvent such as THF, DMF, DCM or MeCN, to give 39.
  • a coupling reagent such as TBTU, HBTU,
  • Scheme 7 Synthesis of sulfone compound 36 by late-stage R B3 functionalization.
  • Step I Oxidation, ii) Hydrolysis, ill) Amide coupling, iv) Cross-coupling/SNAr, v) Amide coupling, vi) Hydrosulfonylation, vii) Cross-coupling, viii) Oxidation, ix) Amide coupling.
  • LC-MS-conditions Analytical. Pump: Waters Acquity Binary, Solvent Manager, MS: Waters SQ Detector or Xevo TQD, DAD: Acquity UPLC PDA Detector.
  • Method Gradient: 2 % B to 98 % B over 2.0 min. Flow: 1.0 mL/min. Detection at 214 nm and MS, retention time IR is given in min.
  • LC-MS- conditions Analytical UPLC on a Agilent Zorbax RRHD SB-Aq (2.1x50 mm, 1.8 .m); detection at 210 nM and MS; UPLC/MS analyses are performed on Acquity UPLC setup; the column temperature is 40°C; Gradient of water/ 0.04% TFA (A) and MeCN (B). The eluent flow rate was 0.8 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the table below (a linear gradient being used between two consecutive time points):
  • Preparative HPLC/MS purifications are performed on a Gilson HPLC system, equipped with a Gilson 215 autosampler, Gilson 333/334 pumps, Finnigan AQA MS detector system, and a Dionex UV detector, using a Waters Xbridge C18 or a Waters Atlantis column, with a linear gradient of water/formic acid 0.02% (A) and MeCN (B) (acidic prep. HPLC ), or water/ammonia 0.02% (A) and MeCN (B) (basic prep. HPLC ).
  • Preparative chiral SFC 1 A Chiralpak AY-H column (30 x 250 mm, 5 m) was used. The modifier was EtOH (10%), run for 10 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C.
  • Preparative chiral SFC 2 A ChiralPak IG column (30 x 250 mm, 5 pm) was used. The modifier was MeOH (20%) with EtaNH (0.1 %), run for 3:80 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C
  • Preparative chiral SFC 4 A ChiralPak IB column (30 x 250 mm, 5 pm) was used. The modifier was MeOH (10%), run for 5 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C
  • Preparative chiral SFC 5 A ChiralPak IC column (30 x 250 mm, 5 pm) was used. The modifier was CHaCN/EtOH 1 :1 (25%), run for 7 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C. FC
  • Flash Chromatographies were performed using an automated system, typically combiflash from Teledyne ISCO.
  • Phase separator cartriges used were Isolute® purchased from Biotage
  • tert-butyl (4,4-difluorocyclohexyl)carbamate (6.23 g, 26.5 mmol, 1 eq) in DMF (50 mL) was added dropwise and the reaction mixture was stirred at 0 °C for 1 h.
  • Methyl iodide (3.30 mL, 52.9 mmol, 2 eq) was added and the reaction mixture was stirred at 0 °C for 3 h.
  • Water (400 mL) was slowly added at 0 °C and the reaction mixture was extracted twice with EtOAc. The combined org.
  • Example 1.3 (S)-1-(5,2'-Dimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and 2-tolylboronic acid in analogy to Example 1.1 to give the title compound.
  • LC-MS (1): t R 1.317 min; [M+H] + : 491.2.
  • Example 1.4 to Example 1.5 were synthesized using 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride, L- proline, the appropriate phenyboronic acid, and following the procedure described in Example 1.1.
  • LC-MS data of Example 1.4 to Example 1.5 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Methyl ((2'-fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)-L-prolinate methyl ((2-bromo-4- methylphenyl)sulfonyl)-L-prolinate (9.97 g, 27.5 mmol, 1 eq), (2-fluorophenyl)boranediol (6.08 g, 41.3 mmol, 1.5 eq), Na2CC>3 (8.79 g, 82.5 mmol, 3 eq) and Pd(dppf)Cl2CH2Cl2 (2.25 g, 2.75 mmol, 0.1 eq) were dissolved in degassed 1,4-dioxane I water 4:1 (1.0 mL) and the resulting mixture was stirred at 70 °C for 2.5 h.
  • Example 1.8 to Example 1.10 were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and the appropriate phenylboronic acid in analogy to Example 1.1.
  • LC-MS data of Example 1.8 to Example 1.10 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.12 to Example 1.16 were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and the appropriate phenylboronic acid in analogy to Example 1.11.
  • LC-MS data of Example 1.12 to Example 1.16 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.18 (S)-1-(2-Cyclohexyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclohex-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound.
  • LC-MS (1): t R 1.390 min; [M+H] + : 483.2.
  • Example 1.20 (S)-1-(2-Cyclopentyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclopent-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound.
  • LC-MS (1): IR 1.33 min; [M+H] + : 469.2.
  • Example 1.22 (S)-1-(2-Cycloheptyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclohept-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound.
  • LC-MS (1): t R 1.444 min; [M+H] + : 497.4.
  • Example 1.23 to Example 1.24 were synthesized using (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and the appropriate amine or amine salt in analogy to Example 1.21.
  • LC-MS data of Example 1.23 to Example 1.24 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.26 to Example 1.30 were synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and the appropriate aryl halide in analogy to Example 1.25.
  • LC-MS data of Example 1.26 to Example 1.30 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.32 to Example 1.37 were synthesized according to the procedures described herein before using (S)- N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide hydrochloride, the appropriate sulfonyl chloride and the appropriate boronic acid or boronic ester.
  • LC-MS data of Example 1.32 to Example 1.37 are listed in the table below.
  • Example 1.38 (S)-1-(4-Methyl-2-pyrimidin-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2- (4, 4, 5, 5-tetramethy I- 1 ,3, 2-d ioxaborol an -2-y l)pheny I )sulfony l)py rrol id i ne-2-carboxamide and 2-bromopyrimidine in analogy to Example 1.25 to give the title compound.
  • LC-MS (1): IR 0.957 min; [M+H] + : 479.3.
  • Example 1.39 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-amide: was synthesized using ((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)-L-proline and 4,4- difluorocyclohexan- 1 -amine in analogy to Example 1 .7 to give the title compound.
  • LC-MS (1): IR 1 .204 min; [M+H] + : 481.2.
  • Example 1.40 (S)-1-(5-Chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide hydrochloride, 2-bromo-4-chlorobenzene-1 -sulfonyl chloride, and 2-fluorophenylboronic acid in analogy to Example 1.31 to give the title compound.
  • LC-MS (1): IR 1.291 min; [M+H] + : 515.1.
  • Example 1.41 to Example 1.49 were synthesized according to the procedures described herein before using ((2- fluoro-5-methyl-[1, -biphenyl]-2-yl)sulfonyl)-L-proline and the appropriate amine or amine salt.
  • Example 1.41 to Example 1.49 are listed in the table below.
  • the LC-MS conditions used were LC-MS (1).
  • Example 1.52 (2S)-1-((2',6-difluoro-[1,r-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide hydrochloride, 2-bromo-3-fluorobenzenesulfonyl chloride, and 2-fluorophenylboronic acid in analogy to Example 1.31 to give the title compound as a mixture of 2 atropisomers.
  • Example 1.53 to Example 1.60 were synthesized according to the procedures described herein before using ((2 - fluoro-5-methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-L-proline and the appropriate amine or amine salt.
  • LC-MS data of Example 1.53 to Example 1.60 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.60 (S)-1-(5-Cyclopropyl-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: (S)-1-(5-chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (20.0 mg, 0.0388 mmol, 1 eq) and SPhos Pd G2 (1.12 mg, 0.00155 mmol, 0.04 eq) were dissolved in THF (0.5 mL) under N2 atmosphere.
  • Example 1.61 (S)-1-(2'-Fluoro-5-isopropyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(5-chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide and 2-propylzinc bromide (0.5 M in THF) in analogy to Example 1.60 to give the title compound.
  • LC-MS (1): IR 1.344 min; [M+H] + : 523.3.
  • Example 1.62 (S)-4,4-Difluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: 2-Bromo-2'-fluoro-5-methyl-1 , 1 '-biphenyl : to a degassed soln, of 2-bromo-5-methylphenylboronic acid (443 mg, 2.00 mmol, 1 eq), 2-fluoroiodobenzene (0.233 mL, 2.00 mmol, 1 eq), and CsF (0.133 mL, 3.60 mmol, 1.8 eq) in dioxane (6 mL), PPh 3 (106 mg, 0.400 mmol, 0.2 eq) and Pd(OAc)2 (22.5 mg, 0.100 mmol, 0.05 eq) were added.
  • Example 1.64 to Example 1.65 were synthesized according to the procedures described herein before using (S)- N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl)sulfony l)pyrrolidine-2-carboxamide and the appropriate aryl halide (chloride, bromide, or iodide).
  • LC-MS data of Example 1.64 to Example 1.65 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.68 to Example 1.83 were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1,1'- biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to example 1.62.
  • LC-MS data of Example 1 .68 to Example 1 .83 are listed in the table below.
  • Example 1.84 (S)-1-(5-Ethyl-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-1-(2'-fluoro-5-vinyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide (28.7 mg, 0.0567 mmol, 1 eq) was dissolved in EtOH (1 mL) and Pd/C (10% Pd, -50% H2O, 6.03 mg, ca 0.00567 mmol, ca 0.1 eq) was added.
  • Example 1.85 (S)-1-[2-(4-Cyano-pyridin-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4- methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and 3- bromoisonicotinonitrile in analogy to Example 1.25 to give the title compound.
  • Example 1.89 to Example 1.93 were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1 ,T- biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to Example 1.62.
  • LC-MS data of Example 1.89 to Example 1.93 are listed in the table below. The LC-MS conditions used were LC- MS (1).
  • Example 1.94 (S)-1-(4-Methyl-2-[1,2,3]triazol-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
  • 2-(2-(Benzylthio)-5-methylphenyl)-2H-1,2,3-triazole 2-(2-bromo-5-methylphenyl)-2H-1 ,2,3-triazole (100 mg, 0.42 mmol, 1 eq), benzyl mercaptan (0.0498 mL, 0.42 mmol, 1 eq) and DIPEA (0.147 mL, 0.84 mmol, 2 eq) were dissolved in degassed dioxane (1.6 mL) and the resulting mixture was stirred at 95 °C.
  • 2-Bromo-2',5,6'-trimethyl-1,1'-biphenyl in a microwave vial, 4-bromo-3-iodotoluene (97%, 100 mg, 0.327 mmol, 1 eq), 2,6-dimethylphenylboronic acid (49.0 mg, 0.327 mmol, 1 eq), K2CO3 (228 mg, 1.63 mmol, 5 eq) and Pd(PPh3)4 (38.9 mg, 0.0327 mmol, 0.1 eq) were dissolved in degassed dioxane I water 4:3 (3.3 mL) and the resulting mixture was stirred at 165 °C for 20 min under microwave irradiations.
  • Example 1.100 to example 1.101 were synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl- 2-(4,4, 5,5-tetramethy 1-1 , 3, 2-dioxaborolan-2-y I) pheny l)su Ifony I) py rrol idine-2-carboxami de and the appropriate bromoaryl in analogy to Example 1.96.
  • LC-MS data of Example 1.100 to Example 1.101 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • 5-(Benzylthio)-4-chloro-2-methylpyridine a mixture of 5-bromo-4-chloro-2-methylpyridine (500 mg, 2.32 mmol, 1 eq), benzyl mercaptan (292 mg, 2.32 mmol, 1 eq) and DIPEA (0.812 mL, 4.65 mmol, 2 eq) in dioxane (10 mL) was degassed with N2. The mixture was rapidly heated to 95 °C, and Pd2(dba)3 (106 mg, 0.116 mmol, 0.05 eq) and XantPhos (137 mg, 0.232 mmol, 0.1 eq) were added.
  • Example 1.104 to Example 1.109 were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1,T- biphenyl]-2-sulfonyl chloride LICI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to Example 1.62.
  • LC-MS data of example 1.104 to Example 1.109 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • (2R,3R)-3-Fluoro-1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)pyrrolidine-2-carboxylic acid to an ice- cooled soln, of (2R,3R)-1-[(tert-butoxy)carbonyl]-3-fluoropyrrolidine-2-carboxylic acid (35 mg, 0.15 mmol, 1 eq) in DCM (3 mL), HCI (4M in dioxane, 0.5 mL) was added. The resulting soln, was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure.
  • Example 1.114 to Example 1.119 were synthesized in analogy to Example 1.98 using the appropriate boronic acids.
  • LC-MS data of Example 1.1 14 to Example 1.119 are listed in the table below.
  • the LC-MS conditions used were LC-MS (1).
  • Example 1.120 2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: l-(tert-Butyl) 5-ethyl 3-methyl-4,5-dihydro-1H-pyrazole-1,5-dicarboxylate: CuCI 2 (26.9 mg, 0.200 mmol, 0.2 eq) was added to a soln, of tert-butyl (E)-2-(1-chloropropan-2-ylidene)hydrazine-1-carboxylate (207 mg, 1.00 mmol, 1 eq), ethyl diazoacetate (0.363 mL, 3.00 mmol, 3 eq), and Na2CO3 (530 mg, 5.00 mmol, 5 eq) in DCM (8
  • Ethyl 1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazole-5-carboxylate to an ice-cooled soln, of (tert-butyl) 5-ethyl 3-methyl-4,5-dihydro-1 H-pyrazole-1 ,5-dicarboxylate (51.3 mg, 0.200 mmol, 1 eq) in DCM (3 mL), HCI (4M in dioxane, 0.5 mL) was added. The resulting soln, was stirred at rt overnight. The volatiles were removed under reduced pressure.
  • Example 1.121 (1S,2S,5R)-3-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-3-aza- bicyclo[3.1.0]hexane-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (1S,2S,5R)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid hydrochloride, 2-bromo-4-methylbenzene-1 -sulfonyl chloride and 2-bromo-3-chloropyridine in analogy to Example 1.110 to give the title compound.
  • LC-MS (1): IR 1.176 min; [M+H] + : 524.3.
  • Example 1.122 (1S,3S,5S)-2-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-2-aza- bicyclo[3.1.0]hexane-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid hydrochloride, 2-bromo-4-methylbenzene-1 -sulfonyl chloride and 2-bromo-3-chloropyridine in analogy to Example 1.110 to give the title compound.
  • LC-MS (1): IR 1.167 min; [M+H] + : 524.2.
  • Example 1.132 to Example 1.135 were synthesized using the appropriate amino acid or amino acid salt according to the procedures described in Example 1.21.
  • LC-MS data of Example 1.132 to Example 1.135 are listed in the table below.
  • the LC-MS conditions used were LC-MS (1).
  • Example 1.136 (S)-1-[4-Methyl-2-(3-methyl-pyrazin-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1 -((4- methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and 2-bromo-3- methylpyrazine in analogy to Example 1.96 to give the title compound.
  • LC-MS (1): IR 1.027 min; [M+H] + : 493.2.
  • Example 1.138 and Example 1.139 (S)-N-(4,4-difluorocyclohexyl)-1-(((Sa)-2'-fluoro-6'-methoxy-5-methyl- [1,1'-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and (S)-N-(4,4-difluorocyclohexyl)-1- (((Ra)-2'-fluoro-6'-methoxy-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide : 2-Bromo-2'-fluoro-6'-methoxy-5-methyl-1,1'-biphenyl: 4-bromo-3-iodotoluene 97% (150 mg, 0.49 mmol, 1 eq),
  • (2S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-6'-methoxy-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide (2S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-6'-methoxy-5-methyl-[1, 1'- biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide (61.7 mg, 0.196 mmol, 1 eq) in DCM (1.5 mL) was added to a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (48.3 mg, 0.196 mmol, 1 eq), and TEA (0.0828 mL, 0.588 m
  • Example 1.142 (S)-1-[2-((2R,5S)-2,5-Dimethyl-pyrrolidin-1-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (30 mg, 0.0688 mmol, 1 eq), c/s-2,5- dimethylpyrrolidine hydrochloride (14.6 mg, 0.103 mmol, 1.5 eq) and KF (12 mg, 0.21 mmol, 3 eq) in DMF (1 mL) was heated to 140 °C for 96 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep.
  • Example 1.143 to Example 1.145 were synthesized using the amine or amine salt in analogy to Example 1.142.
  • LC-MS data of Examples 1.143 to 1.145 are listed in the table below.
  • the LC-MS conditions used were LC-MS (1).
  • 1-(2-Bromo-5-methylphenyl)-3-fluoropiperidine a mixture of 4-bromo-3-iodotoluene (184 mg, 0.60 mmol, 1 eq), 3-fluoropiperidine hydrochloride (104 mg, 0.72 mmol, 1.2 eq), NaOtBu (150 mg, 1.56 mmol, 2.6 eq), XantPhos (53.7 mg, 0.090 mmol, 0.15 eq) and Pd2(dba)3 (22 mg, 0.024 mmol, 0.04 eq) in dioxane (3 mL) was heated to 90 °C for 14 h under an N2 atmosphere. The mixture was diluted with sat. aq.
  • reaction mixture was concentrated and the pale yellow solid was suspended in DCM (2 mL) and stirred at -78 °C.
  • a soln, of SO2CI2 (0.0317 mL, 0.379 mmol, 1 .2 eq) in DCM (1.3 mL) was added at rt and the reaction stirred at rt.
  • the reaction mixture was concentrated under reduced pressure.
  • Example 1.148 (2S)-N-(4,4-difluorocyclohexyl)-1-((2-(2-(methoxymethyl)piperidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20 mg, 0.0459 mmol, 1 eq), rac-2- (methoxymethyl)piperidine (62 mg, 0.46 mmol, 10 eq) and KF (48 mg, 0.83 mmol, 18 eq) in DMF (1 mL) was heated to 140 °C for 18 h.
  • Example 1.150 to Example 1.154 were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methy Ipy rrolidi ne-2-carboxamide and the appropriate boronic acid or boronic ester in analogy to Example 1.1.
  • LC-MS data of Example 1 .150 to Example 1 .154 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Example 1.156 and Example 1.157 (S)-1-(((Ra)-2'-Chloro-5,6'-dimethyl-[1,1'-biphenyl]-2-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and (S)-1-(((Sa)-2'-Chloro-5,6'-dimethyl-[1,r- biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide : were synthesized using 4-bromo-3-iodotoluene and (2-chloro-6-methylphenyl)boronic acid in analogy to Example 1.138 to give the title compound.
  • Example 1.158 (2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,3-dimethylpyrrolidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), 2,3-dimethylpyrrolidine hydrochloride (66 mg, 0.46 mmol, 10 eq) and KF (40 mg, 0.69 mmol, 15 eq) in DMF (2.8 mL) was heated to 140 °C for 1 h. The mixture was allowed to cool to rt. The crude mixture was purified by basic prep. HPLC to give the title compound.
  • Example 1.160 and Example 1.161 (S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-5,6-dimethyl-[1,1'- biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and (S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'- fluoro-5,6-dimethyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide :
  • Methyl ((2-chloro-6-methylpyridin-3-yl)sulfonyl)-L-prolinate a soln, of 2-chloro-6-methylpyridine-3-sulfonyl chloride (1.80 g, 7.56 mmol, 1 eq) in DCM (10 mL) was added to a soln, of L-proline methyl ester hydrochloride (1.38 g, 8.32 mmol, 1 .1 eq), DIPEA (5.21 mL, 30.3 mmol, 4 eq) and DMAP (92.4 mg, 0.756 mmol, 0.1 eq) in DCM (20 mL).
  • Example 1.164 to Example 1.167 were synthesized according to the procedure described in Example 1.163 using the corresponding amine or amine salt.
  • LC-MS data of Example 1.164 to Example 1.167 are listed in the table below.
  • the LC-MS conditions used were LC-MS (1).
  • Methyl ((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-prolinate a mixture of methyl ((2-chloro- 6-methylpyridin-3-yl)sulfonyl)-L-prolinate (133 mg, 0.416 mmol, 1 eq), N-ethylisopropylamine (0.257 mL, 2.08 mmol, 5 eq) and TMP (0.709 mL, 4.16 mmol, 10 eq) was heated to 140 °C for 96 h. The mixture was allowed to cool to rt and purified by basic prep. HPLC to give the title compound.
  • LC-MS (2): IR 0.88 min; [M+H] + : 369.91.
  • tert-Butyl (1,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamate (mixture of 2 stereoisomers): NaH (ca 55% in oil, 304 mg, ca 7.6 mmol, ca 1.5 eq) was added to a soln, of tert-butyl (1 ,1-difluorospiro[2.3]hexan-5-yl)carbamate (1180 mg, ca 5.1 mmol, ca 1 eq) in DMF (20 mL) at 0 °C. The mixture was stirred for 10 min, and methyl iodide (0.631 mL, 10.1 mmol, 2 eq) was added.
  • Benzyl (1,1-difluorospiro[2.5]octan-6-yl)carbamate (mixture of 2 stereoisomers): benzyloxycarbonyl chloride (1.02 mL, 7.21 mmol, 1.5 eq) was added dropwise to a soln, of 1 , 1-difluorospiro[2.5]octan-6-amine hydrochloride (950 mg, 4.81 mmol, 1 eq) and DIPEA (1.86 g, 14.4 mmol) in DCM (30 mL) at O °C. The mixture was stirred for 30 min while warming up to rt. The solvents were removed under reduced pressure.
  • Benzyl (1,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamate (mixture of 2 stereoisomers): NaH (ca 55% in oil, 146 mg, ca 3.66 mmol, ca 1.5 eq) was added to benzyl (1 ,1-difluorospiro[2.5]octan-6-yl)carbamate (720 mg, 2.44 mmol, 1 eq) in DMF (10 mL) at 0 °C. The mixture was stirred for 10 min while warming up to rt. Mel (0.354 mL, 4.88 mmol, 2 eq) was added, and the mixture was stirred for 20 min. The solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound.
  • LC-MS (2): IR 1.07 min; [M+H] + : 310.31.
  • Example 1.172 (S)-1-[6-Methyl-2-((S)-3-methyl-morpholin-4-yl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using (S)-3- methylmorpholine as amine.
  • LC-MS (1): tR 1.118 min; [M+H] + : 501.3.
  • (2S)-3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid to (2S)-3- azabicyclo[3.1.0]hexane-2-carboxylic acid (97.0 mg, 0.756 mmol, 0.9 eq) in aq. 2M NaOH (1.7 mL) was added dropwise to a soln, of 2-chloro-6-methy Ipy ridiny l-3-sulfony I chloride (200 mg, 0.84 mmol, 1 eq) in THF (5 mL). The mixture was stirred at rt for 2 h, and aq.
  • (2S)-3-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (2S)-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (80 mg, ca 0.25 mmol, ca 1 eq), N-ethylisopropylamine (0.156 mL, 1.26 mmol, 5 eq) and TMP (0.43 mL, 2.5 mmol, 10 eq) was heated to 140 °C for 48 h. The mixture was allowed to cool to rt. The mixture was purified by acidic prep HPLC to give the title compound.
  • LC-MS (2): t 0.76 min; [M+H] + : 368.17.
  • Example 1.175 (S)-1-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (2S, 6S)- dimethylpiperidine hydrochloride in analogy to Example 1.170.
  • LC-MS (2): t R 1.03 min; [M+H] + : 514.5.
  • Example 1.176 (S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-amide: was synthesized using 1, 1-difluorospiro[2.5]octan-6-amine as amine in analogy to Example 1.171.
  • LC-MS (1): t R 1.331 min; [M+H] + : 499.3.
  • Example 1.177 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using (3S, 5S)-dimethylmorpholine.
  • LC-MS (1): t R 1.171 min; [M+H] + : 515.4.
  • Example 1.178 (S)-1-[6-Methyl-2-(2-methyl-cyclohex-1-enyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.168 using 4, 4,5,5- tetramethyl-2-(2-methylcyclohex-1-en-1-yl)-1 ,3,2-dioxaborolane.
  • LC-MS (1): t R 1.133 min; [M+H] + : 496.3.
  • Example 1.182 (S)-1-(2-Cyclohex-1-enyl-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.168 using cyclohex-1 en-1- yl(boronic acid).
  • LC-MS (1): t R 1.127 min; [M+H] + : 482.3.
  • Example 1.184 ⁇ (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl ⁇ -thiazolidin- 3-yl-methanone: a mixture of ((2-(ethyl (isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-proline (24.5 mg, 0.0688 mmol, 1 eq), thiazolidine (7.36 mg, 0.0826 mmol, 1.2 eq), HATU (54.9 mg, 0.0722 mmol, 1.05 eq) and DIPEA (0.059 mL, 45 mmol, 5 eq) in DMF (0.8 mL) was stirred at rt overnight.
  • Example 1.185 to Example 1.246 were synthesized according to the procedure described in Example 1.184 using the corresponding amine or amine salt. LC-MS data of Example 1.185 to Example 1.246 are listed in the table below. The LC-MS conditions used were LC-MS (1).
  • Methyl rac-(2R*,4R*)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2- carboxylate a mixture of methyl rac-(2R*,4R*)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2- carboxylate (340 mg, 1.02 mmol, 1 eq), N-ethylisopropylamine (0.631 mL, 5.11 mmol, 5 eq) and TMP (1.74 mL, 10.2 mmol, 10 eq) was heated to 140 °C for 24 h.
  • rac-(2R*,4R*)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2-carboxylic acid a mixture of methyl rac-(2R*,4R*)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4- methylpyrrolidine-2-carboxylate (200 mg, 0.521 mmol, 1 eq) and LIOH (25 mg, 1.04 mmol, 2 eq) in THF (2 mL) and water (1 mL) was stirred for 18 h at rt.
  • Example 1.252 (S)-1-[2-(Ethyl-isopropyl-amino)-6-trifluoromethyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6- (trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (51 mg, 0.105 mmol, 1 eq), N-ethylisopropylamine (0.065, 0.53 mmol, 5 eq) and TMP (0.179 mL, 1.05 mmol, 10 eq) was heated to 140 °C for 72 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound.
  • Example 1.254 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (1,1-difluoro-spiro[2.3]hex-5-yl)-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(1 , 1 -difluorospiro[2.3]hexan-5-yl)pyrrolidine-2-carboxamide (30 mg, 0.072 mmol, 1 eq), (3S, 5S)-3,5- dimethylmorpholine (42 mg, 0.36 mmol, 5 eq) and TMP (0.596 mL, 3.57 mmol, 10 eq) was heated to 140 °C for 18 h.
  • N-(4,4-Difluorocyclohexyl)-N,3-dimethyl-4,5-dihydro-1 H-pyrazole-5-carboxamide hoydrochloride to a soln, of tert-butyl 5-((4,4-difluorocyclohexyl)(methyl)carbamoyl)-3-methyl-4,5-dihydro-1 H-pyrazole-1 -carboxylate (100 mg, 0.278 mmol, 1 eq) in DCM (2 mL) was added HCI (4M in dioxane, 2 mL). The mixture was stirred for 1 h at rt. The solvents were removed under reduced pressure to give the title compound that was used further without further purification.
  • LC-MS (2): t 0.51 min; [M+H] + : 260.33.
  • Example 1.256 (S)-1-(2-lsopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using isopropylamine.
  • LC- MS (1): t R 1.272 min; [M+H] + : 459.2.
  • LC-MS (1): t R 1.207 min; [M+H] + : 473.3.
  • 1-(2-Bromo-5-methylphenyl)-5-cyclopropyl-1 H-pyrazole In a sealed microwave tube, 1-(2-bromo-5- methylphenyl)-5-cyclopropyl-1 H-pyrazole-4-carboxylic acid (177 mg, 0.55 mmol, 1 eq) was suspended in water (2.5 mL). Sulfuric acid (0.0619 mL, 1.16 mmol, 2.1 eq) was added and the mixture was vigorously stirred at 100 °C for 46 h. Concentrated H2SO4 (0.619 mL, 11.6 mmol, 21 eq) was added again and the reaction mixture was stirred at 100 °C for 21 h.
  • Example 1.259 (S)-1-[2-(5-Ethyl-pyrazol-1-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.258 using ethyl (E)-2- ((dimethylamino)methylene)-3-oxopentanoate to give the title compound as a white solid.
  • LC-MS (1): IR 1.155 min; [M+H] + : 495.2.
  • Methyl ((4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)-L-prolinate methyl ((2- bromo-4-methylphenyl)sulfonyl)-L-prolinate (1000 mg, 2.76 mmol, 1 eq), PdCl2(MeCN)2 (14.6 mg, 0.0552 mmol, 0.02 eq) and SPhos (90.7 mg, 0.221 mmol, 0.08 eq) were introduced into a 250 mL round bottom flask which was evacuated and backfilled with N2.
  • Methyl ((4-methyl-2-(3-methylpyrazin-2-yl)phenyl)sulfonyl)-L-prolinate methyl ((4-methyl-2-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)-L-prolinate (50 mg, 0.115 mmol, 1 eq), 2-bromo-3- methylpyrazine (30.4 mg, 0.172 mmol, 1 .5 eq), NaHCOa (29 mg, 0.344 mmol, 3 eq) and Pd(PPha)4 (13.7 mg, 0.0115 mmol, 0.1 eq) were dissolved in degassed DME/water 4: 1, and the resulting mixture was stirred at 85 °C for 3 h.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel aryl sulfone and sulfanone derivatives of Formula (I) wherein R1, R2, RB1, RB3, X1, X2, X3, X4, Ring A, and Ring B are as described in the description, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor (hereinafter also referred to as OX2R), and particularly as agonists of the human orexin-2 receptor (hereinafter also referred to as hOX2R).

Description

ID 407 A
Aryl sulfone and sulfanone derivatives as orexin receptor modulators
The present invention relates to novel aryl sulfone and sulfanone derivatives of Formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor (hereinafter also referred to as OX2R), and particularly as agonists of the human orexin-2 receptor (hereinafter also referred to as hOX2R).
The orexin system (also known as hypocretin system) was discovered in 1998 by two independent research groups and is composed of 2 neuropeptides and 2 receptors (de Lecea L et al.; The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity; Proc Natl Acad Sci U S A. 1998, 95(1 ):322-7; Sakurai T et al.; Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior; Cell. 1998, 92(5): 1 page following 696). Orexin A (OX-A) and orexin B (OX-B) are neuropeptides specifically expressed in a small population of neurons of the lateral, dorsomedial and perifornical hypothalamus. They are proteolytically derived from a single precursor prepro-orexin peptide. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide. Orexins bind to two G-protein-coupled receptors (orexin- 1 receptor (OX1R) and orexin-2 receptor (OX2R)) widely expressed throughout the brain. While OX-A binds to both receptors with similar affinity, OX-B binds preferentially to OX2R. The wide distribution of orexin fibers and receptors in many parts of the brain suggests that orexins have multiple functions.
The orexin system is recognized as being crucial for the stability of wakefulness and the regulation of vigilance in accordance with various physiological processes (de Lecea L; Hypocretins and the neurobiology of sleep-wake mechanisms; Prog Brain Res. 2012, 198: 15-24; Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci. 2007, 8(3): 171 -81 ; Scammell TE et al.; Neural Circuitry of Wakefulness and Sleep; Neuron. 2017, 93(4):747-765). Orexin neurons are primarily active during wakefulness (Lee MG et al.; Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle; J Neurosci. 2005, 25(28):6716- 20). They send excitatory projections to wake-promoting neuronal populations such as the histaminergic neurons of the tuberomammillary nucleus, noradrenergic neurons of the locus coeruleus, serotoninergic neurons of the dorsal raphe, dopaminergic neurons in the ventral tegmental area and cholinergic neurons in the basal forebrain and the pedunculopontine and laterodorsal tegmental nuclei. Different wake-promoting regions of the brain predominantly express OX1R or OX2R, or both (for review see (Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci. 2007, 8(3): 171 -81)). OX-A levels in the brain extracellular and cerebrospinal fluid (CSF) follow a circadian rhythm: they rise during the wake period and drop rapidly during sleep. Increasing orexin levels are necessary to compete with the increasing sleep pressure that builds up during long periods of wakefulness, preventing from falling asleep (Gotter AL et al.; The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold; BMC Neurosci. 2013, 14:90; Modirrousta M et al.; Orexin and MCH neurons express c-Fos differently after sleep deprivation vs. recovery and bear different adrenergic receptors; Eur J Neurosci. 2005, 21 (10):2807-16; Zeitzer JM et al.; Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness; J Neurosci. 2003, 23(8):3555-60).
Moreover, orexin neurons integrate a variety of signals related to internal or external environment (e.g. emotion, light/dark cycles, sleep pressure, energy balance) and send information to a variety of neuronal systems to adjust the arousal level to the one necessary for an appropriate behavioral response (Inutsuka A et al.; The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions; Front Endocrinol (Lausanne). 2013, 4: 18). For this purpose, they do not only follow a circadian related pattern of activation, but also a behaviour-related burst of firing and are, for example, particularly active in periods of heightened arousal associated with emotion and social interaction (Blouin AM et al.; Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction; Nat Commun. 2013, 4:1547).
Evidences from human and animal studies have demonstrated that narcolepsy type 1 , a chronic sleep disorder characterized by excessive daytime sleepiness (EDS), sleep attacks and cataplexy (loss of muscle tone in full consciousness often triggered by positive emotions), is linked to a deficiency in the orexin system (Chemelli RM et al.; Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation; Cell. 1999, 98(4):437-51 ; Lin L et al.; The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene; Cell. 1999, 98(3):365-76; Peyron C et al.; A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains; Nat Med. 2000, 6(9):991 -7; Thannickal TC et al.; Reduced number of hypocretin neurons in human narcolepsy; Neuron. 2000, 27 (3): 469-74). In human, narcolepsy type 1 has been shown to be caused by the loss of orexin-producing neurons (Peyron C et al.; A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains; Nat Med. 2000, 6(9):991 -7) and low OX-A level in the CSF can be used as specific biological measure for the diagnosis (Dauvilliers Y et al.; Narcolepsy and Other Central Hypersomnias; Continuum (Minneap Minn). 2017, 23(4, Sleep Neurology):989-1004). Several genetic animal models (in both mice and dogs) showed that disruption of orexin signaling leads to a narcoleptic phenotype with excessive daytime sleepiness (fragmented wakefulness) and cataplexy (Lin L et al.; The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene; Cell. 1999, 98(3):365-76; Willie JT et al.; Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes; Neuron. 2003, 38(5):715-30). Central administration of OX-A or ectopic expression of the prepro-orexin transgene in the brain of orexin neuron-ablated mice are able to reversed the narcoleptic phenotype (Mieda M et al.; Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice; Proc Natl Acad Sci U S A. 2004, 101 (13): 4649-54). Those data suggest that an orexin receptor agonist would be an appropriate treatment for narcoleptic patients. In addition, intracerebroventricular (i.c.v.) injections of OX-A in rats or mice increased wakefulness and markedly reduced both non-rapid eye movement (NREM) and REM sleep (Piper DC et al.; The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats; Eur J Neurosci. 2000, 12(2)726-30; Huang ZL et al.; Arousal effect of orexin A depends on activation of the histaminergic system; Proc Natl Acad Sci U S A. 2001 , 98(17):9965- 70). Furthermore, optogenetic or chemogenetic studies showed that stimulation of orexin neurons reduced the latency in sleep-to-wake transition from both NREM and REM sleep and induced wakefulness with a very short latency (Adamantidis AR et al.; Neural substrates of awakening probed with optogenetic control of hypocretin neurons; Nature. 2007, 450(7168): 420-4; Sasaki K et al.; Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice; PLoS One. 2011 , 6(5):e20360).
Altogether, it suggests that activation of orexin receptors is a promising therapeutic approach for disease associated with difficulties maintaining wakefulness with patients complaining of: feelings of excessive sleepiness; episodes of inadvertently falling asleep, including sleep attacks (episodes of falling asleep without prodromal symptoms of drowsiness); a prolonged main sleep episode that is unrefreshing; recurrent naps in the same day; and sleep inertia (prolonged difficulty waking up, with irritability, automatic behavior, or confusion).
These can be seen in sleep disorders such as the disorders of hypersomnolence. Based on the international classification of sleep disorders, 3rd edition (ICSD-3) (Sateia MJ; International classification of sleep disorders-third edition: highlights and modifications; Chest. 2014, 146(5): 1387-1394), central disorders of hypersomnolence include narcolepsy (including narcolepsy type 1 and narcolepsy type 2), idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to a medical disorder, hypersomnia due to a medication or substance, hypersomnia associated with psychiatric disorder and insufficient sleep syndrome.
Narcolepsy is supposed to be the result of an autoimmune disorder which specifically destroy orexin-producing neurons. However, symptoms of narcolepsy (or secondary narcolepsy) can occur during the course of other neurologic disorders and be caused by the underlying condition, e.g. inherited disorders (such as Prader-Willi syndrome, Niemann-Pick C disease, or myotonic dystrophy), tumors or head trauma (particularly when the hypothalamus area is involved) (Kanbayashi T et al.; The pathophysiologic basis of secondary narcolepsy and hypersomnia; Curr Neurol Neurosci Rep. 2011 , 11 (2):235-41; Nishino S et al.; Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system; Sleep Med Rev. 2005, 9(4):269-310). Reduced orexin levels in CSF were often seen in those symptomatic narcolepsy and EDS cases.
Other immune-mediated disorders can show a disruption of orexin neurotransmission with patients presenting symptoms reminiscent of narcolepsy (Fronczek R et al.; The orexin/hypocretin system in neuropsychiatric disorders: Relation to signs and symptoms; Handb Clin Neurol. 2021 , 180:343-358). For some of them, destruction of part of the orexin neurons on top of other cell types have been demonstrated. For example, orexin deficiency in the CSF and narcolepsy-like symptoms have been observed in patients with neuromyelitis optica, multiple sclerosis (Kanbayashi T et al.; The pathophysiologic basis of secondary narcolepsy and hypersomnia; Curr Neurol Neurosci Rep. 2011, 11 (2):235-41 ; Kanbayashi T et al.; Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications; Arch Neurol. 2009, 66(12): 1563-6), Guillain- Barre syndrome (Nishino S et al.; CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies; Neurology. 2003, 61 (6):823-5), or anti-Ma2 encephalitis (Overeem S et al.; Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis; Neurology. 2004, 62(1): 138-40).
In neurodegenerative disease, EDS and other sleep disturbances are commonly reported. Loss of orexin neurons has been described in several neurodegenerative disease and is suggested to contribute to EDS and the sleep disturbances, including Alzheimer's (Fronczek R et al.; Hypocretin (orexin) loss in Alzheimer's disease; Neurobiol Aging. 2012, 33(8): 1642-50), Parkinson's (Fronczek R et al.; Hypocretin (orexin) loss in Parkinson's disease; Brain. 2007, 130(Pt 6): 1577-85; Fronczek R et al.; Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease; Brain. 2008, 131 (Pt 1):e88), Lewy body dementia (Kasanuki K et al.; Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies; Neurosci Lett. 2014, 569:68-73), Perry syndrome (Mishima T et al.; Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy; Parkinsonism Relat Disord. 2017, 42:85-89), multiple system atrophy (Benarroch EE et al.; Involvement of hypocretin neurons in multiple system atrophy; Acta Neuropathol. 2007, 113(1)75-80) and Huntington's diseases (Petersen A et al.; Orexin loss in Huntington's disease; Hum Mol Genet. 2005, 14(1 ):39-47).
EDS can also be observed in circadian rhythm sleep-wake disorders such as for example delayed sleep-wake phase disorder, shift work or jet lag disorder and result from a misalignment between the body clock and social requirements (Sateia MJ; International classification of sleep disorders-third edition: highlights and modifications; Chest. 2014, 146(5): 1387-1394; Gandhi KD et al.; Excessive Daytime Sleepiness: A Clinical Review; Mayo Clin Proc. 2021 , 96(5): 1288-1301 ). It is specially the case when the patient needs to be awake but their alertness level secondary to their internal body clock is at its nadir.
Likewise, EDS is accompanying disorders such as obesity, diabetes, depression and objective sleep disturbances such as sleep apnea (Fernandez-Mendoza J et al.; Natural history of excessive daytime sleepiness: role of obesity, weight loss, depression, and sleep propensity; Sleep. 2015, 38(3):351-60). Taking in particular the example of obstructive sleep apnea (OSA), it is suggested that dysregulation of the orexin system could play a role in the pathogenesis of this disorder (Wang W et al.; Orexin: a potential role in the process of obstructive sleep apnea; Peptides. 2013, 42:48-54). Low levels of OX-A in plasma were reported in patients suffering from OSA (Busquets X et al.; Decreased plasma levels of orexin-A in sleep apnea; Respiration. 2004, 71 (6):575-9). In addition, in the orexin knockout narcolepsy mouse model, the frequency of spontaneous sleep apneas increased (Nakamura A et al.; Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice; J Appl Physiol (1985). 2007, 102(1 ):241 -8).
Different from EDS, fatigue is a lack of energy ("an overwhelming sense of tiredness, a feeling of exhaustion") with a reduced ability to perform physical activities that would have previously been easily accomplished. It may be accompanied by mental fatigue with poor concentration and memory, but it is not generally associated with inappropriate episodes of sleep during the day. It is observed in a number of disorders including infections, chronic inflammatory diseases, cancer and neurodegeneration. It is suggested that a dysregulation of the orexin system could contribute to fatigue. In rodents, fatigue (or sickness behavior in animals) induced by lipopolysaccharide was associated with reduced activity of orexin neurons and a reduction of OX-A in the CSF (Grossberg AJ et al.; Inflammation-induced lethargy is mediated by suppression of orexin neuron activity; J Neurosci. 2011 , 31 (31):11376-86). Intracerebroventricular administration of OX-A in lipopolysaccharide-treated rats restored normal home-cage exploratory behavior. Similar findings were retrieved in tumor-bearing rats indicating that the reduction of orexin signaling could play a role in chronic disease.
In human, Bardsen et al., (Bardsen K et al.; lnterleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjogren's syndrome; J Neuroinflammation. 2019, 16(1): 102) showed that OX-A level was decreased in CSF of patients suffering from primary Sjogren's syndrome, a chronic autoimmune disease clinically characterized by inflammation of the exocrine glands where fatigue is an important symptom (Segal B et al.; Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome; Arthritis Rheum. 2008, 59(12): 1780-7).
It generally suggests that a dysfunction of the orexin system could contribute to fatigue and that an orexin receptor agonist could be helpful in chronically ill patients with fatigue, it could improve their quality of life.
Traumatic brain injury (TBI) can induce disorders of consciousness (DOC) such as syndromes of coma, vegetative state, and minimally conscious state (O'Donnell JO et al.; Challenges and demand for modeling disorders of consciousness following traumatic brain injury; Neurosci Biobehav Rev. 2019, 98:336-346). Consciousness is a complex state including arousal and awareness and the ascending reticular activating system (ARAS) is known to play an essential role in maintaining consciousness (Edlow BL et al.; Neuroanatomic connectivity of the human ascending arousal system critical to consciousness and its disorders; J Neuropathol Exp Neurol. 2012, 71 (6):531- 46). The ARAS is a complex and diffuse network of neuronal fibers that connects the brainstem reticular formation (such as the nuclei containing serotoninergic, noradrenergic, dopaminergic, cholinergic and glutamatergic neurons) with nonspecific thalamic nuclei, the basal forebrain, hypothalamus, and the cerebral cortex. Impairment of the ARAS can cause loss of consciousness following TBI (Jang SH et al.; The Relation Between Loss of Consciousness, Severity of Traumatic Brain Injury, and Injury of Ascending Reticular Activating System in Patients With Traumatic Brain Injury; Am J Phys Med Rehabil. 2019, 98(12): 1067-1071). Monoaminergic drugs acting by increasing for instance dopaminergic levels, norepinephrine levels and acetylcholine levels could have some beneficial impacts on DOC. Given its projections to the wake-promoting system and its contribution to the stabilization of wakefulness/arousal, the orexin system is well placed to support and regulate consciousness. Interestingly, in patients with acute moderate and severe TBI, abnormally low level of OX-A in the CSF was reported (Baumann CR et al.; Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury; Neurology. 2005, 65(1 ): 147- 9). Preclinically, in a mouse model of TBI, it was shown that electromagnetic controlled cortical impact depressed orexin levels in both the hypothalamus and hippocampus, and that the diurnal fluctuation amplitudes of orexins were blunted (Willie JT et al.; Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice; J Neurotrauma. 2012, 29(10): 1908-21). Those data indicate that the orexin system is dysregulated following TBI and an orexin receptor agonist could be a useful therapeutic approach.
In addition, in a model of unconscious rats induced by acute alcohol intoxication, i.c.v. administration of OX-A or OX-B reduced the duration of right reflex loss, shortened the coma time, and decreased the delta signal of EEG (Jia X et al.; Arousal effects of orexin A on acute alcohol intoxication-induced coma in rats; Neuropharmacology. 2012, 62(2)775-83). It suggests that orexin receptor agonists could have an arousal-promoting effect in coma induced by acute alcohol intoxication. Furthermore, intranasal or i.c.v. administration of OX-A facilitated the recovery of arousal in a cardiac arrest- induced coma rat model (Koenig MA et al.; Intraventricular orexin-A improves arousal and early EEG entropy in rats after cardiac arrest; Brain Res. 2009, 1255:153-61; Modi HR et al.; Intranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation; PLoS One. 2017, 12(9):e0182707). Orexin agonists could then provide beneficial effects following cardiac failure.
Additionally, in this model of cardiac arrest, OX-A did not only accelerate arousal and behavior recovery, but it also had some anti-inflammatory effects. Other studies raised the potential role of the orexin system in the regulation of inflammation. For instance, Ogawa et al. (Ogawa Y et al.; Peripherally administered orexin improves survival of mice with endotoxin shock; Elife. 2016, 5) showed that, in a model of septic shock in mice, administration of OX-A helped for survival and recovery and that excessive cytokine production was inhibited. In a mouse model of intracerebral hemorrhage, OX-A improved the neurofunctional outcomes and mitigated brain edema (Li T et al.; Orexin A alleviates neuroinflammation via OXR2/CaMKKbeta/AMPK signaling pathway after ICH in mice; J Neuroinflammation. 2020, 17(1):187). It is suggested that OX-A was beneficial because of its anti-inflammatory effects.
Moreover, it is also suggested that orexins facilitate the emergence from anesthetic-induced unconsciousness with anesthesia being either intraperitoneal or gas anesthesia and that inhibiting the orexin signaling delays the emergence (Zhang LN et al.; Orexin-A facilitates emergence from propofol anesthesia in the rat; Anesth Analg. 2012, 115(4)789-96; Kelz MB et al.; An essential role for orexins in emergence from general anesthesia; Proc Natl Acad Sci U S A. 2008, 105(4): 1309-14; Zhang LN et al.; Orexin-A facilitates emergence of the rat from isoflurane anesthesia via mediation of the basal forebrain; Neuropeptides. 2016, 58:7-14; Kushikata T et al.; Orexinergic neurons and barbiturate anesthesia; Neuroscience. 2003, 121 (4): 855-63).
Besides stabilizing wakefulness, the orexins system seems to play a role in the regulation of many other functions such as energy homeostasis, learning and memory, stress/emotion, reward, and pain. The orexin system is involved in the regulation of feeding behaviors and energy homeostasis. Orexin neurons are sensitive to glucose, leptin and ghrelin with high concentrations of glucose and leptin inhibiting orexinergic neurons, while low concentrations of glucose and ghrelin exciting them (Diano S et al.; Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets; Endocrinology. 2003, 144(9):3774-8; Yamanaka A et al.; Hypothalamic orexin neurons regulate arousal according to energy balance in mice; Neuron. 2003, 38(5):701 - 13). The orexin system is suggested to coordinate the behavioral/wakefulness response to the energy needs (Latifi B et al.; Sleep-Wake Cycling and Energy Conservation: Role of Hypocretin and the Lateral Hypothalamus in Dynamic State-Dependent Resource Optimization; Front Neurol. 2018, 9:790; Chieffi S et al.; Orexin System: The Key for a Healthy Life; Front Physiol. 2017, 8:357). Interestingly, narcoleptic mice show a dysregulation of energy homeostasis. Those mice exhibit obesity despite a significant lower calorie consumption which can be explained, to some extent, by a lower energy expenditure (Zhang S et al.; Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy; J Physiol. 2007, 581 (Pt 2):649-63). In addition, the prevalence of obesity is also increased in narcoleptic patients (Mohammad! S et al.; Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis; Sleep Med. 2021 , 81 :268-284). Studies in rodent models of diet-induced obesity showed that central administration of OX-A protects against obesity (Perez-Leighton CE et al.; Behavioral responses to orexin, orexin receptor gene expression, and spontaneous physical activity contribute to individual sensitivity to obesity; Am J Physiol Endocrinol Metab. 2012, 303(7):E865-74).
Altogether it suggests that an orexin receptor agonist could be an interesting therapeutic option for the treatment of disease associated with a dysregulation of feeding behaviors or energy homeostasis.
The orexin system seems to play a role in learning and memory processes. On one hand, given its recognized role for the stability of wakefulness and the regulation of vigilance in accordance with various physiological processes (de Lecea L; Hypocretins and the neurobiology of sleep-wake mechanisms; Prog Brain Res. 2012, 198:15-24; Sakurai T; The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness; Nat Rev Neurosci. 2007, 8(3): 171 -81 ; Scammell TE et al.; Neural Circuitry of Wakefulness and Sleep; Neuron. 2017, 93(4)747-765), it will contribute to the sustained arousal level necessary to learn. On the other hand, the orexin neurons also project to areas involved in learning and memory processing such as the hippocampus (Peyron C et al.; Neurons containing hypocretin (orexin) project to multiple neuronal systems; J Neurosci. 1998, 18(23):9996-10015) which suggest a potential direct effect. Preclinical data have shown that activation of the orexin system can be beneficial for learning and memory. For example, mice data showed that OX-A could contribute to the increase hippocampal plasticity associated with the consolidation of social recognition memory (Yang L et al.; Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice; J Neurosci. 2013, 33(12):5275-84). Intranasal administration of OX-A improved the performance altered by sleep loss on a short-term memory task in sleep-deprived rhesus monkeys without altering task performance in alert non-sleep-deprived animals (Deadwyler SA et al.; Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates; J Neurosci. 2007, 27(52): 14239-47). In addition, i.c.v. injection of OX-A in wild type mice improved memory processing in 2 different avoidance tasks but also improved memory performance in the senescence-accelerated mouse (SAMP8) strain showing age-related deficits in learning and memory (Jaeger LB et al.; Effects of orexin-A on memory processing; Peptides. 2002, 23(9): 1683-8).
Cognitive impairment is a common feature of several neuropsychiatric/neurological disorders and of age/age- related dementias. Age is also affecting the orexin system. Indeed in both human and animals, loss of orexin neurons is reported (for review (Nixon JP et al.; Sleep disorders, obesity, and aging: the role of orexin; Ageing Res Rev. 2015, 20:63-73)). Interestingly, age-related impairments in attentional performance could be improved in rats via intranasal administration of OX-A (Galva CB et al.; Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction; Brain Res. 2020, 1731 : 145921 ; Galva CB et al.; Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats; Front Aging Neurosci. 2019, 11 :362) suggesting a therapeutic benefit of orexin receptor agonist for age-related cognitive disorders.
Furthermore, local intracerebral infusion of OX-A was able to reduced distractor-induced decreases in attention performance in rats (Zajo KN et al.; Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons; Psychopharmacology (Berl). 2016, 233(4):639-47) suggesting that an orexin-receptor agonist could be useful for the treatment of disorders with attentional deficits.
The orexin system plays a role in behaviours needing motivation (Mahler SV et al.; Motivational activation: a unifying hypothesis of orexin/hypocretin function; Nat Neurosci. 2014, 17(10): 1298-303). And motivation (the psychological drive underlying goal-directed behaviour) is important to organize psychological and physiological processes leading to adaptive behaviours. Motivated behaviours support, for example, food seeking, coordinated stress response and the development of coping strategy. Dysregulation of those processes can lead to neuropsychiatric disorders in which orexin receptor agonists could provide beneficial effects.
As an example, stimulation of OX2R promoted coping responses in a decision-making test during social stress in mice (in this test: promotion of escape behaviour) (Staton CD et al.; Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression; Neuropharmacology. 2018, 143:79-94). Stimulation of OX2R also increased resilience to social stress (i.e. social novelty seeking) (Staton CD et al.; Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression; Neuropharmacology. 2018, 143:79-94).
Anhedonia, one of the key symptoms of depression, can be described as the failure to experience pleasure or pursue gratification and encompasses reward-associated disorders such as perturbation in decision-making and motivational drive. Anhedonia symptoms evoke a dysregulation of brain reward processing in which an alteration of the orexin system function could play a role (Coccurello R; Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing; Behav Brain Res. 2019, 372: 112041). Several preclinical and clinical studies have shown a link between dysregulation of the orexin system and depression (Khairuddin S et al.; Dysregulation of the orexinergic system: A potential neuropeptide target in depression; Neurosci Biobehav Rev. 2020, 118:384-396). In Wistar-Kyoto rats, which demonstrate depressive-like behaviours, OX-A immunoreactivity and prepro-orexin mRNA levels were reduced in the hypothalamus compared to Wistar rats (Taheri S et al.; Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats; Neuroreport. 2001 , 12(3):459- 64). In animal models of depression induced by chronic, inescapable stressors such as the social defeat model of chronic stress, downregulation of orexin neurotransmission was observed (Lutter M et al.; Orexin signaling mediates the antidepressant-like effect of calorie restriction; J Neurosci. 2008, 28(12):3071 -5; Nocjar C et al.; The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus; Neuroscience. 2012, 218:138-53). In patients with major depressive disorder (MDD), lower levels of OX-A in the CSF were reported (Brundin L et al.; Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder; Eur Neuropsychopharmacol. 2007, 17(9):573-9) and depressed patients show blunted diurnal variation in CSF orexin levels (Salomon RM et al.; Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects; Biol Psychiatry. 2003, 54(2):96-104).
In addition, in suicidal attempters, low levels of OX-A in the CSF were correlated with psychiatric symptoms of depression such as lassitude, slowness of movement and higher rating of the overall illness (Brundin L et al.; Orexin and psychiatric symptoms in suicide attempters; J Affect Disord. 2007, 100(1 -3): 259-63).
Orexin neurons project to many brain regions involved in the regulation of pain, including the spinal dorsal horn, the ventrolateral periaqueductal gray, the rostral ventromedial medulla or the trigeminal caudate nucleus (Peyron C et al.; Neurons containing hypocretin (orexin) project to multiple neuronal systems; J Neurosci. 1998, 18(23):9996-10015). Administration of orexin into the spinal cord or centrally in brain areas associated with the descending pain regulatory circuits reduces nociceptive responses in animal models of inflammatory pain and in chronic neuropathic pain models. Accordingly, intrathecal injections or local injections in pain-regulating brain areas of orexin receptor antagonists modulate pain responses (for review see: (Kang X et al.; Research progress on the mechanism of orexin in pain regulation in different brain regions; Open Life Sci. 2021 , 16(1):46-52)). In addition, pain threshold is lower in orexin knockout mice following peripheral local inflammation (Watanabe S et al.; Persistent pain and stress activate pain-inhibitory orexin pathways; Neuroreport. 2005, 16(1):5-8). Interestingly, lower CSF orexin levels were reported in patients suffering from cluster headache (Barloese M et al.; Reduced CSF hypocretin-1 levels are associated with cluster headache; Cephalalgia. 2015, 35(10):869-76) and the prevalence of migraine is increased in narcoleptic patients (Dahmen N et al.; Increased frequency of migraine in narcoleptic patients: a confirmatory study; Cephalalgia. 2003, 23(1):14-9).
Overall, it suggests that orexin receptor agonists could have beneficial effect in the therapeutic approach against pain. US 2014/0051700 discloses cyclic guanidinyl OX2R agonists useful for enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag. WO 2014/198880 discloses 2-(2-aminophenoxy)-3-chloronaphthalene-1, 4-dione compounds having orexin 2 receptor agonist activities, and their use therapeutic active substances for the treatment of conditions mediated by agonizing the orexin 2 receptor. WO 2017/135306 discloses substituted piperidine compounds having an orexin type 2 receptor agonist activity, and their use as prophylactic or therapeutic agents for narcolepsy. WO 2018/164191 (English-language family member US 2021/0385345) discloses substituted pyrrolidine compounds having an orexin type 2 receptor agonist activity. WO 2019/117148 (English-language family member US 2021/0078955) discloses sulfonamide derivatives showing an orexin receptor agonist activity. WO 2019/027003, WO 2019/027058, WO 2020/004537/US 2021/198240, WO 2020/122092 and WO 2020/122093 disclose heterocyclic compounds having orexin type 2 receptor agonist activity. WO 2020/167706 discloses 5-alkyl pyrrolidine orexin receptor agonists. Orexin receptor agonists are further reported in WO 2018/164192, WO 2021/106975, WO 2020/158958, US 2021/0155636, WO 2020/167701 , WO 2021/026047, WO 2021/107023, WO 2016/133160, WO 2021/065893, and WO 2019/191327.
Selected indolyl and pyrrolyl aryl sulfones are disclosed as anti-HIV agents (Silvestri R et al., Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations: Synthesis and SAR Studies, J. Med. Chem. 2003, 46:2482-2493; Ragno R et al., Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones. Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non-Nucleoside Binding Site and Design of Highly Active N-(2- Hydroxyethyl)carboxamide and N-(2-Hydroxyethyl)carbohydrazide Derivatives, J. Med. Chem. 2005, 48:213-223; Ragno R et al., Design, Molecular Modeling, Synthesis, and Anti-HIV-1 Activity of New Indolyl Aryl Sulfones. Novel Derivatives of the lndole-2-carboxamide, J. Med. Chem. 2006, 49:3172-3184; Chamjangali A, Modelling of cytotoxicity data (CC50) of anti-HIV 1-[5-chlorophenyl)sulfonyl]-1 H-pyrrole derivatives using calculated molecular descriptors and levenberg-marquardt artificial neural network, Chemical Biology and Drug Design, 2009, 73(4):456- 465; Xu H et al., Development of indoles an anti-HIV-1 inhibitors, Current Pharmaceutical Design, 2009, 15(18):2120-2148). Selected benzene sulfonamide derivatives are disclosed as Smac analogs for cancer (Baravkar S et al. Synthesis and anticancer activity of conformationally constrained Smac mimetics containing pseudo |3 turns. Tetrahedron Letters, 2018, 59 (38): 3473-3476). Selected benzene sulfonamide derivatives are further disclosed in Vijayadas K et al., Reversal of H-bonding direction by N-sulfonation in a synthetic reverse-turn peptide motif (Organic and Biomolecular Chemistry, 2015, 13(10):3064-3069) and in Vijayadas K et al., An unusual conformational similarity of two peptide folds featuring sulfonamide and carboxamide on the backbone. (Chemical Communications, 2012, 48(78):9747-9749). Certain benzene sulfonamide derivatives are disclosed as selective potassium channel activators (Mattmann M et al., Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1- tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator, 2012, 22(18):5936-5941). WO 2005/097162 describes selected aryl sulfonyl derivatives as steroid sparing agents. WO 00/04892, WO 2010/007027, US 2003/0130506 and US 5,753,653 each disclose certain hydroxamic acid-comprising benzene sulfonyl derivatives as MMP inhibitors. US 2001/0056184 describes pipecolinic acid derivatives as MMP inhibitors. WO 97/18194 and US6225311 discloses certain hydroxamic acidcomprising benzene sulfonamide derivatives as MMP and TACE inhibitors, respectively. WO 2005/030728 describes selected aryl sulfonamide derivatives as MMP inhibitors. WO 2013/020440 discloses certain aryl sulfonamide derivatives as 11-p hydroxy steroid dehydrogenase type I inhibitors. EP0469984 refers to N-sulfonyl- indoline derivatives as binding to vasopressin and oxytocin receptors. WO 2014/098098 describes selected aryl sulfonamide antagonists of TRPA1. JP 2006124387, referring to MCH receptor antagonists, discloses certain sulfone-comprising pyridine derivatives.
WO 2012/025877 discloses certain proline sulfonamide derivatives as orexin receptor antagonists. WO 2008/038251 describes selected non-peptide antagonists of orexin receptors. Further orexin receptor antagonists are described in: WO 2002/051838, WO 2004/004733, WO 2004/085403, WO 2005/118548, WO 2008/020405, WO 2008/026149, WO 2008/065626, WO 2008/078291, WO 2008/081399, WO 2008/087611, WO 2008/117241,
WO 2008/139416, WO 2009/004584, WO 2009/016560, WO 2009/016564, WO 2009/022311, WO 2009/040730,
WO 2009/104155, WO 2009/133522, WO 2009/150614, WO 2009/156951, WO 2010/004507, WO 2010/038200,
WO 2010/131191, WO 2010/131192, WO 2012/063207, and WO 2012/110986.
The following compounds are known as chemical library compounds: 1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-piperidinecarboxamide (CAS no. 2174271-82-8); 1 -([1,1'-biphenyl]-2-ylsulfonyl)-N-methyl-2-piperidinecarboxamide (CAS no. 2421462-12-4); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-pyrrolidinecarboxamide (CAS no. 1956132-61-8); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 1951549-56-6); 1 -([1,1'-biphenyl]-2-ylsulfonyl)-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 2180339-78-8); N-cyclopropyl-1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-2-pyrrolidinecarboxamide (CAS no. 1957026-44-6); 1-([1,T-biphenyl]-2-ylsulfonyl)-N-propyl-2-pyrrolidinecarboxamide (CAS no. 1101182-03-9); 1-[(4-ethoxy-3-pyridinyl)sulfonyl]-2-(methoxymethyl)-N-methyl-2-pyrrolidinecarboxamide (CAS no. 2223951-41-3); N, N-diethyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 1444098-57-0); N-(1, 1-dimethylethyl)-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 2175321- 07-8); N-cyclopropyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-4-thiazolidinecarboxamide (CAS no. 1953618- 16-0); 3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-N-(1-methylethyl)-4-thiazolidinecarboxamide (CAS no. 2174321-10-7); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-cyclopropyl-N-methyl-4-thiazolidinecarboxamide (CAS no. 1315694-49- 5); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(2-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1315666-22-8); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(cyclopropylmethyl)-4-thiazolidinecarboxamide (CAS no. 1316038-32-0); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(1-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1316017-19-2); [3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 1948116-54-8); [1-([1,1'-biphenyl]-2-ylsulfonyl)-2-piperidinyl]-1 -pyrrolidinylmethanone (CAS no. 1277333-36-4); [3-([1,T-biphenyl]-2-ylsulfonyl)-4-thiazolidinyl]-4-thiomorpholinylmethanone (CAS no. 1259167-90-2); [(2S,4R)-1-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-fluoro-2-pyrrolidinyl]-4-morpholinylmethanone (CAS no. 1941933-69-2); [3-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 2174528-45-9); and [1 -[(4-ethoxy-3-pyridinyl)sulfonyl]-2-pyrrolidinyl]-4-thiomorpholinylmethanone (CAS no. 1945338-12-4).
1) A first aspect of the invention relates to compounds of the Formula (I) wherein
Ring B is a 6-membered aromatic ring, wherein independently:
• in said Ring B X1 represents N or CRB2, wherein RB2 represents hydrogen, halogen (especially fluoro), or (Ci-3)alkyl (especially methyl), and X2 represents CH; [notably such X1 represents CH, C-CH3, or N]; or X1 represents CH and X2 represents N; and
• RB1 represents hydrogen, (Ci-3)alkyl (especially methyl, ethyl, or isopropyl), (Ci-3)alkoxy (especially methoxy), halogen (especially fluoro or chloro), (C2-4)al keny I (especially -CH=CH2), monocyclic (C3-e)cycl oalky I (especially cyclopropyl or cyclobutyl), or (Ci-3)fluoroalkyl (especially trifluoromethyl); and
• RB3 represents: OR01, wherein R01 represents (C2-s)alkyl (especially ethyl, propyl, isopropyl, sec-butyl, or isobutyl) that is substituted with zero, one or two (Ci)fluoroalkyl (especially difluoromethyl or trifluoromethyl); wherein R01 contains a total of at least 3 carbon atoms; [notably OR01 represents propoxy, isopropoxy, sec-butoxy, isobutoxy, (1 , 1 -d if I uoropropan-2-y l)-oxy , (3, 3-d ifl uoro-2, 2-d I methy l-propy l)-oxy , (1 ,1 ,1 -trifl uoropropan-2- yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1 ,1 , 1 ,3, 3, 3- hexafluoropropan-2-yl)-oxy; in particular OR01 represents sec-butoxy]; NRN1RN2, wherein independently:
■ RN1 represents:
• hydrogen; or
• (Ci-3)alkyl (especially methyl, ethyl, or isopropyl); and ■ RN2 represents:
• (C2-5)alkyl (especially propyl, isopropyl, sec-butyl, or fert-butyl); wherein said (C2-5)alkyl is unsubstituted, or mono- or di-substituted (especially unsubstituted or monosubstituted); wherein the substituents are independently selected from the group consisting of: (Ci)fluoroalkyl (especially trifluoromethyl), (C^cycloalkyl (especially cyclopropyl), and (Ci-3)alkoxy (especially methoxy); or
• monocyclic (C3-5)cycloalkyl (especially cyclopropyl), wherein said monocyclic (C3-5)cycloalkyl is unsubstituted or mono-substituted with (Ci-s)alkyl (especially methyl); and especially wherein the total number of carbon atoms in RN1 and RN2 is at least 3;
[notably such group NRN1RN2 represents isopropyl-amino, sec-butyl-amino, terf-butyl-amino, (l-methyl-cyclopropyl)-amino, (l-cyclopropyl-ethyl)-amino, (1 -methoxy propan-2-yl)-ami no, (1, 1 ,1 -tr if I uoropropan-2-y l)-ami no, (1 , 1 ,1 -trifl uorobu tan-2 -y I )-am I no, (1 -cy clopropy I-2, 2, 2- trifluoroethyl)-amino, (isopropyl)-(methyl)-amino, (ferf-butyl)-(methyl)-amino, (cyclopropyl)- (methyl)-amino, diethyl-amino, (ethyl)-(isopropyl)-amino, (cyclopropyl)-(ethyl)-amino, (sec- butyl)-(ethyl)-amino, diisopropyl-amino, (isopropyl)-(2-methoxyethyl)-amino, or (ethyl)-(1- methoxypropan-2-yl)-amino]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), (Ci. 2)fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoroethyl), and (Ci^)alkoxy-(Ci-3)alkyl (especially methoxymethyl); [notably such group NRN1RN2 represents pyrrolidin-1 -yl, piperidin-1 - yl, 2-methylpyrrolidin-1-yl, 2-(trifluoromethyl)pyrrolidin-1-yl, 2-methylpiperidin-1-yl, 3- fluoropiperidin-1-yl, 4-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2- (methoxymethyl)piperidin-l-yl, 2,5-dimethylpyrrolidin-1-yl, 2,3-dimethylpyrrolidin-1-yl, 2-ethyl-5- methylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1 -yl, azepan-1-yl, 3-methylmorpholin-4-yl, 3-(2,2,2- trifluoroethyl)morpholin-4-yl, or 3,5-dimethylmorpholin-4-yl]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom; [notably such group NRN1RN2 represents 2-azabicyclo[2.2.1]heptan-2-yl, 7- azabicyclo[2.2.1 heptan-7-yl, 2-oxa-5-azabicyclo[2.2.2]octan-5-yl, or 3-oxa-8- azabicyclo[3.2.1]octan-8-yl)]; or a saturated or mono-unsaturated monocyclic (C5-z)cycloalkyl (notably cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1 -yl, cycloheptyl, or cyclohept-1-en-1-yl); wherein said (C4-6)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently (Ci-s)al ky I (especially methyl) or halogen (especially fluoro); [notably such RB3 represents cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1-yl, cycloheptyl, cyclohept-1-en-1-yl, 2-methylcyclohexyl, 2-methylcyclohex-1- en-1 -yl, 6-methylcyclohex-1-en-1-yl, 4,4-dimethylcyclohex-1-en-1-yl, or 4,4-difluorocyclohex-1-en-1-yl]; or 5,6-dihydro-2H-pyran-3-yl; or a saturated or mono-unsaturated bridged bicyclic (C6-8)cycloalkyl; [notably such RB3 represents bicyclo[2.2.1 ]heptanyl or bicyclo[2.2.1 ]hept-2-en-2-yl]; or phenyl or 5- or 6-membered heteroaryl comprising one to three ring heteroatoms independently selected from N, 0, and S (notably isothiazolyl, oxazolyl, pyrazolyl, triazolyl, pyridinyl, or pyrazinyl); wherein said phenyl or 5- or 6-membered heteroaryl is independently unsubstituted, or mono-, or di- or tri-substituted (especially mono-, di- or tri-substituted, wherein especially at least one substituent is in para position with regard to the point of attachment of the rest of the molecule); wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro or chloro), (Ci-s)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), (Ci-3)alkoxy (especially methoxy), (Ci^)fluoroalkyl (especially trifluoromethyl), (Ci-3)fluoroalkoxy (especially trifluoromethoxy), and cyano; [notably such RB3 represents phenyl, 2-methylphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-cy anophenyl, 2-methoxyphenyl, 2- (trifluoromethoxy)phenyl, 4-fluorophenyl, 2-fluoro-3-methylphenyl, 2,3-difluorophenyl, 2-chloro-3- fluorophenyl, 3-chloro-2-fluorophenyl, 4-fluoro-2-methoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-dimethylphenyl, 2-fluoro-6-methylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 2-fluoro-6- methoxyphenyl, isothiazol-3-yl, 4-methylisothiazol-3-yl, oxazol-2-yl, 5-methyloxazol-2-yl, 5-methyl-1 H- pyrazol-1-yl, 5-ethyl-1 H-pyrazol-1-yl, 5-cyclopropyl-1 H-pyrazol-1-yl, 2/7-1,2,3-triazol-2-yl, 2-methylpyridin- 3-yl, 2-fluoropyridin-3-yl, 2-chloropyridin-3-yl, 2-cyanopyridin-3-yl, 4-methylpyridin-3-yl, 4-fluoropyridin-3- yl, 4-chloropyridin-3-yl, 4-cyanopyridin-3-yl, 3-methylpyridin-2-yl, 3-fluoropyridin-2-yl, 3-chloropyridin-2-yl, 3-(trifluoromethyl)pyridin-2-yl, 3-methoxypyridin-2-yl, 2-chloro-4-methylpyridin-3-yl, 2,4-difluoropyridin-3- yl, 3-methylpyrazin-2-yl, 3-fluoropyrazin-2-yl, or 3-methoxypyrazin-2-yl]; and
X3 represents 0 or NRN3, wherein RN3 represents hydrogen, (Ci-s)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom (especially oxetanyl or tetrahydrofuranyl), a 5-membered saturated bridged bicyclic cycloalkyl (especially bicyclo[1.1.1]pentanyl), phenyl, or pyridinyl; [notably X3 represents 0, N-methyl, NH, or N-cyclopropyl]; and
X4 represents CH or N such that: when X4 represents CH, Ring A represents a monocyclic (C5-6)cycloalkan-diyl; or when X4 represents N, Ring A represents: • a 4- to 7-membered (notably 5- to 7-membered) saturated monocyclic heterocycloalkan-diyl comprising X4, and zero or one further ring heteroatom selected from 0 or S (especially azetidin-diyl, pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl; in particular pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl); wherein said saturated heterocycloalkan-diyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-s)alkyl (especially methyl), halogen (especially fluoro), (Ci^alkoxy (especially methoxy), (Ci-3)alkylidene (especially H2C=), and oxo; [notably such Ring A represents azetidin-1 ,2- diyl, 4-methylazetidin-1 ,2-diyl, 3,3-difluoroazetidin-1 ,2-diyl, pyrrolidin-1 ,2-diyl, 5-methylpyrrolidin-1,2- diyl, 4-methylpyrrolidin-1,2-diyl, 4-fluoropyrrolidin-1 ,2-diyl, 3-fluoropyrrolidin-1 ,2-diyl, 4- methoxypyrrolidin-1,2-diyl, 4-methylenepyrrolidin-1 ,2-diyl, 4-oxopyrrolidin-1 ,2-diyl, 4,4- dimethy I pyrrol idi n- 1 ,2-diyl, 4, 4-d ifluoropy rrol id I n- 1 ,2-diyl, piperidin-1 ,2-diyl, azepan-1 ,2-diyl, thiazolidin-2,3-diyl, thiazolidin-3,4-diyl, oxazolidin-3,4-diyl, oxazolidin-2,3-diyl, 1 ,3-oxazinan-2,3-diyl, or morpholin-3,4-diyl]; or
• a 4- to 6-membered (notably 5-membered) mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring N atom (especially dihydro-1 /7-pyrrol-diyl, dihydropyridin- 1 (2/-/)-diyl, or dihydro-1 /7-pyrazol-diyl); wherein the double bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4; wherein said mono-unsaturated heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci-s)alkyl (especially methyl); [notably such Ring A represents 2, 5-d i hydro- 1 /7-py rrol- 1 ,2-diyl, 2, 3-d i hydro- 1 /7-py rrol- 1 ,5-diyl, 3, 6-d I hydropy ri di n-1 (2/7)- 1 ,2-diyl, 4,5-dihydro-1 H-pyrazol-1 ,5-diyl, or 3-methyl-4,5-dihydro-1 /7-pyrazol-1,5-diyl]; or
• a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom (notably hexahydrocyclopenta[b]pyrrol-1 (2/7),2-diy I, hexahydro-4/-/- furo[3,2-b]pyrrol-4,5-diyl, azabicyclo[2.1.1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, or azaspiro[2.4]heptan-diyl; in particular azabi cyclo [2.1 .1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, azaspiro[2.4]heptan-diyl, or 6- azaspiro[2.5]octan-diyl); wherein said bicyclic heterocycloalkan-diyl is unsubstituted, or monosubstituted with (Ci-s)alkyl (especially methyl) or di-substituted with fluoro; [notably such Ring A represents hexahydrocyclopenta[b]pyrrol-1 (2/7),2-diyl, hexahydro-4H-furo[3,2-b]pyrrol-4,5-diyl, 4- methyl-2-azabicyclo[2.1 ,1]hexan-1 ,2-diyl, 2-azabicyclo[3.1.0]hexan-2,3-diyl, 3- azabicyclo[3.1 .0] hexan-2, 3-diy 1 , 2-azabicyclo[2.2.1 ]heptan- 1 ,2-diyl, 5-azaspi ro[2.4]heptan-4, 5-diy 1, 5- azaspiro[2.4]heptan-5,6-diyl, 1, 1-difluoro-5-azaspiro[2.4]heptan-5,6-diyl, or 6-azaspiro[2.5]octan-5,6- diyl]; and
R1 represents: hydrogen; or (Ci-3)alkyl (especially methyl or ethyl); wherein said (Ci-3)alkyl is unsubstituted, or mono-substituted with (Ci-3)alkoxy (especially methoxy); and
R2 represents: (Ci-6)alkyl (especially linear (C2-e)alkyl or branched (C3-e)alkyl); wherein said (Ci-e)alkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently halogen (especially fluoro or chloro) or (Ci-3)alkoxy (especially methoxy); or -(CH2)q-Cy1; wherein q is 0 or 1 (especially 0) and Cy1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl or isopropyl), (Ci-3)alkoxy (especially methoxy), cyano, and hydroxy; [notably such R2 represents (cyclopropyl)methyl, 2- isopropylcyclopropyl, (2-trifluoromethyl)-cyclopropyl, (difluorocyclopropyl)methyl, cyclobutyl, (cyclobutyl)methyl, 3-(trifluoromethyl)cyclobutyl, 3-(difluoromethyl)cyclobutyl, 3-methoxycyclobutyl, 3,3- dimethylcyclobutyl, 3,3-difluorocyclobutyl, (3,3-difluorocyclobutyl)methyl, (cyclopentyl)methyl, 1- cyanocyclopentyl, 1 -fluorocyclopentyl, 2-fluorocyclopentyl, 2-methoxycyclopentyl, 2-cyanocyclopentyl, 3- fluorocyclopentyl, 3-cyanocyclopentyl, 3-hydroxycyclopentyl, 3-methoxycyclopentyl, (1- fluorocyclopentyl)methyl, 3,3-dimethylcyclopentyl, 3,3-difluorocyclopentyl, cyclohexyl. 1 -methylcyclohexyl,
2-methylcyclohexyl, 2-hydroxycyclohexyl, 2-methoxycyclohexyl, 3-methylcyclohexyl, 3-hydroxycyclohexyl,
3-methoxycyclohexyl, 3-cyanocyclohexyl, 4-methylcyclohexyl, 4-hydroxycyclohexyl, 4-methoxycyclohexyl, 4, 4-di methylcyclohexyl, 4,4-difluorocyclohexyl, or cycloheptyl]; or -(CH2)n-Cy2; wherein n is 0 or 1 (especially 0) and Cy2 represents a 4- to 7-membered saturated or monounsaturated (especially saturated) monocyclic heterocycle comprising one ring heteroatomic group selected from -O-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- (notably said heterocycle is oxetanyl, tetrahydrofuranyl, tetrahydro-2/7-pyranyl, 3,6-dihydro-2/7-pyranyl, tetrahydro-2H-thiopyran-1,1 -dioxide, 1- imino-1-oxidohexahydro-1-A6-thiopyranyl, or 1 -methylimino-1-oxidohexahydro-1-A6-thiopyranyl); in particular said heterocycle is tetrahydrofuranyl, tetrahydro-2/7-pyranyl, or tetrahydro-2/7-thiopyran-1,1- dioxide); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci^)fluoroalkyl (especially difluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl), and (Ci-3)alkoxy (especially methoxy); [notably such R2 represents [3-(difluoromethyl)oxetan-3-yl]methyl, tetrahydrofuran-3-yl, 3-methyltetrahydrofuran-3-yl, (3- methyltetrahydrofuran-3-yl)methyl, tetrahydro-2/7-pyran-4-yl, (tetrahydro-2H-pyran-3-yl)methyl, (tetrahydro-2H-pyran-4-yl)methyl, 4-methyltetrahydro-2H-pyran-4-yl, 3-methyltetrahydro-2/7-pyran-4-yl, 3- methoxytetrahydro-2H-pyran-4-yl, 2-methyltetrahydro-2/7-pyran-4-yl, 5,5-difluorotetrahydro-2H-pyran-2-yl, 6,6-dimethyltetrahydro-2/7-pyran-3-yl, 2,6-dimethyltetrahydro-2/7-pyran-3-yl, 2,6-dimethyltetrahydro-2/-/- pyran-4-yl, 2J2-dimethyltetrahydro-2/7-pyran-4-yl, 5-fluoro-3,6-dihydro-2/-/-pyran-2-yl, 1 ,1- dioxidotetrahydro-2/7-thiopyran-4-yl, 1-imino-1-oxidohexahydro-1-A6-thiopyran-4-yl, or 1-methylimino-1- oxidohexahydro-1-A6-thiopyran-4-yl]; or -(CH2)m-Cy3; wherein m is 0 or 1 (especially 0) and Cy3 represents a saturated spiro, fused, or bridged bicyclic (C^cycloalkyl (notably bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, spiro[3.3]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[2.2.1]heptanyl, spiro[2.4]heptanyl, or spiro[2.5]octanyl); wherein said bicyclic (Cs-sjcycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from halogen (especially fluoro) or (Ci^alkyl (especially methyl); [notably such R2 represents bicyclo[1 .1 .1]pentan-1-yl, 3-methylbicyclo[1 .1 .1]pentan-1-yl, bicyclo[3.1.0]hexan-2-yl, spiro[2.3]hexan-5-yl, 1 ,1-difluorospiro[2.3]hexan-5-yl, spiro[3.3]heptan-2-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[2.2.1]heptan-2-yl, bicyclo[2.2.1]heptan-1-yl, (bicyclo[2.1.1]hept-2-yl)methyl, spiro[2.4]heptan-5-yl, 1 , 1-difluorospiro[2.4]heptan-5-yl, spiro[2.4]heptan-1-yl, spiro[2.5]octan-4-yl, spiro[2.5]octan-6-yl, or 1 ,1- difluorospiro[2.5]octan-6-yl]; or a 7-membered saturated spiro or bridged bicyclic heterocycle comprising one ring oxygen atom (notably 2- oxaspiro[3.3]heptanyl or 7-oxabicyclo[2.2.1]heptanyl); [notably such R2 represents 2-oxaspiro[3.3]heptan- 6-yl or 7-oxabicyclo[2.2.1]heptan-2-yl]; or
R1 and R2 together with the nitrogen to which they are attached form:
• a 5- or 6-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S (notably said 5- or 6-membered heterocycle is pyrrolidine, piperidine, thiazolidine, thiomorpholine, or morpholine); wherein said 5- or 6-membered heterocycle is unsubstituted, or mono-, di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: hydroxy, (Ci-3)fluoroalkyl (especially trifluoromethyl), halogen (especially fluoro), (Ci^alkyl (especially methyl), (Ci-3)alkyl-(Ci-3)alkoxy (especially methoxymethyl or ethoxymethyl), ethynyl, and (Ci-3)alkoxy (especially methoxy or ethoxy); [notably such heterocycle represents 2-(methoxymethyl)pyrrolidin-1 -yl, 2-(ethoxymethyl)pyrrolidin-1 - yl, 3-methylpyrrolidin-1 -yl, 2,3-dimethylpyrrolidin-1 -yl, 2,5-dimethylpyrrolidin-1-yl, 3,3- dimethylpyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, 4,4-difluoro-2-methylpyrrolidin-1-yl, 2- methylpiperidin-1 -yl, 2-(methoxymethyl)piperidin-1-yl, 3-methylpiperidin-1-yl, 3-fluoropiperidin-1-yl, 3- hydroxypiperidin-1-yl, 4-methylpiperidin-1-yl, 4-fluoropiperidin-1 -yl, 4-(trifluoromethyl)piperidin-1 -yl, 4- ethynylpiperidin-1-yl, 3,3-difluoropiperidin-1-yl, 4,4-dimethylpiperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-methoxy-3,3-dimethylpiperidin-1 -yl, thiazolidin-3-yl, thiomorpholin-4-yl, 2- (methoxymethyl)morpholin-4-yl, 2-(trifluoromethyl)morpholin-4-yl, or 3,5-dimethylmorpholin-4-yl]; or
• a 7- to 11-membered (especially 8-membered) saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms (notably said heterocycle is 2- azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan-
6-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan- 2-yl, 1-oxa-6-azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8- azaspiro[5.5]undecan-8-yl, 3-oxa-9-azaspiro[5.5]undecan-9-yl, 1 ,4-dioxa-8-azaspiro[4.6]undecan-8- yl, 8-oxa-2-azaspiro[4.5]decan-2-yl, or 8-azaspiro[4.5]decan-8-yl; in particular said heterocycle is 6- azaspiro[2.5]octan-6-yl); wherein said heterocycle is unsubstituted or mono-substituted with hydroxy; or
• an 8- to 10-membered saturated or mono-unsaturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom (notably said heterocycle is hexahydrocyclopenta[c]pyrrol-2(1 /-/)-yl, octahy d roq ui nol I n-1 (2/7)-y I , hexahy d rofu ro[3, 2-c] py rid I n- 5(4/-/)-yl, or 1 ,3,3a, 4,7, 7a-hexahydro-2/-/-isoindol-2-yl); or
• a 7- to 9-membered (especially 7- to 8-membered) saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom (notably said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3- oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; in particular said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl or 8-azabicyclo[3.2.1]octan-8-yl); wherein said 7- to 9-membered bridged heterocycle is unsubstituted, or mono-, di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: hydroxy, halogen (especially fluoro), (Ci^)alkyl (especially methyl), and (Ci -3)alkoxy (especially methoxy or ethoxy); [notably such 7- to 9-membered bridged heterocycle represents 7-azabicyclo[2.2.1]heptan-7-yl, 2-hydroxy-7-azabicyclo[2.2.1]heptan-
7-yl, 2-methoxy-7-azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-methyl-8- azabicyclo[3.2.1]octan-8-yl, 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl, 3-ethoxy-8- azabicyclo[3.2.1]octan-8-yl, 3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl, 1 ,3,3-trimethyl-8- azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 9-aza-bicyclo[3.3.1]non-9-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl]; or
• a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms (notably 2-azaadamantan-2-yl or 2-oxa-6-azaadamantan-6-yl); with the exception of the following compounds: 1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-piperidinecarboxamide (CAS no. 2174271-82-8); 1 -([1 ,1 '-biphenyl]-2-ylsulfonyl)-N-methyl-2-piperidinecarboxamide (CAS no. 2421462-12-4); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-pyrrolidinecarboxamide (CAS no. 1956132-61-8); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 1951549-56-6); 1 -([1 ,T-biphenyl]-2-ylsulfonyl)-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 2180339-78-8); N-cyclopropyl-1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-2-pyrrolidinecarboxamide (CAS no. 1957026-44-6); 1-([1JT-biphenyl]-2-ylsulfonyl)-N-propyl-2-pyrrolidinecarboxamide (CAS no. 1101182-03-9); 1-[(4-ethoxy-3-pyridinyl)sulfonyl]-2-(methoxymethyl)-N-methyl-2-pyrrolidinecarboxamide (CAS no. 2223951-41-3); N,N-diethyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 1444098-57-0); N-(1 , 1-dimethylethyl)-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 2175321- 07-8); N-cyclopropyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-4-thiazolidinecarboxamide (CAS no. 1953618- 16-0); 3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-N-(1-methylethyl)-4-thiazolidinecarboxamide (CAS no. 2174321-10-7); 3-([1 ,T-biphenyl]-2-ylsulfonyl)-N-cyclopropyl-N-methyl-4-thiazolidinecarboxamide (CAS no. 1315694-49- 5); 3-([1 JT-biphenyl]-2-ylsulfonyl)-N-(2-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1315666-22-8); 3-([1 JT-biphenyl]-2-ylsulfonyl)-N-(cyclopropylmethyl)-4-thiazolidinecarboxamide (CAS no. 1316038-32-0); 3-([1 ,T-biphenyl]-2-ylsulfonyl)-N-(1-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1316017-19-2); [3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 1948116-54-8); [1-([1,1'-biphenyl]-2-ylsulfonyl)-2-piperidinyl]-1 -pyrrolidinylmethanone (CAS no. 1277333-36-4); [3-([1,T-biphenyl]-2-ylsulfonyl)-4-thiazolidinyl]-4-thiomorpholinylmethanone (CAS no. 1259167-90-2); [(2S,4R)-1-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-fluoro-2-pyrrolidinyl]-4-morpholinylmethanone (CAS no. 1941933-69-2); [3-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 2174528-45-9); and [1 -[(4-ethoxy-3-pyridinyl)sulfonyl]-2-pyrrolidinyl]-4-thiomorpholinylmethanone (CAS no. 1945338-12-4).
The compounds of Formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, which may be present in (R)- or (S)-configuration. The compounds of Formula (I) may further encompass compounds with one or more double bonds which may be present in Z- or E-configuration and/or compounds with substituents at a ring system which may be present, relative to each other, in cis- or transconfiguration. The compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
In case a particular compound (or generic structure) is designated as (R)- or (S)-enantiomer, such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, enantiomeric form. Likewise, in case a specific asymmetric center in a compound is designated as being in (R)- or (S)-configuration or as being in a certain relative configuration, such designation is to be understood as referring to the compound that is in enriched, especially essentially pure, form with regard to the respective configuration of said asymmetric center. In analogy, cis- or trans-designations are to be understood as referring to the respective stereoisomer of the respective relative configuration in enriched, especially essentially pure, form. In case a particular compound (or generic structure) contains one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, which may be present in (R)- or (S)-configuration, but where one (or more) of said stereogenic or asymmetric centers is not explicitly designated as (R)- or (S)-, it is understood that said stereogenic or asymmetric center may be in (R)- or (S)-configuration. Such compound name or generic structure is understood to encompass the compound I generic structure where such center is in (R)- or (S)- configuration, or any mixture of epimers with regard to such center. Likewise, in case such stereogenic or asymmetric center is designated as being in (RS)-configuration, this means that such stereogenic or asymmetric center in such compound may be present in (R)-configuration, in (S)-configuration, or in any mixture of epimers with regard to such center. In case two or more such stereogenic or asymmetric centers (in undesignated or designated (RS)-configuration) are present in one molecule, it is understood that the order of absolute configuration does not indicate any defined relative configuration with regard to the two or more centers.
In case any defined relative configuration with regard to the two or more centers is present, such centers are denominated with (R*,R*) or (R*,S*) nomenclature indicating in the first instance that the respective centers are either (R,R) or (S,S), and in the second instance that the respective centers are either (R,S) or (S,R), in each case encompassing any mixture of these stereoisomers including the racemate. It is understood that explicitly designated (R)- or (S)-configuration, undesignated or designated (RS)-configuration, and relative (R*,R*)- or (R*,S*)- configuration can co-exist in one and the same molecule and are to be interpreted accordingly. For example, the compound (2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide encompasses enantiomerically enriched (2R,4R)-1-[2-(Ethyl- isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide, (2S,4S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide, or any mixture of these stereoisomers of said compound.
In case a particular compound (or generic structure) is designated as Z- or E-stereoisomer (or in case a specific double bond in a compound is designated as being in Z- or E-configuration), such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, stereoisomeric form (or to the compound that is in enriched, especially essentially pure, form with regard to the respective configuration of the double bond).
In case a particular compound (or generic structure) is designated as Sa- or Ra-stereoisomer (i.e., designating an conformational isomer, or atropisomer, arising from a hindered rotation around a single bond), such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, stereoisomeric form.
The term "enriched", when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a ratio of at least 70:30, especially of at least 90: 10 (i.e., in a purity of at least 70% by weight, especially of at least 90% by weight), with regard to the respective other stereoisomer I the entirety of the respective other stereoisomers.
The term "essentially pure”, when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a purity of at least 95% by weight, especially of at least 99% by weight, with regard to the respective other stereoisomer I the entirety of the respective other stereoisomers.
The present invention also includes isotopically labelled, especially 2H (deuterium) labelled compounds of Formula (I) according to embodiments 1) to 27), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially 2H (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
In this patent application, a bond drawn as a dotted line shows the point of attachment of the radical drawn. For example, the radical drawn below is the 4,4-difluorocyclohexyl group.
In some instances, the compounds of Formula (I) may contain tautomeric forms. Such tautomeric forms are encompassed in the scope of the present invention. In case tautomeric forms exist of a certain residue, and only one form of such residue is disclosed or defined, the other tautomeric form(s) are understood to be encompassed in such disclosed residue.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.
Any reference to compounds of Formula (I) according to embodiments 1) to 27) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see for example "Handbook of Pharmaceutical Salts. Properties, Selection and Use.”, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and "Pharmaceutical Salts and Co-crystal s”, Johan Wouters and Luc Quere (Eds.), RSC Publishing, 2012.
Definitions provided herein are intended to apply uniformly to the compounds of Formula (I), as defined in any one of embodiments 1) to 27), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein.
Whenever a substituent is denoted as optional, it is understood that such substituent may be absent, in which case all positions having a free valency (to which such optional substituent could have been attached to; such as for example in an aromatic ring the ring carbon atoms and I or the ring nitrogen atoms having a free valency) are substituted with hydrogen where appropriate.
The term "halogen” means fluorine, chlorine, bromine, or iodine; especially fluorine, chlorine, or bromine; preferably fluorine or chlorine.
The term "alkyl”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated straight or branched chain hydrocarbon group containing one to six carbon atoms. The term “(Cx-y)alkyl” (x and y each being an integer), refers to an alkyl group as defined before, containing x to y carbon atoms. For example a (Ci-e)alkyl group contains from one to six carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, fert-butyl, 3-methyl-butyl, 2,2-dimethyl-propyl, and 3,3-dimethyl-butyl. For avoidance of any doubt, in case a group is referred to as e.g. propyl or butyl, it is meant to be n-propyl, respectively n-butyl. Preferred are methyl and ethyl. Most preferred is methyl. Examples of RB1 representing (Ci-3)alkyl are methyl, ethyl, and isopropyl. An example of RB2 representing (Ci-3)alkyl is methyl. Examples of R01 representing (C2-5)alkyl are ethyl, propyl, isopropyl, sec-butyl, and isobutyl; such R01 representing (C^alkyl may be unsubstituted or substituted as explicitly defined. Examples of RN1 representing (Ci-s)alkyl are methyl, ethyl, and isopropyl. Examples of RN2 representing (C^alkyl are propyl, isopropyl, sec-butyl, and fert-butyl; such RN2 representing (C2-5)alkyl may be unsubstituted or substituted as explicitly defined. Examples of (Ci-s)alkyl as substituent of a group RB3 are methyl and ethyl, and especially methyl. Examples of RN3 representing (Ci-s)alkyl are methyl and ethyl. An example of (Ci-s)alkyl as substituent of Ring A is methyl. Examples of R1 representing (Ci-3)alkyl are methyl and ethyl; such R1 representing (Ci-3)alkyl may be unsubstituted or substituted as explicitly defined. Examples of R2 representing (Ci-e)alkyl are methyl, ethyl, propyl, isopropyl, 2,2-dimethyl-propyl, n-butyl, 3- methyl-butyl, 3,3-dimethyl-butyl, and fert-butyl; such R2 representing (Ci^alkyl may be unsubstituted or substituted as explicitly defined. Examples of (Ci-s)alkyl as substituent of a group Cy1 are methyl and isopropyl. An example of (Ci-3)alkyl as substituent of a group Cy2 or Cy3 is methyl. An example of (Ci^)alkyl as substituent of a 5- or 6- membered saturated monocyclic heterocycle formed by R1 and R2, together with the nitrogen to which they are attached, is methyl. An example of (Ci-3)alkyl as substituent of a 7- to 9-membered saturated bridged bicyclic heterocycle formed by R1 and R2, together with the nitrogen to which they are attached, is methyl.
The term "alkoxy”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl-O- group wherein the alkyl group is as defined before. The term "(Cx-y)alkoxy” (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (Ci-4)alkoxy group means a group of the formula (Ci-4)alkyl-O- in which the term “(Ci-4)alkyl” has the previously given significance. Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, secbutoxy, and tert-butoxy. Preferred is methoxy. An example of RB1 representing (Ci -3)alkoxy is methoxy. An example of (Ci-3)alkoxy as substituent of RB3 is methoxy. An example of (Ci-3)alkoxy as substituent of Ring A is methoxy. An example of (Ci-3)alkoxy as substituent of a group R1 is methoxy. An example of (Ci-3)alkoxy as substituent of a group R2 is methoxy. Examples of (Ci-3)alkoxy as substituent of a 5- to 6-membered saturated monocyclic heterocycle formed by R1 and R2, together with the nitrogen to which they are attached, are methoxy and ethoxy. Examples of (Ci-3)al koxy as substituent of a 7- to 9-membered saturated bridged bicyclic heterocycle formed by R1 and R2, together with the nitrogen to which they are attached, are methoxy and ethoxy.
An example of a "(Ci-4)alkoxy-(C2-4)alkyl" group is methoxy methyl. Examples of (Ci^)alkyl-(Ci-3)alkoxy as substituent of a 5- or 6-membered saturated monocyclic heterocycle formed by R1 and R2, together with the nitrogen to which they are attached, are methoxymethyl and ethoxymethyl.
The term "fluoroalkyl”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term "(Cx.y fluoroalkyl” (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms. For example, a (Ci-3)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkyl groups include trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, and 2,2,2- trifluoroethyl; especially trifluoromethyl. Preferred are (Ci-3)fluoroalkyl groups such as trifluoromethyl. An example of RB1 representing (Ci-3)fluoroalkyl is trifluoromethyl. Examples of (Ci)fluoroalkyl as substituent of R01 are difluoromethyl and trifluoromethyl. An example of (Ci)fluoroalkyl as substituent of RN2 representing a (C^alkyl is trifluoromethyl. Examples of (Ci-2)fl uoroalky I as substituent of a 5- to 7-membered saturated monocyclic heterocycle formed by RN1 and RN2, together with the nitrogen to which they are attached, are trifluoromethyl and 2,2,2- trifluoroethyl. An example of (Ci-3)fluoroalkyl as substituent of RB3 representing phenyl or a 5- or 6-membered heteroaryl is trifluoromethyl. Examples of (Ci-3)fluoroalkyl as substituent of Cy1 are difluoromethyl and trifluoromethyl. An example of (Ci ^fluoroalkyl as substituent of Cy2 is difluoromethyl. An example of (Ci-3)fluoroalkyl as substituent of R1 and R2 together with the nitrogen to which they are attached forming a 5- or 6- membered saturated monocyclic heterocycle (comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S) is trifluoromethyl. The term "fluoroalkoxy”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term "(Cx-y)fluoroalkoxy” (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms. For example, a (Ci-3)fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2 -fluoroethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy. Preferred are (Ci)fluoroalkoxy groups such as trifluoromethoxy and difluoromethoxy, as well as 2,2,2-trifluoroethoxy. Examples of RB3 representing OR01, wherein R01 represents (C2- s)alkyl substituted with one or two (Ci)fluoroalkyl, and wherein R01 contains a total of at least 3 carbon atoms; are (1, 1-difluoropropan-2-yl)oxy, 3,3-difluoro-2,2-dimethyl-propoxy, (1 ,1, 1-trifluoropropan-2-yl)oxy, (4,4,4- trifluorobutan-2-yl)oxy, (1 ,1 , 1 ,3, 3, 3- hexafluoropropan-2-yl)oxy. An example of (Ci-3)fluoroalkyl as substituent of RB3 representing phenyl or 5- or 6-membered heteroaryl is trifluoromethoxy.
The term "hydroxy" refers to a group -OH.
The term "cyano" refers to a group -ON.
The term "oxo" refers to a group =0 which is preferably attached to a chain or ring carbon or sulfur atom as for example in a carbonyl group -(CO)-, or a sulfonyl group -(SO2)-.
The term "(Cx-Y)alkylidene” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before, containing x to y carbon atoms, wherein said alkyl group is linked to the rest of the molecule via a double bond. An example of (Ci^alkylidene is the methylidene group =CH2.
The term "(Cx-Y)alkenyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to an alkyl group as defined before, containing x to y carbon atoms, wherein said alkyl group contains a double bond and wherein said alkyl group is linked to the rest of the molecule via a single bond. An example of a (C2-4)alkenyl is vinyl group -CHOH2.
The term "ethynyl" refers to a group -C CH.
The term "cycloalkyl”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated monocyclic hydrocarbon ring containing three to eight carbon atoms. The term " (Cx-y)cycloalky I" (x and y each being an integer), refers to a cycloalkyl containing x to y carbon atoms. For example, a (Cs ejcycloalky I group contains from three to six carbon atoms.
The term "(Cx.y)cycloalkyl", "monocyclic (Cx.y)cycloalkyl" or "saturated monocyclic (Cx.y)cycloalkyl”, refers to a saturated monocyclic cycloalkyl group as defined before, containing x to y carbon atoms. Examples of monocyclic cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Examples of RB1 representing a monocyclic (C3-4)cycloalkyl are cyclopropyl and cyclobutyl. An example of RN2 representing a monocyclic (C^cycloalkyl is cyclopropyl; such RN2 representing a monocyclic (C^cycloalkyl may be unsubstituted or substituted as explicitly defined. An example of (C^cycloalkyl as substituent of RN2 representing (C^alkyl is cyclopropyl. Examples of RB3 representing a saturated monocyclic (C4-6)cycloalkyl are cyclopentyl, cyclohexyl, and cycloheptyl; such RB3 representing a saturated monocyclic (C4-6)cycloalkyl may be unsubstituted or substituted as explicitly defined. An example of (C3-6)cycloalkyl as substituent of RB3 representing phenyl or a 5- or 6-membered heteroaryl is cyclopropyl. Examples of RN3 representing a monocyclic (C3-6)cycloalkyl are cyclopropyl, cyclopentyl and cyclohexyl.
The term "mono-unsaturated monocyclic (Cx-y)cycloalkyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a mono-unsaturated monocyclic hydrocarbon ring containing x to y carbon atoms (i.e., said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds). Examples of RB3 representing a mono-unsaturated monocyclic (C5-
7)cycloalkyl are cyclopent-1 -en-1-yl, cyclohex-1 -en-1-yl, and cyclohept-1-en-1-yl; such RB3 representing a monounsaturated monocyclic (Cs-zjcycloalkyl may be unsubstituted or substituted as explicitly defined.
The term “(Cx-y)cycloalkan-diyl” or "monocyclic (Cx-y)cycloalkan-diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to bivalently bound cycloalkyl group, as defined before, containing x to y carbon atoms. When X4 represents CH and Ring A represents a monocyclic (Cs-ejcycloalkan-diyl, the points of attachment of said (C5-6)cycloalkan-diy I in Formula (I) are on X4 and on a carbon atom neighboring X4; examples are cyclopentane-1 ,2-diyl and cyclohexane-1 ,2-diyl; such monocyclic (C5-6)cycloalkan-diyl may be unsubstituted or substituted as explicitly defined.
The term "saturated bicyclic (Cx-y)spirocycloalkyl" or "saturated spiro bicyclic (Cx.y) cycloalkyl" (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated spiro-bicyclic hydrocarbon ring containing x to y carbon atoms. Examples of R1 representing a saturated bicyclic (C6-8)spirocycloalkyl are spiro[2.3]hexanyl, spiro[3.3]heptanyl, spiro[2.4]heptanyl, and spiro[2.5]octanyl (especially spiro[2.3]hexanyl and spiro[2.5]octanyl); such saturated bicyclic (Ce-sjspirocycloalkyl may be unsubstituted or substituted as explicitly defined. Examples of Cy3 representing a saturated spiro bicyclic (C5-
8)cycloalkyl are spiro[2.3]hexanyl, spiro[3.3]heptanyl, spiro[2.4]heptanyl, and spiro[2.5]octanyl; such Cy3 may be unsubstituted or substituted as explicitly defined.
The term "saturated fused or bridged bicyclic (Cx-y)cycloalkyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated fused or bridged bicyclic hydrocarbon ring containing x to y carbon atoms. An example of RN3 representing a 5-membered saturated bridged bicyclic cycloalkyl is bicyclo[1.1.1]pentanyl. An example of RB3 representing a saturated bridged bicyclic (C6-8)cycloalkyl is bicyclo[2.2.1]heptanyl. Examples of Cy3 representing a saturated fused or bridged bicyclic (C5- 8)cycloalkyl are bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, bicyclo[4.1.0]heptanyl, and bicyclo[2.2.1]heptanyl; such Cy3 may be unsubstituted or substituted as explicitly defined. The term "mono-unsaturated bridged bicyclic (Cx-y)cycloalkyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a mono-unsaturated bridged bicyclic hydrocarbon ring containing x to y carbon atoms (i.e., said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds). An example of RB3 representing a mono-unsaturated bridged bicyclic (C6-8)cycloalkyl is bicyclo[2.2.1 ]hept-2-en-2-yl.
The term "heterocycle” or "saturated monocyclic heterocycle”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated monocyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups). The term "x- to y-membered heterocycle or "x- to y-membered saturated monocyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. Such heterocycles are unsubstituted or substituted as explicitly defined. Examples of NRN1RN2 wherein RN1 and RN2 together with the nitrogen to which they are attached form a 5- to 7- membered saturated monocyclic heterocycle are pyrrolidinyl, piperidinyl, azepanyl, and morpholinyl; such 5- to 7- membered saturated monocyclic heterocycle may be unsubstituted or substituted as explicitly defined. Examples of RN3 representing a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom are oxetanyl and tetrahydrofuranyl. Examples of Cy2 representing a 4- to 7-membered saturated monocyclic heterocycle comprising one ring heteroatomic group selected from -0-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- are oxetanyl, tetrahydrofuranyl, tetrahydro-2/7-pyranyl, tetrahydro-2/7-thiopyran-1,1 -dioxide, 1-imino-1- oxidohexahydro-1 -A6-thiopyranyl, and 1 -methylimino-1-oxidohexahydro-1 -A6-thiopyranyl; such Cy2 are substituted or unsubstituted as explicitly defined. Examples of R1 and R2, together with the nitrogen to which they are attached, forming a 5- or 6-membered saturated monocyclic heterocycle (comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S) are pyrrolidine, piperidine, thiazolidine, thiomorpholine, and morpholine; such 5- or 6-membered saturated monocyclic heterocycle may be unsubstituted or substituted as explicitly defined.
The term "mono-unsaturated monocyclic heterocycle”, used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a mono-unsaturated monocyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups), said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds. The term "x- to y-membered heterocycle or "x- to y-membered saturated monocyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. Such heterocycles are unsubstituted or substituted as explicitly defined. An example of Cy2 representing a 4- to 7-membered mono-unsaturated monocyclic heterocycle comprising one ring heteroatomic group selected from -O-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- is 3,6-dihydro-2/-/-pyranyl.
The term "saturated spiro bicyclic heterocycle", used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated spiro bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e. , such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups). The term "x- to y-membered saturated spiro bicyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. An example of R2 representing a 7-membered saturated spiro bicyclic heterocycle comprising one ring oxygen atom is 2-oxaspiro[3.3]heptanyl. Examples of R1 and R2, together with the nitrogen to which they are attached, forming a 7- to 11 -membered saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms, are 2-azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan-6-yl, 2- oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan-2-yl, 1-oxa-6- azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8-azaspiro[5.5]undecan-8-yl, 3-oxa-9- azaspiro[5.5]undecan-9-yl, 1 ,4-dioxa-8-azaspiro[4.6]undecan-8-yl, 8-oxa-2-azaspiro[4.5]decan-2-yl, and 8- azaspiro[4.5]decan-8-yl; such 7- to 11-membered saturated spiro bicyclic heterocycle may be unsubstituted or substituted as explicitly defined.
The term "saturated fused bicyclic heterocycle", used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated fused bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups). The term "x- to y-membered saturated fused bicyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. Examples of R1 and R2, together with the nitrogen to which they are attached, forming an 8- to 10-membered saturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom, are hexahydrocyclopenta[c]pyrrol-2(1 H)-yl, octahydroqui nol in- 1 (2H)-yl, and hexahydrofuro[3,2-c]py ridi n-5(4H)-yl .
The term "mono-unsaturated fused bicyclic heterocycle", used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a fused bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups), and wherein said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds. The term "x- to y-membered mono-unsaturated fused bicyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. An example of R1 and R2, together with the nitrogen to which they are attached, forming an 8- to 10-membered mono-unsaturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom, is 1 , 3, 3a, 4, 7,7a- hexahydro-2H-isoindol-2-yl.
The term "saturated bridged bicyclic heterocycle", used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated bridged bicyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups). The term "x- to y-membered saturated bridged bicyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. An example of R2 representing a 7-membered saturated bridged bicyclic heterocycle comprising one ring oxygen atom is 7-oxabicyclo[2.2.1]heptanyl. Examples of NRN1RN2 wherein RN1 and RN2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom (and zero or one additional ring oxygen atom) are 2-azabicyclo[2.2.1]heptan-2-yl, 7-azabicyclo[2.2.1 heptan-7-yl, 2-oxa- 5-azabicyclo[2.2.2]octan-5-yl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl. Examples of 7- to 9-membered saturated bridged bicyclic heterocycles formed by R1 and R2 together with the nitrogen to which they are attached (comprising said nitrogen atom and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom) are 7-azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, and 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; such 7- to 9-membered saturated bridged bicyclic heterocycle may be unsubstituted or substituted as explicitly defined.
The term "saturated bridged tricyclic heterocycle", used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a saturated bridged tricyclic hydrocarbon ring comprising one or two ring heteroatoms or heteroatomic groups independently selected from N, 0, S, or SO2; wherein it is understood that in each instance, the number and nature of ring heteroatoms or heteroatomic groups are as explicitly defined or may be defined more narrowly (i.e., such ring contains I comprises the defined ring heteroatom(s) or heteroatomic groups, and no further ring heteroatoms or heteroatomic groups). The term "x- to y-membered saturated bridged tricyclic heterocycle” (x and y each being an integer) refers to such a heterocycle containing x to y ring atoms. Examples of R1 and R2, together with the nitrogen to which they are attached, forming a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms, are 2- azaadamantan-2-yl and 2-oxa-6-azaadamantan-6-yl. The term "x- to y-membered heterocycloalkan-diyl” or "x- to y-membered saturated monocyclic heterocycloalkan- diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a bivalently bound heterocycloalkyl as defined before; wherein in each instance, the number and nature of ring heteroatoms or heteroatomic groups are explicitly defined. When X4 represents N and Ring A represents a 4- to 7-membered saturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring heteroatoms selected from 0 or S, the points of attachment of said heterocycloalkan-diyl in Formula (I) are on X4 and on the carbon atom attached to the group -CO-N(R1)(R2); examples of such Ring A are azetidin-diyl, pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, and oxazolidin-diyl; such Ring A is unsubstituted, or substituted as explicitly defined. In a particular embodiment, the carbon atom of Ring A attached to the group -CO-N(R1)(R2) is not further substituted.
The term "x- to y-membered mono-unsaturated monocyclic heterocycloalkan-diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a bivalently bound monocyclic hydrocarbon ring containing x to y ring atoms of which one or two (especially one) ring atoms are heteroatoms independently selected from N, 0, or S, and wherein said ring comprises a single unsaturated (double) bond and otherwise contains saturated bonds. When X4 represents N and Ring A represents a 4- to 6- membered mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4and zero or one further ring N atom, and no further ring heteroatoms, the points of attachment of said mono-unsaturated heterocycloalkan-diyl in Formula (I) are on X4 and on the carbon atom attached to the group -CO-N(R1)(R2); the unsaturated (double) bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4. Examples of such Ring A are 2, 5-dihy d ro- 1 H- pyrrol-1 ,2-diyl, 2,3-dihydro-1 H-pyrrol-1 ,5-diyl, 3,6-dihydropyridin-1 (2H)-1 ,2-diyl, and 4,5-dihydro-1 H-pyrazol-1,5- diyl); such Ring A may be unsubstituted or substituted as explicitly defined. In a particular embodiment, the carbon atom of Ring A attached to the group -CO-N(R1)(R2) is not further substituted.
The term "x- to y-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl” (x and y each being an integer), used alone or in combination and if not explicitly defined in a broader or more narrow way, refers to a bivalently bound saturated spiro, fused or bridged bicyclic hydrocarbon ring containing x to y ring atoms of which one or two (especially one) ring atoms are heteroatoms independently selected from N, 0, or S. When X4 represents N and Ring A represents a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom, the points of attachment of said bicyclic heterocycloalkan-diyl in Formula (I) are on X4 and on the carbon atom attached to the group -C0-N(R1)(R2). Examples of such Ring A are hexahydrocyclopenta[b]pyrrol-1 (2/-/),2-diyl, hexahydro-4H-furo[3,2-b]pyrrol-4,5-diyl, 2-azabicyclo[2.1.1]hexan-1 ,2- diyl, 2-azabicyclo[3.1.0]hexan-2,3-diyl, 3-azabicyclo[3.1.0]hexan-2,3-diyl, 2-azabicyclo[2.2.1]heptan-1 ,2-diyl, 5- azaspiro[2.4]heptan-4,5-diyl, 5-azaspiro[2.4]heptan-5,6-diyl, and 6-azaspiro[2.5]octan-5,6-diyl); such Ring A is unsubstituted, or substituted as explicitly defined. The term "aryl", used alone or in combination, means phenyl or naphthyl, especially phenyl. The above-mentioned aryl groups are unsubstituted or substituted as explicitly defined.
When RB3 represents phenyl, such phenyl may be unsubstituted or substituted as explicitly defined. When RB3 represents a mono-, di- or tri-substituted (especially mono- or di-substituted) phenyl, especially at least one of the substituent(s) is attached in para position with regard to the point of attachment of the rest of the molecule. Especially such substituent(s) in para position is/are (Ci-3)alkyl (notably methyl), halogen (notably fluoro), or (Ci-3)alkoxy (especially methoxy).
The term "heteroaryl", used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing one to a maximum of four heteroatoms (especially one to a maximum three), each independently selected from N, 0, or S. Examples of such heteroaryl groups are 5-membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, and tetrazolyl; 6-membered heteroaryl groups such as pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl; and 8- to 10-membered bicyclic heteroaryl groups such as indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, furopyridinyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, thienopyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl, imidazopyridinyl, imidazopyridazinyl, and imidazothiazolyl. The above- mentioned heteroaryl groups are unsubstituted or substituted as explicitly defined. When RB3 represents a 5- or 6- membered heteroaryl, such heteroaryl comprises one to three ring heteroatoms independently selected from N, 0, or S, wherein said heteroaryl is especially linked to the rest of the molecule via a ring carbon atom. Such RB3 is notably isothiazolyl, oxazolyl, pyrazolyl, triazolyl, pyridinyl, or pyrazinyl; such 5- or 6-membered heteroaryl may be unsubstituted or substituted as explicitly defined.
Whenever the word "between” is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. For example: if a temperature range is described to be between 40 °C and 80 °C, this means that the end points 40 °C and 80 °C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1 , 2, 3, or 4.
Unless used regarding temperatures, the term "about” placed before a numerical value "X” refers in the current application to an interval extending from X minus (10% of X) to X plus (10% of X), and preferably to an interval extending from X minus (5% of X) to X plus (5% of X). Likewise, the term "about” placed before a numerical range "X to Y” refers in the current application to an interval extending from X minus (10% of X) to Y plus (10% of Y), and preferably to an interval extending from X minus (5% of X) to Y plus (5% of Y). In the particular case of temperatures, the term "about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C. Besides, the term "room temperature” as used herein refers to a temperature of about 25°C. Further embodiments of the invention are presented hereinafter:
2) Another embodiment relates to compounds according to embodiment 1), wherein X1 represents N or CRB2, wherein RB2 represents hydrogen, halogen (especially fluoro), or (Ci-3)alkyl (especially methyl), and X2 represents CH [in particular X1 represents CH, C-CH3, or N, and X2 represents CH],
3) Another embodiment relates to compounds according to embodiment 1), wherein X1 represents CH and X2 represents N.
4) Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein RB1 represents (Ci-3)alkyl (especially methyl, ethyl, or isopropyl) or (Ci)fluoroalkyl (especially trifluoromethyl) [in particular RB1 represents methyl or trifluoromethyl].
5) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein RB3 represents: OR01, wherein R01 represents (C^alkyl (especially propyl, isopropyl, sec-butyl, or isobutyl) that is substituted with zero, one or two (Ci)fluoroal ky I (especially difluoromethyl or trifluoromethyl); [notably OR01 represents propoxy, isopropoxy, sec-butoxy, isobutoxy, (1,1-difluoropropan-2-yl)-oxy, (3,3-difluoro-2,2- dimethyl-propyl)-oxy, (1,1 , 1-trifluoropropan-2-yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1, 1 ,1 , 3,3,3— hexafl uoropropan-2-yl)-oxy; in particular OR01 represents sec-butoxy]; or NRN1RN2, wherein independently:
■ RN1 represents:
• hydrogen; or
• (Ci-3)alkyl (especially methyl, ethyl, or isopropyl); and
■ RN2 represents:
• (C2-5)alkyl (especially propyl, isopropyl, sec-butyl, or fert-butyl); wherein said (C2-5)alkyl is unsubstituted, or mono- or di-substituted (especially unsubstituted or monosubstituted); wherein the substituents are independently selected from the group consisting of: (Ci)fluoroalkyl (especially trifluoromethyl), (C^cycloalkyl (especially cyclopropyl), and (Ci-3)alkoxy (especially methoxy); or
• monocyclic (C3-5)cycloalkyl (especially cyclopropyl), wherein said monocyclic (C3-5)cycloalkyl is unsubstituted or mono-substituted with (Ci-3)alkyl (especially methyl); and especially wherein the total number of carbon atoms in RN1 and RN2 is at least 3;
[notably such group NRN1RN2 represents isopropyl-amino, sec-butyl-amino, terf-butyl-amino, (l-methyl-cyclopropyl)-amino, (l-cyclopropyl-ethyl)-amino, (1 -methoxy propan-2-yl)-ami no, (1, 1 ,1 -tr if I uoropropan-2-y l)-ami no, (1 , 1 ,1 -trifl uorobu tan-2 -y I )-am i no, (1 -cy clopropy I-2, 2, 2- trifluoroethyl)-amino, (isopropyl)-(methyl)-amino, (ferf-butyl)-(methyl)-amino, (cyclopropyl)- (methyl)-amino, diethyl-amino, (ethyl)-(isopropyl)-amino, (cyclopropyl)-(ethyl)-amino, (sec- butyl)-(ethyl)-amino, diisopropyl-amino, (isopropyl)-(2-methoxyethyl)-amino, or (ethyl)-(1- methoxypropan-2-yl)-amino]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), (Ci. 2)fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoroethyl), and (Ci-3)alkoxy-(Ci-3)alkyl (especially methoxymethyl); [notably such group NRN1RN2 represents pyrrolidin-1 -yl, piperidin-1 - yl, 2-methylpyrrolidin-1-yl, 2-(trifluoromethyl)pyrrolidin-1-yl, 2-methylpiperidin-1-yl, 3- fluoropiperidin-1-yl, 4-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2- (methoxymethyl)piperidin-l-yl, 2,5-dimethylpyrrolidin-1-yl, 2,3-dimethylpyrrolidin-1-yl, 2-ethyl-5- methylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1 -yl, azepan-1-yl, 3-methylmorpholin-4-yl, 3-(2,2,2- trifluoroethyl)morpholin-4-yl, or 3,5-dimethylmorpholin-4-yl]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom; [notably such group NRN1RN2 represents 2-azabicyclo[2.2.1]heptan-2-yl, 7- azabicyclo[2.2.1 heptan-7-yl, 2-oxa-5-azabicyclo[2.2.2]octan-5-yl, or 3-oxa-8- azabicyclo[3.2.1]octan-8-yl)]; or a saturated or mono-unsaturated monocyclic (Cs-zjcycloalkyl (notably cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1 -yl, cycloheptyl, or cyclohept-1-en-1-yl); wherein said (C4-6)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently (Ci-3)al ky I (especially methyl) or halogen (especially fluoro); [notably such RB3 represents cyclopentyl, cyclopent-1 -en-1-yl, cyclohexyl, cyclohex-1 -en-1-yl, cycloheptyl, cyclohept-1-en-1-yl, 2-methylcyclohexyl, 2-methylcyclohex-1- en-1 -yl, 6-methylcyclohex-1-en-1-yl, 4,4-dimethylcyclohex-1-en-1-yl, or 4,4-difluorocyclohex-1-en-1-yl]; or 5,6-dihydro-2H-pyran-3-yl; or a saturated or mono-unsaturated bridged bicyclic (Ce-sjcycloalkyl; [notably such RB3 represents bicyclo[2.2.1 ]heptanyl or bicyclo[2.2.1 ]hept-2-en-2-yl]; or phenyl; wherein said phenyl is mono-, di- or tri-substituted (notably mono- or di-substituted; in particular wherein at least one substituent is in para position with regard to the point of attachment of the rest of the molecule); wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro or chloro), (Ci^)alkyl (especially methyl), (Ci-3)alkoxy (especially methoxy), (Ci-3)fluoroalkoxy (especially trifluoromethoxy), and cyano; [notably such RB3 represents 2-methyl phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-cy anophenyl, 2-methoxyphenyl, 2-(trifluoromethoxy)phenyl, 4- fluorophenyl, 2-fluoro-3-methylphenyl, 2,3-difluorophenyl, 2-chloro-3-fluorophenyl, 3-chloro-2- fluorophenyl, 4-fluoro-2-methoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-dimethylphenyl, 2- fluoro-6-methyl phenyl, 2-chloro-6-methylpheny 1, 2,6-difluorophenyl, or 2-fluoro-6-methoxyphenyl]; or 5- or 6-membered heteroaryl selected from isothiazolyl, oxazolyl, pyrazolyl, triazolyl, pyridinyl, or pyrazinyl (in particular from isothiazolyl, pyrazolyl, pyridinyl, or pyrazinyl); wherein said 5- or 6-membered heteroaryl is independently unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro or chloro), (Ci-3)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), (Ci-3)alkoxy (especially methoxy), (Ci^)fluoroalkyl (especially trifluoromethyl), and cyano; [notably such RB3 represents isothiazol-3-yl, 4-methylisothiazol-3- yl, oxazol-2-yl, 5-methyloxazol-2-yl, 5-methyl-1 H-pyrazol-1-yl, 5-ethyl-1 H-pyrazol-1-yl, 5-cyclopropyl-1 H- pyrazol-1-yl, 2/7-1 ,2,3-triazol-2-yl, 2-methylpyridin-3-yl, 2-fluoropyridin-3-yl, 2-chloropyridin-3-yl, 2- cyanopyridin-3-yl, 4-methylpyridin-3-yl, 4-fluoropyridin-3-yl, 4-chloropyridin-3-yl, 4-cyanopyridin-3-yl, 3- methylpyridin-2-yl, 3-fluoropyridin-2-yl, 3-chloropyridin-2-yl, 3-(trifluoromethyl)pyridin-2-yl, 3- methoxypyridin-2-yl, 2-chloro-4-methylpyridin-3-yl, 2,4-difluoropyridin-3-yl, 3-methylpyrazin-2-yl, 3- fluoropyrazin-2-yl, or 3-methoxypyrazin-2-yl; in particular such RB3 represents 4-methylisothiazol-3-yl, 5- ethyl-1/7-pyrazol-1-yl, 2-methylpyridin-3-yl, 2-chloro-4-methylpyridin-3-yl, 2,4-difluoropyridin-3-yl, 3- methylpyrazin-2-yl, or 3-fluoropyrazin-2-yl],
6) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein RB3 represents: propoxy, isopropoxy, sec-butoxy, isobutoxy, (1 ,1-difluoropropan-2-yl)-oxy, (3,3-difluoro-2,2-dimethyl- propyl)-oxy, (1 ,1 ,1-trifluoropropan-2-yl)-oxy, (4,4,4-trifluorobutan-2-yl)-oxy, or (1 , 1 ,1 , 3,3,3- hexafluoropropan-2-yl)-oxy [in particular RB3 represents sec-butoxy]; or NRN1RN2, wherein independently:
■ RN1 represents:
• hydrogen; or
• (Ci-3)alkyl (especially methyl, ethyl, or isopropyl); and
■ RN2 represents:
• unsubstituted (C^alkyl (especially propyl, isopropyl, sec-butyl, or fert-butyl); especially wherein the total number of carbon atoms in RN1 and RN2 is at least 3; [in particular such group NRN1RN2 represents (ethyl)-(isopropyl)-amino, diisopropyl-amino, (isopropyl)- (methyl)-amino, isopropyl-amino, or fert-butyl-amino]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom (especially pyrrolidinyl, piperidinyl, azepanyl, or morpholinyl); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl) and (Ci. 2)fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoroethyl); [in particular such group NRN1RN2 represents piperidin-1-yl, 2-methylpiperidin-1-yl, 2-(trifluoromethyl)piperidin-1-yl, 2,5- dimethylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1-yl, azepan-1-yl, or 3,5-dimethylmorpholin-4-yl]; or a saturated monocyclic (C4-e)cycloalkyl (notably cyclohexyl); wherein said saturated (C4-6)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently (Ci-s)al ky I (especially methyl); or a mono-unsaturated monocyclic (Ce-zjcycloalkyl (notably cyclohex-1 -en-1-yl, or cyclohept-1-en-1-yl); wherein said mono-unsaturated (Ce-zjcycloalkyl is unsubstituted, or mono-substituted with (Ci-s)alkyl (especially methyl); [in particular such RB3 represents cyclohex-1 -en-1-yl, cyclohept-1-en-1-yl, or 2- methylcyclohex-1-en-1-yl]; or a mono-unsaturated bridged bicyclic (Cz)cycloalkyl [in particular such RB3 represents bicyclo[2.2.1 ]hept-2- en-2-yl]; or phenyl; wherein said phenyl is mono- or di-substituted (in particular wherein at least one substituent is in para position with regard to the point of attachment of the rest of the molecule); wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro or chloro), (Ci-3)alkyl (especially methyl), and (Ci^alkoxy (especially methoxy); [notably such RB3 represents 2-methyl phenyl,
2-fluorophenyl, 2-methoxyphenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-6- methylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, or 2-fluoro-6-methoxyphenyl]; or 5- or 6-membered heteroaryl selected from isothiazolyl, oxazolyl, pyrazolyl, triazolyl, pyridinyl, or pyrazinyl (in particular from isothiazolyl, pyrazolyl, pyridinyl, or pyrazinyl); wherein said 5- or 6-membered heteroaryl is mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro or chloro) and (Ci-s)alkyl (especially methyl or ethyl); [notably such RB3 represents 4-methylisothiazol-3-yl, 5-ethyl-1 H-pyrazol-1 -yl, 2-methylpyridin-3-yl, 2-chloro-4-methylpyridin-
3-yl, 2,4-difluoropyridin-3-yl, 3-methylpyrazin-2-yl, or 3-fluoropyrazin-2-yl],
7) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein RB3 represents: NRN1RN2, wherein independently:
■ RN1 represents (Ci-3)alkyl (especially methyl, ethyl, or isopropyl); and
■ RN2 represents (C^alkyl (especially isopropyl);
[in particular such group NRN1RN2 represents (ethyl)-(isopropyl)-amino, diisopropyl-amino, or (isopropyl)-(methyl)-amino]; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a heterocycle selected from pyrrolidinyl, piperidinyl, or morpholinyl; wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl) and (Ci-2)fluoroalkyl (especially trifluoromethyl or 2,2,2- trifluoroethyl); [in particular such group NRN1RN2 represents piperidin-1-yl, 2-methylpiperidin-1 -yl, 2-(trifluoromethyl)piperidin-1 -yl, 2,5-dimethylpyrrolidin-1-yl, 2,6-dimethylpiperidin-1-yl, or 3,5- dimethylmorpholin-4-yl]; or a mono-unsaturated monocyclic (C6-z)cycloalkyl (notably cyclohex- 1-en-1 -yl, or cyclohept-1 -en-1 -yl); or a mono-unsaturated bridged bicyclic (Cz)cycloalkyl [in particular such RB3 represents bicyclo[2.2.1 ]hept-2- en-2-yl]; or phenyl; wherein said phenyl is mono- or di-substituted (in particular wherein at least one substituent is in para position with regard to the point of attachment of the rest of the molecule); wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro), (Ci-3)alkyl (especially methyl), and (Ci^alkoxy (especially methoxy); [notably such RB3 represents 2-fluorophenyl, 2-fluoro-6- methylphenyl, 2,6-difluorophenyl, or 2-fluoro-6-methoxyphenyl]; or 5- or 6-membered heteroaryl selected from isothiazolyl or pyridinyl; wherein said 5- or 6-membered heteroaryl is mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro) and (Ci-3)alkyl (especially methyl); [notably such RB3 represents 4-methylisothiazol-3-yl, 2,4-difluoropyridin-3-yl].
8) Another embodiment relates to compounds according to embodiment 1), wherein Ring B represents 2- isopropoxy-6-methylpyridin-3-yl, 6-methyl-2-propoxypyridin-3-yl, 2-(sec-butoxy)-6-methylpiridin-3-yl, 2-isobutoxy- 6-methylpyridin-3-yl, 2-((1,1-difluoropropan-2-yl)oxy)-4-methylphenyl, 2-(3,3-difluoro-2,2-dimethyl-propoxy)-4- methy I phenyl , 4-methy l-2-((1 , 1 ,1 -trifl uoropropan-2-yl)oxy) phenyl , 6-methy l-2-(1 ,1 , 1 -trifl uoropropan-2- yl)oxy)pyridin-3-yl, 4-methyl-2-((4,4,4-trifluorobutan-2-yl)oxy)phenyl, 2-((1 ,1,1 ,3,3,3— hexafluoropropan-2-yl)oxy)-4- methylphenyl, 2-(isopropylamino)-4-methylphenyl, 2-(isopropylamino)-6-methylpyridin-3-yl, 2-(sec-butylamino)-6- methylpyridin-3-yl, 2-(ferf-butylamino)-6-methylpyridin-3-yl, 6-methyl-2-((1-methylcyclopropyl)amino)pyridin-3-yl, 2- ((1-cyclopropylethyl)amino)-6-methylpyridin-3-yl, 2-((1-methoxypropan-2-yl)amino)-6-methylpyridin-3-yl, 6-methyl- 2-((1 , 1 , 1 -trifl uoropropan-2-y l)amino) py ridin-3-y I, 6-methy I -2-((1 , 1 ,1 -trif luorobutan-2-y I) ami no)py rid I n-3-y 1 , 2-((1 - cyclopropyl-2,2,2-trifluoroethyl)amino)-6-methylpyridin-3-yl, 2-(isopropyl(methyl)amino)-6-methylpyridin-3-yl, 2- (ferf-butyl(methyl)amino)-6-methylpyridin-3-yl, 2-(cyclopropyl(methyl)amino)-6-methylpyridin-3-yl, 2- (diethylamino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6- (trifluoromethyl)pyridin-3-yl, 2-(ethyl(isopropyl)amino)-4-methylphenyl, 2-(cyclopropyl(ethyl)amino)-6- methylpyridin-3-yl, 2-((sec-butyl)-(ethyl)-amino)-6-methylpyridin-3-yl, 2-(diisopropylamino)-6-methylpyridin-3-yl, 2- (isopropyl(2-methoxyethyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(1-methoxypropan-2-yl)amino)-6-methylpyridin-3- yl, 6-methyl-2-(pyrrolidin-1-yl)phenyl, 4-methyl-2-(piperidin-1-yl)phenyl, 6-methyl-2-(piperidin-1-yl)pyridin-3-yl, 6- methyl-2-(2-methylpyrrolidin-1-yl)pyridin-3-yl, 6-methyl-2-(2-(trifluoromethyl)pyrrolidin-1-yl)pyridin-3-yl, 4-methyl-2- (2-methylpiperidin-1-yl)phenyl, 6-methyl-2-(2-methylpiperidin-1 -yl)pyridin-3-yl, 6-methyl-4-(2-methylpiperidin-1- yl)pyridin-3-yl, 2-(3-fluoropiperidin-1-yl)-4-methylphenyl, 6-methyl-2-(4-methylpiperidin-1-yl)pyridin-3-yl, 6-methyl- 2-(2-(trifluoromethyl)piperidin-1-yl)pyridin-3-yl, 2-(2-methoxymethyl)piperidin-1-yl)-6-methylpyridin-3-yl, 2-(2,5- dimethylpyrrolidin-1-yl)-6-methylpyrridin-3-yl, 2-(2,3-dimethylpyrrolidin-1-yl)-6-methylpyrridin-3-yl, 2-(2-ethyl-5- methylpyrrolidin-1-yl)-6-methylpyrridin-3-yl, 2-(2,6-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl, 2-(azepan-1-yl)-4- methylphenyl, 2-(azepan-1-yl)-6-methylpyridin-3-yl, 2-(3-methylmorpholino)-6-(trifluoromethyl)pyridin-3-yl, 6- methyl-2-(3-(2,2,2-trifluoroethyl)morpholino)pyridin-3-yl, 2-(3,5-dimethylmorpholino)-6-methylpyridin-3-yl, 2-(3,5- dimethylmorpholino)-6-(trifluoromethyl)pyridin-3-yl, 2-(3,5-dimethylmorpholino)-4-methylphenyl, 2-(2- azabicyclo[2.2.1]heptan-2-yl)-6-methylpyridin-3-yl, 2-(7-azabicyclo[2.2.1]heptan-7-yl)-6-methylpyridin-3-yl, 2-(3- oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-methylpyridin-3-yl, 2-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-6-methylpyridin-3- yl, 2-cyclopentyl-4-methylphenyl, 2-(cyclopent-1-en-1-yl)-4-methylphenyl, 2-cyclohexyl-4-methylphenyl, 2- cyclohexyl-6-methylpyridin-3-yl, 2-(cyclohexen-1-en-1-yl)-4-methylphenyl, 2-(cyclohexen-1-en-1-yl)-6- methylpyridin-3-yl, 2-cycloheptyl-4-methylphenyl, 2-(cyclohept-1-en-1-yl)-4-methylphenyl, 6-methyl-2-(2- methylcyclohexyl)pyridin-3-yl, 6-methyl-2-(2-methylcyclohex-1-en-1-yl)pyridin-3-yl, 6-methyl-2-(6-methylcyclohex- 1-en-1-yl)pyridin-3-yl, 2-(4,4,-dimethylcyclohex-1-en-1-yl)-4-methylphenyl, 2-(4, 4, -difluorocyclohex-1 -en-1-yl)-4- methylphenyl, 2-(5J6-dihydro-2/7-pyran-3-yl)-4-methylphenyl, 2-(bicyclo[2.2.1]heptan-2-yl)-4-methylphenyl, 2- (bi cycl o [2.2.1 ] hept-2-en-2-y l)-4-methy Ipheny 1 , 6-methy I -[1 , 1 ' -bi pheny l]-2-y 1 , 5-methy I -[1 , 1 ' -bi pheny l]-2-y 1 , 2'- methyl-[1 ,1’-biphenyl]-2-yl, 2’,5-dimethyl-[1 ,1’-biphenyl]-2-yl, 5-fluoro-2’-methyl-[1 , 1’-biphenyl]-2-yl, 2’,6-difluoro- [1 , 1 '-biphenyl]-2-yl, 2’-fluoro-5-methyl-[1 , T-bi pheny l]-2-yl , 5-ethy l-2’-fluoro-[1 , T-bi pheny l]-2-y 1 , 2’-fluoro-5- isopropyl-[1 ,1'-biphenyl]-2-yl, 5-cyclopropyl-2'-fluoro-[1 , 1'-biphenyl]-2-yl, 5-cyclobutyl-2'-fluoro-[1 , 1'-biphenyl]-2-yl, 2’,5-difluoro-[1, 1’-biphenyl]-2-yl, 5-chloro-2’-fluoro-[1 , 1’-biphenyl]-2-yl, 2’-fluoro-5-methoxy-[1 ,1’-biphenyl]-2-yl, 2’- fluoro-5-vinyl-[1 , 1'-biphenyl]-2-yl, 2'-fluoro-5,6-dimethyl-[1 , 1'-biphenyl]-2-yl, 2',6-difluoro-5-methyl-[1 ,1'-biphenyl]-2- yl, 2-(2-fluorophenyl)-6-methylpyridin-3-yl, 2-(2-chlorophenyl)-6-methylpyridin-3-yl, 2'-chloro-5-fluoro-[1 ,1'- bi pheny l]-2-y 1 , 2'-chloro-5-methoxy-[1 , 1 ’ -bi pheny l]-2-y 1 , 2'-cyano-5-methyl-[1 , 1 ’ -bi pheny l]-2-y 1 , 2'-methoxy-5- methy l-[1 , 1 ’ -bi pheny l]-2-yl , 5-methy I-2’- (trifl uoromethoxy)-[ 1 , 1 ’-bi phenyl]-2-y I, 4’ -fl uoro-5-methy l-[1 , 1 ’-bi pheny -2- yl, 2-(2-fluoro-3-methylphenyl)-6-methylpyridin-3-yl, 2',3'-difluoro-5-methyl-[1 ,1'-biphenyl]-2-yl, 2-(2-chloro-3- fluorophenyl)-6-methylpyridin-3-yl, 2-(3-chloro-2-fluorophenyl)-6-methylpyridin-3-yl, 4'-fluoro-2'-methoxy-5-methyl- [1 , 1’-biphenyl]-2-yl, 2’,4’-fluoro-5-methyl-[1 ,1’-biphenyl]-2-yl, 2-(2,5-difluorophenyl)-6-methylpyridin-3-yl, 2-(2’,5’- difluoro-5-methyl-[1 ,1'-biphenyl]-2-yl, 2',5,6'-trimethyl-[1 ,1'-biphenyl]-2-yl, 2-(2-fluoro-6-methylphenyl)-6- methylpyridin-3-yl, 2’-chloro-5,6’-dimethyl-[1 ,1'-biphenyl]-2-yl, 2-(2,6-difluorophenyl)-6-methylpyridin-3-yl, 2-(2,6- difluorophenyl)-6-methoxypyridin-3-yl, 2',6'-difluoro-5-methyl-[1 , 1'-biphenyl]-2-yl, 2'-fluoro-6'-methoxy-5-methyl- [1 , 1 ' -bi pheny l]-2-y 1 , 2-(i soth i azol -3-yl)-4-methy Ipheny 1 , 4-methy l-2-(4-methy I i soth i azol-3-y I )pheny 1 , 4-methyl-2- (oxazol-2-yl)phenyl, 4-methyl-2-(5-methyloxazol-2-yl)phenyl, 4-methyl-2-(5-methyl-1 H-pyrazol-1 -yl)phenyl, 4- methyl-2-(5-ethyl-1 H-pyrazol-1-yl)phenyl, 4-methyl-2-(5-cyclopropyl-1 H-pyrazol-1 -yl)phenyl, 4-methyl-2-(2H-1 ,2,3- triazol-2-yl)phenyl, 4-methyl-2-(2-methylpyridin-3-yl)phenyl, 2-(4-fluoropyridin-3-yl)-4-methylphenyl, 2-(4- chloropyridin-3-yl)-4-methylphenyl, 2-(4-cyanopyridin-3-yl)-4-methylphenyl, 4-methyl-2-(3-methylpyridin-2- yl)phenyl, 2-(3-fluoropyridin-2-yl)-4-methylphenyl, 2-(3-chloropyridin-2-yl)-4-methylphenyl, 4-methyl-2-(3- (trifluoromethyl)pyridin-2-yl)phenyl, 2-(3-methoxypyridin-2-yl)-4-methylphenyl, 2-(2-chloro-4-methylpyridin-3-yl)-4- methylphenyl, 2-(2,4-difluoropyridin-3-yl)-4-methylphenyl, 4-methyl-2-(3-methylpyrazin-2-yl)phenyl, 2-(3- fluoropyrazin-2-yl)-4-methylphenyl, or 2-(3-methoxypyrazin-2-yl)-4-methylphenyl.
9) Another embodiment relates to compounds according to embodiment 1), wherein Ring B represents 2-(sec- butoxy)-6-methylpiridin-3-yl, 2-(isopropylamino)-6-methylpyridin-3-yl, 2-(fert-butylamino)-6-methylpyridin-3-yl, 2- (isopropyl(methyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl, 2- (ethyl(isopropyl)amino)-6-(trifluoromethyl)pyridin-3-yl, 2-(ethyl(isopropyl)amino)-4-methylphenyl, 2- (diisopropylamino)-6-methylpyridin-3-yl, 4-methyl-2-(piperidin-1-yl)phenyl, 6-methyl-2-(piperidin-1-yl)pyridin-3-yl, 4-methyl-2-(2-methylpiperidin-1-yl)phenyl, 6-methyl-2-(2-methylpiperidin-1-yl)pyridin-3-yl, 6-methyl-4-(2- methylpiperidin-1-yl)pyridin-3-yl, 6-methyl-2-(2-(trifluoromethyl)piperidin-1-yl)pyridin-3-yl, 2-(2,5-dimethylpyrrolidin-
1-yl)-6-methylpyrridin-3-yl, 2-(2,6-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl, 2-(azepan-1-yl)-4-methylphenyl, 2-
(3,5-dimethylmorpholino)-6-methylpyridin-3-yl, 2-(3,5-dimethylmorpholino)-6-(trifluoromethyl)pyridin-3-yl, 2-(3,5- dimethylmorpholino)-4-methylphenyl, 2-cyclohexyl-4-methylphenyl, 2-cyclohexyl-6-methylpyridin-3-yl, 2- (cyclohexen-1 -en-1-yl)-4-methylphenyl, 2-(cyclohexen-1-en-1-yl)-6-methylpyridin-3-yl, 2-(cyclohept-1-en-1-yl)-4- methylphenyl, 6-methyl-2-(2-methylcyclohex-1-en-1-yl)pyridin-3-yl, 2-(bicyclo[2.2.1]hept-2-en-2-yl)-4- methylphenyl, 2',5-dimethyl-[1 ,1'-biphenyl]-2-yl, 2'-fluoro-5-methyl-[1, 1'-biphenyl]-2-yl, 2’-fluoro-5,6-dimethyl-[1 , 1'- biphenyl]-2-yl, 2'-methoxy-5-methyl-[1 ,1'-biphenyl]-2-yl, 2',3'-difluoro-5-methyl-[1, 1'-biphenyl]-2-yl, 2',4'-fluoro-5- methyl-[1 ,1'-biphenyl]-2-yl, 2-(2’,5’-difluoro-5-methyl-[1 ,1'-biphenyl]-2-yl, 2-(2-fluoro-6-methylphenyl)-6- methylpyridin-3-yl, 2’-chloro-5,6’-dimethyl-[1 ,1'-biphenyl]-2-yl, 2-(2,6-difluorophenyl)-6-methylpyridin-3-yl, 2',6'- difluoro-5-methyl-[1 ,1'-biphenyl]-2-yl, 2'-fluoro-6'-methoxy-5-methyl-[1 , 1'-biphenyl]-2-yl, 4-methyl-2-(4- methylisothiazol-3-yl)phenyl, 4-methyl-2-(5-ethyl-1 H-pyrazol-1 -yl)phenyl, 4-methyl-2-(2-methylpyridin-3-yl)phenyl,
2-(2-chloro-4-methylpyridin-3-yl)-4-methylphenyl, 2-(2,4-difluoropyridin-3-yl)-4-methylphenyl, 4-methyl-2-(3- methylpyrazin-2-yl)phenyl, or 2-(3-fluoropyrazin-2-yl)-4-methylphenyl [in particular, Ring B represents 2- (isopropyl(methyl)amino)-6-methylpyridin-3-yl, 2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl, 2- (ethyl(isopropyl)amino)-6-(trifluoromethyl)pyridin-3-yl, 2-(ethyl(isopropyl)amino)-4-methylphenyl, 2- (diisopropylamino)-6-methylpyridin-3-yl, 4-methyl-2-(piperidin-1-yl)phenyl, 4-methyl-2-(2-methylpiperidin-1- yl)phenyl, 6-methyl-2-(2-methylpiperidin-1-yl)pyridin-3-yl, 6-methyl-2-(2-(trifluoromethyl)piperidin-1-yl)pyridin-3-yl,
2-(2,5-dimethylpyrrolidin-1-yl)-6-methylpyrridin-3-yl, 2-(2,6-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl, 2-(3,5- dimethylmorpholino)-6-methylpyridin-3-yl, 2-(3,5-dimethylmorpholino)-4-methylphenyl, 2-(cyclohexen-1-en-1-yl)-4- methylphenyl, 2-(cyclohept-1-en-1 -yl)-4-methylphenyl, 2-(bicyclo[2.2.1]hept-2-en-2-yl)-4-methylphenyl, 2'-fluoro-5- methyl-[1 ,1'-biphenyl]-2-yl, 2'-fluoro-5,6-dimethyl-[1 , 1'-biphenyl]-2-yl, 2-(2-fluoro-6-methylphenyl)-6-methylpyridin-
3-yl, 2',6'-difluoro-5-methyl-[1 ,1'-biphenyl]-2-yl, 2'-fluoro-6'-methoxy-5-methyl-[1 ,1'-biphenyl]-2-yl, 4-methyl-2-(4- methylisothiazol-3-yl)phenyl, 2-(2,4-difluoropyridin-3-yl)-4-methylphenyl].
10) Another embodiment relates to compounds according to any one of embodiments 1) to 9), wherein X3 represents 0.
11) Another embodiment relates to compounds according to any one of embodiments 1) to 9), wherein X3 represents NRN3, wherein RN3 represents hydrogen, (Ci-3)alkyl (especially methyl or ethyl), (C3-6)cycloalkyl (especially cyclopropyl), a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom (especially oxetanyl or tetrahydrofuranyl), a 5-membered saturated bridged bicyclic cycloalkyl (especially bicyclo[1.1.1]pentanyl), phenyl, or pyridinyl.
12) Another embodiment relates to compounds according to any one of embodiments 1) to 9), wherein X3 represents NRN3, wherein RN3 represents hydrogen, (Ci-3)alkyl (especially methyl), or (C3-6)cycloalkyl (especially cyclopropyl).
13) Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X4 represents N and Ring A represents:
• a 4- to 7-membered (notably 5- to 7-membered) saturated monocyclic heterocycloalkan-diyl comprising X4, and zero or one further ring heteroatom selected from 0 or S (especially azetidin-diyl, pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl; in particular pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl); wherein said heterocycloalkan-diyl is unsubstituted, or mono- or disubstituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), halogen (especially fluoro), (Ci-3)alkoxy (especially methoxy), (Ci-3)alkylidene (especially H2C=), and oxo; [notably such Ring A represents azetidin-1 ,2-diyl, 4- methylazetidin-1 , 2-diyl, 3, 3-difluoroazetidin-1 ,2-diyl, pyrrolidin-1 ,2-diyl, 5-methylpyrrolidin-1 ,2-diyl, 4- methylpyrrolidin-1 ,2-diyl, 4-fluoropyrrolidin-1 , 2-diyl, 3-fluoropyrrolidin-1, 2-diyl, 4-methoxypyrrolidin- 1 ,2-diyl, 4-methylenepyrrolidin-1 , 2-diyl, 4-oxopyrrolidin-1 ,2-diyl, 4, 4-dimethylpyrrolidin-1 , 2-diyl, 4,4- difluoropyrrolidin-1 , 2-diyl, piperidin-1 , 2-diyl, azepan-1, 2-diyl, thiazolidin-2,3-diyl, thiazolidin-3,4-diyl, oxazolidin-3,4-diyl, oxazolidin-2,3-diyl, 1 ,3-oxazinan-2,3-diyl, or morpholin-3,4-diyl; in particular such Ring A represents pyrrolidin-1 , 2-diyl, 5-methylpyrrolidin-1 ,2-diyl, 4-methylpyrrolidin-1 ,2-diyl, 4- fluoropyrrolidin-1 , 2-diyl, 3-fluoropyrrolidin-1 , 2-diyl, 4-methoxypyrrolidin-1 , 2-diyl, 3- methylenepyrrol id i n- 1 ,2-diyl, 4, 4-d I methy Ipy rrolidin- 1 ,2-diyl, azepan-1 ,2-diyl, thiazolidi n-2, 3-d iy I, thiazolidin-3,4-diyl, or oxazolidin-2,3-diyl];
• a 4- to 6-membered (notably 5-membered) mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring N atom (especially dihydro-1 H-pyrrol-diyl, dihydropyridin- 1 (2/7)-diyl, or dihydro-1 /7-pyrazol-diyl); wherein the double bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4; wherein said mono-unsaturated heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci-3)alkyl (especially methyl); [notably such Ring A represents 2, 5-d i hydro- 1 /7-pyrrol- 1 ,2-diyl, 2, 3-d i hydro- 1 /7-py rrol-1 ,5-diyl, 3, 6-d I hydropy ri di n-1 (2/7)-
1 ,2-diyl, 4,5-dihydro-1 H-pyrazol-1 ,5-diyl, or 3-methyl-4,5-dihydro-1 H-pyrazol-1 ,5-diyl; in particular such Ring A represents 2,5-dihydro-1 H-pyrrol-1 ,2-diyl or 3-methyl-4,5-dihydro-1 H-pyrazol-1 ,5-diyl];
• a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom (notably hexahydrocyclopenta[b]pyrrol-1 (2/7),2-diy I, hexahydro-4/-/- furo[3,2-b]pyrrol-4,5-diyl, azabicyclo[2.1.1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, or azaspiro[2.4]heptan-diyl; in particular azabi cyclo [2.1 .1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, azaspiro[2.4]heptan-diyl, or 6- azaspiro[2.5]octan-diyl); wherein said bicyclic heterocycloalkan-diyl is unsubstituted, or monosubstituted with (Ci-3)alkyl (especially methyl) or di-substituted with fluoro.
14) Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X4 represents N and Ring A represents:
• a 5- to 7-membered saturated monocyclic heterocycloalkan-diyl comprising X4, and zero or one further ring heteroatom selected from 0 or S (especially pyrrolidin-diyl, azepan-diyl, thiazolidin-diyl, or oxazolidin-diyl); wherein said heterocycloalkan-diyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl (especially methyl), halogen (especially fluoro), (Ci-3)alkoxy (especially methoxy), and (Ci-3)alkylidene (especially H2C=); [notably such Ring A represents pyrrolidin-1 ,2-diyl, 5-methylpyrrolidin-1 ,2-diyl, 4- methylpyrrolidin-1 ,2-diyl, 4-fluoropyrrolidin-1 , 2-diyl, 3-fluoropyrrolidin-1, 2-diyl, 4-methoxypyrrolidin-
1.2-diyl, 3-methylenepyrrolidin-1 ,2-diyl, 4, 4-dimethylpyrrolidin-1 , 2-diyl, azepan-1 , 2-diyl, thiazolidin-
2.3-diyl, thiazolidin-3,4-diyl, or oxazolidin-2,3-diyl]; or
• a 5-membered mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring N atom (especially dihydro-1 /7-pyrrol-diyl or dihydro-1 /7-pyrazol-diyl); wherein the double bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4; wherein said monounsaturated heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci^)alkyl (especially methyl); [notably such Ring A represents 2, 5-dihydro-1 /7-pyrrol-1 , 2-diyl or 3-methyl-4,5-dihydro-1 H- pyrazol-1 ,5-diyl]; or • a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom (notably azabicyclo[2.1.1]hexan-diyl, azabicyclo[3.1.0]hexan-diyl, azabicyclo[2.2.1]heptan-diyl, or azaspiro[2.4]heptan-diyl); wherein said bicyclic heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci-s)alkyl (especially methyl).
15) Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X4 represents N and Ring A represents hexahydrocyclopenta[b]pyrrol-1 (2/-/),2-diyl, hexahydro-4/-/-furo[3,2-b]pyrrol- 4,5-diyl, 4-methyl-2-azabicyclo[2.1 ,1]hexan-1 ,2-diyl, 2-azabicyclo[3.1.0]hexan-2,3-diyl, 3-azabicyclo[3.1.0]hexan- 2,3-diyl, 2-azabicyclo[2.2.1]heptan-1,2-diyl, 5-azaspiro[2.4]heptan-4,5-diyl, 5-azaspiro[2.4]heptan-5,6-diyl, 1,1- difluoro-5-azaspiro[2.4]heptan-5,6-diyl, or 6-azaspiro[2.5]octan-5,6-diyl.
16) Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X4 represents N and Ring A represents 4-methyl-2-azabicyclo[2.1 .1]hexan-1 ,2-diyl, 2-azabicyclo[3.1 .0] hexan-2, 3-diy I , 3-azabicyclo[3.1.0]hexan-2,3-diyl, 2-azabicyclo[2.2.1]heptan-1 ,2-diyl, or 5-azaspiro[2.4]heptane-4,5-diyl, 5- azaspiro[2.4]heptan-5,6-diyl [notably 4-methyl-2-azabicyclo[2.1.1]hexan-1,2-diyl, 3-azabicyclo[3.1.0]hexan-2,3- diyl, or 2-azabicyclo[2.2.1]heptan-1 ,2-diyl],
17) Another embodiment relates to compounds according to any one of embodiments 1) to 12), wherein X4 represents CH and Ring A represents a monocyclic (Cs-ejcycloalkan-diyl .
18) Another embodiment relates to compounds according to embodiment 17), wherein the substituents -S(=O)(=X3)-(Ring B) and -C(=O)N(R1)(R2) of Ring A are in relative trans configuration.
Thus, according to this embodiment, a compound of Formula (I) represents either a compound of Formula (II), or a compound of Formula (III), or any mixture thereof (especially enantiomerically-enriched compound of Formula (II)):
Formula (II) Formula (III).
19) Another embodiment relates to compounds according to any one of embodiments 1) to 18), wherein R1 represents hydrogen; methyl or ethyl. 20) Another embodiment relates to compounds according to any one of embodiments 1) to 19), wherein R2 represents: -(CH2)q-Cy1; wherein q is 0 or 1 (especially 0) and Cy1 represents a saturated monocyclic (CsjJcycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl or isopropyl), (Ci-3)alkoxy (especially methoxy), cyano, and hydroxy; [notably such R2 represents (cyclopropyl)methyl, 2- isopropylcyclopropyl, (2-trifluoromethyl)-cyclopropyl, (difluorocyclopropyl)methyl, cyclobutyl, (cyclobutyl)methyl, 3-(trifluoromethyl)cyclobutyl, 3-(difluoromethyl)cyclobutyl, 3-methoxycyclobutyl, 3,3- dimethylcyclobutyl, 3,3-difluorocyclobutyl, (3,3-difluorocyclobutyl)methyl, (cyclopentyl)methyl, 1- cyanocyclopentyl, 1 -fluorocyclopentyl, 2-fluorocyclopentyl, 2-methoxycyclopentyl, 2-cyanocyclopentyl, 3- fluorocyclopentyl, 3-cyanocyclopentyl, 3-hydroxycyclopentyl, 3-methoxycyclopentyl, (1- fluorocyclopentyl)methyl, 3,3-dimethylcyclopentyl, 3,3-difluorocyclopentyl, cyclohexyl. 1 -methylcyclohexyl,
2-methylcyclohexyl, 2-hydroxycyclohexyl, 2-methoxycyclohexyl, 3-methylcyclohexyl, 3-hydroxycyclohexyl,
3-methoxycyclohexyl, 3-cyanocyclohexyl, 4-methylcyclohexyl, 4-hydroxycyclohexyl, 4-methoxycyclohexyl, 4, 4-di methylcyclohexyl, 4,4-difluorocyclohexyl, or cycloheptyl; in particular such R2 represents 2- isopropylcyclopropyl, 3-(trifluoromethyl)cyclobutyl, 3-(difluoromethyl)cyclobutyl, 3,3-dimethylcyclobutyl, 3,3-difluorocyclobutyl, (3,3-difluorocyclobutyl)methyl, (cyclopentyl)methyl, 2-methoxycyclopentyl, 2- cyanocyclopentyl, 3-fluorocyclopentyl, 3-cyanocyclopentyl, 3,3-dimethylcyclopentyl, 3,3- difluorocyclopentyl, cyclohexyl. 2-methylcyclohexyl, 2-hydroxycyclohexyl, 2-methoxycyclohexyl, 3- methylcyclohexyl, 3-hydroxycyclohexyl, 3-methoxycyclohexyl, 3-cyanocyclohexyl, 4-methylcyclohexyl, 4- methoxycyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, or cycloheptyl]; or -(CH2)n-Cy2; wherein n is 0 or 1 (especially 0) and Cy2 represents a 4- to 7-membered saturated or monounsaturated (especially saturated) monocyclic heterocycle comprising one ring heteroatomic group selected from -O-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)- (notably said heterocycle is oxetanyl, tetrahydrofuranyl, tetrahydro-2/7-pyranyl, 3,6-dihydro-2/7-pyranyl, tetrahydro-2H-thiopyran-1,1 -dioxide, 1- imino-1-oxidohexahydro-1-A6-thiopyranyl, or 1 -methylimino-1-oxidohexahydro-1-A6-thiopyranyl); in particular said heterocycle is tetrahydrofuranyl, tetrahydro-2/7-pyranyl, or tetrahydro-2/7-thiopyran-1,1- dioxide); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci^)fluoroalkyl (especially difluoromethyl), halogen (especially fluoro), (Ci-s)alkyl (especially methyl), and (Ci-3)alkoxy (especially methoxy); [notably such R2 represents [3-(difluoromethyl)oxetan-3-yl]methyl, tetrahydrofuran-3-yl, 3-methyltetrahydrofuran-3-yl, (3- methyltetrahydrofuran-3-yl)methyl, tetrahydro-2/7-pyran-4-yl, (tetrahydro-2H-pyran-3-yl)methyl, (tetrahydro-2H-pyran-4-yl)methyl, 4-methyltetrahydro-2H-pyran-4-yl, 3-methyltetrahydro-2/7-pyran-4-yl, 3- methoxytetrahydro-2H-pyran-4-yl, 2-methyltetrahydro-2/7-pyran-4-yl, 5,5-difluorotetrahydro-2H-pyran-2-yl, 6,6-dimethyltetrahydro-2/-/-pyran-3-yl, 2J6-dimethyltetrahydro-2/7-pyran-3-yl, 2,6-dimethyltetrahydro-2/-/- pyran-4-yl, 2J2-dimethyltetrahydro-2/7-pyran-4-yl, 5-fluoro-3,6-dihydro-2H-pyran-2-yl, 1 ,1- dioxidotetrahydro-2/7-thiopyran-4-yl, 1-imino-1-oxidohexahydro-1-A6-thiopyran-4-yl, or 1-methylimino-1- oxidohexahydro-1-A6-thiopyran-4-yl; in particular such R2 represents 3-methyltetrahydrofuran-3-yl, (3- methyltetrahydrofuran-3-yl)methyl, tetrahydro-2/7-pyran-4-ylJ 3-methoxytetrahydro-2/-/-pyran-4-yl, 2- methyltetrahydro-2/-/-pyran-4-yl, 6,6-dimethyltetrahydro-2/-/-pyran-3-yl, 2,6-dimethyltetrahydro-2/7-pyran-4- yl, 2,2-dimethyltetrahydro-2H-pyran-4-yl, or 1, 1-dioxidotetrahydro-2/7-thiopyran-4-yl; or -(CH2)m-Cy3; wherein m is 0 or 1 (especially 0) and Cy3 represents a saturated spiro, fused, or bridged bicyclic (C^cycloalkyl (notably bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, spiro[3.3]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[2.2.1]heptanyl, spiro[2.4]heptanyl, or spiro[2.5]octanyl); wherein said bicyclic (Cs-sjcycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from halogen (especially fluoro) or (Ci^alkyl (especially methyl); [notably such R2 represents bicyclo[1 .1 .1]pentan-1-yl, 3-methylbicyclo[1 .1 .1]pentan-1-yl, bicyclo[3.1.0]hexan-2-yl, spiro[2.3]hexan-5-yl, 1 ,1-difluorospiro[2.3]hexan-5-yl, spiro[3.3]heptan-2-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[2.2.1]heptan-2-yl, bicyclo[2.2.1]heptan-1-yl, (bicyclo[2.1.1]hept-2-yl)methyl, spiro[2.4]heptan-5-yl, 1 , 1-difluorospiro[2.4]heptan-5-yl, spiro[2.4]heptan-1-yl, spiro[2.5]octan-4-yl, spiro[2.5]octan-6-yl, or 1 ,1- difluorospiro[2.5]octan-6-yl; in particular such R2 represents bicyclo[1.1.1]pentan-1-yl, bicyclo[3.1.0]hexan- 2-yl, 1 ,1-difluorospiro[2.3]hexan-5-yl, spiro[3.3]heptan-2-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[2.2.1]heptan-
2-yl, (bicyclo[2.1.1]hept-2-yl)methyl, spiro[2.4]heptan-5-yl, 1 ,1-difluorospiro[2.4]heptan-5-yl, spiro[2.4]heptan-1-yl, spiro[2.5]octan-4-yl, spiro[2.5]octan-6-yl, or 1 ,1-difluorospiro[2.5]octan-6-yl]; or a 7-membered saturated spiro or bridged bicyclic heterocycle comprising one ring oxygen atom [notably such R2 represents 2-oxaspiro[3.3]heptan-6-yl or 7-oxabicyclo[2.2.1]heptan-2-yl; in particular such R2 7- oxabicyclo[2.2.1]heptan-2-yl],
21) Another embodiment relates to compounds according to any one of embodiments 1) to 19), wherein R2 represents: -(CH2)q-Cy1; wherein q is 0 or 1 (especially 0) and Cy1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl (especially difluoromethyl or trifluoromethyl), halogen (especially fluoro), (Ci-3)alkyl (especially methyl or isopropyl), (Ci-3)alkoxy (especially methoxy), cyano, and hydroxy; [notably such R2 represents 2-isopropylcyclopropyl,
3-(trifluoromethyl)cyclobutyl, 3-(difluoromethyl)cyclobutyl, 3,3-dimethylcyclobutyl, 3,3-difluorocyclobutyl, (3,3-difluorocyclobutyl)methyl, (cyclopentyl)methyl, 2-methoxycyclopentyl, 2-cyanocyclopentyl, 3- fluorocyclopentyl, 3-cyanocyclopentyl, 3,3-dimethylcyclopentyl, 3,3-difluorocyclopentyl, cyclohexyl. 2- methylcyclohexyl, 2-hydroxycyclohexyl, 2-methoxycyclohexyl, 3-methylcyclohexyl, 3-hydroxycyclohexyl, 3- methoxycyclohexyl, 3-cyanocyclohexyl, 4-methylcyclohexyl, 4-methoxycyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, or cycloheptyl]; or -(CH2)n-Cy2; wherein n is 0 or 1 (especially 0) and Cy2 represents a 4- to 7-membered saturated monocyclic heterocycle comprising one ring heteroatomic group selected from -0- or -(SO2)- (notably said heterocycle is tetrahydrofuranyl, tetrahydro-2/7-pyranyl, or tetrahydro-2/7-thiopyran-1, 1 -dioxide); wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro), (Ci-s)alkyl (especially methyl), and (Ci-3)alkoxy (especially methoxy); [notably such R2 represents 3-methyltetrahydrofuran-3-yl, (3- methyltetrahydrofuran-3-yl)methyl, tetrahydro-2/7-pyran-4-yl, 3-methoxytetrahydro-2H-pyran-4-yl, 2- methyltetrahydro-2/-/-pyran-4-yl, 6,6-dimethyltetrahydro-2/7-pyran-3-yl, 2,6-dimethyltetrahydro-2/7-pyran-4- yl, 2,2-dimethyltetrahydro-2H-pyran-4-yl, or 1, 1-dioxidotetrahydro-2/7-thiopyran-4-yl]; or -(CH2)m-Cy3; wherein m is 0 or 1 (especially 0) and Cy3 represents a saturated spiro, fused, or bridged bicyclic (C^cycloalkyl (notably bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, spiro[3.3]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[2.2.1]heptanyl, spiro[2.4]heptanyl, or spiro[2.5]octanyl); wherein said bicyclic (C^cycloalkyl is unsubstituted, mono-substituted with (Ci-s)alkyl (especially methyl), or di-substituted with halogen (especially fluoro); [notably such R2 represents bicyclo[1.1.1]pentan-1-yl, bicyclo[3.1.0]hexan-2-yl, 1 ,1-difluorospiro[2.3]hexan-5-yl, spiro[3.3]heptan-2-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[2.2.1]heptan-2-yl, (bicyclo[2.1.1]hept-2-yl)methyl, spiro[2.4]heptan-5-yl, 1 ,1- difluorospiro[2.4]heptan-5-yl, spiro[2.4]heptan-1-yl, spiro[2.5]octan-4-yl, spiro[2.5]octan-6-yl, or 1 ,1- difluorospiro[2.5]octan-6-yl]; or a 7-membered saturated bridged bicyclic heterocycle comprising one ring oxygen atom (notably 7- oxabicyclo[2.2.1]heptanyl).
22) Another embodiment relates to compounds according to any one of embodiments 1) to 19), wherein R2 represents: -(CH2)q-Cy1; wherein q is 0 and Cy1 represents a saturated monocyclic (C3-z)cycloalkyl; wherein said monocyclic (Cs-zjcycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen (especially fluoro), (Ci-s)alkyl (especially methyl), (Ci-3)alkoxy (especially methoxy), and cyano; [notably such R2 represents 3,3-dimethylcyclobutyl,
3-fluorocyclopentyl, 3-cyanocyclopentyl, 3,3-dimethylcyclopentyl, 3,3-difluorocyclopentyl, cyclohexyl. 2- methylcyclohexyl, 2-methoxycyclohexyl, 3-methylcyclohexyl, 3-hydroxycyclohexyl, 3-methoxycyclohexyl,
4-methylcyclohexyl, 4-methoxycyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, or cycloheptyl]; or -(CH2)n-Cy2; wherein n is 0 and Cy2 represents a 4- to 7-membered saturated monocyclic heterocycle comprising one ring heteroatomic group selected from -0- or -(SO2)- (notably said heterocycle is tetrahydro- 2/-/-pyranyl or tetrahydro-2H-thiopyran-1,1 -dioxide); wherein said heterocycle is mono- or di-substituted; wherein the substituents are independently selected from halogen (especially fluoro) or (Ci-3)alkyl (especially methyl); [notably such R2 represents 2-methyltetrahydro-2/-/-pyran-4-yl, 2,6-dimethyltetrahydro- 2/-/-pyran-4-yl, 2,2-dimethyltetrahydro-2/-/-pyran-4-yl, or 1 ,1-dioxidotetrahydro-2/-/-thiopyran-4-yl]; or -(CH2)m-Cy3; wherein m is 0 and Cy3 represents a saturated spiro, fused, or bridged bicyclic (C^cycloalkyl (notably bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, bicyclo[4.1.0]heptanyl, bicyclo[2.2.1]heptanyl, spiro[2.4]heptanyl, or spiro[2.5]octanyl); wherein said bicyclic (C^cycloalkyl is unsubstituted or disubstituted with halogen (especially fluoro); [notably such R2 represents bicyclo[3.1.0]hexan-2-yl, 1 , 1- difluorospiro[2.3]hexan-5-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[2.2.1]heptan-2-yl, 1 ,1- difluorospiro[2.4]heptan-5-yl, spiro[2.5]octan-4-yl, or 1 , 1-difluorospiro[2.5]octan-6-yl]; or a 7-membered saturated bridged bicyclic heterocycle comprising one ring oxygen atom (notably 7- oxabicyclo[2.2.1]heptanyl).
23) Another embodiment relates to compounds according to any one of embodiments 1 ) to 18), wherein R1 and R2 together with the nitrogen to which they are attached form:
• a 7- to 11-membered (especially 8-membered) saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms (notably said heterocycle is 2- azaspiro[3.3]heptan-2-yl, 5-azaspiro[2.4]heptan-5-yl, 2-azaspiro[3.4]octan-2-yl, 6-azaspiro[2.5]octan- 6-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 6-oxa-2-azaspiro[3.5]nonan- 2-yl, 1-oxa-6-azaspiro[3.5]nonan-6-yl, 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-8- azaspiro[5.5]undecan-8-yl, 3-oxa-9-azaspiro[5.5]undecan-9-yl, 1 ,4-dioxa-8-azaspiro[4.6]undecan-8- yl, 8-oxa-2-azaspiro[4.5]decan-2-yl, or 8-azaspiro[4.5]decan-8-yl; in particular said heterocycle is 6- azaspiro[2.5]octan-6-yl); wherein said heterocycle is unsubstituted or mono-substituted with hydroxy; or
• a 7- to 9-membered (especially 7- to 8-membered) saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom (notably said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3- oxa-8-azabicyclo[3.2.1]octan-8-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl; in particular said 7- to 9-membered bridged heterocycle is 7- azabicyclo[2.2.1]heptan-7-yl or 8-azabicyclo[3.2.1]octan-8-yl); wherein said 7- to 9-membered bridged heterocycle is unsubstituted, or mono-, di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: hydroxy, halogen (especially fluoro), (Ci^)alkyl (especially methyl), and (Ci -3)alkoxy (especially methoxy or ethoxy); [notably such 7- to 9-membered bridged heterocycle represents 7-azabicyclo[2.2.1]heptan-7-yl, 2-hydroxy-7-azabicyclo[2.2.1]heptan- 7-yl, 2-methoxy-7-azabicyclo[2.2.1]heptan-7-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-methyl-8- azabicyclo[3.2.1]octan-8-yl, 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl, 3-ethoxy-8- azabicyclo[3.2.1]octan-8-yl, 3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl, 1 ,3,3-trimethyl-8- azabicyclo[3.2.1]octan-8-yl, 3-thia-8-azabicyclo[3.2.1]octan-8-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 9-aza-bicyclo[3.3.1]non-9-yl, 3-dioxa-9-azabicyclo[3.3.1]nonan-9-yl, or 3,7-dioxa-9- azabicyclo[3.3.1]nonan-9-yl]; or
• a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms (notably 2-azaadamantan-2-yl or 2-oxa-6-azaadamantan-6-yl).
24) Another embodiment relates to compounds according to any one of embodiments 1 ) to 18), wherein R1 and R2 together with the nitrogen to which they are attached form:
• an 8-membered saturated spiro bicyclic heterocycle comprising said nitrogen atom (notably said heterocycle is 6-azaspiro[2.5]octan-6-yl); or
• a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom (notably said 7- to 8-membered bridged heterocycle is 7-azabicyclo[2.2.1]heptan-7-yl or 8- azabicyclo[3.2.1]octan-8-yl); wherein said 7- to 8-membered bridged heterocycle is unsubstituted, or mono-substituted with (Ci-3)alkoxy (especially methoxy); [notably such 7- to 8-membered bridged heterocycle represents 7-azabicyclo[2.2.1 ]heptan-7-yl or 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl]; or
• a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms (notably 2-azaadamantan-2-yl or 2-oxa-6-azaadamantan-6-yl).
25) Another embodiment relates to compounds according to any one of embodiments 1 ) to 18), wherein R1 and R2 together with the nitrogen to which they are attached represent: (4,4-difluorocyclohexyl)-(methyl)-amino, (4,4- difluorocyclohexyl)-amino, (3-cyanocyclopentyl)-amino, (1,1-difluorospiro[2.5]octan-6-yl)-(methyl)-amino, (1 ,1- difluorospiro[2.5]octan-6-yl)-amino, (3-fluorocyclopentyl)-amino, (bicyclo[4.1.0]heptan-3-yl)-amino,
(bicyclo[4.1.0]heptan-3-yl)-(methyl)-amino, (1 , 1-difluorospiro[2.3]hexan-5-yl)-amino, (bicyclo[2.2.1]heptan-2-yl)- amino, (3,3-difluorocyclopentyl)-amino, (2,6-dimethyltetrahydro-2/7-pyran-4-yl)-amino, (2-methylcyclohexyl)- amino, (2-methoxycyclohexyl)-amino, (3,3-dimethyl-cyclobutyl)-amino, (2,6-dimethyltetrahydro-2/-/-pyran-4-yl)- (methyl)-amino, (1 , 1-difluorospiro[2.3]hexan-5-yl)-(methyl)-amino, (3,3-dimethyl-cyclopentyl)-amino, (cyclohexyl)- (methyl)-amino, 2-azaadamantan-2-yl, (4-methoxy-cyclohexyl)-amino, (3-methoxycyclohexyl)-(methyl)-amino, (3- cyanocyclopentyl)-(methyl)-amino, (4,4-dimethylcyclohexyl)-(methyl)-amino, (2,2-dimethyl-tetrahydro-2/7-pyran-4- yl)-(methyl)-amino, 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl, (1 , 1-difluorospiro[2.4]heptan-5-yl)-amino, 2-oxa-6- azaadamantan-6-yl, (2-methyl-tetrahydropyran-4-yl)-(methyl)-amino, (7-oxa-bicyclo[2.2.1]heptan-2-yl)-amino, (1, 1- dioxidotetrahydro-2/-/-thiopyran-4-yl)-(methyl)-amino, (1 , 1-difluorospiro[2.4]heptan-5-yl)-(methyl)-amino, 7- azabicyclo[2.2.1]heptan-7-yl; (4-methylcyclohexyl)-amino, (4-methylcyclohexyl)-(methyl)-amino, (3- methylcyclohexyl)-amino, (cycloheptyl)-amino, (spiro[2.5]octan-4-yl)-amino, (3-hydroxycyclohexyl)-amino, (bicyclo[3.1.0]hexan-2-yl)-amino, (3-trifluoromethyl-cyclobutyl)-amino, ((3,3-difluorocyclobutyl)-methyl)-amino, ((2- isopropyl)-cyclopropyl)-amino, (3-cyanocyclopentyl)-(methyl)-amino, (spiro[2.5]octan-4-yl)-(methyl)-amino, ((3- methyltetrahydrofuran-3-yl)-methyl)-amino, (2-hydroxycyclohexyl)-amino, (3-methoxyltetrahydropyran-4-yl)- (methyl)-amino, 6-azaspiro[2.5]octan-6-yl, (spiro[2.4]heptan-5-yl)-amino, (3-methyltetrahydrofuran-3-yl)-amino, ((bicyclo[2.2.1]heptan-2-yl)-methyl)-amino, (2-methoxycyclopentyl)-(methyl)-amino, (spiro[3.3]heptan-2-yl)-amino, (tetrahydropyran-4-yl)-(methyl)-amino, (spiro[2.4]heptan-1-yl)-amino, (6,6-dimethyltetrahydro-2/7-pyran-3-yl)- (methyl)-amino, 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl, (2-cyanocyclopentyl)-amino, (2,2-dimethyltetrahydro- 2/7-pyran-4-yl)-amino, (3,3-dimethyl-cyclopentyl)-(methyl)-amino, (bicyclo[1 .1 ,1]pentan-1-yl)-amino, (3- cyanocyclohexyl)-amino, (3-difluoromethyl-cyclobutyl)-amino, ((cyclopentyl)-methyl)-(methyl)-amino, or (4,4- cyclohexyl)-(ethyl)-amino.
26) Another aspect of the invention relates to compounds of the Formula (I) according to any one of embodiments 1) to 25) which are also compounds of the Formula (IV) (i.e. , the absolute configuration of the ring carbon atom to which the group -C(=O)N(R1)(R2) is attached, is as depicted in Formula (IV) below):
Formula (IV).
27) Another embodiment relates to compounds according to embodiment 1) which are selected from the following compounds:
{(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-((1 S,3R,5R)-3-methoxy-8-aza- bicy clo [3.2.1 ]oct-8-yl)-methanone;
{(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-(2-oxa-6-aza- tricy clo [3.3.1 .13,7]dec-6-yl)-methanone;
{(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-((1S,3R,5R)-3- methoxy-8-aza-bicyclo[3.2.1]oct-8-yl)-methanone;
(2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide; (2S,4S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(1R,2S)-2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-amide;
(1S,2R)-2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-amide
5-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-aza-spiro[2.4]heptane-6-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
5-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-aza-spiro[2.4]heptane-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
3-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (1, 1-difluoro-spiro[2.5]oct-6-yl)-N-methyl- amide;
2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methyl-2-aza-bicyclo[2.1 ,1]hexane-1-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-azepane-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide; 1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4,4-dimethyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-N-(Cyclopentylmethyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)-N-(methyl-d3)pyrrolidine-2- carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'-fluoro-6'-methoxy-5-methyl-[1 JT-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-6'-methoxy-5-methyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-(methyl-d3)-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'-fluoro-5,6-dimethyl-[1 , T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide; (S)-N-((SR)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1-((2-(ethyl(isopropyl)amino)-4-methylphenyl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Dimethylcyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Dimethylcyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Difluorocyclopentyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((RS)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1-((2-(ethyl(isopropyl)amino)-4- methylphenyl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((1R*,3S*)-3-Cyanocyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((4-methyl-2-((S)-2-methylpiperidin-1-yl)phenyl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((1R*,3S*)-3-Cyanocyclopentyl)-1-((2'-fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-((1R*,3R*)-3-Cyanocyclohexyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-[6-Methyl-2-((1 S,2R)-2-methyl-cyclohexyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[6-Methyl-2-(2-methyl-cyclohex-1-enyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 , 1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(3-methyl-pyrazin-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro-spiro[2.5]oct- 6-yl)-N-methyl-amide; (S)-1-[4-Methyl-2-(2-methyl-pyridin-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-trifluoromethyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid spiro[3.3]hept-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid spiro[2.4]hept-1- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(tetrahydro- pyran-4-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(4-methyl- cyclohexyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(2-methyl- tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cyclohexyl-N-methyl- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cycloheptylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[4.1.0]hept-3- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[3.1.0]hex-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[2.2.1]hept-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[1 .1 .1]pent-1- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (bicyclo[4.1 ,0]hept-3- yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (bicyclo[2.2.1]hept-2- ylmethyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (7-oxa- bicy clo [2.2.1 ] hept-2-y l)-amide ;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4-methyl-cyclohexyl)- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4-methoxy- cyclohexyl)-amide; (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-trifluoromethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-methyl-cyclohexyl)- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-methoxy-tetrahydro- pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-difluoromethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-dimethyl- cyclopentyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-dimethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-difluoro- cyclobutylmethyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2-cyano-cyclopentyl)- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6-dimethyl- tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,2-dimethyl- tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 R,2R,4S)- bicy clo [2.2.1 ] hept-2-y I amide ;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.5]oct-6-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.4]hept-5-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.3]hex-5-yl)-amide; (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.3]hex-5-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6-dimethyl-tetrahydro- pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(5-Ethyl-pyrazol-1-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-[2-(3-Fluoro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro-spiro[2.5]oct- 6-yl)-N-methyl-amide;
(S)-1-[2-(2,6-Difluoro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl- spiro[2.5]oct-6-yl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl- (2-methyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cyclohexyl-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicy clo [4.1 .0]hept-3-ylamide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicy clo [4.1 .0]hept-3-yl-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- dimethyl-cyclohexyl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide; (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,2- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.5]oct-6-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.4]hept-5-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.3]hex-5-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.3]hex-5-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid
((2S,4S,6R)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid ((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((2R,5S)-2,5-Dimethyl-pyrrolidin-1-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-(6'-Methyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-(5,2'-Dimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2-tert-Butylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide; (S)-1-(2-lsopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Diisopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Cyclohexyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2-Cyclohex-1-enyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Cyclohept-1-enyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Bicyclo[2.2.1]hept-2-en-2-yl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-(2-Azepan-1-yl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Methoxy-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-ethyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (1,1 -dioxo-hexahydro-1 l6-thiopyran-4- yl)-N-methyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methylene-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2,5-dihydro-1 H-pyrrole-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-(2',6'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2',5'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2',4'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2',3'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide; (S)-1-((S)-2,6'-Dimethyl-3,4,5,6-tetrahydro-2H-[1 J4']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((S)-2,6'-Dimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid
(4,4-difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-spiro[2.5]octan-4-yl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-3-methyltetrahydrofuran-3-yl)pyrrolidine-
2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S*,3S*)-3-methoxycyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S*,2R*)-2-methylcyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,3S*)-3-methoxycyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R* 3S*)-3-fluorocyclopentyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,3R*)-3-hydroxycyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-isopropylcyclopropyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-hydroxycyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2R*)-2-methylcyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-(((RS)-3-methyltetrahydrofuran-3- yl)methyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((RS)-sec-Butoxy)-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((SR)-2,2-dimethyltetrahydro-2H- pyran-4-yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-spiro[2.4]heptan-5- yl)pyrrolidine-2-carboxamide; (S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-6,6-dimethyltetrahydro-2H- pyran-3-yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((2R,4SR,6S)-2,6-dimethyltetrahydro-
2H-pyran-4-yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((2R,4SR,6S)-2,6-dimethyltetrahydro-
2H-pyran-4-yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R,2S)-2- methoxycyclopentyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S,2R)-2- methoxycyclopentyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-methoxycyclopentyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2- methoxycyclohexyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2- hydroxycyclohexyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-2,2-dimethyltetrahydro-2H-pyran-4- yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-2,2-dimethyltetrahydro-2H-pyran-4- yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-(((Sa)-2'-Chloro-5,6'-dimethyl-[1, 1'-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(S)-1-(((Ra)-2'-Chloro-5,6'-dimethyl-[1, 1'-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(7-Aza-bicyclo[2.2.1]hept-7-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone;
(6-Aza-spiro[2.5]oct-6-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone;
(6-Aza-spiro[2.5]oct-6-yl)-{(S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin- 2-yl}-methanone; (2S,5S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-4-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2 -carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-fluoro-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(25.45)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methoxy-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(2S,4R)-4-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(2S)-N-(Bicyclo[4.1.0]heptan-3-yl)-1-((2'-fluoro-5-methyl-[1, -biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(2'-fluoro-5-methyl-[1 , T-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5,6'-dimethyl-[1, -biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(6-methyl-2-((S)-2-methylpiperidin-1-yl)pyridin-3-yl)- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,4-difluoropyridin-3-yl)-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl-[1 ,1'-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl-[1 , -biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-((3R,6s)-1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl-6-methyl-pyridin-3- yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide; (2S)-1-((2-(2-Chloro-4-methylpyridin-3-yl)-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(2R,3S)-3-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(2-Aza-tricyclo[3.3.1 .13,7]dec-2-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone;
(2-Aza-tricyclo[3.3.1 .13,7]dec-2-yl)-{(S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]- pyrrolidin-2-yl}-methanone;
(1S,3S,5S)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(1S,2S,5R)-3-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-3-aza-bicyclo[3.1 ,0]hexane-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(1S,2S,5R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-3-aza-bicyclo[3.1 ,0]hexane-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(1S,2R)-2-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4- difluoro-cyclohexyl)-amide;
(1S,2R)-2-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro-cyclohexyl)-amide;
(1RS,2SR)-N-(4,4-Difluorocyclohexyl)-2-((2-((2S,6S)-2,6-dimethylpiperidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)cyclopentane-1-carboxamide;
(1R,3S,4S)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
((S)-1-[2-(lsopropyl-methyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide; and
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-5J6-dimethyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide.
The compounds of Formula (I) according to embodiments 1) to 27) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral e.g. in form of a tablet or a capsule) or parenteral administration (including topical application or inhalation).
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants. The present invention also relates to a method for the prevention I prophylaxis or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I) according to embodiments 1) to 27).
For avoidance of any doubt, if compounds are described as useful for the prevention I prophylaxis or treatment of certain diseases, such compounds are likewise suitable for use in the preparation of a medicament for the prevention I prophylaxis or treatment of said diseases. Likewise, such compounds are also suitable in a method for the prevention I prophylaxis or treatment of such diseases, comprising administering to a subject (mammal, especially human) in need thereof, an effective amount of such compound.
The compounds of Formula (I) according to any one of embodiments 1 ) to 27) are useful for the prevention I prophylaxis or treatment of diseases or disorders relating to the OX2R receptor, and notably in disease and disorders in which agonism of OX2R plays a role. Disease and disorders in which agonism of OX2R plays a role are particularly disease and disorders associated with difficulties maintaining wakefulness. Subjects presenting disease and disorders associated with difficulties maintaining wakefulness complain of: feelings of excessive sleepiness; episodes of inadvertently falling asleep, including sleep attacks (episodes of falling asleep without prodromal symptoms of drowsiness); a prolonged main sleep episode that is unrefreshing; recurrent naps in the same day; or sleep inertia (prolonged difficulty waking up, with irritability, automatic behavior or confusion).
Thus, the compounds of Formula (I) according to embodiments 1) to 27) are useful for improving wakefulness in a subject (especially in a subject having hypersomnia or narcolepsy, or presenting excessive daytime sleepiness (EDS)).
The term "improving wakefulness in a subject” refers to improving symptoms of, or to the prevention I prophylaxis or treatment of: hypersomnia, particularly prevention I prophylaxis or treatment of:
• narcolepsy; including especially narcolepsy type 1 and narcolepsy type 2;
• secondary narcolepsy associated with inherited disorders (such as Prader-Willi syndrome, Niemann- Pick C disease, or myotonic dystrophy);
• secondary narcolepsy associated with tumors, especially symptoms of narcolepsy associated with tumors that involve the hypothalamus area;
• secondary narcolepsy associated with head trauma, especially symptoms of narcolepsy associated with head trauma affecting the hypothalamic area;
• idiopathic hypersomnia; or
• Kleine-Levin syndrome; excessive daytime sleepiness (EDS), particularly: • improving symptoms of EDS in subjects having a circadian rhythm sleep-wake disorder, particularly improving symptoms of EDS in subjects having: delayed sleep-wake phase disorder, shift work disorder, or jet lag disorder;
• improving symptoms of EDS due to or associated with a medical disorder, wherein said medical disorder is especially an objective sleep disturbance, obesity, diabetes, a neurodegenerative disorder, an auto-immune disorder, a psychiatric disorder, or insufficient sleep syndrome; in particular:
■ improving symptoms of EDS associated with objective sleep disturbances (notably sleep apnea);
■ improving symptoms of EDS associated with obesity and/or diabetes;
■ improving symptoms of EDS associated with a neurodegenerative disorder, notably associated with: Alzheimer's, Parkinson's, Lewy body dementia, Perry syndrome, multiple system atrophy, or Huntington's disease;
■ improving symptoms reminiscent of narcolepsy in subjects having an auto-immune disorder (especially neuromyelitis optica, multiple sclerosis, Guillain-Barre syndrome, or anti-Ma2 encephalitis);
■ improving symptoms of EDS I treatment of hypersomnia associated with a psychiatric disorder, such as depression; or
■ improving symptoms of EDS I treatment of hypersomnia associated with insufficient sleep syndrome; or
• improving symptoms of EDS I treatment of hypersomnia due to a medication or substance; or fatigue (especially including chronic fatigue), particularly:
• fatigue accompanied by mental fatigue with poor concentration and memory;
• fatigue associated with infections (viral or bacterial), chronic inflammatory diseases, cancer, or neurodegeneration; or
• fatigue associated with autoimmune disease primary Sjogren's syndrome.
The term "narcolepsy type 1” describes a chronic sleep disorder characterized by excessive daytime sleepiness (EDS), sleep attacks and cataplexy (loss of muscle tone in full consciousness often triggered by positive emotions).
Fatigue is characterized by a lack of energy ("an overwhelming sense of tiredness, a feeling of exhaustion").
Further disease and disorders in which agonism of OX2R plays a role include:
• eating disorders;
• obesity, particularly obesity in narcoleptic subjects;
• attention deficit disorders;
• neuropsychiatric disorders, notably mood disorders, particularly depression (such as major depressive disorder (MDD)); • pain, particularly inflammatory pain, or chronic neuropathic pain;
• inflammation, particularly inflammation following cardiac arrest, intracerebral hemorrhage, or septic shock; and
• cognitive impairments, particularly age-related deficits in learning and memory or cognitive impairments due to sleep loss.
Additionally, agonism of OX2R plays a role in:
• disorders of consciousness, notably coma, vegetative state and minimally conscious state induced by traumatic brain injury
• recovery of arousal following unconsciousness associated with cardiac arrest or acute alcohol intoxication, or following anesthetic-induced unconsciousness.
In the context of the present invention, the term "subject” refers to a mammal, especially a human; in the context of a certain diagnosis or disease, the term "subject” and "patient” are to be understood as being interchangeable.
The compounds of Formula (I) according to any one of embodiments 1) to 27) are in particular useful as therapeutic agents for the prevention I prophylaxis or treatment of a disease and disorders associated with difficulties maintaining wakefulness. They can be used as single therapeutic agents or in combination with one or more additional therapeutic agents. Such therapeutic agents include modafinil, pitolisant, sodium oxybate, solriamfetol, armodafinil, dextroamphetamine, methylphenidate, clarithromycin, venlafaxine, clomipramine and lithium (see for example Mask! K. et al. J Clin Sleep Med. 2021 , 17(9), 1881-1893; Bassett! C. et al. Eur J Neurol. 2021 , 00, 1-16).
The invention, thus, also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and one or more additional therapeutic agents.
The invention, thus, further relates to a kit comprising a pharmaceutical composition, said composition comprising a pharmaceutically acceptable carrier material, and: a compound of Formula (I) according to any one of embodiments 1) to 27); and instructions how to use said pharmaceutical composition for improving wakefulness in a subject presenting excessive daytime sleepiness (EDS).
Besides, any preferences and (sub-)embodiments indicated for the compounds of Formula (I) (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, or uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of Formula (II), Formula (III) and Formula (IV). Compounds of the present invention may be further characterized with regard to their general pharmacokinetic and pharmacological properties using conventional assays well known in the art; for example relating to their bioavailablility in different species (such as rat or dog) including metabolic stability potentially affecting (human) bioavailability and/or dosage requirements, or relating to their ability to cross the blood-brain barrier, using for example a human P-glycoprotein 1 (MDR 1) substrate assay, or an in vivo assay to determine drug concentrations in the brain, e.g. in rats after oral dosing; or relating to their functional behavior in different disease related animal models (for example: the general stimulant effect of the compound using Electroencephalography (EEG) and Electromyography (EMG) signal measurements [Yukitake H et al.; TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice; Pharmacol Biochem Behav. 2019, 187:172794], the effect of the compound on narcolepsy-cataplexy symptoms [Irukayama-Tomobe Y et al.; Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models; Proc Natl Acad Sci U S A. 2017, 114(22):5731-5736]); or for their properties with regard to drug safety and/or toxicological properties using conventional assays well known in the art, for example relating to cytochrome P450 enzyme inhibition and time dependent inhibition, pregnane X receptor (PXR) activation, glutathione binding, or phototoxic behavior.
Preparation of compounds of Formula (I)
A further aspect of the invention is a process for the preparation of compounds of Formula (I). Compounds according to Formula (I) of the present invention can be prepared from commercially available or well known starting materials according to the methods described in the experimental part, by analogous methods, or according to the general sequence of reactions outlined below, wherein R1, R2, RB1, RB3, X1, X2, X3, X4, Ring A, and Ring B are as defined for Formula (I). Other abbreviations used herein are explicitly defined, or are as defined in the experimental section. In some instances, the generic groups R1, R2, RB1, RB3, X1, X2, X3 and X4 might be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T. W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place. The compounds obtained may also be converted into salts, especially pharmaceutically acceptable salts thereof in a manner known perse.
General preparation routes:
Compound 9, belonging to Formula (I) wherein X3=O and X4= N can be prepared by an amide coupling reaction between an appropriate carboxylic acid with structure 2 and an appropriate amine with structure 3 (or the corresponding salt, like HOI or TFA salts) in a solvent such as THF, DMF, DOM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDO or similar and a base such as DIPEA, TEA or N-methylmorpholine (Scheme 1). Amines 3 are either commercially available, prepared following procedures described in the literature, or prepared as described in the experimental part. Compound 4 can be deprotected using standard deprotection methods known in the literature and familiar to the person skilled in the art to give 5 (or the corresponding salt, like HCI or TFA salts). Amine 5 is condensed with a sulfonyl chloride 6 (where Hal is a halogen such as I, Br, Cl, or F) in solvent such as DCM, DMF, MeCN and in presence of a base such as TEA or DIPEA to give 7. The RB3 group can be introduced from intermediate 7, wherein Hal= I, Br, or Cl, by e.g. a Suzuki-Miyaura cross-coupling reaction with an arylboronic acid or an arylboronic ester in a solvent such as THF or DME and in presence of a base as K2CO3, NaHCOa or K3PO4 and a Pd catalyst as Pd(PPh3)4, by e.g. a Negishi cross coupling reaction with an organozinc reagent in a solvent such as THF and in presence of a Pd precatalyst such as SPhos Pd G2, or by a Stille cross-coupling reaction with the appropriate organostannyl reagent in a solvent such a dioxane or toluene and in presence of a Pd catalyst such as Pd(PPhs)4 or Pd(dppf)Cl2, to yield compound with general formula 9. Alternatively, intermediate 7 (wherein Hal= I, Br, or Cl) can be converted into its boronic acid or boronic ester analogue 8 by e.g. reaction with boronic acid pinacol ester in presence of a Pd catalyst such as PdCI2(MeCN)2 and a ligand such as SPhos in a solvent such as 1,4-dioxane and in presence of a base such as TEA, followed by a Suzuki-Miyaura cross-coupling in similar conditions as described herein before to yield 9. Final compound 9 wherein RB3 is either -N or -0 linked with Ring B can be prepared from 7 (wherein Hal= F or Cl) via a SNAP (nucleophilic aromatic substitution) reaction with the corresponding amine and an inorganic base such as K2CO3 in a solvent such as DMSO or DME or with the corresponding alcohol in presence of a base such as NaH and in a solvent such as THF. Alternatively, amine 5 can also be condensed with a sulfonyl chloride of general formula 10 in solvent such as DCM, DMF, MeCN and in presence of a base such as TEA or DIPEA to give 9. Sulfonyl chlorides 6 and 10 and amines 3 may be commercially available, prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
Scheme 1. Synthesis of sulfonamide compound 9 by variation of sulfonamide part in the last step. Step I) Amide coupling, ii) Deprotection, ill) Sulfonamide formation, iv) Arylboronic acid/ester formation, v) Cross-coupling, vi) Cross-coupling/SNAr reaction, vii) Sulfonamide formation. Alternatively, variation in the amide functional group can be introduced at the very last step following the procedures described in Scheme 2. An appropriate aminoester 11 (or the corresponding salt, like HCI or TFA salts) can be reacted with sulfonyl chloride 6 (where Hal is a halogen such as I, Br, Cl, or F) in solvent such as DCM, DMF, MeCN, and in presence of a base such as TEA or DIPEA to yield intermediate 12. Introduction of RB3 can take place by a cross-coupling reaction such as e.g. a Suzuki-Miyaura, Negishi, or Stille reaction using similar conditions as described in Scheme 1 starting from intermediate 12 (wherein Hal= Cl, Br, I) to yield 13. Intermediate 13 can also be synthesized starting from aminoester 11 (or the corresponding salt, like HCI or TFA salts) by condensation with a sulfonyl chloride 10 comprising RB3. Ester 13 can then be hydrolysed into the corresponding acid (14) using a base such as LiOH or NaOH in a mixture of solvents such as THF/water. Amide formation between carboxylic acid 14 and amine 3 in a solvent such as THF, DMF, DCM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDC or similar and a base such as DIPEA, TEA or N-methylmorpholine yields compound with formula 9. Final compound 9, wherein RB3 is either -N or -0 linked with Ring B, can be prepared by subjecting 12 (wherein Hal= F or Cl) to a hydrolysis (using a base such as LiOH or NaOH in a mixture of solvents such as
THF/Water) to obtain the corresponding acid (15), followed by an SNAP reaction with the corresponding amine and an inorganic base such as K2CO3 in a solvent such as DMSO or DME, or with the corresponding alcohol in presence of a base such as NaH and in a solvent such as THF, to give 14. Finally, carboxylic acid 14 can be subjected to an amide coupling to give 9 as described herein before.
Scheme 2. Synthesis of sulfonamide 9 by variation of the amide substituent in the last step. Step I) Sulfonamide formation, ii) Cross-coupling, ill) Hydrolysis, iv) Amide formation, v) Hydrolysis vi) SNAP reaction. Sulfonimidamide (SI A) compounds with structure 20, belonging to Formula (I) wherein X3= NRN1 (RN1= alkyl) and X4= N, can be prepared as described in Scheme 3. An arylthiol (16) can be oxidized into its corresponding sulfinate ester 17 by reaction with NBS and MeOH in a solvent such as DCM. Sulfinate ester 17 can be converted into sulfinamide with general structure 19 by reaction with primary amine 18 (or the corresponding salt, like HCI or TFA salts) using a base such as n-BuLi in a solvent like THF. Compound 19 can then be condensed with 5 in presence of a chlorinating agent such as fert-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2- dichloroethane to give SIA derivative 20. If not commercially available, arylthiols 16 are prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
Scheme 3. Synthesis of SIA derivatives 20. Step I) Oxidation, II) Sulfinamide formation, ill) SIA formation.
Compound 24, belonging to Formula (I) wherein X3= NRN1 (RN1= H) and X4= N can be produced as described in Scheme 4. Sulfinate ester 17 can be converted into sulfinamide 21 by reaction with lithium hexamethyldisilazide (LHMDS) in a solvent like THF and hydrolysis with sat. aq. NH4CI. Intermediate 21 can be protected with an appropriate protecting group (PG) to yield 22 using standard protection methods known in the literature and familiar to the person skilled in the art. Compound 22 can be condensed with 5 in presence of a chlorinating agent such as ferf-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2-dichloroethane to give SIA intermediate 23. Compound 24 can then be produced by subjecting intermediate 23 to standard deprotection methods known in the literature and familiar to the person skilled in the art.
Scheme 4. Synthesis of SIA derivative 24. Step i) Sulfinamide formation, ii) Protection, iii) SIA formation, iv) Deprotection.
Alternatively, 20 and 24 can be obtained via a late-stage RB3 functionalization as described in Scheme 5. An arylthiol (25) can be oxidised into its corresponding sulfinate ester (26) and converted into sulfinamide 27 in a similar way as described herein before for the preparation of intermediates 17 and 21. Sulfinamide 28 can be protected with an appropriate protecting group (PG) to yield 28 using standard protection methods known in the literature and familiar to the person skilled in the art. SIA 29 can be obtained by reacting intermediate 28 with 5 in presence of a chlorinating agent such as ferf-butyl hypochlorite or N-chlorosuccinimide in a solvent such as DCM or 1 ,2- dichloroethane. The RB3 group can be introduced from 29, wherein Hal= I, Br, or Cl, by e.g. a Stille cross-coupling reaction with the appropriate organostannyl reagent in a solvent such a dioxane or toluene and in presence of a Pd catalyst such as Pd(PPha)4 or Pd(dppf)Cl2, to yield compound 30. Intermediate 30, wherein RB3 is -N linked with Ring B, can be prepared from 29 (wherein Hal= F or Cl) via an SNAP reaction with the appropriate amine (or the corresponding salt, like HCI or TFA salts) and an inorganic base as K2CO3 in a solvent such as DMSO or DME. The PG can be cleaved using standard deprotection methods known in the literature and familiar to the person skilled in the art to yield 24. SIA 20 can be obtained by subjecting 24 to alkylation using a base such as NaH or KOfBu and an alkylating agent such as an alkyl halide, or an alkyl sulfonates, in a solvent such as DMF. If not commercially available, arylthiols 25 can be prepared following the procedures described in the literature, a method analogous thereto, or as described in the experimental part herein below.
Scheme 5. Alternative synthesis of 20 by late-stage RB3 functionalization. Step i) Oxidation, ii) Sulfinamide formation, iii) Protection, iv) SIA formation, v) Cross-coupling/SNAr reaction, vi) Deprotection, vii) Alkylation.
Sulfone compounds with structure 36, belonging to Formula (I) wherein X3= 0 and X4= C can be prepared as described in Scheme 6. Michael addition between arylthiol 25 (wherein Hal= I, Br, Cl) and commercially available a,p-unsaturated ester 31 in a solvent such as piperidine yields thioether 32. Intermediate 32 is subjected to a Suzuki-Miyaura cross-coupling reaction with the appropriate arylboronic acid or ester in a solvent such as THF or DME and in presence of a base such as K2CO3, NaHCOa or K3PO4 and a Pd catalyst such as Pd (PPhs)4 to give 33. Thioether 33 can be oxidized in presence of an oxidant such as MCPBA and in a solvent such as DOM to lead to sulfone 34. Derivative 34 can be hydrolysed using standard methods as described herein before into its corresponding carboxylic acid 35 with frans-relative configuration. Subsequent amide coupling between 35 and a secondary amine 3 (or the corresponding salt, like HCI or TFA salts) in a solvent such as THF, DMF, DCM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDC, pyClop (or similar), and a base such as DIPEA, TEA or N-methylmorpholine yields 36.
Scheme 6. Synthesis of sulfone compound 36. Step i) Michael addition, ii) Cross-coupling, ill) Oxidation, iv) Hydrolysis, v) Amide Coupling.
Alternatively, 36 can be produced by a RB3 late-stage functionalization as described in the sequence in Scheme 7. Thioether 32, wherein Hal= I, Cl, or Br is subjected to oxidation into its corresponding sulfone (37) by reaction with an oxidant such as MCPBA and in a solvent such as DCM. Hydrolysis of the ester using a base such as LiOH or NaOH in a mixture of solvents such as THF/Water gives carboxylic acid 38 with frans-relative stereochemistry. Subsequent amide coupling between 38 and a secondary amine 3 (or the corresponding salt, like HCI or TFA salts) in a solvent such as THF, DMF, DCM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDC, pyClop (or similar) and a base such as DIPEA, TEA or N-methylmorpholine yields 39. Intermediate 39, wherein Hal= I, Br, or Cl, can be subjected to a Suzuki-Miyaura cross-coupling reaction with the appropriate arylboronic acid or boronic ester in a solvent such as THF or DME and in presence of a base as K2CO3, NaHCOa or KaPO4 and a Pd catalyst such as Pd(PPha)4 to give 36. Intermediate 39, wherein Hal= F, can alternatively be prepared starting from commercially available a,p-unsaturated ester 31 by amide coupling with an amine 3 (or the corresponding salt, like HCI or TFA salts) in a solvent such as THF, DMF, DCM or MeCN in presence of a coupling reagent such as TBTU, HBTU, HATU, EDC, pyClop (or similar) and a base such as DIPEA, TEA or N- methylmorpholine to give 40. Amide 40 can be subjected to hydrosulfonylation in presence of an iridium catalyst as tris(2-phenylpyridine)iridium and a radical reducing agent such as (TMS^SIH in a solvent such as MeCN and under blue LED irradiation (Angew.Chem.lnt.Ed. 2020,59,11620-11626). The formed diastereomers can be separated by flash chromatography on silica gel, HPLC or chiral HPLC or chiral SFC. Intermediate 39, wherein Hal= F, can also be prepared starting from a iodoaryl (41) by cross-coupling with an arylthiol 42 using a catalyst such as Pd(OAc)2 and a ligand such as XantPhos in a solvent like dioxane to yield thioether 43. Intermediate 43 can be oxidised into 44 using an oxidant such as MCPBA and in a solvent such as DCM. Carboxylic acid 44 can be activated using a coupling reagent such as TBTU, HBTU, HATU, EDC, pyCloP (or similar) and be subjected to amide coupling with amine 3 (or the corresponding salt, like HCI or TFA salts) in presence of a base such as DIPEA, TEA, or N-methylmorpholine, in a solvent such as THF, DMF, DCM or MeCN, to give 39. Final compound 36, wherein RB3 is N-linked with Ring B, can be obtained by reacting 39, wherein Hal= F or Cl, with the appropriate amine (or the corresponding salt, like HCI or TFA salts) and an inorganic base such as K2CO3, in a solvent such as DMSO or DME, via an SNAP reaction.
Scheme 7. Synthesis of sulfone compound 36 by late-stage RB3 functionalization. Step I) Oxidation, ii) Hydrolysis, ill) Amide coupling, iv) Cross-coupling/SNAr, v) Amide coupling, vi) Hydrosulfonylation, vii) Cross-coupling, viii) Oxidation, ix) Amide coupling.
Experimental Part Abbrevations (as used herein and in the description above):
Ac Acetyl (such as in OAc = acetate, AcOH = acetic acid)
AcOH Acetic acid
AIBN 2,2'-Azobis(2-methylpropionitrile) anh. Anhydrous aq. aqueous atm Atmosphere tBME fert-Butylmethylether
Bn Benzyl Boc ferf-Butoxycarbonyl
BOC2O di-ferf-Butyl dicarbonate
BSA Bovine serum albumine
Bu Butyl such as in tBu = fert-butyl = tertiary butyl ca circa
CAS chemical abstract system
CHO Chinese Hamster Ovary cone. Concentrated
CPME Cyclopentyl methyl ether d Day(s)
DavePhos 2-Dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl dba dibenzylideneacetone
DBU 1 ,8-Diazabicyclo[5.4.0]undec-7-ene
DCE 1 ,2-Dichloroethane
DCM Dichloromethane
DEA Diethylamine
DIPEA Diisopropylethylamine
DMA Dimethylacetamide
DMAP 4-(N,N-Dimethylamino)pyridine
DME Dimethoxyethane
DMF N,N-Dimethylformamide
DMPU N,N'-Dimethylpropyleneurea
DMSO Dimethyl sulfoxide dppf [1 , 1 '-Bis(d i phenyl phosphino)ferrocene]
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
ELSD Evaporative Light-Scattering Detection eq Equivalent(s)
ES Electron spray
Et Ethyl
Et20 Diethyl ether
EtOAc Ethyl acetate
EtOH Ethanol
Ex. Example
FC Flash Chromatography on silica gel
FCS Foetal calf serum FLIPR Fluorescent imaging plate reader
Fmoc Fluorenylmethoxycarbonyl h Hour(s)
Hal Halogen
HATU 1-[Bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium
3-oxide hexafluorophosphate
HBSS Hank's balanced salt solution
HBTU 2-(1 H-Benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
HEPES 4-(2-Hydroxyethyl)-piperazine-1 -ethanesulfonic acid
Hept Heptane
1H-NMR Nuclear magnetic resonance of the proton
HOBt Hydroxybenzotriazole
HPLC High performance liquid chromatography
IPAc Isopropyl acetate
LC-MS Liquid chromatography - Mass Spectroscopy
LDA Lithium diisopropylamide
LHMDS Lithium hexamethyldisilazide
Lit. Literature
M Exact mass (as used for LC-MS)
M Molarity [mol L’1]
MCPBA 3-Chloroperbenzoic acid
Me Methyl
MeCN Acetonitrile
MeOH Methanol
Mel Methyl iodide
MHz Megahertz min Minute(s)
MS Mass spectroscopy
N Normality
NBS N-Bromosuccinimide
NCS N-Chlorosuccinimide
NMO N-Methylmorpholine N-oxide
NMP N-Methyl-2-pyrrolidone org. Organic
Pd(OAc)2 Palladium diacetate Pd(PPha)4 Tetrakis(triphenyiphosphine)palladium(0)
PL-HCO3 Polymer supported hydrogen carbonate
Ph Phenyl
Prep Preparative pyCloP Chlorotripyrrolidinophosphonium hexafluorophosphate
PTFE Polytetrafluoroethylene
Rf Retention factor rt Room temperature sat. saturated
SIA Sulfonimidamide
SFC Supercritical fluid chromatography soln. Solution
SPhos Dicyclohexyl(2',6'-dimethoxy[1, 1'-biphenyl]-2-yl)phosphane
SPhos Pd G2 Chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1 , 1 '-biphenyl)[2-(2'-amino-1 ,1 ' biphenyl)]palladium(ll), CAS # 1375325-64-6
TBME ferf-Butyl methyl ether
TBTU 2-(1 H-Benzotriazole-1-yl)-1, 1,3,3-tetramethylaminium tetrafluoroborate tBu ferf-Butyl
TEA Triethylamine
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TMP 2,2,6,6-Tetramethylpiperidine
IR Retention time
UPLC Ultra performance liquid chromatography
Wt. Weight
XantPhos 9,9-Dimethyl-4,5-(diphenylphospino)anthene
I. Chemistry
All temperatures are stated in °C. Commercially available starting materials were used as received without further purification. Unless otherwise specified, all reactions were carried out in oven-dried glassware under an atmosphere of nitrogen. Synthesized compounds were purified by flash column chromatography (manual or automatized) on silica gel, or by preparative HPLC. Compounds described in the invention are characterised by LC-MS data (retention time IR is given in min; molecular weight obtained from the mass spectrum is given in g/mol) using the conditions listed below. Racemates can be separated into their enantiomers by preparative HPLC or SFC. N-methyl amines were prepared from the corresponding primary amines by Boc-protection, N-methylation and Boc- deprotection, as described in S. T. Cheung, N. L. Benoiton, Can. J. Chemistry, 1977, 55, 506. Many commercial and prepared amines were used either as free base or as hydrochloride salt in amide couplings and in SiAr-type reactions; unless stated otherwise, the amount of base necessary for running these reactions was used in excess and not adapted to the form of the reacting amine.
NMR
1H-spectra were recorded at rt with a Brucker NMR 500 spectrometer. Chemical shifts are reported in ppm downfield from tetramethylsilane using residual solvent signals as internal reference. The multiplicity is described as singulet s, doublet d, triplet t, quadruplet q, multiplet m. Broad signals are indicated as br.
LC-MS conditions
LC-MS (1)
LC-MS-conditions: Analytical. Pump: Waters Acquity Binary, Solvent Manager, MS: Waters SQ Detector or Xevo TQD, DAD: Acquity UPLC PDA Detector. Column: Acquity UPLC CSH C18 1.7 .m, 2.1 x 50 mm from Waters, thermostated in the Acquity UPLC Column Manager at 60°C. Eluents: A1 : H2O + 0.05 % formic acid; B1 : MeCN + 0.045 % formic acid. Method: Gradient: 2 % B to 98 % B over 2.0 min. Flow: 1.0 mL/min. Detection at 214 nm and MS, retention time IR is given in min.
LC-MS (2)
LC-MS- conditions: Analytical UPLC on a Agilent Zorbax RRHD SB-Aq (2.1x50 mm, 1.8 .m); detection at 210 nM and MS; UPLC/MS analyses are performed on Acquity UPLC setup; the column temperature is 40°C; Gradient of water/ 0.04% TFA (A) and MeCN (B). The eluent flow rate was 0.8 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the table below (a linear gradient being used between two consecutive time points):
LC-MS (3)
LC-MS- conditions: Analytical UPLC on a Waters BEH C18 (2.1x50 mm, 2.5 .m); detection at 210 nM and MS; UPLC/MS analyses are performed on Acquity UPLC setup; the column temperature is 40°C; gradient of water/ 0.04% NH3 [c(NH3) = 13 mmol/l] (A) and MeCN (B). The eluent flow rate was 0.8 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the table below (a linear gradient being used between two consecutive time points):
Preparative LC-MS (Prep. HPLC) methods:
Preparative HPLC/MS purifications are performed on a Gilson HPLC system, equipped with a Gilson 215 autosampler, Gilson 333/334 pumps, Finnigan AQA MS detector system, and a Dionex UV detector, using a Waters Xbridge C18 or a Waters Atlantis column, with a linear gradient of water/formic acid 0.02% (A) and MeCN (B) (acidic prep. HPLC ), or water/ammonia 0.02% (A) and MeCN (B) (basic prep. HPLC ).
Preparative chiral SFC methods:
Preparative chiral SFC purifications were performed on a Sepiatec Prep SFC 360 system. The following parameters were used:
Preparative chiral SFC 1 : A Chiralpak AY-H column (30 x 250 mm, 5 m) was used. The modifier was EtOH (10%), run for 10 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C.
Preparative chiral SFC 2: A ChiralPak IG column (30 x 250 mm, 5 pm) was used. The modifier was MeOH (20%) with EtaNH (0.1 %), run for 3:80 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C
Preparative chiral SFC 3 A ChiralPak IF column (30 x 250 mm, 5 pm) was used. The modifier was CHaCN/EtOH 1 :1 (30%), run for 3.0 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C.
Preparative chiral SFC 4: A ChiralPak IB column (30 x 250 mm, 5 pm) was used. The modifier was MeOH (10%), run for 5 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C
Preparative chiral SFC 5: A ChiralPak IC column (30 x 250 mm, 5 pm) was used. The modifier was CHaCN/EtOH 1 :1 (25%), run for 7 min and at a flow rate of 160 mL/min. The following system settings were used: backpressure 100 bar, temperature pumphead 5 °C, temperature fraction module 20 °C, and temperature column department 40 °C. FC
Flash Chromatographies were performed using an automated system, typically combiflash from Teledyne ISCO.
Phase-separator
Phase separator cartriges used were Isolute® purchased from Biotage
Preparation of Examples:
Methods for the preparation of sulfonamides compounds (Examples 1.x)
Example 1.1 (S)-1-(2'-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide: tert-Butyl (4,4-difluorocyclohexyl)(methyl)carbamate: in a round bottom double-neck flask under N2, NaH (55- 65% in mineral oil, 1.52 g, ca 39.7 mmol, ca 1.5 eq) was suspended in DMF (150 mL) and was stirred at 0 °C. Then, tert-butyl (4,4-difluorocyclohexyl)carbamate (6.23 g, 26.5 mmol, 1 eq) in DMF (50 mL) was added dropwise and the reaction mixture was stirred at 0 °C for 1 h. Methyl iodide (3.30 mL, 52.9 mmol, 2 eq) was added and the reaction mixture was stirred at 0 °C for 3 h. Water (400 mL) was slowly added at 0 °C and the reaction mixture was extracted twice with EtOAc. The combined org. layers were washed with water, dried over MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. 1H NMR (500 MHz, CDCI3) 6: 2.75 (s, 3 H), 2.10-2.25 (m, 2 H), 1.69-1.97 (m, 6 H), 1.64-1.68 (m, 1 H), 1.48 (s, 9 H).
4,4-Difluoro-N-methylcyclohexan-1-amine hydrochloride: HCI (4M in dioxane, 99 mL, 0.40 mol, 15 eq) was added dropwise to a soln, of tert-butyl (4,4-difluorocyclohexyl)(methyl)carbamate (6.60 g, 26.5 mmol, 1 eq) in DCM (250 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was triturated with Et20, filtered, washed with Et20 and dried under reduced pressure to give the title compound. 1H NMR (500 MHz, CDCI3) 6: 9.68-9.89 (m, 2 H), 3.03-3.14 (m, 1 H), 2.70 (t, J = 5.6 Hz, 3 H), 2.25-2.34 (m, 4 H), 1.96-2.06 (m, 2 H), 1.76-1.91 (m, 2 H).
((2-Bromophenyl)sulfonyl)-L-proline: L-proline (1.00 g, 8.64 mmol, 1 eq) was dissolved in aq. NaOH (2M, 17.3 mL, 34.6 mmol, 4 eq). The colorless soln, was cooled to 0 °C and 2-bromobenzenesulfonyl chloride (2.21 g, 8.64 mmol, 1 eq) in THF (13.3 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 5 min, then warmed up to rt and stirred at rt for 1 h. The solvent was removed under reduced pressure, the residue was acidified with aq. 1 M HCI until pH 1-2, and extracted with EtOAc. The org. layer was dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR = 0.74 min; [M+H]+: 334.10.
(S)-1-((2-Bromophenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide: ((2- bromophenyl)sulfonyl)-L-proline (540 mg, 1.60 mmol, 1.1 eq) was dissolved in DMF (10 mL), and DIPEA (0.996 mL, 5.82 mmol, 4 eq) followed by HATU (741 mg, 1 .89 mmol, 1 .3 eq) were added. 4,4-difluoro-N-methylcyclohexan- 1-amine hydrochloride (300 mg, 1.45 mmol, 1 eq) in DMF (4 mL) was immediately added and the yellow soln, was stirred at rt overnight. The mixture was diluted with water and extracted with EtOAc. The org. layer was washed with water and brine, dried over MgSC , filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 4:6) followed by acidic prep. HPLC to give the title compound. Rf (Hept/ EtOAc 1 :2) = 0.38. LC-MS (2): tR = 0.94 min; [M+H]+: 465.97.
(S)-1-(2'-Methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide: to a soln, of (S)-1-((2-bromophenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (40 mg, 0.086 mmol, 1 eq) in degassed DME (0.85 mL) was added 2-tolylboronic acid (14.8 mg, 0.103 mmol, 1.2 eq), followed by aq. 2M K2CO3, (0.052 mL, 0.10 mmol, 1.20 eq) and Pd(PPh3)4 (29.8 mg, 0.0258 mmol, 0.3 eq). The resulting mixture was stirred at 88 °C for 4 h. The reaction mixture was filtered through a PTFE 0.45pm filter, rinsed with EtOAc and water. The layers were separated and the org. layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.257 min; [M+H]+: 477.2.
Example 1.2 (S)-1-(5-Methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide:
((2-Bromo-4-methylphenyl)sulfonyl)-L-proline: L-proline (150 mg, 1.30 mmol, 1 eq) was dissolved in aq. 2M NaOH (2.60 mL, 5.19 mmol, 4 eq). The soln, was cooled to 0 °C and 2-bromo-4-methyl-benzenesulfonyl chloride (349 mg, 1 .30 mmol, 1 eq) in THF (2 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 5 min then at rt for 3 h. The solvent was removed under reduced pressure, the residue was acidified with aq. 1 M HCI to pH 1-2, and was extracted with EtOAc. The org. layer was dried over MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step. LC-MS (2): tR = 0.79 min; [M+H]+: 348.15.
(S)-1-((2-Bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide: ((2-bromo-4-methylphenyl)sulfonyl)-L-proline (193 mg, 0.533 mmol, 1.1 eq) was dissolved in DMF (3 mL). DIPEA (0.332 mL, 1.94 mmol, 4 eq) followed by HATU (247 mg, 0.63 mmol, 1.3 eq) were added. 4,4-Difluoro-N- methylcyclohexan-1 -amine hydrochloride (100 mg, 0.485 mmol, 1 eq) in DMF (1.8 mL) was immediately added and the soln, was stirred at rt for 2 h. The reaction mixture was filtered through a PTFE 0.45 pm filter and directly purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 0.99 min; [M+H]+: 479.10.
(S)-1-(5-Methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide: was synthesized using (S)-1 -((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide and phenylboronic acid in analogy to Example 1.1 to give the title compound. LC- MS (1): tR = 1.266 min; [M+H]+: 477.2. Example 1.3 (S)-1-(5,2'-Dimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and 2-tolylboronic acid in analogy to Example 1.1 to give the title compound. LC-MS (1): tR = 1.317 min; [M+H]+: 491.2.
Example 1.4 to Example 1.5: were synthesized using 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride, L- proline, the appropriate phenyboronic acid, and following the procedure described in Example 1.1. LC-MS data of Example 1.4 to Example 1.5 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.6 (S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-(methyl-d3)-[1 ,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide: tert-Butyl (S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate: 4,4-difluoro-N- methylcyclohexan-1 -amine hydrochloride (33.0 g, 0.178 mol, 1 eq), Boc-L-proline (46.4 g, 0.213 mol, 1.2 eq) and HOBt (32.7 g, 0.213 mol, 1.2 eq) were mixed with DMF (250 mL) and TEA (99.1 mL, 0.711 mol, 4 eq). The soln, was stirred for 10 min at rt, then EDC HCI (41.3 g, 0.213 mol, 1.2 eq) was added at rt. The temperature was kept below 30 °C by the use of a cold water bath and the mixture was stirred for 1 .5 h. The water bath was then removed and the reaction mixture was stirred overnight at rt. The mixture was diluted with IPAc and water. The layers were separated. The org. layer was washed with aq. 1 M HCI and water, dried over MgSO4, filtered, and the solvent was removed under reduced pressure to give the title compound as a yellow oil, which was used as such in the next step. Rf (Hept/EtOAc 1 :1)= 0.22. LC-MS (2): tR = 0.88 min; [M+H]+: 347.27.
(S)-N-(4,4-Difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide: HCI (5M in /-PrOH, 160 mL, 0.808 mol, 5 eq) was added dropwise to tert-butyl (S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidine-1 -carboxylate (56.0 g, 0162 mol, 1 eq) and the reaction mixture was stirred at rt for 1 h. The solvent was removed under reduced pressure. CPME and water were added. The mixture was basified with aq. 1 M NaOH and extracted with DCM. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound. LC-MS (2): tR = 0.51 min; [M+H]+: 247.26.
((2-Bromo-4-chlorophenyl)sulfonyl)-L-proline: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide and 2-bromo-4-chlorobenzene-1 -sulfonyl chloride in analogy to Example 1.3 to give the title compound. LC-MS (2): tR = 1 .03 min; [M+H]+: 499.07. (S)-1-((5-Chloro-2'-fluoro-[1,1'-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: was synthesized using ((2-bromo-4-chloropheny l)sulfony l)-L-proli ne and 2-fluoropheny Iboronic acid in analogy to Example 1.3 to give the title compound. LC-MS (2): tR = 1.09 min; [M+H]+: 515.15.
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-(methyl-d3)-[1,r-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine- 2-carboxamide: to a degassed soln, of (S)-1-((5-chloro-2'-fluoro-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (51.5 mg, 0.100 mmol, 1 eq), methyl-d3-boronic acid (25.2 mg, 0.400 mmol, 4 eq), and CsF (0.0113 mL, 0.300 mmol, 3 eq) in dioxane (1 mL), Pd(OAc)2 (3.44 mg, 0.015 mmol, 0.15 eq) and DavePhos (12.2 mg, 0.030 mmol, 0.3 eq) were added in sequence. The mixture was degassed with N2 for 2 min and stirred at 100 °C for 72 h. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (1): tR = 1.238 min; [M+H]+: 498.2.
Example 1.7 (S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-(methyl- d3)pyrrolidine-2-carboxamide: tert-Butyl (4,4-difluorocyclohexyl)(methyl-d3)carbamate: in a round bottom double-neck flask under N2 atmosphere, to an ice-cooled NaH (55-65%, 244 mg, ca 6.38 mmol, ca 1.5 eq) suspension in DMF (30 mL), was added tert-butyl (4,4-difluorocyclohexyl)carbamate (1000 mg, 4.25 mmol, 1 eq) portionwise. The reaction mixture was stirred at 0 °C for 20 min, then CD3I (0.532 mL, 8.50 mmol, 2 eq) was added. The resulting mixture was stirred at rt for 2 h. The mixture was partitioned between water and EtOAc. The layers were separated and the aq. layer was extracted with EtOAc. The combined org. layers were washed with aq. sat. NaCI, dried over MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): tR = 0.98 min; [M-CH3]+: 238.19. 1H NMR (500 MHz, d6-DMSO) 5: 3.77-4.05 (m, 1 H), 1.83-2.10 (m, 4 H), 1.57-1.76 (m, 4 H), 1.41 (s, 9 H).
4,4-Difluoro-N-(methyl-d3)cyclohexan-1-amine hydrochloride: to an ice-cooled soln, of tert-butyl (4,4- difluorocyclohexyl)(methyl-d3)carbamate (1.10 g, 4.36 mmol, 1 eq) in DOM (20 mL) was added HOI (4M in dioxane, 4 mL, 16 mmol). The resulting mixture was stirred at 0 °C for 10 min then at rt overnight. The reaction mixture was concentrated under reduced pressure to give the title compound. LC-MS (2): tR = 0.32 min; [M+H]+: 153.18.
Methyl ((2-bromo-4-methylphenyl)sulfonyl)-L-prolinate: 2-bromo-4-methylbenzene-1 -sulfonyl chloride (9.99 g, 35.2 mmol, 1.1 eq) was added at rt to a stirred soln, of L-proline methyl ester hydrochloride (5.30 g, 32.0 mmol, 1 eq) and TEA (13.4 mL, 96.0 mmol, 3 eq) in DCM. The resulting soln, was stirred at rt for 1 h. The reaction mixture was diluted with DCM and washed once with brine. The org. layer was separated and the aq. layer was extracted again with DCM. The combined org. layers were dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 7:3) to give the title compound. LC-MS (2): tR = 0.91 min; [M+H]+: 362.1. Methyl ((2'-fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)-L-prolinate: methyl ((2-bromo-4- methylphenyl)sulfonyl)-L-prolinate (9.97 g, 27.5 mmol, 1 eq), (2-fluorophenyl)boranediol (6.08 g, 41.3 mmol, 1.5 eq), Na2CC>3 (8.79 g, 82.5 mmol, 3 eq) and Pd(dppf)Cl2CH2Cl2 (2.25 g, 2.75 mmol, 0.1 eq) were dissolved in degassed 1,4-dioxane I water 4:1 (1.0 mL) and the resulting mixture was stirred at 70 °C for 2.5 h. The reaction mixture was diluted with brine and extracted with DCM. The layers were separated by a separation cartridge. The solvent was removed under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 7:3) to give the title compound. LC-MS (2): tR = 1.00 min; [M+H]+: 378.10.
((2'-Fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)-L-proline: to a soln, of methyl ((2'-fluoro-5-methyl-[1,T- biphenyl]-2-yl)sulfonyl)-L-prolinate (8.30 g, 22.0 mmol, 1 eq) in H2O (41.5 mL) and THF (145 mL) was added at rt UOH H2O (1.40 g, 33.0 mmol, 1.5 eq) and the soln, was stirred during 4 h. The soln, was diluted with brine and washed with DCM. The aq. layer was acidified with aq. 1 M HCI and extracted with DCM. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound as a white solid. LC-MS (2): tR = 0.87 min; [M+H]+: 364.23.
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-(methyl-d3)pyrrolidine- 2-carboxamide: to a soln, of ((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)-L-proline (30.8 mg, 0.0849 mmol, 1 eq) and 4,4-difluoro-N-(methyl-d3)cyclohexan-1-amine hydrochloride (16.0 mg, 0.0849 mmol, 1 eq) in DMF (2 mL), TEA (0.0597 mL, 0.424 mmol, 5 eq) and HATU (34.9 mg, 0.0891 mmol, 1.05 eq) were added in sequence. The resulting mixture was stirred at rt overnight. The mixture was then concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.240 min; [M+H]+: 498.2.
Example 1.8 to Example 1.10: were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and the appropriate phenylboronic acid in analogy to Example 1.1. LC-MS data of Example 1.8 to Example 1.10 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.11 (S)-1-(2-Cyclopent-1-enyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: a soln. of (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (30.0 mg, 0.0626 mmol, 1 eq), cyclopent-1 -en-1-ylboronic acid (10.7 mg, 0.0939 mmol, 1.5 eq), Pd(dppf)Cl2CH2Cl2 (10.7 mg, 0.0131 mmol, 0.2 eq), and NaHCOa (15.8 mg, 0.188 mmol, 3 eq) in H2O (0.12 mL) and DME (0.48 mL) was degassed with N2 for 15 min and stirred at 100 °C for 16 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 6:4) to give the title compound. LC-MS (1): tR= 1.313 min; [M+H]+: 467.2.
Example 1.12 to Example 1.16: were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and the appropriate phenylboronic acid in analogy to Example 1.11. LC-MS data of Example 1.12 to Example 1.16 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.17 (S)-1-(2-Bicyclo[2.2.1]hept-2-yl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: (S)-1-(2-bicyclo[2.2.1]hept-2-en-2-yl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (24.2 mg, 0.0491 mmol, 1 eq) was dissolved in EtOH (1 mL) and Pd/C (10% Pd, -50% H2O, ca 5.23 mg, ca 0.00491 mmol, 0.1 eq) was added. The reaction mixture was purged with H2 and was then stirred at rt for 24 h under a H2 atmosphere. The suspension was filtered through a pad of Celite®, rinsed with DCM, and the filtrate concentrated under reduced pressure to give the title compound as a 1 : 1 mixture of diastereomers. LC-MS (1): tR= 1.313 min; [M+H]+: 467.2.
Example 1.18 (S)-1-(2-Cyclohexyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclohex-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound. LC-MS (1): tR= 1.390 min; [M+H]+: 483.2. Example 1.19 (S)-1-[2-(5,6-Dihydro-2H-pyran-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and 2-(5,6-dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolane in analogy to Example 1.11 to give the title compound. LC-MS (1): IR= 1.151 min; [M+H]+: 483.2.
Example 1.20 (S)-1-(2-Cyclopentyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclopent-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound. LC-MS (1): IR= 1.33 min; [M+H]+: 469.2.
Example 1.21 (S)-1-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide:
(S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide hydrochloride: HCI (4M in dioxane, 46.0 mL, 184 mmol, 19.15 eq) was added dropwise to the soln, of tert-butyl (S)-2-((4,4- difluorocyclohexyl)(methyl)carbamoyl)pyrrolidine-1 -carboxylate (3.88 g, 9.62 mmol, 1 eq) in DCM (96 mL) and the reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated to give the title compound which was used as such in the next step without further purification. LC-MS (2): IR= 0.52 min; [M+H]+: 247.34.
(S)-N-(4,4-Difluorocyclohexyl)-1-((2-fluoro-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: to a mixture of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide hydrochloride (150 mg, ca 0.509 mmol, 1 eq), and TEA (0.717 mL, 5.09 mmol, 10 eq) in DCM (5 mL) was added 2-fluoro-4-methylbenzenesulfonyl chloride (106 mg, 0.509 mmol, 1 eq) and the mixture was stirred at rt for 1 h. Water (5 mL) was added and the reaction mixture was stirred for 10 min, and filtered through phase separator. The org. layer was concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/ EtOAc 1 : 1 ) to give the title compound. LC- MS (2): tR= 0.95 min; [M+H]+: 419.19.
(S)-1-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide: (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2- carboxamide (20.0 mg, 0.0468 mmol, 1 eq) and piperidine (0.0241 mL, 0.234 mmol, 5 eq) were dissolved in DMSO (0.5 mL) and the mixture was stirred at 120 °C for 22 h. The reaction mixture was diluted with water and extracted with EtOAc. The org. layer was washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.225 min; [M+H]+: 484.3.
Example 1.22 (S)-1-(2-Cycloheptyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(2-cyclohept-1-enyl-4-methyl-benzenesulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide in analogy to Example 1.17 to give the title compound. LC-MS (1): tR= 1.444 min; [M+H]+: 497.4.
Example 1.23 to Example 1.24: were synthesized using (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and the appropriate amine or amine salt in analogy to Example 1.21. LC-MS data of Example 1.23 to Example 1.24 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.25 (S)-1-[2-(2-Fluoro-pyridin-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
(S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide: (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (1.00 g, 2.09 mmol, 1 eq), PdCl2(MeCN)2 (11 mg, 0.0417 mmol, 0.02 eq) and SPhos (68.5 mg, 0.167 mmol, 0.08 eq) were put in a microwave vial. The vial was sealed and purged with N2. Dioxane (10 mL), TEA (0.877 mL, 6.26 mmol, 3 eq) and boronic acid pinacol ester (422 mg, 3.13 mmol, 1.5 eq) were added and the resulting mixture was stirred at 110 °C for 2 h. The reaction mixture was filtered through a pad of Celite® and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue purified by FC (Hept to Hept/EtOAc 4:6) to give the title compound. Rf (Hept/ EtOAc 1 :1)= 0.25. LC-MS (2): tR= 1.06 min; [M+H]+: 527.30.
(S)-1-[2-(2-Fluoro-pyridin-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide (20 mg, 0.038 mmol, 1 eq), 2-fluoro-3-iodopyridine (17 mg, 0.076 mmol, 2 eq), NaHCOa (9.6 mg, 0.11 mmol, 3 eq) and Pd(PPha)4 (4.5 mg, 0.0038 mmol, 0.1 eq) were dissolved in degassed DME/water 4: 1 (0.3 mL) and the resulting mixture was stirred at 85 °C for 1 h. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.1 18 min; [M+H]+: 496.2.
Example 1.26 to Example 1.30: were synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and the appropriate aryl halide in analogy to Example 1.25. LC-MS data of Example 1.26 to Example 1.30 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.31 (S)-1-(5,2'-Difluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide:
(S)-1-((2-Bromo-4-fluorophenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide hydrochloride and 2- bromo-4-fluorobenzenesulfonyl chloride in analogy to Example 1.21 to give the title compound. LC-MS (2): tR= 0.96 min; [M+H]+: 483.03.
(S)-1-(5,2'-Difluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide: (S)-1-((2-bromo-4-fluorophenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0414 mmol, 1 eq), 2-fluorophenylboronic acid (11.8 mg, 0.0828 mmol, 2 eq), Na2CO3 (13.2 mg, 0.124 mmol, 3 eq) and Pd(dppf)Cl2CH2Cl2 (3.38 mg, 0.00414 mmol, 0.1 eq) were dissolved in degassed 1 ,4-dioxane I water 4: 1 (0.6 mL) and the resulting mixture was stirred at 70 °C for 1 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The residue was purified basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.216 min; [M+H]+: 499.2.
Example 1.32 to Example 1.37: were synthesized according to the procedures described herein before using (S)- N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide hydrochloride, the appropriate sulfonyl chloride and the appropriate boronic acid or boronic ester. LC-MS data of Example 1.32 to Example 1.37 are listed in the table below.
Example 1.38 (S)-1-(4-Methyl-2-pyrimidin-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2- (4, 4, 5, 5-tetramethy I- 1 ,3, 2-d ioxaborol an -2-y l)pheny I )sulfony l)py rrol id i ne-2-carboxamide and 2-bromopyrimidine in analogy to Example 1.25 to give the title compound. LC-MS (1): IR= 0.957 min; [M+H]+: 479.3.
Example 1.39 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-amide: was synthesized using ((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)-L-proline and 4,4- difluorocyclohexan- 1 -amine in analogy to Example 1 .7 to give the title compound. LC-MS (1): IR= 1 .204 min; [M+H]+: 481.2. Example 1.40: (S)-1-(5-Chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide hydrochloride, 2-bromo-4-chlorobenzene-1 -sulfonyl chloride, and 2-fluorophenylboronic acid in analogy to Example 1.31 to give the title compound. LC-MS (1): IR= 1.291 min; [M+H]+: 515.1.
Example 1.41 to Example 1.49: were synthesized according to the procedures described herein before using ((2- fluoro-5-methyl-[1, -biphenyl]-2-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of
Example 1.41 to Example 1.49 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.51 (S)-1-(5-Cyclobutyl-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-1-(5-chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide (15 mg, 0.0291 mmol, 1 eq) and SPhos Pd G2 (0.84 mg, 0.0012 mmol, 0.04 eq) were dissolved in THF (0.5 mL) under N2 atmosphere. Cyclobutylzinc bromide (0.5 M in THF, 0.175 mL, 0.0874 mmol, 3.0 eq) was added and the reaction mixture was stirred at 55 °C for 5.5 h. The reaction mixture was partitioned between aq. sat. NH4CI and DCM and stirred for 20 min. The org. layer was separated and dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.386 min; [M+H]+: 535.2. Example 1.52 (2S)-1-((2',6-difluoro-[1,r-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide hydrochloride, 2-bromo-3-fluorobenzenesulfonyl chloride, and 2-fluorophenylboronic acid in analogy to Example 1.31 to give the title compound as a mixture of 2 atropisomers. LC-MS (1): IR= 1.173 min; [M+H]+: 499.2. Example 1.53 to Example 1.60: were synthesized according to the procedures described herein before using ((2 - fluoro-5-methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of Example 1.53 to Example 1.60 are listed in the table below. The LC-MS conditions used were LC-MS (1). Example 1.60 (S)-1-(5-Cyclopropyl-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: (S)-1-(5-chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (20.0 mg, 0.0388 mmol, 1 eq) and SPhos Pd G2 (1.12 mg, 0.00155 mmol, 0.04 eq) were dissolved in THF (0.5 mL) under N2 atmosphere. Cyclopropylzinc bromide (0.5 M in THF, 0.234 mL, 0.1 17 mmol, 3 eq) was added and the reaction mixture was stirred at 55 °C for 5 h. The reaction mixture was partitioned between aq. sat. NH4CI and DCM and stirred for 20 min. The org. layer was separated and dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.286 min; [M+H]+: 521.4.
Example 1.61 (S)-1-(2'-Fluoro-5-isopropyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-(5-chloro-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide and 2-propylzinc bromide (0.5 M in THF) in analogy to Example 1.60 to give the title compound. LC-MS (1): IR= 1.344 min; [M+H]+: 523.3.
Example 1.62 (S)-4,4-Difluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: 2-Bromo-2'-fluoro-5-methyl-1 , 1 '-biphenyl : to a degassed soln, of 2-bromo-5-methylphenylboronic acid (443 mg, 2.00 mmol, 1 eq), 2-fluoroiodobenzene (0.233 mL, 2.00 mmol, 1 eq), and CsF (0.133 mL, 3.60 mmol, 1.8 eq) in dioxane (6 mL), PPh3 (106 mg, 0.400 mmol, 0.2 eq) and Pd(OAc)2 (22.5 mg, 0.100 mmol, 0.05 eq) were added. The reaction mixture was stirred at 120 °C for 20 h. The mixture was allowed to cool to rt, diluted with H2O and extracted with DCM. The combined org. layers were dried over MgSC , filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound. Rf (Hept/EtOAc 9:1 )= 0.55. LC-MS (2): tR= 1.08 min; [M+H]+: not seen. 1H NMR (500 MHz, d6-DMSO) 5 7.62 (d, J = 8.1 Hz, 1 H), 7.46-7.51 (m, 1 H), 7.28-7.35 (m, 3 H), 7.17-7.22 (m, 2 H), 2.32 (s, 3 H).
2'-Fluoro-5-methyl-[1,1'-biphenyl]-2-sulfonyl chloride LiCI: to a soln, of 2-bromo-2'-fluoro-5-methyl-1,T- biphenyl (220 mg, 0.83 mmol, 1 eq) in THF (2 mL), cooled to -78 °C, n-BuLi (2.5 M in hexanes, 0.400 mL, 0.996 mmol, 1 .2 eq) was added dropwise. The mixture was stirred at -78 °C for 30 min. SO2 (0.5 M in THF, 3.32 mL, 1 .66 mmol, 2 eq) was added, and the mixture was stirred at -78 °C for 5 h, then allowed to warm to rt and stirred at rt for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was suspended in hexane (8 mL) and cooled to -78 °C. A soln, of SO2CI2 (0.0832 mL, 0.996 mmol, 1 .2 eq) in hexane (2 mL) was added. The reaction mixture was stirred at -78 °C for 30 min, allowed to warm to rt and stirred at rt for 30 min. The reaction mixture was concentrated under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): tR= 1 .06 min; [M+H]+: not seen. 1H NMR (500 MHz, d6-DMSO) 5 7.80 (d, J = 8.0 Hz, 1 H), 7.42 (td, Ji = 1 .8 Hz, J2 = 7.6 Hz, 1 H), 7.26-7.31 (m, 1 H), 7.15 (ddd, Ji = 0.6 Hz, J2 = 1.7 Hz, J3 = 8.0 Hz, 1 H), 7.06-7.12 (m, 2 H), 6.90 (s, 1 H), 2.30 (s, 3 H).
(S)-4,4-Difluoro-1-((2'-fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)pyrrolidine-2-carboxylic acid: to an ice- cooled soln, of (2S)-4,4-difluoropyrrolidine-2-carboxylic acid (62.3 mg, 0.4 mmol, 1 eq) in aq. 2M NaOH (1 mL, 2 mmol, 5 eq), a suspension of 2'-fluoro-5-methyl-[1 , T-biphenyl]-2-sulfonyl chloride LiCI (131 mg, ca 0.40 mmol, 1 eq) in THF (1 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 10 min and then at rt for 1 .5 h. The reaction mixture was diluted with water and acidified with aq. 1 M HCI to pH 1. The mixture was extracted with EtOAc. The combined org. layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 0.94 min; [M+H]+: 400.06.
(S)-4,4-Difluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: to a soln, of (S)-4,4-difluoro-1-((2'-fluoro-5-methyl-[1 , T-biphenyl]-2- yl)sulfonyl)pyrrolidine-2-carboxylic acid (39.9 mg, 0.100 mmol, 1 eq.) in DMF (1 mL), DIPEA (0.0685 mL, 0.400 mmol, 4 eq) and HATU (49.4 mg, 0.130 mmol, 1.3 eq) were added in sequence. 4,4-Difluoro-N-methylcyclohexan- 1-amine hydrochloride (18.6 mg, 0.100 mmol, 1 eq) was added and the mixture was stirred at rt for 6 h. The mixture was purified by acidic prep. HPLC to give the title compound as a white solid. LC-MS (1): tR= 1.288 min; [M+H]+: 531.2. Example 1.63 (S)-1-(2'-Fluoro-5-vinyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-1-((5-chloro-2'-fluoro-[1 , T-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide (46.0 mg, 0.0893 mmol, 1 eq), K2CO3 (24.7 mg, 0.179 mmol, 2 eq), Pd(PPh3)4 (10.3 mg, 0.00893 mmol, 0.1 eq) and 2,4,6-trivinylcyclotriboroxane pyridine complex (21.5 mg, 0.0893 mmol, 1 eq) were dissolved in DME (0.8 mL) and H2O (0.2 mL), and the reaction mixture was degassed for 3 min, then stirred at 100 °C for 6 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.267 min; [M+H]+: 507.2.
Example 1.64 to Example 1.65: were synthesized according to the procedures described herein before using (S)- N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl)sulfony l)pyrrolidine-2-carboxamide and the appropriate aryl halide (chloride, bromide, or iodide). LC-MS data of Example 1.64 to Example 1.65 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.66 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-(2-methoxy-ethyl)-amide:
4,4-Difluoro-N-(2-methoxyethyl)cyclohexan-1-amine hydrochloride: 2-methoxy-ethylamine (0.300 mL, 3.38 mmol, 1 eq), 4,4-difluorocyclohexanone (463 mg, 3.38 mmol, 1 eq), sodium triacetoxyborohydride (2.27 g, 10.2 mmol, 3 eq) and AcOH (0.194 mL, 3.38 mmol, 1 eq) were dissolved in DCM (10 mL) and the reaction mixture was stirred at rt for 18 h. The reaction mixture was poured into water and acidified to pH 2 with aq. 5M HCI. The layers were separated and the aq. layer was basified by addition of aq. 5M NaOH and extracted with DCM. The org. layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was suspended in Et20 and HCI (4M in dioxane) was added. The white suspension was stirred at rt for 15 min and filtered. The solid was washed with Et20 and dried to give the title compound. 1H NMR (500 MHz, CDCI3) 5: 3.52 (m, 2 H), 3.39 (s, 3 H), 2.81 (m, 2 H), 2.61-2.69 (m, 1 H), 2.07-2.18 (m, 2 H), 1.89-1.94 (m, 2 H), 1.70-1.84 (m, 4 H).
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-(2- methoxy-ethyl)-amide: ((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)-L-proline (28.3 mg, ca 0.0779 mmol, ca 1.1 eq) was dissolved in DMF (0.7 mL) then DIPEA (0.0485 mL, 0.283 mmol, 4 eq) and HATU (36.1 mg, 0.0921 mmol, 1.3 eq) were added. 4,4-Difluoro-N-(2-methoxyethyl)cyclohexan-1-amine hydrochloride (16.3 mg, 0.0709 mmol, 1 eq) was immediately added and the yellow soln, was stirred at rt for 2.5 h. The reaction mixture was filtered through a PTFE 0.45 m filter and purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.285 min; [M+H]+: 539.3.
Example 1.67 (S)-1-[2-(2-Cyano-pyridin-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4- methy l-2-(4, 4, 5,5-tetramethy 1-1 , 3, 2-dioxaborol an-2-y I) phenyl)su Ifony l)py rrol idi ne-2-carboxami de and 3- bromopyridine-2-carbonitrile in analogy to Example 1.25 to give the title compound. LC-MS (1): IR = 1.089 min; [M+H]+: 503.2.
Example 1.68 to Example 1.83: were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1,1'- biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to example 1.62. LC-MS data of Example 1 .68 to Example 1 .83 are listed in the table below.
Example 1.84 (S)-1-(5-Ethyl-2'-fluoro-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-1-(2'-fluoro-5-vinyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide (28.7 mg, 0.0567 mmol, 1 eq) was dissolved in EtOH (1 mL) and Pd/C (10% Pd, -50% H2O, 6.03 mg, ca 0.00567 mmol, ca 0.1 eq) was added. The reaction mixture was purged with H2 and was then stirred at rt for 20 h under an H2 atmosphere. The reaction mixture was filtered through Celite® and the filtrate was concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 6:4) to give the title compound. Rf (Hept/ EtOAc 1 :1)= 0.30. LC-MS (1): tR = 1.267 min; [M+H]+: 507.2.
Example 1.85 (S)-1-[2-(4-Cyano-pyridin-3-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4- methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and 3- bromoisonicotinonitrile in analogy to Example 1.25 to give the title compound. LC-MS (1): tR= 1.059 min; [M+H]+: 503.2. Example 1.86 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid methyl- (tetrahydro-pyran-4-yl)-amide: was synthesized using ((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)-L-proline and N-methyloxan-4-amine in analogy to Example 1.7 to give the title compound. LC-MS (1): tR= 1.076 min; [M+H]+: 461.2.
Example 1.87 (2S,5R)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized according to the procedures described herein before using (2S,5R)-1-[(tert-butoxy)carbonyl]-5-methylpyrrolidine-2-carboxylic acid, 2'-fluoro-5-methyl-[1 ,1 '-biphenyl]-2- sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochloride in analogy to Example 1.6 to give the title compound. LC-MS (2): tR= 0.94 min; [M+H]+: 378.12.
Example 1.88 (S)-1-(4-Methyl-2-oxazol-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide (20.0 mg, 0.0417 mmol, 1 eq), 2-(tri-n-butylstannyl)oxazole (29.9 mg, 0.0834 mmol, 2 eq) and Pd(dppf)Cl2CH2Cl2 (3.41 mg, 0.004 mmol, 0.1 eq) were dissolved in dioxane (0.5 mL) and the resulting mixture was stirred at 100 °C for 1 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by basic prep. HPLC conditions to give the title compound. LC-MS (1): tR= 1.027 min; [M+H]+: 468.2.
Example 1.89 to Example 1.93: were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1 ,T- biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to Example 1.62. LC-MS data of Example 1.89 to Example 1.93 are listed in the table below. The LC-MS conditions used were LC- MS (1). Example 1.94 (S)-1-(4-Methyl-2-[1,2,3]triazol-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
2-(5-Methyl-2-nitrophenyl)-2H-1,2,3-triazole: 1 H-1 ,2,3-triazole (0.839 mL, 14.5 mmol, 1 eq) and 3-fluoro-4- nitrotoluene (2.25 g, 14.5 mmol, 1 eq) and K2CO3 (2.02 g, 14.5 mmol, 1 eq) were dissolved in DMF (25 mL), and the reaction mixture was stirred at 75 °C for 15 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined org. layers were washed with brine, dried over MgSC , filtered, and the solvent removed under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 4:6) to give 2-(5-methyl-2- nitrophenyl)-2H-1 ,2,3-triazole (first eluting isomer) and 1-(5-methyl-2-nitrophenyl)-1 H-1 ,2,3-triazole. 2-(5-Methyl-2- nitrophenyl)-2H-1 ,2,3-triazole: Rf (Hept/EtOAc 1 : 1) = 0.62, LC-MS (2): tR= 0.83 min; [M+H]+: 205.24. 1-(5-methyl- 2-nitrophenyl)-1 H-1 ,2,3-triazole: Rf (Hept/EtOAc 1 : 1) = 0.28, LC-MS (2): tR= 0.72 min; [M+H]+: 205.24.
4-Methyl-2-(2H-1,2,3-triazol-2-yl)aniline: 2-(5-methyl-2-nitrophenyl)-2H-1,2,3-triazole (890 mg, 4.36 mmol, 1 eq) was dissolved in MeOH (50 mL) and Pd/C (10% Pd, -50% H2O, 928 mg, ca 0.436 mmol, ca 0.1 eq) was added. The reaction mixture was purged with H2 and the mixture was then stirred at rt for 1 .5 h under an H2 atmosphere at atmospheric pressure. The reaction mixture was filtered through a Celite® pad and the filtrate was concentrated under reduced pressure to give the title compound, which was used without further purification in the next step. LC- MS (2): tR= 0.69 min; [M+H]+: 175.44.
2-(2-Bromo-5-methylphenyl)-2H-1 ,2,3-triazole: CuE (0.136 mL, 2.87 mmol, 1 eq) was dissolved in CH3CN (10 mL) and tert-butyl nitrite (0.419 mL, 3.16 mmol, 1 .1 eq) was added. The solution was cooled to 0 °C and a soln, of 4-methyl-2-(2H-1 ,2,3-triazol-2-yl)aniline (500 mg, 2.87 mmol, 1 eq) in CH3CN (5 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 1 h and then at rt for 1 h. The reaction mixture was cooled down to 0 °C and quenched with an aq. soln, of sulfamic acid (1mL containing 56.1 mg, 0.574 mmol, 0.2 eq), followed by the addition of aq. 2M HCI (2.16 mL, 4.31 mmol, 1.5 eq). The mixture was then diluted with water and extracted with EtOAc. The combined org. layers were washed with water, dried with MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound as a yellow oil. Rf (Hept/EtOAc 8:2)= 0.40. LC-MS (2): tR= 0.89 min; [M+H]+: 238.18.
2-(2-(Benzylthio)-5-methylphenyl)-2H-1,2,3-triazole: 2-(2-bromo-5-methylphenyl)-2H-1 ,2,3-triazole (100 mg, 0.42 mmol, 1 eq), benzyl mercaptan (0.0498 mL, 0.42 mmol, 1 eq) and DIPEA (0.147 mL, 0.84 mmol, 2 eq) were dissolved in degassed dioxane (1.6 mL) and the resulting mixture was stirred at 95 °C. Pd2(dba)3 (19.2 mg, 0.021 mmol, 0.05 eq) and XantPhos (24.8 mg, 0.042 mmol, 0.1 eq) were added, and the reaction mixture was stirred at 95 °C for 24 h. Benzyl mercaptan (0.0498 mL, 0.42 mmol, 1 eq), DIPEA (0.147 mL, 0.84 mmol, 2 eq), Pd2(dba)3 (19.2 mg, 0.021 mmol, 0.05 eq) and XantPhos (24.8 mg, 0.042 mmol, 0.1 eq) were added again and the reaction mixture was stirred at 95 °C for 48 supplementary hours. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EA 95:5) to give the title compound. LC-MS (2): tR= 1.04 min; [M+H]+: 282.23. 4-Methyl-2-(2H-1,2,3-triazol-2-yl)benzenesulfonyl chloride: 2-(2-(benzylthio)-5-methylphenyl)-2H-1 ,2,3-triazole (50 mg, 0.102 mmol, 1 eq) was dissolved in DCM (1.5 mL) and stirred at 0 °C. Water (73.2 JLLL, 0.406 mmol, 4 eq), AcOH (23.2 |j.L, 0.406 mmol, 4 eq) and SO2CI2 (33.9 JLLL, 0.406 mmol, 4 eq) were added dropwise and the reaction mixture was stirred at 0 °C for 5 min then at rt for 1 .5 h. The reaction mixture was cooled down to 0 °C and water (1 mL) was added. The phases were separated and the aq. layer was extracted with DCM. The combined org. layers were washed with cold water, dried with MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR= 0.89 min; [M+H]+: 258.04.
(S)-1-(4-Methyl-2-[1,2,3]triazol-2-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: to a mixture of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (25.0 mg, 0.102 mmol, 1 eq), and TEA (0.0429 mL, 0.305 mmol, 3 eq) in DCM (1 mL) was added 4-methyl-2-(2H- 1 ,2,3-triazol-2-yl)benzenesulfonyl chloride (26.2 mg, 0.102 mmol, 1 eq) and the mixture was stirred at rt for 10 min. H2O (1 mL) was added and the reaction mixture was stirred for 5-10 min and the mixture filtered over a phase separator. The org. phase was concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 3:7) to give the title compound. Rf (Hept/EtOAc 1 : 1)= 0.10. LC-MS (1): IR= 1.031 min; [M+H]+: 468.2.
Example 1.95 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-oxo-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using 4-oxo-L-proline hydrobromide, 2'-fluoro-5-methyl- [1 , 1 '-biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochloride in analogy to Example 1.62 to give the title compound. LC-MS (1): IR= 1.215 min; [M+H]+: 509.1.
Example 1.96 (S)-1-[4-Methyl-2-(5-methyl-oxazol-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide (20 mg, 0.037 mmol, 1 eq), 2- bromo-5-methyl-oxazole (12 mg, 0.075 mmol, 2 eq), Na2CO3 (12 mg, 0.11 mmol, 3 eq) and Pd(dppf)Cl2CH2Cl2 (3 mg, 0.0037 mmol, 0.1 eq) were dissolved in degassed 1 ,4-dioxane/water 4: 1 (0.5 mL) and the resulting mixture was stirred at 70 °C for 1.5 h. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to 100% EtOAc) to give the title compound. Rf (Hept/ EtOAc 2:8)= 0.25. LC-MS (1): IR= 1.082 min; [M+H]+: 482.2.
Example 1.97 (S)-1-(5,2',6'-Trimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide:
2-Bromo-2',5,6'-trimethyl-1,1'-biphenyl: in a microwave vial, 4-bromo-3-iodotoluene (97%, 100 mg, 0.327 mmol, 1 eq), 2,6-dimethylphenylboronic acid (49.0 mg, 0.327 mmol, 1 eq), K2CO3 (228 mg, 1.63 mmol, 5 eq) and Pd(PPh3)4 (38.9 mg, 0.0327 mmol, 0.1 eq) were dissolved in degassed dioxane I water 4:3 (3.3 mL) and the resulting mixture was stirred at 165 °C for 20 min under microwave irradiations. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (100% Hept) to give the title compound. Rf (Hept)= 0.38. LC-MS (2): IR= 1.16 min; [M+H]+: not seen. 1H NMR (500 MHz, CDCI3) 6: 7.57 (d, J = 8.2 Hz, 1 H), 7.20-7.24 (m, 1 H), 7.12-7.14 (m, 2 H), 7.05 (dd, Ji = 2.0 Hz, J2 = 8.3 Hz, 1 H), 6.98-7.00 (m, 1 H), 2.36 (s, 3 H), 2.02 (s, 6 H).
2,,5,6'-Trimethyl-[1,1'-biphenyl]-2-sulfonyl chloride LiCI: 2-bromo-2', 5, 6’-trimethyl-1 ,1 '-biphenyl (50 mg, 0.145 mmol, 1 eq) was dissolved in THF (1.5 mL) and stirred at -78 °C. n-BuLi (1.6 M in hexanes, 0.109 mL, 0.174 mmol, 1.2 eq) was added dropwise and the reaction mixture was stirred at -78°C for 2 h. SO2 (0.5 M in THF, 0.582 mL, 0.291 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 1 h then at rt for 22 h. The reaction mixture was concentrated under reduce pressure and the residue was suspended in DCM (1 .5 mL) and stirred at - 78 °C. A soln, of SO2CI2 (0.0146 mL, 0.174 mmol, 1.2 eq) in DCM (2 mL) was added. The reaction mixture was stirred at -78 °C for 45 min, allowed to warm to rt and concentrated to give the title compound, which was used as such in the next steps. LC-MS (2): IR= 1.13 min; [M+H]+: not seen.
(S)-1-(5,2',6'-Trimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide: to a mixture of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (36.0 mg, 0.146 mmol, 1 eq), and TEA (0.0617 mL, 0.438 mmol, 3 eq) in DCM (1.5 mL) was added 2',5,6'-trimethyl-[1 , T-biphenyl]- 2-sulfonyl chloride LiCI (49 mg, ca 0.146 mmol, 1 eq) and the mixture was stirred at rt for 17 h. Water (1 mL) was added and the reaction mixture was stirred for 5-10 min, filtered over phase separator and the solvent removed under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 6:4) followed by basic prep. HPLC to give the title compound. Rf (Hept/EtOAc 1 :1)= 0.30. LC-MS (1): IR= LC-MS (2): IR= 1.271 min; [M+H]+: 505.2.
Example 1.98 (S)-1-[2-(2-Chloro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
(S)-1-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: to a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (401 mg, 1.63 mmol, 1.2 eq), DIPEA (0.927 mL, 5.42 mmol, 4 eq) and DMAP (16.6 mg, 0.136 mmol, 0.1 eq) in DCM (2 mL) was added 2-chloro-6-methylpyridine-3-sulfonyl chloride (450 mg, 1.36 mmol, 1 eq) at rt. The mixture was stirred for 1 h at rt, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.91 min; [M+H]+: 436.22.
(S)-1-[2-(2-Chloro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), 2-chlorophenylboronic acid (14.6 mg, 0.0918 mmol, 2 eq) and Na2CO3 (11.6 mg, 0.138 mmol, 3 eq) in a 4:1 mixture of DME and water (0.3 mL) was degassed with N2. The mixture was rapidly heated to 100 °C, and Pd(PPhs)4 (5.5 mg, 0.0046 mmol, 0.1 eq) was added. The mixture was stirred at 100 °C for 1 h, and allowed to cool to rt. The mixture was filtered and the solvents removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.113 min; [M+H]+: 512.2. Example 1.99 (S)-1-[2-(2-Fluoro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (15.0 mg, 0.0334 mmol, 1 eq), 2-fluorophenylboronic acid (9.9 mg, 0.069 mmol, 2 eq) and Na2COa (8.7 mg, 0.10 mmol, 3 eq) in a 4:1 mixture of DME and water (0.3 mL) was degassed with N2. The mixture was rapidly heated to 100 °C, and Pd(PPh3)4 (4.1 mg, 0.0034 mmol, 0.1 eq) was added. The mixture was stirred at 100 °C for 1 h, and allowed to cool to rt. The mixture was filtered and the solvents removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC- MS (1): tR = 1.070 min; [M+H]+: 496.2.
Example 1.100 to example 1.101 : were synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl- 2-(4,4, 5,5-tetramethy 1-1 , 3, 2-dioxaborolan-2-y I) pheny l)su Ifony I) py rrol idine-2-carboxami de and the appropriate bromoaryl in analogy to Example 1.96. LC-MS data of Example 1.100 to Example 1.101 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.102 (S)-1-[4-(2-Chloro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
5-(Benzylthio)-4-chloro-2-methylpyridine: a mixture of 5-bromo-4-chloro-2-methylpyridine (500 mg, 2.32 mmol, 1 eq), benzyl mercaptan (292 mg, 2.32 mmol, 1 eq) and DIPEA (0.812 mL, 4.65 mmol, 2 eq) in dioxane (10 mL) was degassed with N2. The mixture was rapidly heated to 95 °C, and Pd2(dba)3 (106 mg, 0.116 mmol, 0.05 eq) and XantPhos (137 mg, 0.232 mmol, 0.1 eq) were added. The mixture was heated under microwave irradiation at 95 °C for 15 min, and was allowed to cool to rt. The mixture was filtered and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to EtOAc I Hept 7:3) to give the title compound. LC-MS (2): tR = 0.89 min; [M+H]+: 250.25.
4-Chloro-6-methylpyridine-3-sulfonyl chloride: to a soln, of 5-(benzylthio)-4-chloro-2-methylpyridine (495 mg, 1 .98 mmol) in THF (2 mL), AcOH (0.2 mL) and water (0.4 mL) at 0 °C was added 1 , 3-dich loro-5,5-dimethy I hydantoi n (1.21 g, 5.95 mmol, 3 eq) in portions. The mixture was stirred for 1 h at 0 °C. DCM (30 mL) was added, and this mixture was washed with aq. sat. NaHCOs and brine. The org. layer was dried through a phase separator, filtered, and the solvents were removed under reduced pressure to give the title compound, wich was used without further purification. (S)-1-((4-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: to a mixture of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (458 mg, 1.86 mmol, 1.2 eq), DIPEA (1.59 mL, 9.29 mmol, 6 eq) and DMAP (18.9 mg, 0.155 mmol, 0.1 eq) in DCM (2 mL) was added 4-chloro-6-methylpyridine-3-sulfonyl chloride (350 mg, ca 1.55 mmol, ca 1 eq) in DCM (1 mL). The mixture was stirred for 1 h at rt, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to EtOAc) to give the title compound. LC-MS (2): tR = 0.90 min; [M+H]+: 436.21.
(S)-1-[4-(2-Chloro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((4-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (50.0 mg, 0.115 mmol, 1 eq), 2-chlorophenylboronic acid (36.6 mg, 0.229 mmol, 2 eq) and Na2CO3 (29.0 mg, 0.344 mmol, 3 eq) in a 4:1 mixture of DME and water (2 mL) was degassed with N2. The mixture was rapidly heated to 100 °C, and Pd(PPh3)4 (13.7 mg, 0.0115 mmol, 0.1 eq) was added. The mixture was stirred at 100 °C for 18 h, and allowed to cool to rt. The mixture was filtered and the solvents removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.150 min; [M+H]+: 512.1.
Example 1.103 (S)-1-[4-(2-Fluoro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((4-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (50.0 mg, 0.115 mmol, 1 eq), 2-fluorophenylboronic acid (32.8 mg, 0.229 mmol, 2 eq) and Na2CO3 (29.0 mg, 0.344 mmol, 3 eq) in a 4:1 mixture of DME and water (2 mL) was degassed with N2. The mixture was rapidly heated to 100 °C, and Pd(PPh3)4 (13.7 mg, 0.0115 mmol, 0.1 eq) was added. The mixture was stirred at 100 °C for 18 h, and allowed to cool to rt. The mixture was filtered and the solvents removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.094 min; [M+H]+: 496.2.
Example 1.104 to Example 1.109: were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1,T- biphenyl]-2-sulfonyl chloride LICI and 4,4-difluorocyclohexan-1-amine hydrochlororide in analogy to Example 1.62. LC-MS data of example 1.104 to Example 1.109 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.110 (S)-1-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-4,4-difluoro-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
(S)-1-((2-Bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-4,4-difluoro-N-methylpyrrolidine-2- carboxamide: was synthesized using (2S)-4,4-difluoropyrrolidine-2-carboxylic acid and 2-bromo-4- methylbenzene-1 -sulfonyl chloride in analogy to Example 1.1 to give the title compound. LC-MS (2): IR = 1.05 min; [M+H]+: 515.08.
(S)-N-(4,4-Difluorocyclohexyl)-4,4-difluoro-N-methyl-1-((4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide: was synthesized using (S)-1-((2-bromo-4- methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-4,4-difluoro-N-methylpyrrolidine-2-carboxamide in analogy to Example 1.25 to give the title compound. LC-MS (2): IR= 1.11 min; [M+H]+: 563.23.
(S)-1-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-4,4-difluoro-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-4,4-difluoro-N- methyl-1-((4-methyl-2-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2 -carboxamide and 2-bromo-3-chloropyridine in analogy to Example 1.25 to give the title compound. LC-MS (1): IR= 1.198 min; [M+H]+: 548.2.
Example 1.111 2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: tert-Butyl -1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-5-carboxylate: to a soln, of tert-butyl-4,5-dihydro-1 H-pyrazole-5-carboxylate (40.0 mg, 0.235 mmol, 1 eq) in MeCN (3 mL), K2CO3 (162 mg, 1.18 mmol, 5 eq) and 2'-fluoro-5-methyl-[1 , 1 '-biphenyl]-2-sulfonyl chloride LICI (66.9 mg, ca 0.235 mmol, 1 eq) were added in sequence and the reaction mixture was heated at 80 °C overnight. The reaction mixture was allowed to cool to rt and was concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 1.04 min; [M+H]+: 419.27.
1-((2'-Fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-4,5-dihydro-1 H-pyrazole-5-carboxylic acid: to a soln, of tert-butyl 1-((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)-4,5-dihydro-1 H-pyrazole-5-carboxylate (39 mg, 0.0932 mmol, 1 eq) in DCM (2 mL), TFA (0.0721 mL, 0.932 mmol, 10 eq) was added dropwise. The resulting mixture was stirred at rt overnight. The volatiles were removed under reduced pressure to give the title compound. LC-MS (2): tR= 0.83 min; [M+H]+: 363.25.
2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: to a soln, of 1-((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)-4,5-dihydro-1 H- pyrazole-5-carboxylic acid (15.4 mg, 0.0424 mmol, 1 eq) and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (7.87 mg, 0.0424 mmol, 1 eq) in DMF (1 mL), TEA (0.0298 mL, 0.212 mmol, 5 eq) and HATU (17.4 mg, 0.0445 mmol, 1.05 eq) were added in sequence. The resulting mixture was stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.157 min; [M+H]+: 494.2.
Example 1.112: (2S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5,6'-dimethyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide:
2'-Fluoro-5,6'-dimethyl-[1 ,1'-biphenyl]-2-sulfonyl chloride LICI: was synthesized using 4-bromo-3-iodotoluene and 2-fluoro-6-methylphenylboronic acid in analogy to Example 1.97 to give the title compound. LC-MS (2): tR= 1.07 min; [M+H]+: not seen.
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5,6'-dimethyl-[1 ,1'-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide: was synthesized using 2'-fluoro-5,6'-dimethyl-[1,T-biphenyl]-2-sulfonyl chloride LiCI and (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 1.97 to give the title compound. LC-MS (2): tR= 1.270 min; [M+H]+: 509.3.
Example 1.113 1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4,5-dihydro-1 H-pyrrole-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
(2R,3R)-3-Fluoro-1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)pyrrolidine-2-carboxylic acid: to an ice- cooled soln, of (2R,3R)-1-[(tert-butoxy)carbonyl]-3-fluoropyrrolidine-2-carboxylic acid (35 mg, 0.15 mmol, 1 eq) in DCM (3 mL), HCI (4M in dioxane, 0.5 mL) was added. The resulting soln, was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in DCM (2 mL), and TEA (0.105 mL, 0.75 mmol, 5 eq) and 2'-fluoro-5,6'-dimethyl-[1 ,T-biphenyl]-2-sulfonyl chloride LiCI (49 mg, ca 0.15 mmol, 1 eq) were added in sequence. The resulting soln, was stirred at rt overnight. The solvent was removed under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR= 0.88 min; [M+H]+: 382.28.
1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4,5-dihydro-1 H-pyrrole-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a soln. of (2R,3R)-3-fluoro-1-((2'-fluoro-5-methyl-[1,T-biphenyl]-2- yl)sulfonyl)pyrrolidine-2-carboxylic acid (19 mg, 0.05 mmol, 1 eq) and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (9.3 mg, ca 0.05 mmol, 1 eq) in DCM (2 mL) were treated with TEA (0.028 mL, 0.20 mmol, 4 eq) and HATU (21 mg, 0.055, 1.1 eq). The resulting soln, was stirred at rt overnight. The solvent was removed under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.248 min; [M+H]+: 493.2.
Example 1.114 to Example 1.119: were synthesized in analogy to Example 1.98 using the appropriate boronic acids. LC-MS data of Example 1.1 14 to Example 1.119 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.120: 2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: l-(tert-Butyl) 5-ethyl 3-methyl-4,5-dihydro-1H-pyrazole-1,5-dicarboxylate: CuCI2 (26.9 mg, 0.200 mmol, 0.2 eq) was added to a soln, of tert-butyl (E)-2-(1-chloropropan-2-ylidene)hydrazine-1-carboxylate (207 mg, 1.00 mmol, 1 eq), ethyl diazoacetate (0.363 mL, 3.00 mmol, 3 eq), and Na2CO3 (530 mg, 5.00 mmol, 5 eq) in DCM (8 mL), and the reaction mixture was stirred at rt for 5 h. The mixture was then filtered through a Celite® pad and washed with DCM. After removal of the solvent, the residue was purified by FC (Hept to Hept/EtOAc 1 :1) to give the title compound. Rf (Hept/EtOAc 1 : 1)= 0.25; 1H NMR (500 MHz, CDCI3) 6: 4.70 (dd, Ji = 5.8 Hz, J2 = 12.2 Hz, 1 H), 4.19- 4.29 (m, 2 H), 3.18 (dd, Ji = 17.9 Hz, J2 = 12.6 Hz, 1 H), 2.85 (dd, Ji = 18.0 Hz, J2 = 6.0 Hz, 1 H), 2.05 (s, 3 H), 1 .47-1 .56 (m, 9 H), 1 .30 (t, J = 7.1 Hz, 3 H); LC-MS (2): tR = 0.76 min; [M+H]+: not seen.
Ethyl 1-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazole-5-carboxylate: to an ice-cooled soln, of (tert-butyl) 5-ethyl 3-methyl-4,5-dihydro-1 H-pyrazole-1 ,5-dicarboxylate (51.3 mg, 0.200 mmol, 1 eq) in DCM (3 mL), HCI (4M in dioxane, 0.5 mL) was added. The resulting soln, was stirred at rt overnight. The volatiles were removed under reduced pressure. The residue was dissolved in DCM (2 mL), and TEA (0.139 ml, 1.00 mmol, 5 eq) and 2'-fluoro-5,6'-dimethyl-[1,T-biphenyl]-2-sulfonyl chloride LICI (65.4 mg, ca 0.2 mmol,1 eq) were added in sequence. The resulting soln, was stirred at rt overnight. The solvent was removed under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.99 min; [M+H]+: 405.29.
1-((2'-Fluoro-5-methyl-[1 J'-biphenyl]-2-yl)sulfonyl)-3-methyl-4,5-dihydro-1 H-pyrazole-5-carboxylic acid: to a soln, of ethyl 1-((2'-fluoro-5-methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-3-methyl-4,5-dihydro-1 H-pyrazole-5-carboxylate (19.7 mg, 0.0487 mmol, 1 eq) in THF (2 mL) and EtOH (1 mL) was added aq. 1 M NaOH (1 mL) and the reaction stirred overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (2): IR= 0.86 min; [M+H]+: 377.29.
2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: to a soln, of 1-((2'-fluoro-5-methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-3-methyl- 4,5-dihydro-1 H-pyrazole-5-carboxylic acid (16 mg, 0.0424 mmol, 1 eq) and 4,4-difluoro-N-methylcyclohexan-1- amine hydrochloride (7.87 mg, ca 0.0424 mmol, 1 eq) in DMF (1 mL), TEA (0.0298 mL, 0.212 mmol, 5 eq) and HATU (17.4 mg, 0.0445 mmol, 1.05 eq) were added in sequence. The resulting mixture was stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.178 min; [M+H]+: 508.2.
Example 1.121 (1S,2S,5R)-3-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-3-aza- bicyclo[3.1.0]hexane-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (1S,2S,5R)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid hydrochloride, 2-bromo-4-methylbenzene-1 -sulfonyl chloride and 2-bromo-3-chloropyridine in analogy to Example 1.110 to give the title compound. LC-MS (1): IR= 1.176 min; [M+H]+: 524.3.
Example 1.122 (1S,3S,5S)-2-[2-(3-Chloro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-2-aza- bicyclo[3.1.0]hexane-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid hydrochloride, 2-bromo-4-methylbenzene-1 -sulfonyl chloride and 2-bromo-3-chloropyridine in analogy to Example 1.110 to give the title compound. LC-MS (1): IR= 1.167 min; [M+H]+: 524.2.
Example 1.123 (S)-1-(6'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), piperidine (0.0114 mL, 0.1 15 mmol, 2.5 eq) and K2CO3 (32.0 mg, 0.229 mmol, 5 eq) in DMSO (1 mL) and DME (0.25 mL) was heated to 100 °C for 24 h. The mixture was allowed to cool to rt and diluted with water (2 mL) and DCM (50 mL). The layers were separated, and the aq. layer was extracted with DCM (2x). The combined org. layers were washed with brine, dried over MgSO4, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.275 min; [M+H]+: 485.3. Examples 1.124 to 1.130: were synthesized in analogy to Example 1.123 using the corresponding amines. LC- MS data of Example 1.124 to Example 1.130 are listed in the table below. The LC-MS conditions used were LC- MS (1). Example 1.131 (S)-1-(2',6'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide:
(S)-N-(4,4-Difluorocyclohexyl)-1-((2-iodo-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: to a mixture of (S)-N-(4,4-difl uorocyclohexy l)-N-methy Ipy rrolidi ne-2-carboxamide (739 mg, 3.00 mmol, 1 eq), and TEA (1.27 mL, 9.00 mmol, 3 eq) in DCM (29.6 mL) was added 2-iodo-4-methylbenzene-1 -sulfonyl chloride (1.00 g, 3.00 mmol, 1 eq) and the mixture was stirred at rt for 1 h. Water was added at rt, the reaction mixture was stirred for 5 min then filtered over phase separator. The solvent was evaporated under reduced pressure. The residue was purified by FC (Hept to Hept/EAtOAc 4:6) to give the title compound. LC-MS (2): IR = 1 .05 min; [M+H]+: 527.08.
(S)-1-(2',6'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide: in an oven dried sealed microwave vial, to a soln, of 2,6-difluoroiodobenzene (0.061 mL, 0.35 mmol, 2.3 eq) in DMPU (0.152 mL, 0.152 mmol, 1 eq) was added Et2Zn (1.0 M in hexanes, 0.228 mL, 0.228 mmol, 1.5 eq) at rt. The soln, was warmed to 77 °C and stirred for 3 h. The soln, was cooled to rt. The seal was removed, (S)- N-(4,4-difluorocyclohexyl)-1-((2-iodo-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide (80 mg, 0.152 mmol, 1 eq), 1 , 10-phenanthroline (5.65 mg, 0.0304 mmol, 0.2 eq) and Cui (2.89 mg, 0.0152 mmol, 0.1 eq) were added, the vial sealed again, purged with N2 and heated to 120 °C and stirred overnight. Aq. 1 M HCI and DCM were added and mixture was stirred for 5 min. The two phases were separated by a separation cartridge. The solvent was removed under reduced pressure and the residue was purified by acidic prep HPLC followed by FC (Hept to Hept/EtOAc 1 : 1) to give the title compound. LC-MS (1): IR = 1.227 min; [M+H]+: 513.2.
Example 1.132 to Example 1.135: were synthesized using the appropriate amino acid or amino acid salt according to the procedures described in Example 1.21. LC-MS data of Example 1.132 to Example 1.135 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.136 (S)-1-[4-Methyl-2-(3-methyl-pyrazin-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1 -((4- methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide and 2-bromo-3- methylpyrazine in analogy to Example 1.96 to give the title compound. LC-MS (1): IR = 1.027 min; [M+H]+: 493.2.
Example 1.137 (S)-1-[4-Methyl-2-(5-methyl-pyrazol-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-N-(4,4-difluorocyclohexyl)-1-((2-iodo-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide (150 mg, 0.285 mmol, 1 eq), 3-methylpyrazole (24.1 mg, 0.285 mmol, 1 eq), CU2O (1.36 mg, 0.0095 mmol, 0.1 eq), salicylaldoxime (16.0 mg, 0.114 mmol, 0.4 eq) and CS2CO3 (186 mg, 0.57 mmol, 2 eq) in CH3CN (2.85 mL) was degassed with a N2 flux during 10 min and heated to reflux for 18 h. The mixture was filtered, the solvent removed under reduced pressure and the residue was purified by FC (Hept/EtOAc 3:7) followed by basic HPLC to give the title compound. LC-MS (3): IR = 0.97 min; [M+H]+: 481.17. (S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(3-methyl-1 H-pyrazol-1- yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide: LC-MS (3): IR = 0.98 min; [M+H]+: 481.85.
Example 1.138 and Example 1.139 (S)-N-(4,4-difluorocyclohexyl)-1-(((Sa)-2'-fluoro-6'-methoxy-5-methyl- [1,1'-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and (S)-N-(4,4-difluorocyclohexyl)-1- (((Ra)-2'-fluoro-6'-methoxy-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide : 2-Bromo-2'-fluoro-6'-methoxy-5-methyl-1,1'-biphenyl: 4-bromo-3-iodotoluene 97% (150 mg, 0.49 mmol, 1 eq),
2-fluoro-6-methoxyphenylboronic acid (83.3 mg, 0.490 mmol, 1 eq), K2CO3 (342 mg, 2.45 mmol, 5 eq) and Pd(PPh3)4 (58.4 mg, 0.049 mmol, 0.1 eq) were dissolved in degassed dioxane/water 4:3 (4.9 mL) and the resulting mixture was stirred at 150 °C for 30 min under microwave irradiations. The reaction mixture was then filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound. Rf (Hept/EtOAc 9:1)= 0.44. LC- MS (2): tR = 1.07 min; [M+H]+: 295.18.
(2S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-6'-methoxy-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide: 2-bromo-2'-fluoro-6'-methoxy-5-methyl-1,T-biphenyl (65.0 mg, 0.196 mmol, 1 eq) was dissolved in THF (2 mL) and stirred at -78 °C. n-BuLi (1.6 M in hexanes, 0.147 mL, 0.235 mmol, 1.2 eq) was added dropwise and the reaction mixture was stirred at -78 °C for 2 h. SO2 (0.5 M in THF, 0.784 mL, 0.392 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 1 h then at rt overnight. The reaction mixture was concentrated and the pale yellow solid was suspended in DCM (2 mL) and stirred at -78 °C. A soln, of SO2CI2 (0.0197 mL, 0.235 mmol, 1.2 eq) in DCM (2 mL) was added. The reaction mixture was stirred at -78 °C for 45 min then at rt for 1 h. SO2CI2 (0.0082 mL, 0.098 mmol, 0.5 eq) in DCM (1 mL) was added again at -78 °C and the reaction mixture was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure to give the title compound, which was used without further purification.
(2S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-6'-methoxy-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide: (2S)-N-(4,4-difluorocyclohexyl)-1-((2'-fluoro-6'-methoxy-5-methyl-[1, 1'- biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide (61.7 mg, 0.196 mmol, 1 eq) in DCM (1.5 mL) was added to a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (48.3 mg, 0.196 mmol, 1 eq), and TEA (0.0828 mL, 0.588 mmol, 3 eq) in DCM (0.5 mL) and the mixture was stirred at rt for 2.5 h. Water was added and the reaction mixture was stirred for 10 min, filtered over phase separator and the solvent removed under reduced pressure. The org. phase layer concentrated under reduced pressure and purified by FC (Hept to Hept/EtOAc 5.5:4.5) followed by basic prep. HPLC to give a first eluting atropisomer and a second eluting atropisomer. First eluting atropisomer: LC-MS (1): tR = 1.194 min; [M+H]+: 525.3. Second eluting atropisomer: LC- MS (1): tR = 1.229 min; [M+H]+: 525.2.
Example 1.140 (2S)-1-((2-(2-Chloro-4-methylpyridin-3-yl)-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide:
3-(2-Bromo-5-methylphenyl)-2-chloro-4-methylpyridine: 2-bromo-5-methylphenylboronic acid (0.0212 mL, 0.0903 mmol, 1 eq), 2-chloro-3-iodo-4-methylpy ridine (46.7 mg, 0.181 mmol, 2 eq), NaHCOs (22.8 mg, 0.271 mmol, 3 eq) and Pd(PPh3)4 (10.8 mg, 0.00903 mmol, 0.1 eq) were dissolved in degassed DME/water 4: 1 (1 mL) and the resulting mixture was stirred at 85 °C overnight. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound. Rf (Hept/EtOAc 1 : 1)= 0.69. LC-MS (2): IR = 1.0 min; [M+H]+: 296.08.
(2S)-1-((2-(2-Chloro-4-methylpyridin-3-yl)-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide: was synthesized using 2-(2-bromo-5-methylphenyl)-6-chloro-3- methylpyridine and (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 1.138 to give the title compound. LC-MS (1): IR= 1.145 min; [M+H]+: 526.3.
Example 1.141 (S)-1-[2-(2,6-Difluoro-phenyl)-6-methoxy-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
(S)-1-((2-Chloro-6-methoxypyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: to a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (370 mg, 1.31 mmol, 1.1 eq), DIPEA (0.819 mL, 4.76 mmol, 4 eq) and DMAP (14.5 mg, 0.119 mmol, 0.1 eq) in DCM (2 mL) was added 2-chloro-6-methoxypyridine-3-sulfonyl chloride (300 mg, 1.19 mmol, 1 eq) at rt. The mixture was stirred for 1 h at rt, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.98 min; [M+H]+: 452.19.
(S)-1-[2-(2,6-Difluoro-phenyl)-6-methoxy-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methoxypyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (99 mg, 0.219 mmol, 1 eq), 2,6-difluorophenylboronic acid (72.2 mg, 0.438 mmol, 2 eq) and Na2CO3 (55.4 mg, 0.657 mmol, 3 eq) in a 4: 1 mixture of DME and water (2 mL) was degassed with N2. The mixture was rapidly heated to 100 °C, and Pd(PPh3)4 (26.1 mg, 0.0219 mmol, 0.1 eq) was added. The mixture was stirred at 100 °C for 18 h, and allowed to cool to rt. The mixture was filtered and the solvents removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.181 min; [M+H]+: 530.2.
Example 1.142 (S)-1-[2-((2R,5S)-2,5-Dimethyl-pyrrolidin-1-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (30 mg, 0.0688 mmol, 1 eq), c/s-2,5- dimethylpyrrolidine hydrochloride (14.6 mg, 0.103 mmol, 1.5 eq) and KF (12 mg, 0.21 mmol, 3 eq) in DMF (1 mL) was heated to 140 °C for 96 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 0.996 min; [M+H]+: 499.4.
Example 1.143 to Example 1.145: were synthesized using the amine or amine salt in analogy to Example 1.142. LC-MS data of Examples 1.143 to 1.145 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.146 (S)-1-[2-(2-Ethyl-5-methyl-pyrrolidin-1-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), 2-ethyl-5- methylpyrrolidine hydrochloride (72.3 mg, 0.459 mmol, 10 eq) and KF (48.0 mg, 0.83 mmol, 18 eq) in DMA (1 mL) was heated to 140 °C for 2 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.087 min; [M+H]+: 513.4.
Example 1.147 (2S)-N-(4,4-difluorocyclohexyl)-1-((2-(3-fluoropiperidin-1-yl)-4-methylphenyl)sulfonyl)-N- methylpyrrolidine-2-carboxamide:
1-(2-Bromo-5-methylphenyl)-3-fluoropiperidine: a mixture of 4-bromo-3-iodotoluene (184 mg, 0.60 mmol, 1 eq), 3-fluoropiperidine hydrochloride (104 mg, 0.72 mmol, 1.2 eq), NaOtBu (150 mg, 1.56 mmol, 2.6 eq), XantPhos (53.7 mg, 0.090 mmol, 0.15 eq) and Pd2(dba)3 (22 mg, 0.024 mmol, 0.04 eq) in dioxane (3 mL) was heated to 90 °C for 14 h under an N2 atmosphere. The mixture was diluted with sat. aq. NaHCOa and extracted with EtOAc. The org. layer was dried over MgSC>4, filtered, and the solvent removed under reduced pressure. The residue was purified by FC (Hept to Hept/EA 9: 1) to give the title compound. LC-MS (2): IR = 1.06 min; [M+H]+: 272.24.
(2S)-N-(4,4-difluorocyclohexyl)-1-((2-(3-fluoropiperidin-1-yl)-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-
2-carboxamide: 1 -(2-bromo-5-methylphenyl)-3-fluoropiperidine (86.0 mg, 0.316 mmol, 1 eq) was dissolved in THF (3.24 mL) and stirred at -78° C. n-BuLi (1 .6 M in hexanes, 0.238 mL, 0.379 mmol, 1 .2 eq) was added dropwise and the reaction mixture was stirred at -78 °C for 2 h. SO2 (0.5 M in THF, 1.27 mL, 0.632 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 1 h then at rt overnight. The reaction mixture was concentrated and the pale yellow solid was suspended in DCM (2 mL) and stirred at -78 °C. A soln, of SO2CI2 (0.0317 mL, 0.379 mmol, 1 .2 eq) in DCM (1.3 mL) was added at rt and the reaction stirred at rt. The reaction mixture was concentrated under reduced pressure. The crude material was dissolved in DCM (0.5 mL) and (S)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide (22.7 mg, 0.0922 mmol) and TEA (0.0389 mL, 0.277 mmol) in DCM (0.5 mL) and the mixture was stirred at rt for 2 h. The solvent was removed under reduced pressure and the residue was purified by acidic prep. HPLC to give the title compound as a mixture of 2 stereoisomers. LC-MS (1): IR = 1.232 min; [M+H]+: 502.2. Example 1.148 (2S)-N-(4,4-difluorocyclohexyl)-1-((2-(2-(methoxymethyl)piperidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20 mg, 0.0459 mmol, 1 eq), rac-2- (methoxymethyl)piperidine (62 mg, 0.46 mmol, 10 eq) and KF (48 mg, 0.83 mmol, 18 eq) in DMF (1 mL) was heated to 140 °C for 18 h. The mixture was allowed to cool to rt. Thecrude mixture was purified by basic prep. HPLC to give the title compound as a mixture of 2 stereoisomers. LC-MS (1): IR = 1.232 min; [M+H]+: 529.4.
Example 1.149: (2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,4-difluoropyridin-3-yl)-4-methylphenyl)sulfonyl)-N- methylpyrrolidine-2-carboxamide:
3-(2-Bromo-5-methylphenyl)-2,4-difluoropyridine: 2-bromo-5-methylphenylboronic acid (0.106 mL, 0.451 mmol, 1 eq), 2,4-difluoro-3-iodopyridine (229 mg, 0.903 mmol, 2 eq), NaHCOa (114 mg, 1.35 mmol, 3 eq) and Pd(PPh3)4 (53.8 mg, 0.0451 mmol, 0.1 eq) were dissolved in degassed DME I water 4:1 (4.5 mL) and the resulting mixture was stirred at 85 °C for 17 h. Pd(PPha)4 (26.9 mg, 0.0225 mmol, 0.05 eq) was added again and the reaction mixture was stirred at 85 °C overnight. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/ EtOAc 95:5) to give the title compound. LC-MS (2): IR = 1.01 min; [M+H]+: 284.13.
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,4-difluoropyridin-3-yl)-4-methylphenyl)sulfonyl)-N- methylpyrrolidine-2-carboxamide: was synthesized using 3-(2-bromo-5-methylphenyl)-2,4-difluoropyridine in analogy to Example 1.147 to give the title compound as a white solid. LC-MS (1): IR = 1.121 min; [M+H]+: 514.3.
Example 1.150 to Example 1.154: were synthesized using (S)-1-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methy Ipy rrolidi ne-2-carboxamide and the appropriate boronic acid or boronic ester in analogy to Example 1.1. LC-MS data of Example 1 .150 to Example 1 .154 are listed in the table below. The LC-MS conditions used were LC-MS (1). Example 1.155 (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (12.0 mg, 0.0275 mmol, 1 eq), ethylisopropylamine (0.034 mL, 0.28 mmol, 10 eq) and KF (24 mg, 0.41 mmol, 15 eq) in DMF (1 mL) was heated to 140 °C overnight. The mixture was allowed to cool to rt. The crude mixture was purified by by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.168 min; [M+H]+: 487.2.
Example 1.156 and Example 1.157: (S)-1-(((Ra)-2'-Chloro-5,6'-dimethyl-[1,1'-biphenyl]-2-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and (S)-1-(((Sa)-2'-Chloro-5,6'-dimethyl-[1,r- biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide : were synthesized using 4-bromo-3-iodotoluene and (2-chloro-6-methylphenyl)boronic acid in analogy to Example 1.138 to give the title compound. First eluting atropisomer: LC-MS (1): tR = 1.316 min; [M+H]+: 525.3. Second eluting atropisomer: LC-MS (1): tR = 1.360 min; [M+H]+: 525.3.
Example 1.158 (2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,3-dimethylpyrrolidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), 2,3-dimethylpyrrolidine hydrochloride (66 mg, 0.46 mmol, 10 eq) and KF (40 mg, 0.69 mmol, 15 eq) in DMF (2.8 mL) was heated to 140 °C for 1 h. The mixture was allowed to cool to rt. The crude mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.356 min; [M+H]+: 499.4.
Example 1.159 (S)-1-[6-Methyl-2-((R)-2-trifluoromethyl-pyrrolidin-1-yl)-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20.0 mg, 0.0459 mmol, 1 eq), (R)-2- (trifluoromethyl)pyrrolidine (64 mg, 0.46 mmol, 10 eq) and KF (40 mg, 0.69 mmol, 15 eq) in DMF (2.8 mL) was heated to 140 °C overnight. The mixture was allowed to cool to rt. The crude mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.331 min; [M+H]+: 539.2.
Example 1.160 and Example 1.161 : (S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-5,6-dimethyl-[1,1'- biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and (S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'- fluoro-5,6-dimethyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide :
2'-Fluoro-2,3-dimethyl-6-nitro-1,r-biphenyl: 2-bromo-3,4-dimethyl-1-nitrobenzene (300 mg, 1.30 mmol, 1 eq), 2-fluorophenylboronic acid (223 mg, 1.56 mmol, 1.2 eq), K3PO4 H2O (802 mg, 3.48 mmol, 2.67 eq) and Pd(PPha)4 (155 mg, 0.130 mmol, 0.1 eq) were dissolved in degassed DME I water 4:1 (13 mL) and the resulting mixture was stirred at 85 °C for 18 h. The reaction mixture was filtered through a PTFE 0.45 pm filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 95:5) to give the title compound. Rf (Hept/EtOAc 95:5)= 0.25. LC-MS (3): tR = 1.05 min; [M+H]+: not seen. 1H NMR (500 MHz, CDCI3) 5: 7.77 (d, J = 8.3 Hz, 1 H), 7.42 (m, 1 H), 7.34 (d, J = 8.3 Hz, 1 H), 7.17-7.24 (m, 2 H), 7.12 (td, Ji = 1.8 Hz, J2 = 7.4 Hz, 1 H), 2.43 (s, 3 H), 2.05 (s, 3 H).
2'-Fluoro-5,6-dimethyl-[1,r-biphenyl]-2-amine: Fe (powder, 683 mg, 12.2 mmol, 10 eq) and NH4CI (65.8 mg, 1.22 mmol, 1 eq) were dissolved in EtOH/water 8: 1 (5 mL) and the resulting suspension was stirred at 85 °C. A soln, of 2'-fluoro-2,3-dimethyl-6-nitro-1,1 '-biphenyl (300 mg, 1.22 mmol, 1 eq) in EtOH (20 mL) was then added dropwise and the reaction mixture was stirred at 85 °C for 18 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOH. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound. Rf (Heptane I EtOAc 9: 1)= 0.18. LC-MS (2): IR = 0.72 min; [M+H]*: 216.25.
6-Bromo-2'-fluoro-2,3-dimethyl-1,r-biphenyl: CuBr2 (325 mg, 1.44 mmol, 1.1 eq) was suspended in CH3CN (9 mL) and tert-butyl nitrite (0.191 mL, 1 .44 mmol, 1 .1 eq) was added. The reaction mixture was stirred at 0 °C before the dropwise addition of a soln, of 2'-fluoro-5,6-dimethyl-[1 ,T-biphenyl]-2-amine (282 mg, 1.31 mmol, 1 eq) in CH3CN (4 mL). The reaction mixture was stirred at rt for 16 h. The reaction mixture was cooled down to 0 °C and quenched with a soln, of sulfamic acid (25.6 mg, 0.262 mmol, 0.2 eq) in water (7 mL) followed by the addition of aq. 2M HOI (0.985 mL, 1.97 mmol, 1.5 eq). The reaction mixture was extracted with EtOAc (25 mL). The aq. layer was extracted with EtOAc (20 mL). The combined org. layers were washed with brine, dried with MgSO4, filtered and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 95:5) followed by basic prep. HPLC to give the title compound. LC-MS (2): IR = 1.12 min; [M+H]+: not seen.
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-5,6-dimethyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide and (S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'-fluoro-5,6-dimethyl-[1,r- biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: 6-bromo-2'-fluoro-2,3-dimethyl-1 , T-biphenyl
(101 mg, 0.362 mmol, 1 eq) was dissolved in THF (4 mL) and stirred at -78 °C. n-BuLi (1.6 M in hexanes, 0.249 mL, 0.398 mmol, 1.1 eq) was added dropwise and the reaction mixture was stirred at -78 °C for 30 min. SO2 (0.5 M in THF, 1.45 mL, 0.723 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 1 h then at rt for 21 h. The reaction mixture was concentrated under reduced pressure and the residue was suspended in DOM (4 mL) and stirred at -78 °C. A soln, of SO2CI2 (36.3 L, 0.434 mmol, 1.2 eq) in CH2CI2 (1 mL) was added. The reaction mixture was stirred at rt for 3 h allowed to warm to rt and concentrated under reduced pressure. The residue was dissolved in DOM (1 mL) and added to a mixture of (S)-N-(4, 4-difl uorocyclohexyl)-N-methy Ipy rrolidine- 2-carboxamide (89.2 mg, 0.362 mmol, 1 eq), and TEA (0.153 mL, 1.09 mmol, 3 eq) in DOM (3.6 mL), and the mixture was stirred at rt for 1 h. Water (3 mL) was added and the reaction mixture was stirred for 10 min and filtered over phase separator. The solvent was removed under reduced pressure and residue was purified by basic prep. HPLC to give a first eluting atropisomer and a second eluting atropisomer: LC-MS (1): IR = 1.256 min; [M+H]+: 509.4. Second eluting atropisomer: LC-MS (1): IR = 1.286 min; [M+H]+: 509.3. Example 1.162 (S)-1-((2R,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
Methyl ((2-chloro-6-methylpyridin-3-yl)sulfonyl)-L-prolinate: a soln, of 2-chloro-6-methylpyridine-3-sulfonyl chloride (1.80 g, 7.56 mmol, 1 eq) in DCM (10 mL) was added to a soln, of L-proline methyl ester hydrochloride (1.38 g, 8.32 mmol, 1 .1 eq), DIPEA (5.21 mL, 30.3 mmol, 4 eq) and DMAP (92.4 mg, 0.756 mmol, 0.1 eq) in DCM (20 mL). The mixture was stirred for 20 min, and the solvents were removed under reduced pressure. The residue was purified by by FC (Hept to EtOAc) to give the title compound. LC-MS (2): IR = 0.82 min; [M+H]+: 319.15.
((2-((2R,6S)-2,6-Dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)sulfonyl)-L-proline: a mixture of methyl ((2- chloro-6-methylpyridin-3-yl)sulfonyl)-L-prolinate (150 mg, 0.471 mmol, 1 eq), (2R, 6S)-2,6-dimethylpiperidine (224 mg, 1.88 mmol, 4 eq) and TMP (0.314 mL, 1.88 mmol, 4 eq) was heated to 140 °C for 48 h. The mixture was allowed to cool to rt and the mixture was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.65 min; [M+H]+: 382.21.
(S)-1-((2R,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of ((2-((2R,6S)-2,6-dimethylpiperidin-1-yl)-6- methylpyridin-3-yl)sulfonyl)-L-proline (50.0 mg, 0.131 mmol, 1 eq), 4,4-difluoro-N-methylcyclohexanamine hydrochloride (48.7 mg, 0.262 mmol, 2 eq), HATU (149 mg, 0.393 mmol, 3 eq) and DIPEA (0.113 mL, 0.655 mmol, 5 eq) in DMF (2 mL) was stirred for 20 min at rt. The solvents were removed under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (1): IR = 0.935 min; [M+H]+: 513.3.
Example 1.163 (S)-1-(2-Diisopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (20 mg, 0.046 mmol, 1 eq), diisopropylamine (9.3 mg, 0.092 mmol, 2 eq) and TMP (0.193 mL, 1.15 mmol, 25 eq) was heated to 140 °C for 48 h. The mixture was allowed to cool to rt. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.88 min; [M+H]+: 501.33.
Example 1.164 to Example 1.167: were synthesized according to the procedure described in Example 1.163 using the corresponding amine or amine salt. LC-MS data of Example 1.164 to Example 1.167 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.168 (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((6-methyl-2-((RS)-6-methylcyclohex-1-en-1- yl)pyridin-3-yl)sulfonyl)pyrrolidine-2-carboxamide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)- N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (30.0 mg, 0.0688 mmol, 1 eq), rac-3- methylcyclohex-1-en-2-boronic acid (31.5 mg, 0.138 mmol, 2 eq) and aq. K3PO4 (0.5 M, 0.30 mL, 0.15 mmol, 2.2 eq) in THF (1 mL) was degassed for 5 min. XPhosPd G2 (2.2 mg, 0.0014 mmol, 0.02 eq) was added. The mixture was stirred at 50 °C for 15 h. The mixture was allowed to cool to rt, and was extracted with DCM. The org. layer was dried through a phase separator filtered, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.213 min; [M+H]+: 496.2.
Example 1.169 (S)-4-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-morpholine-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
Methyl (S)-4-((2-chloro-6-methylpyridin-3-yl)sulfonyl)morpholine-3-carboxylate: a mixture (S)-methyl morpholine-3-carboxylate (205 mg, 1.37 mmol, 1.2 eq), 2-chloro-6-methylpyridine-3-sulfonyl chloride (271 mg, 1.14 mmol, 1 eq), DIPEA (0.785 mL, 4.56 mmol, 4 eq) and DMAP (13.9 mg, 0.114 mmol, 0.1 eq) in DCM (8 mL) was stirred at rt for 20 min. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.79 min; [M+H]+: 335.12.
Methyl (S)-4-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)morpholine-3-carboxylate: A mixture of methyl (S)-4-((2-chloro-6-methylpyridin-3-yl)sulfonyl)morpholine-3-carboxylate (150 mg, 0.448 mmol, 1 eq), N- ethylisopropylamine (0.277 mL, 2.24 mmol, 5 eq) and TMP (0.764 mL, 4.48 mmol, 10 eq) was heated to 140 °C for 24 h. The mixture was allowed to cool to rt. The crude mixture was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.88 min; [M+H]+: 385.91.
(S)-4-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)morpholine-3-carboxylic acid: LiOH H2O (1 .6 mg, 0.067 mmol, 2 eq) was added to a soln, of methyl (S)-4-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)morpholine-3-carboxylate (13.0 mg, 0.034 mmol, 1 eq) in THF (2 mL) and water (1 mL) at 0 °C. The mixture was stirred for 1.5 h while warming up to rt. The solvents were removed under reduced pressure to give the title compound, which was used in the next step without further purification. LC-MS (2): IR = 0.71 min; [M+H]+: 372.17.
(S)-4-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-morpholine-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a mixture of (S)-4-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)morpholine-3-carboxylic acid (18 mg, ca 0.047 mmol, 1 eq), 4,4-difluoro-N-methylcyclohexanamine hydrochloride (9.6 mg, 0.052 mmol, 1.1 eq), HATU (53 mg, 0.14 mmol, 3 eq) and DIPEA (0.040 mL, 0.23 mmol, 5 eq) in DMF (2 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (1): IR = 1 .264 min; [M+H]+: 503.3.
Example 1.170 (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.3]hex-5-yl)-N-methyl-amide:
Methyl ((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-prolinate: a mixture of methyl ((2-chloro- 6-methylpyridin-3-yl)sulfonyl)-L-prolinate (133 mg, 0.416 mmol, 1 eq), N-ethylisopropylamine (0.257 mL, 2.08 mmol, 5 eq) and TMP (0.709 mL, 4.16 mmol, 10 eq) was heated to 140 °C for 96 h. The mixture was allowed to cool to rt and purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.88 min; [M+H]+: 369.91.
((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-proline: a mixture of methyl ((2- (ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-prolinate (80.0 mg, 0.217 mmol, 1 eq) and LiOH (10 mg, 0.43 mmol, 2 eq) in THF (2 mL) and water (1 mL) was stirred at 0 °C for 15 min, then at rt for 1 h. The solvents were removed under reduced pressure, and the residue was dried under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): IR = 0.71 min; [M+H]+: 356.19. tert-Butyl (1,1-difluorospiro[2.3]hexan-5-yl)carbamate (mixture of 2 stereoisomers): a mixture of 1 ,1- difluorospiro[2.3]hexan-5-amine hydrochloride (1.00 g, 5.60 mmol, 1 eq), K2CO3 (464 mg, 3.36 mmol, 0.6 eq) and BOC2O (1 .36 g, 6.16 mmol, 1 .1 eq) in toluene (5 mL) was stirred at 35 °C for 2.5 h. The mixture was allowed to cool to rt, and 3-(dimethylamino)-1 -propylamine (0.144 mL, 1.12 mmol, 0.2 eq) was added. The mixture was stirred for 10 min. The mixture was washed with aq. 1 M HCI. The org. layer was dried over Na2SO4, filtered, and the solvents were removed under reduced pressure to give the title compound, which was used in the next step without further purification. LC-MS (2): IR = 0.71 min; [M+H]+: 356.19. tert-Butyl (1,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamate (mixture of 2 stereoisomers): NaH (ca 55% in oil, 304 mg, ca 7.6 mmol, ca 1.5 eq) was added to a soln, of tert-butyl (1 ,1-difluorospiro[2.3]hexan-5-yl)carbamate (1180 mg, ca 5.1 mmol, ca 1 eq) in DMF (20 mL) at 0 °C. The mixture was stirred for 10 min, and methyl iodide (0.631 mL, 10.1 mmol, 2 eq) was added. The mixture was stirred overnight while warming up to rt. A few drops of water were added, and the solvents were removed under reduced pressure to give the title compound, which was used in the next step without further purification. 1H NMR (500 MHz, MeOD) 5: 2.89 (s, 3 H), 2.89 (s, 3 H), 2.58- 2.63 (m, 2 H), 2.38-2.50 (m, 6 H), 2.21-2.28 (m, 2 H), 1.48 (s, 9 H), 1.48 (s, 9 H), 1.25-1.36 (m, 9 H).
1.1-Difluoro-N-methylspiro[2.3]hexan-5-amine hydrochloride (mixture of 2 stereoisomers): a mixture of tertbutyl (1,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamate (1.30 g, ca 4.99 mmol, ca 1 eq) in HCI (4M in dioxane, 2.1 mL) was stirred at rt for 2.5 h. The solvents were removed under reduced pressure to yield the title compound.
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro- spiro[2.3]hex-5-yl)-N-methyl-amide (mixture of 2 stereoisemers): a mixture of ((2-(ethy l(isopropyl)amino)-6- methylpyridin-3-yl)sulfonyl)-L-proline (25 mg, ca 0.070 mmol, 1 eq), 1,1-difluoro-N-methylspiro[2.3]hexan-5-amine hydrochloride (14 mg, ca 0.077 mmol, ca 1.1 eq), HATU (80 mg, 0.21 mmol, 3 eq) and DIPEA (0.061 mL, 0.45 mmol, 5 eq) in DMF (2 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.192 min; [M+H]+: 485.2.
Example 1.171 (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide (mixture of 2 stereoisomers):
Benzyl (1,1-difluorospiro[2.5]octan-6-yl)carbamate (mixture of 2 stereoisomers): benzyloxycarbonyl chloride (1.02 mL, 7.21 mmol, 1.5 eq) was added dropwise to a soln, of 1 , 1-difluorospiro[2.5]octan-6-amine hydrochloride (950 mg, 4.81 mmol, 1 eq) and DIPEA (1.86 g, 14.4 mmol) in DCM (30 mL) at O °C. The mixture was stirred for 30 min while warming up to rt. The solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the the title compound as a cis- and trans- mixture of diastereomers. LC-MS (2): IR = 1.01 min; [M+H]+: 296.25.
Benzyl (1,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamate (mixture of 2 stereoisomers): NaH (ca 55% in oil, 146 mg, ca 3.66 mmol, ca 1.5 eq) was added to benzyl (1 ,1-difluorospiro[2.5]octan-6-yl)carbamate (720 mg, 2.44 mmol, 1 eq) in DMF (10 mL) at 0 °C. The mixture was stirred for 10 min while warming up to rt. Mel (0.354 mL, 4.88 mmol, 2 eq) was added, and the mixture was stirred for 20 min. The solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 1.07 min; [M+H]+: 310.31.
1.1-Difluoro-N-methylspiro[2.5]octan-6-amine (mixture of 2 stereoisomers): a mixture of benzyl (1,1- difluorospiro[2.5]octan-6-yl)(methyl)carbamate (630 mg, 2.04 mmol) and Pd/C (10% wet, 75 mg) in EtOH (20 mL) was purged with N2, and then with H2. The mixture was stirred under an H2-atmosphere for 2 h at rt. The mixture was filtered through a Whatman® filter, and the solvents were removed under reduced pressure to yield the title compound, which was used without further purification. LC-MS (2): IR = 0.48 min; [M+H]+: 217.25.
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide (mixture of 2 stereoisomers): a mixture of ((2-(ethyl(isopropyl)amino)-6- methylpyridin-3-yl)sulfonyl)-L-proline (25 mg, ca 0.070 mmol, 1 eq), 1 ,1-difluoro-N-methylspiro[2.5]octan-6-amine (16 mg, 0.077 mmol, 1.1 eq), HATU (80 mg, 0.21 mmol, 3 eq) and DIPEA (0.061 mL, 0.45 mmol, 5 eq) in DMF (2 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.241 min; [M+H]+: 513.3.
Example 1.172 (S)-1-[6-Methyl-2-((S)-3-methyl-morpholin-4-yl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using (S)-3- methylmorpholine as amine. LC-MS (1): tR = 1.118 min; [M+H]+: 501.3.
Example 1.173 (2S)-3-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-3-aza-bicyclo[3.1.0]hexane-
2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide :
(2S)-3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid: to (2S)-3- azabicyclo[3.1.0]hexane-2-carboxylic acid (97.0 mg, 0.756 mmol, 0.9 eq) in aq. 2M NaOH (1.7 mL) was added dropwise to a soln, of 2-chloro-6-methy Ipy ridiny l-3-sulfony I chloride (200 mg, 0.84 mmol, 1 eq) in THF (5 mL). The mixture was stirred at rt for 2 h, and aq. 1 M HCI was added to adjust the pH to 1-2. The mixture was extracted with DCM. The org. layer was dried in a phase separator (Isolute®), filtered, and the solvents were removed under reduced pressure to give the title compound, which was used in the next step without further purification. LC-MS (2): tR = 0.71 min; [M+H]+: 317.14.
(2S)-3-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid: (2S)-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (80 mg, ca 0.25 mmol, ca 1 eq), N-ethylisopropylamine (0.156 mL, 1.26 mmol, 5 eq) and TMP (0.43 mL, 2.5 mmol, 10 eq) was heated to 140 °C for 48 h. The mixture was allowed to cool to rt. The mixture was purified by acidic prep HPLC to give the title compound. LC-MS (2): t = 0.76 min; [M+H]+: 368.17.
(2S)-3-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (2S)-3-((2-(ethyl(isopropyl)amino)-6-methylpyridin-
3-yl)sulfonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (30 mg, 0.082 mmol, 1 eq), 4,4-difluoro-N- methylcyclohexan-1 -amine hydrochloride (16.7 mg, 0.089 mmol, 1.1 eq), HATU (93 mg, 0.24 mmol, 3 eq) and DIPEA (0.070 mL, 0.41 mmol, 5 eq) in DMF (2 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): t = 1.128 min; [M+H]+: 499.2.
Example 1.174 (2S,4S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-fluoro-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
Methyl (2S,4S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-4-fluoropyrrolidine-2-carboxylate: to a mixture of methyl (2S,4S)-4-fluoropyrrolidine-2-carboxylate (134 mg, 0.756 mmol, 1.1 eq), DIPEA (0.434 mL, 2.52 mmol, 4 eq) and DMAP (7.7 mg, 0.063 mmol, 0.1 eq) in DCM (2 mL) was added dropwise a soln, of 2-chloro-6- methylpyridinyl-3-sulfonyl chloride (150 mg, 0.63 mmol, 1 eq) in DCM (1 mL). The mixture was stirred at rt for 15 min, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to EtOAc) to give the title compound. LC-MS (2): tR = 0.79 min; [M+H]+: 337.13.
(25.45)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4-fluoropyrrolidine-2-carboxylic acid: a mixture of methyl (2S,4S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-4-fluoropyrrolidine-2-carboxylate (130 mg, 0.386 mmol, 1 eq), N-ethylisopropylamine (0.238 mL, 1.93 mmol, 5 eq) and TMP (0.658 mL, 3.86 mmol, 10 eq) was heated to 140 °C for 4 days. The mixture was allowed to cool to rt and partitioned between DCM and water. The org. layer was dried through a phase separator (Isolute®), filtered, and the solvents were removed under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): tR = 0.70 min; [M+H]+: 374.16.
(25.45)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-fluoro-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (2S,4S)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)-4-fluoropyrrolidine-2-carboxylic acid (40 mg, ca 0.107 mmol, ca 1 eq), 4,4-difluoro-N-methylcyclohexan- 1 -amine hydrochloride(21 .9 mg, 0.118 mmol, 1.1 eq), HATU (122 mg, 0.321 mmol, 3 eq) and DIPEA (0.092 mL, 0.69 mmol, 5 eq) in DMF (2 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.102 min; [M+H]+: 505.4.
Example 1.175 (S)-1-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (2S, 6S)- dimethylpiperidine hydrochloride in analogy to Example 1.170. LC-MS (2): tR = 1.03 min; [M+H]+: 514.5.
Example 1.176 (S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-amide: was synthesized using 1, 1-difluorospiro[2.5]octan-6-amine as amine in analogy to Example 1.171. LC-MS (1): tR = 1.331 min; [M+H]+: 499.3.
Example 1.177 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using (3S, 5S)-dimethylmorpholine. LC-MS (1): tR = 1.171 min; [M+H]+: 515.4.
Example 1.178 (S)-1-[6-Methyl-2-(2-methyl-cyclohex-1-enyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.168 using 4, 4,5,5- tetramethyl-2-(2-methylcyclohex-1-en-1-yl)-1 ,3,2-dioxaborolane. LC-MS (1): tR = 1.133 min; [M+H]+: 496.3.
Example 1.179 (S)-3-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-oxazolidine-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
(S)-3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)oxazolidine-4-carboxylic acid: to a mixture of (S)-oxazolidine- 4-carboxylic acid hydrochloride (100 mg, 0.619 mmol, 1 eq) and NaHCOa (104 mg, 1.24 mmol, 2 eq) in water (3.5 mL) was added a soln, of 2-chloro-6-methylpyridine-3-sulfonyl chloride (221 mg, 0.928 mmol, 1.5 eq) in DMF (3.5 mL). The mixture was stirred for 30 min at rt, and the solvents were removed under reduced pressure. The residue was partitioned between DCM and aq. 1 M HCI. The org. layer was dried through a phase separator (Isolute®), and the solvents were removed under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): tR = 0.65 min; [M+H]+: 307.08.
(S)-3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methyloxazolidine-4- carboxamide: a mixture of (S)-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)oxazolidine-4-carboxylic acid (50 mg, 0.163 mmol, 1 eq), 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (33.3 mg, 0.179 mmol, 1.1 eq), HATU (186 mg, 0.489 mmol, 3 eq) and DIPEA (0.14 mL, 0.82 mmol, 5 eq) in DMF (2 mL) was stirred for 2 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 0.90 min; [M+H]+: 438.14.
(S)-3-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-oxazolidine-4-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: a mixture of (S)-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methyloxazolidine-4-carboxamide (14.3 mg, 0.0228 mmol, 1 eq), N-ethylisopropylamine (0.0282 mL, 0.228 mmol, 10 eq) and TMP (0.19 mL, 1.14 mmol, 50 eq) was heated to 140 °C for 18 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.296 min; [M+H]+: 489.2.
Example 1.180 and Example 1.181 (S)-1-(((Ra)-2',6-Difluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and (S)-1-(((Sa)-2',6-Difluoro-5-methyl-[1,1'- biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide : were synthesized using 2-bromo-3-fluoro-4-methyl-1 -nitrobenzene in analogy to Example 1.161 to give a first eluting atropisomer and a second eluting atropoisomer: LC-MS (1): tR = 1.257 min; [M+H]+: 513.2. Second eluting atropisomer: LC-MS (1): tR = 1.281 min; [M+H]+: 513.3.
Example 1.182 (S)-1-(2-Cyclohex-1-enyl-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.168 using cyclohex-1 en-1- yl(boronic acid). LC-MS (1): tR = 1.127 min; [M+H]+: 482.3.
Example 1.183 (S)-1-(2-Cyclohexyl-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: a soln, of (S)-1-(2-cyclohex-1-enyl-6-methyl-pyridine-3-sulfonyl)- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (85.0 mg, 0.176 mmol, 1 eq) in EtOH (10 mL) was degassed with N2. Pd/C (10%, 50% wet, 10 mg) was added, and the mixture was stirred under a H2 atmosphere overnight. The mixture was filtered (Whatmann filter), and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): t = 1.331 min; [M+H]+: 484.3.
Example 1.184 {(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-thiazolidin- 3-yl-methanone: a mixture of ((2-(ethyl (isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-proline (24.5 mg, 0.0688 mmol, 1 eq), thiazolidine (7.36 mg, 0.0826 mmol, 1.2 eq), HATU (54.9 mg, 0.0722 mmol, 1.05 eq) and DIPEA (0.059 mL, 45 mmol, 5 eq) in DMF (0.8 mL) was stirred at rt overnight. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.070 min; [M+H]+: 427.2. Example 1.185 to Example 1.246: were synthesized according to the procedure described in Example 1.184 using the corresponding amine or amine salt. LC-MS data of Example 1.185 to Example 1.246 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.247 rac-(2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: Methyl rac-(2R*,4R*)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2-carboxylate: to a mixture of methyl rac-(2R*,4R*)-4-methylpyrrolidine-2 -carboxylate (206 mg, 1.37 mmol, 1.2 eq), DIPEA (0.784 mL, 4.55 mmol, 4 eq) and DMAP (13.9 mg, 0.114 mmol, 0.1 eq) in DCM (20 mL) was added dropwise to a soln, of 2- chloro-6-methylpyridinyl-3-sulfonyl chloride (271 mg, 1 .14 mmol, 1 eq) in DCM (10 mL). The mixture was stirred at rt for 20 min, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 0.88 min; [M+H]+: 333.18.
Methyl rac-(2R*,4R*)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2- carboxylate: a mixture of methyl rac-(2R*,4R*)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2- carboxylate (340 mg, 1.02 mmol, 1 eq), N-ethylisopropylamine (0.631 mL, 5.11 mmol, 5 eq) and TMP (1.74 mL, 10.2 mmol, 10 eq) was heated to 140 °C for 24 h. The mixture was allowed to cool to rt and partitioned between DCM and water. The org. layer was dried through a phase separator (Isolute®), filtered, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC- MS (2): tR = 0.93 min; [M+H]+: 384.24. rac-(2R*,4R*)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2-carboxylic acid: a mixture of methyl rac-(2R*,4R*)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-4- methylpyrrolidine-2-carboxylate (200 mg, 0.521 mmol, 1 eq) and LIOH (25 mg, 1.04 mmol, 2 eq) in THF (2 mL) and water (1 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): tR = 0.75 min; [M+H]+: 370.13. rac-(2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of rac-(2R*,4R*)-1-((2-(ethyl(isopropyl)amino)-6- methylpyridin-3-yl)sulfonyl)-4-methylpyrrolidine-2-carboxylic acid (50.0 mg, ca 0.135 mmol, ca 1 eq), 4,4-difluoro- N-methylcyclohexan-1 -amine hydrochloride (27.6 mg, 0.149 mmol, 1.1 eq), HATU (103 mg, 0.271 mmol, 2 eq) and DIPEA (0.070 mL, 0.41 mmol, 3 eq) in DMF (2 mL) was stirred for 1 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.204 min; [M+H]+: 501.4.
Example 1.248 (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.3]hex-5-yl)-amide:
((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-L-proline: to a mixture of L-proline (200 mg, 1.74 mmol, 1 eq) and NaHCOa (292 mg, 3.47 mmol, 2 eq) in water (3.5 mL) and THF (2 mL) was added a soln, of 2-chloro-6- methy Ipy ridi ne-3-sulfony I chloride (496 mg, 2.08 mmol, 1 .2 eq) in THF (2 mL). The mixture was stirred for 1 h at rt, and the solvents were removed under reduced pressure. The residue was partitioned between DCM and aq. 1 M HCI. The org. layer was dried through a phase separator (Isolute®), filtered, and the solvents were removed under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): tR = 0.67 min; [M+H]+: 305.02. (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1,1-difluorospiro[2.3]hexan-5-yl)pyrrolidine-2- carboxamide: a mixture of ((2-chloro-6-methylpyridin-3-yl)sulfonyl)-L-proline (80 mg, 0.263 mmol, 1 eq), 1 ,1- difluorospiro[2.3]hexan-5-amine hydrochloride (51.6 mg, 0.289 mmol, 1.1 eq), HATU (200 mg, 0.525 mmol, 2 eq) and DIPEA (0.136 mL, 0.79 mmol, 3 eq) in DMF (2 mL) was stirred for 1 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 0.89 min; [M+H]+: 420.17.
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro- spiro[2.3]hex-5-yl)-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1 ,1- difluorospiro[2.3]hexan-5-yl)pyrrolidine-2-carboxamide (30 mg, 0.072 mmol, 1 eq), N-ethylisopropylamine (0.044 mL, 0.36 mmol, 5 eq) and TMP (0.122 mL, 0.714 mmol, 10 eq) was heated to 140 °C for 1 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.254 min; [M+H]+: 471.2.
Example 1.249 (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((6-methyl-2-((1 R*,2S*)-2- methylcyclohexyl)pyridin-3-yl)sulfonyl)pyrrolidine-2-carboxamide: a soln, of (S)-1-[6-methyl-2-(2-methyl- cyclohex-1-enyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (25 mg, 0.050 mmol, 1 eq) in EtOH (3 mL) was degassed with N2. Pd/C (10%, 50% wet, 5 mg) was added, and the mixture was stirred under a H2 atmosphere for 5 h. The mixture was filtered (Whatmann filter), and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.406 min; [M+H]+: 498.4.
Example 1.250 (S)-1-[6-Methyl-2-((1 R,2S)-2-methyl-cyclohexyl)-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide and (S)-1-[6-methyl-2-((1S,2R)-2-methyl- cyclohexyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: the mixture of stereoisomers from Example 1.249 was separated by preparative chiral SFC (SFC 1 -conditions) to give the first eluting diatereomer (t = 2.20 min) and the second eluting diastereomer, (t = 2.80 min). First eluting diastereoisomer: LC-MS (1): tR = 1.404 min; [M+H]+: 498.3; Second eluting diastereoisomer: LC-MS (1 :) tR = 1.406 min; [M+H]+: 498.4.
Example 1.251 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-trifluoromethyl-pyridine-3-sulfonyl]- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
(S)-1-((2-Chloro-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: to a mixture of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (200 mg, 0.674 mmol, 1 eq), DIPEA (0.464 mL, 2.70 mmol, 4 eq) and DMAP (8.2 mg, 0.067 mmol, 0.1 eq) in DCM (20 mL) was added dropwise to a soln, of 2-chloro-6-trifluoromethylpyridinyl-3-sulfonyl chloride (199 mg, 0.674 mmol, 1 eq) in DCM (10 mL). The mixture was stirred at rt for 20 min, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 1.03 min; [M+H]+: 490.16. (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-trifluoromethyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6- (trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (30 mg, 0.062 mmol, 1 eq), (3S, 5S)-3,5-dimethylmorpholine (73 mg, 0.61 mmol, 10 eq) and TMP (0.51 mL, 3.06 mmol, 50 eq) was heated to 140 °C for 1 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.311 min; [M+H]+: 569.2.
Example 1.252 (S)-1-[2-(Ethyl-isopropyl-amino)-6-trifluoromethyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of (S)-1-((2-chloro-6- (trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (51 mg, 0.105 mmol, 1 eq), N-ethylisopropylamine (0.065, 0.53 mmol, 5 eq) and TMP (0.179 mL, 1.05 mmol, 10 eq) was heated to 140 °C for 72 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.425 min; [M+H]+: 541.3.
Example 1.253 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-amide:
(S)-1-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1,1-difluorospiro[2.5]octan-6-yl)pyrrolidine-2- carboxamide: a mixture of ((2-chloro-6-methylpyridin-3-yl)sulfonyl)-L-proline (110 mg, ca 0.361 mmol, ca 1 eq), 1 , 1 -difluorospiro[2.5]octan-6-amine hydrochloride (82.6 mg, 0.397 mmol, 1.1 eq), HATU (274 mg, 0.722 mmol, 2 eq) and DIPEA (0.186 mL, 1.08 mmol, 3 eq) in DMF (2 mL) was stirred for 1 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.95 min; [M+H]+: 448.17.
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1 ,1- difluorospiro[2.5]octan-6-yl)pyrrolidine-2-carboxamide (30 mg, 0.067 mmol, 1 eq), (3S, 5S)-3,5-dimethylmorpholine (80 mg, 0.67 mmol, 10 eq) and TMP (0.558 mL, 3.35 mmol, 50 eq) was heated to 140 °C for 18 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.235 min; [M+H]+: 527.3.
Example 1.254 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (1,1-difluoro-spiro[2.3]hex-5-yl)-amide: a mixture of (S)-1-((2-chloro-6-methylpyridin-3- yl)sulfonyl)-N-(1 , 1 -difluorospiro[2.3]hexan-5-yl)pyrrolidine-2-carboxamide (30 mg, 0.072 mmol, 1 eq), (3S, 5S)-3,5- dimethylmorpholine (42 mg, 0.36 mmol, 5 eq) and TMP (0.596 mL, 3.57 mmol, 10 eq) was heated to 140 °C for 18 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.157 min; [M+H]+: 499.3. Example 1.255 2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-5-methyl-3,4-dihydro-2H- pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: l-(tert-Butyl) 5-ethyl 3-methyl-4,5-dihydro-1 H-pyrazole-1,5-dicarboxylate: to a soln, of 1 ,1 -dimethylethyl 2-(2- chloro-1-methylethylidene)hydrazinecarboxylate (2.87 g, 2.63 mmol) in DCM (80 mL) were added ethyl diazoacetate (13% wt. in DCM, 2.63 mL, 21.8 mmol, 3 eq), Na2CO3 (4.88 g, 36.3 mmol, 5 eq) and CuCh (201 mg, 1 .45 mmol, 0.2 eq). The mixture was stirred for 4 h at rt. The mixture was partitioned between aq. sat. NaHCOa and DCM. The aq. layer was extracted with DCM twice. The combined org. layers were dried through a phase separator (Isolute®), and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to EtOAc I Hept 1 : 1) to give the title compound. LC-MS (2): tR = 0.77 min.
1-(tert-Butoxycarbonyl)-3-methyl-4,5-dihydro-1 H-pyrazole-5-carboxylic acid: to a soln, of 1 -(tert-butyl) 5-ethyl 3-methyl-4,5-dihydro-1 H-pyrazole-1 ,5-dicarboxylate (500 mg, 1.95 mmol, 1 eq) in THF (24 mL) at 0 °C was added a sol. of LiOH H2O (94 mg, 3.9 mmol, 2 eq) in water (8 mL). The mixture was allowed to warm up to rt, and was stirred at rt for 2 h. The solvents were removed under reduced pressure and the residue was dried under high vacuum to give the title compound, which was used without further purification. LC-MS (2): tR = 0.56 min. tert-Butyl 5-((4,4-difluorocyclohexyl)(methyl)carbamoyl)-3-methyl-4,5-dihydro-1 H-pyrazole-1-carboxylate: a mixture of 1-(tert-butoxycarbonyl)-3-methyl-4,5-dihydro-1 H-pyrazole-5-carboxylic acid (120 mg, ca 0.526 mmol, ca 1 eq), 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (107 mg, 0.578 mmol, 1.1 eq), HATU (400 mg, 1.05 mmol, 2 eq) and DIPEA (0.271 mL, 1.58 mmol, 3 eq) in DMF (2 mL) was stirred for 2 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 0.82 min; [M+H]+: 360.25.
N-(4,4-Difluorocyclohexyl)-N,3-dimethyl-4,5-dihydro-1 H-pyrazole-5-carboxamide hoydrochloride: to a soln, of tert-butyl 5-((4,4-difluorocyclohexyl)(methyl)carbamoyl)-3-methyl-4,5-dihydro-1 H-pyrazole-1 -carboxylate (100 mg, 0.278 mmol, 1 eq) in DCM (2 mL) was added HCI (4M in dioxane, 2 mL). The mixture was stirred for 1 h at rt. The solvents were removed under reduced pressure to give the title compound that was used further without further purification. LC-MS (2): t = 0.51 min; [M+H]+: 260.33.
1-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1,1-difluorospiro[2.5]octan-6-yl)-N,3-dimethyl-4,5-dihydro- 1 H-pyrazole-5-carboxamide: to a mixture of N-(4,4-difluorocyclohexyl)-N,3-dimethyl-4,5-dihydro-1 H-pyrazole-5- carboxamide hydrochloride (78.5 mg, ca 0.265 mmol, ca 1 eq), DIPEA (0.183 mL, 1.06 mmol, 4 eq) and DMAP (3.2 mg, 0.027 mmol, 0.1 eq) in DCM (4 mL) was added dropwise a soln, of 2-chloro-6-methylpyridinyl-3-sulfonyl chloride (60 mg, 0.265 mmol, 1 eq) in DCM (1 mL). The mixture was stirred at rt for 20 min, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC- MS (2): tR = 0.87 min; [M+H]+: 449.02. 2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: a mixture of 1-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(1 , 1- difluorospiro[2.5]octan-6-yl)-N,3-dimethyl-4,5-dihydro-1 H-pyrazole-5-carboxamide (11 mg, 0.025 mmol, 1 eq), N- ethylisopropylamine (0.015 mL, 0.12 mmol, 5 eq) and TMP (0.042 mL, 0.25 mmol, 10 eq) was heated to 140 °C for 7 h. The mixture was allowed to cool to rt. The mixture was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.106 min; [M+H]+: 500.3.
Example 1.256 (S)-1-(2-lsopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using isopropylamine. LC- MS (1): tR = 1.272 min; [M+H]+: 459.2.
Example 1.257 (S)-1-[2-(lsopropyl-methyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using N- methylisopropylamine. LC-MS (1): tR = 1.207 min; [M+H]+: 473.3.
Example 1.258 (S)-1-[2-(5-Cyclopropyl-pyrazol-1-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
Ethyl 1-(2-bromo-5-methylphenyl)-5-cyclopropyl-1 H-pyrazole-4-carboxylate: (2-bromo-5- methylphenyl)hydrazine (130 mg, 0.614 mmol, 1 eq) was dissolved in EtOH (6.1 mL). Ethyl -2- (cyclopropanecarbonyl)-3-(dimethylamino)acrylate (130 mg, 0.614 mmol, 1 eq) and TEA (0.215 mL, 1.54 mmol, 2.5 eq) were added and the resulting mixture was stirred at 85 °C for 14 h. The reaction mixture was diluted with EtOAc and washed with aq. 0.5N HCI, water and brine. The org. phase was dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 8:2) to give the title compound. Rf (Hept/EtOAc)= 0.53. LC-MS (2): tR = 1.05 min; [M+H]+: 349.11.
1-(2-Bromo-5-methylphenyl)-5-cyclopropyl-1 H-pyrazole-4-carboxylic acid: ethyl 1-(2-bromo-5-methylphenyl)- 5-cyclopropyl-1 H-pyrazole-4-carboxylate (237 mg, 0.679 mmol, 1 eq) was dissolved in EtOH (5 mL), and aq. 2 M NaOH (1.35 mL, 2.71 mmol, 4 eq) was added dropwise. The reaction mixture was stirred at 60 °C for 1 h. The reaction mixture was partitioned between EtOAc and water. The aq. layer was acidified to pH 1 with aq. 32% HCI and extracted with EtOAc. The combined org. layers were washed with brine, dried with MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such without further purification in the next step. LC-MS (2): tR = 0.85 min; [M+H]+: 321.03.
1-(2-Bromo-5-methylphenyl)-5-cyclopropyl-1 H-pyrazole: In a sealed microwave tube, 1-(2-bromo-5- methylphenyl)-5-cyclopropyl-1 H-pyrazole-4-carboxylic acid (177 mg, 0.55 mmol, 1 eq) was suspended in water (2.5 mL). Sulfuric acid (0.0619 mL, 1.16 mmol, 2.1 eq) was added and the mixture was vigorously stirred at 100 °C for 46 h. Concentrated H2SO4 (0.619 mL, 11.6 mmol, 21 eq) was added again and the reaction mixture was stirred at 100 °C for 21 h. The reaction mixture was poured into cold aq. sat. NaHCOa (100 mL) and was extracted with EtOAc (100 mL). The org. phase was dried with MgSC , filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR = 0.96 min; [M+H]+: 277.13.
2-(5-Cyclopropyl-1 H-pyrazol-1-yl)-4-methylbenzenesulfonyl chloride: 1-(2-bromo-5-methylphenyl)-5- cyclopropyl-1 H-pyrazole (60 mg, 0.216 mmol, 1 eq) was dissolved in THF (2 mL) and stirred at -78 °C. n-BuLi (1.6 M in hexanes, 0.149 mL, 0.238 mmol, 1.1 eq) was added dropwise and the reaction mixture was stirred at -78 °C for 30 min. SO2 (0.5 M in THF, 0.866 mL, 0.433 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 30 min. SO2 (0.5 M in THF, 0.866 mL, 0.433 mmol, 2 eq) was added again and the reaction mixture was stirred at -78 °C for 1 h at rt for 2 h. The reaction mixture was concentrated to give a pale yellow solid which was then suspended in DCM (2 mL) and stirred at -78 °C. A soln, of SO2CI2 (0.0217 mL, 0.26 mmol, 1.2 eq) in DCM (1 mL) was added. The reaction mixture was stirred at rt for 1.5 h, allowed to warm to rt, and concentrated under reduced pressure. The was dissolved in DCM (2 mL) and was added to a mixture of (S)-N-(4, 4-difl uorocyclohexy I)- N-methylpyrrolidine-2-carboxamide (53.2 mg, 0.216 mmol, 1 eq) and TEA (0.0912 mL, 0.648 mmol, 3 eq) in DCM (2 mL), and the mixture was stirred at rt for 15 h. Water was added and the reaction mixture was stirred for 10 min, and then filtered over a phase separator. The org. phase was concentrated and the residue was purified by acidic prep. HPLC to give the title compound as a white solid. LC-MS (1): IR= 1.151 min; [M+H]+: 507.2.
Example 1.259 (S)-1-[2-(5-Ethyl-pyrazol-1-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.258 using ethyl (E)-2- ((dimethylamino)methylene)-3-oxopentanoate to give the title compound as a white solid. LC-MS (1): IR= 1.155 min; [M+H]+: 495.2.
Example 1.260 (S)-1-[4-Methyl-2-(3-methyl-pyrazin-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide:
Methyl ((4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)-L-prolinate: methyl ((2- bromo-4-methylphenyl)sulfonyl)-L-prolinate (1000 mg, 2.76 mmol, 1 eq), PdCl2(MeCN)2 (14.6 mg, 0.0552 mmol, 0.02 eq) and SPhos (90.7 mg, 0.221 mmol, 0.08 eq) were introduced into a 250 mL round bottom flask which was evacuated and backfilled with N2. Dioxane (13 mL), TEA (1.16 mL, 8.28 mmol, 3 eq) and boronic acid pinacol ester (558 mg, 4.14 mmol, 1.5 eq) were added, and the resulting mixture was stirred at 110 °C for 1 h. The reaction mixture was filtered through a pad of Celite® and rinsed with EtOAc. The filtrate was concentrated under reduced pressure, and the residue was purified by FC (Hept to Hept/EtOAc 6.5:3.5) to give the title compound. Rf (Hept/ EtOAc 2: 1)= 0.25. LC-MS (2): 1.02 min; [M+H]*: 410.29.
Methyl ((4-methyl-2-(3-methylpyrazin-2-yl)phenyl)sulfonyl)-L-prolinate: methyl ((4-methyl-2-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)-L-prolinate (50 mg, 0.115 mmol, 1 eq), 2-bromo-3- methylpyrazine (30.4 mg, 0.172 mmol, 1 .5 eq), NaHCOa (29 mg, 0.344 mmol, 3 eq) and Pd(PPha)4 (13.7 mg, 0.0115 mmol, 0.1 eq) were dissolved in degassed DME/water 4: 1, and the resulting mixture was stirred at 85 °C for 3 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified basic prep HPLC to give the title compound. LC-MS (2): 0.84 min; [M+H]+: 376.23.
((4-Methyl-2-(3-methylpyrazin-2-yl)phenyl)sulfonyl)-L-proline: to a soln, of methyl ((4-methyl-2-(3- methylpyrazin-2-yl)phenyl)sulfonyl)-L-prolinate (34.3 mg, 0.0914 mmol, 1 eq) in H2O (0.17 mL) and THF (0.60 mL), LiOH H2O (5.81 mg, 0.137 mmol, 1.5 eq) was added at rt and the reaction mixture was stirred at rt for 1 h. The reaction mixture was partitioned between brine and DCM. The phases were separated and the aq. phase was acidified to pH 1 with aq. 1 M HCI, and extracted with DCM. The combined org. layers were dried with MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): 0.73 min; [M+H]+: 362.15.
(S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-methyl-1-((4-methyl-2-(3-methylpyrazin-2- yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide: to a soln, of ((4-methyl-2-(3-methylpyrazin-2-yl)phenyl)sulfonyl)- L-proline (17.4 mg, 0.0458 mmol, 1 eq) in DMF (0.7 mL) was added DIPEA (0.024 mL, 0.137 mmol, 3 eq) followed by HATU (23.3 mg, 0.0595 mmol, 1.3 eq) and 1 ,1-difluoro-N-methylspiro[2.5]octan-6-amine (8.02 mg, 0.0458 mmol, 1 eq), and the yellow soln, was stirred at rt overnight. The reaction mixture was filtered through a PTFE 0.45 pm filter and directly purified by basic prep HPLC to give the title compound. LC-MS (1): 1 .116 min; [M+H]+: 519.13.
Example 1.261 (S)-1-[2-(3-Methoxy-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
((2-(3-Methoxypyrazin-2-yl)-4-methylphenyl)sulfonyl)-L-proline: was synthesized in analogy to Example 1.260 using 2-iodo-3-methoxypyrazine and methyl ((4-methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl)sulfonyl)-L-prolinate to give the title compound as a white solid. LC-MS (2): 0.76 min; [M+H]+: 378.22.
(S)-1-[2-(3-Methoxy-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.260 using ((2-(3-methoxypyrazin-2-yl)-4- methylphenyl)sulfonyl)-L-proline and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride to give the title compound as a pale yellow solid. LC-MS (1): 1.086 min; [M+H]+: 509.2.
Example 1.262 (S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
((2-(3-Fluoropyrazin-2-yl)-4-methylphenyl)sulfonyl)-L-proline: was synthesized in analogy to Example 1.260 using 2-fluoro-3-iodopyrazine and methyl ((4-methyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- y l)pheny l)sulfony l)-L-prol I nate to give the title compound as a white solid. LC-MS (3): 0.87 min; [M+H]+: not seen.
(S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.260 using ((2-(3-fluoropyrazin-2-yl)-4- methylphenyl)sulfonyl)-L-proline and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride to give the title compound as a pale yellow solid. LC-MS (1): 1.081 min; [M+H]+: 497.2.
Example 1.263 {(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2- yl}-((1S,3R,5R)-3-methoxy-8-aza-bicyclo[3.2.1]oct-8-yl)-methanone: ((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-L-proline: a mixture of ((2-chloro-6- methylpyridin-3-yl)sulfonyl)-L-proline (200 mg, ca 0.656 mmol, ca 1 eq), (3S, 5S)-3,5-dimethylmorpholine (156, 1 .31 mmol, 2 eq) and TMP (1 .79 mL, 10.5 mmol, 16 eq) was heated to 140 °C for 10 days. The mixture was allowed to cool to rt, filtered, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.82 min; [M+H]+: 384.13. {(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-((1S,3R,5R)-3- methoxy-8-aza-bicyclo[3.2.1]oct-8-yl)-methanone: a mixture of ((2-((3S,5S)-3,5-dimethylmorpholino)-6- methylpyridin-3-yl)sulfonyl)-L-proline (10 mg, 0.026 mmol, 1 eq), (3-endo)-3-methoxy-8-azabicyclo[3.2.1]octane hydrochloride (5.4 mg, 0.0.29 mmol, 1.1 eq), HATU (20 mg, 0.052 mmol, 2 eq) and DIPEA (0.14 mL, 0.078 mmol, 3 eq) in DMF (1 mL) was stirred for 18 h at rt. The solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.137 min; [M+H]+: 507.2.
Example 1.264 to Example 1.271 : were synthesized using the corresponding amine or amine salt and the corresponding carboxylic acid according to the procedure described in Example 1.263. LC-MS data of Example 1.264 to Example 1.271 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.272 to Example 1.274: were synthesized using the appropriate carboxylic acid and the appropriate amine or amine salt according to the procedures described in Example 1.260. LC-MS data of Example 1.272 to Example 1.274 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.275 to Example 1.278: were synthesized using the appropriate amino acid, 2'-fluoro-5-methyl-[1,T- biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluorocyclohexan-1-amine hydrochlororide according to the procedures described in Example 1.6. LC-MS data of Example 1.275 to Example 1.278 are listed in the table below. The LC- MS conditions used were LC-MS (1). Example 1.279 to Example 1.291 : were synthesized using the appropriate amine or amine salt and the appropriate carboxylic acid according to the procedures described in Examples 1.184. LC-MS data of Example 1.279 to Example 1.291 are listed in the table below.
Example 1.292 and Example 1.293 (S)-1-[4-Methyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzenesulfonyl]- pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide and (S)-1-[4-Methyl-2-((R)-2,2,2- trifluoro-1-methyl-ethoxy)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide: NaH (55-65 % dispersion in mineral oil, 4.3 mg, ca 0.11 mmol, ca 1.5 eq) was suspended in dry THF (0.2 mL) under N2 atmosphere and stirred at rt. 1,1,1 -trifl uoro-2-propanol (16.9 mg, 0.143 mmol, 2 eq) was added dropwise and the reaction mixture was stirred at rt for 20 min. (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide (30 mg, 0.0717 mmol, 1 eq) in dry THF (0.4 mL) was added dropwise and the reaction mixture was stirred at rt for 19 h then at 70 °C for 1 h. The mixture was cooled down to rt, quenched with water and extracted with EtOAc. The organic layer was dried over MgSC , filtered, and concentrated under reduced pressure. The residue was purified by basic prep. HPLC to give the first eluting diastereomer and the second eluting diastereomer. First eluting diastereomer: LC-MS (1): tR = 1.175 min; [M+H]+: 513.3. Second eluting diastereomer: LC-MS (1): tR= 1.197 min; [M+H]+: 513.2.
Example 1.294 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using the appropriate amino acid, 2'-fl uoro-5-methy I- [1,1'-biphenyl]-2-sulfonyl chloride LiCI and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride in analogy to Example 1.62. LC-MS (1): tR= 1.295 min; [M+H]+: 507.2.
Example 1.295 (S)-1-(2-lsopropylamino-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and isopropylamine in analogy to Example 1.21 to give the title compound as a white solid. LC-MS (1): tR = 1.295 min; [M+H]+: 458.3.
Example 1.296 to Example 1.300: were synthesized using the appropriate amine or amine salt according to the procedure described in Example 1.256. LC-MS data of Example 1.296 to Example 1.300 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.301 (S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid
(1,1-difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide: was synthesized using ((2-(3-fluoropyrazin-2-yl)-4- methylphenyl)sulfonyl)-L-proline and 1 , 1-difluoro-N-methylspiro[2.5]octan-6-amine in analogy to Example 1.262. LC-MS (1): tR= 1 .162 min; [M+H]+: 523.2.
Example 1.302 to Example 1.347: were synthesized using the appropriate amine or amine salt in analogy to Example 1 .256. LC-MS data of Example 1 .302 to Example 1 .347 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.348 to Example 1.350: were synthesized using the appropriate amine or amine salt in analogy to Example 1 .256. LC-MS data of Example 1 .348 to Example 1 .350 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.351 to Example 1.358: were synthesized using the appropriate amine or amine salt in analogy to Example 1 .256. LC-MS data of Example 1 .351 to Example 1 .358 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.359 (S)-1-(2-lsobutoxy-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: NaH (ca 60% in oil, 7.4 mg, ca 0.23 mmol, ca 4 eq) was added to a soln, of 2- methyl-1-propanol (0.021 mL, 0.229 mmol, 4 eq) in DMF (1 mL). The mixture was stirred for 30 min, and (S)-1 -((2- chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (25 mg, 0.057 mmol, 1 eq) was added. The mixture was stirred at rt for 1 h. Water was added to quench the reaction mixture. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.276 min; [M+H]+: 474.2.
Example 1.360 to Example 1.363: were synthesized using the appropriate amine or amine salt in analogy to Example 1 .359. LC-MS data of Example 1 .360 to Example 1 .363 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.364 (S)-1-[6-Methyl-2-(1-methyl-cyclopropylamino)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.169 using 1- methylcyclopropan-1 -amine. LC-MS (1): IR = 1.225 min; [M+H]+: 471.2. Example 1.365 (S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid dimethylamide: was synthesized using ((2-(3-fluoropyrazin-2-yl)-4-methylphenyl)sulfonyl)-L-proline and 1 , 1- difluoro-N-methylspiro[2.3]hexan-5-amine hydrochloride in analogy to Example 1.262 to give the title compound as a white solid. LC-MS (1): tR = 1.102 min; [M+H]+: 495.2. Example 1.366 (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((6-methyl-2-((RS)-3-(2,2,2- trifluoroethyl)morpholino)pyridin-3-yl)sulfonyl)pyrrolidine-2-carboxamide: was synthesized using rac-3- (2,2,2-trifluoroethyl)morpholine in analogy to Example 1.169 to give the title compound. LC-MS (1): tR = 1.251 min; [M+H]+: 569.3.
Example 1.367 (S)-1-[6-Methyl-2-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-pyridine-3-sulfonyl]-pyrrolidine- 2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.359 using hexafluoroisopropanol. LC-MS (1): tR = 1.283 min; [M+H]+: 568.1.
Example 1.368 to Example 1.369: were synthesized using (S)-N-(4,4-difluorocyclohexyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and the appropriate alcohol as reported in Example 1.292. LC-MS data of Example 1.368 to Example 1.369 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.370 to Example 1.377: were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.263. LC-MS data of Example 1.370 to Example 1.377 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.378 5-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-aza-spiro[2.4]heptane-4-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide: was synthesized using the appropriate Boc-protected amino acid and 4,4- difluoro-N-methylcyclohexan-1 -amine hydrochloride in analogy to Example 1.6 to give the title compound as a white solid. LC-MS (1): tR = 1.302 min; [M+H]+: 521.2.
Example 1.379 (S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide:
Methyl ((4-methyl-2-(4-methylisothiazol-3-yl)phenyl)sulfonyl)-L-prolinate: methyl ((4-methyl-2-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)-L-prolinate (266 mg, 0.611 mmol, 1 eq), 3-bromo-4-methyl- isothiazole (163 mg, 0.916 mmol, 1.5 eq), Na2COa (195 mg, 1.83 mmol, 3 eq) and Pd(dppf)Cl2CH2Cl2 (49.9 mg, 0.061 1 mmol, 0.1 eq) were dissolved in degassed 1,4-dioxane I water 4:1 (6 mL) and the resulting mixture was stirred at 70 °C for 22 h. The reaction mixture was filtered through a PTFE 0.45 m filter and rinsed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by FC (Hept to Hept/EtOAc 8:2) to give the title compound. Rf (Hept/EtOAc 2:1)= 0.28. LC-MS (2): tR = 0.94 min; [M+H]+: 381.19.
((4-Methyl-2-(4-methylisothiazol-3-yl)phenyl)sulfonyl)-L-proline: methyl ((4-methyl-2-(4-methylisothiazol-3- yl)phenyl)sulfonyl)-L-prolinate (73 mg, 0.175 mmol, 1 eq) was dissolved in H2O (0.5 mL) and THF (2 mL), and UOH H2O (22.2 mg, 0.524 mmol, 3 eq) was added at rt. The reaction mixture was stirred at rt for 1.5 h. LIOH H2O (22.2 mg, 0.524 mmol, 3 eq) was added again and the reaction mixture was stirred again at rt for 21 h. The reaction mixture was partitioned between water and DCM. The layers were separated and the aq. layer was acidified to pH 1 with aq. cone. HCI, and was extracted with EtOAc. The combined org. layers were dried with MgSO4, filtered, and concentrated to give the title compound, which was used as such in the next step without further purification. LC- MS (2): tR = 0.82 min; [M+H]+: 367.17. (S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide: was synthesized using ((4-methyl-2-(4-methylisothiazol-3- yl)phenyl)sulfonyl)-L-proline (13.4 mg, 0.0365 mmol, 1 eq) and 1 ,1-difluoro-N-methylspiro[2.5]octan-6-amine in analogy to Example 1.260 to give the title compound as a white solid. LC-MS (1): IR= 1.251 min; [M+H]+: 524.3.
Example 1.380 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (2,6-dimethyl-tetrahydro-pyran-4-yl)-amide: was synthesized using 2,6-dimethyltetrahydro-2H- pyran-4-amine to give the title compound in analogy to Example 1.263. LC-MS (1): tR = 1.086 min; [M+H]+: 495.3.
Example 1.381 to Example 1.382: were synthesized using ((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1 .170. LC-MS data of Example 1.381 to Example 1.382 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.383 (2-Aza-tricyclo[3.3.1.13,7]dec-2-yl)-{(S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl- pyridine-3-sulfonyl]-pyrrolidin-2-yl}-methanone: was synthesized using 2-azatricyclo[3.3.1.1,3,7]decane hydrochloride in analogy to Example 1.263. LC-MS (1): tR = 1.255 min; [M+H]+: 503.3.
Example 1.384 (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(1-methyl-cyclohexyl)-amide: was synthesized in analogy to Example 1.170 using ((2- (ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-L-proline and N, 1-dimethylcyclohexan-1 -amine to give the title compound. LC-MS (1): tR = 1.338 min; [M+H]+: 465.3.
Example 1.385 to Example 1.391 : were synthesized in analogy to Example 1.263 using ((2-((3S,5S)-3,5- dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of Example 1.385 to Example 1.391 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.392 (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((4-methyl-2-(((RS)-4,4,4-trifluorobutan-2- yl)oxy)phenyl)sulfonyl)pyrrolidine-2-carboxamide: was synthesized using (S)-N-(4,4-difluorocyclohexyl)-1 -((2- fluoro-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2-carboxamide and 4,4,4-trifluoro-2-butanol in analogy to Example 1.292 to give the title compound as a white solid. LC-MS (1): IR = 1.214 min; [M+H]+: 527.3.
Example 1.393 (S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1,1-difluoro-spiro[2.3]hex-5-yl)-N-methyl-amide: was synthesized using ((4-methyl-2-(4-methylisothiazol-3- yl)phenyl)sulfonyl)-L-proline and 1,1-difluoro-N-methylspiro[2.3]hexan-5-amine hydrochloride in analogy to Example 1.379 to give the title compound as a white solid. LC-MS (1): IR = 1.196 min; [M+H]+: 496.3.
Example 1.394 (S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-methyl-1-((4-methyl-2-(((RS)-1,1,1-trifluoropropan- 2-yl)oxy)phenyl)sulfonyl)pyrrolidine-2-carboxamide:
Methyl ((2-fluoro-4-methylphenyl)sulfonyl)-L-prolinate: 2-fluoro-4-methylbenzenesulfonyl chloride (154 mg, 0.739 mmol, 1.05 eq) was added to a mixture of L-proline methyl ester hydrochloride (120 mg, 0.717 mmol, 1 eq), DIPEA (0.368 mL, 2.15 mmol, 3 eq) and DMAP (8.8 mg, 0.072 mmol, 0.1 eq) in DCM (10 mL) at rt. The mixture was stirred overnight. The mixture was partitioned between DCM and aq. sat. NaHCOa. The org. layer was washed with water, dried over MgSO4, and filtered. The solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 0.89 min; [M+H]+: 302.11.
((2-Fluoro-4-methylphenyl)sulfonyl)-L-proline: LIOH (1 M in H2O, 2.15 mL, 2.15 mmol, 3 eq) was added to a soln, of methyl ((2-fluoro-4-methylphenyl)sulfonyl)-L-prolinate (215 mg, 0.713 mmol, 1 eq) in THF (8 mL) at rt. The mixture was stirred for 2 h, and the solvents were removed under reduced pressure. The residue was partitioned between DCM and aq. 1 M HCI. The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure to yield the title compound, which was used without further purification. LC-MS (2): IR = 0.76 min; [M+H]+: 288.14. ((4-Methyl-2-(((RS)-1,1,1-trifluoropropan-2-yl)oxy)phenyl)sulfonyl)-L-proline: was synthesized using ((2- fluoro-4-methylphenyl)sulfonyl)-L-proline and 1 , 1 ,1 -trifl uoro-2-propanol in analogy to Example 1.292 to give the title compound as a yellow solid. LC-MS (2): IR = 0.86 and 0.87 min; [M+H]+: 382.21.
(S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-methyl-1-((4-methyl-2-(((RS)-1,1,1-trifluoropropan-2- yl)oxy)phenyl)sulfonyl)pyrrolidine-2-carboxamide: was synthesized using ((4-methyl-2-((1 ,1 , 1 -trifluoropropan- 2-yl)oxy)phenyl)sulfonyl)-L-proline and 1 ,1-difluoro-N-methylspiro[2.5]octan-6-amine in analogy to Example 1.292 to give the title compound as a white solid. LC-MS (1): IR = 1.271 ; [M+H]+: 539.2.
Example 1.395 (S)-N-((RS)-3,3-dimethylcyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6- methylpyridin-3-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: was synthesized in analogy to Example 1.263 using N,3,3-trimethylcyclopentan-1-amine hydrochloride to give the title compound. LC-MS (1): IR = 1.328 min; [M+H]+: 493.3.
Example 1.396 (S)-1-[2-((S)-2-Methoxy-1-methyl-ethylamino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized in analogy to Example 1.163 using (S)-1-methoxypropan-2-amine to give the title compound. LC-MS (1): IR = 1.212 min; [M+H]+: 489.2.
Example 1.397 (S)-N-((1 R*,3S*)-3-cyanocyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6- methylpyridin-3-yl)sulfonyl)pyrrolidine-2-carboxamide: was synthesized in analogy to Example 1.263 using rac-(1 R,3S)-3-aminocyclopentane-1 -carbonitrile to give the title compound. LC-MS (1): IR = 1.328 min; [M+H]+: 493.3.
Example 1.398 to Example 1.403: were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.263. LC-MS data of Example 1.398 to Example 1.403 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.404 (S)-1-{2-[lsopropyl-(2-methoxy-ethyl)-amino]-6-methyl-pyridine-3-sulfonyl}-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using N-(2-methoxyethyl)propan- 2-amine in analogy to Example 1.163 to give the title compound. LC-MS (1): IR = 1.247 min; [M+H]+: 517.4.
Example 1.405 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2- carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide:
(35.55)-3,5-dimethyl-4-(5-methyl-2-nitrophenyl)morpholine: to a stirred soln. 3-fluoro-4-nitrotoluene (250 mg, 1.61 mmol, 1 eq) in DMSO (1.75mL) was added (3S,5S)-3,5-dimethyl-morpholine (391 mg, 3.29 mmol, 2.041 eq) and DIPEA (0.883 mL, 4.83 mmol, 3 eq). The mixture was stirred at 110 °C for 84 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined org. layers were washed with brine, dried over MgSC , filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9:1) to give the title compound. LC-MS (2): IR = 0.98 min; [M+H]+: 251 .29.
2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylaniline: to a soln, of (3S,5S)-3,5-dimethyl-4-(5-methyl-2- nitrophenyl)morpholine (200 mg, 0.8 mmol, 1 eq) in EtOH (3.3 mL) and water (1.1 mL), Fe (powder, 447 mg, 8 mmol, 10 eq) and NH4CI (215 mg, 4 mmol, 5 eq) were added, and the soln, was stirred at 85 °C for 2 h. The reaction mixture was filtered through a paper filter and rinsed with EtOH. The filtrate was concentrated under reduced pressure and the residue was dissolved in EtOAc and washed with water. The org. layer was separated and the aq. layer was extracted with EtOAc. The combined org. extracts were dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound as a brown oil. LC-MS (2): IR = 0.58 min; [M+H]+: 221.29.
(35.55)-4-(2-Bromo-5-methylphenyl)-3,5-dimethylmorpholine: CuE (116 mg, 0.513 mmol, 1 eq) was dissolved in CH3CN (3.0 mL) and t-butyl nitrite (0.0748 mL, 0.564 mmol, 1.1 eq) was added. The reaction mixture was stirred at O °C and a suspension of 2-((3S,5S)-3,5-dimethylmorpholino)-4-methylaniline (113 mg, 0.513 mmol, 1 eq) in CH3CN (1.5 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, then at rt for 15 h. The reaction mixture was cooled to 0 °C and quenched with a soln, of sulfamic acid (10 mg, 0.10 mmol, 0.2 eq) in water (50 mL), followed by the addition of aq. 2M HCI (0.386 mL, 0.769 mmol, 1.5 eq). The reaction mixture was extracted with EtOAc, the layers separated and the aq. layer was extracted again with EtOAc (50 mL). The combined org. layers were washed with brine, dried with MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9: 1) to give the title compound. LC-MS (2): IR = 0.85 min; [M+H]+: 284.16. (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: (3S,5S)-4-(2-bromo-5-methylphenyl)-3,5-dimethylmorpholine (43 mg, 0.15 mmol, 1 eq) was dissolved in THF (2 mL) and stirred at -78 °C. n-BuLi (1.6 M in hexanes, 0.103 mL, 0.166 mmol, 1.1 eq) was added dropwise and the reaction mixture was stirred at -78 °C for 30 min. SO2 (0.5 M in THF, 0.606 mL, 0.303 mmol, 2 eq) was added and the reaction mixture was stirred at -78 °C for 3 h. The reaction mixture was concentrated to give a pale yellow solid which was suspended in DCM (2 mL) and stirred at -78 °C. A soln, of SO2CI2 (15 piL, 0.182 mmol, 1.2 eq) in DCM (1 mL) was added. The reaction mixture was stirred at rt for 2.5 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in DCM (1 mL) and was added to a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (37.2 mg, 0.151 mmol, 1 eq) and TEA (0.0638 mL, 0.453 mmol, 3 eq) in DCM (2mL) and the mixture was stirred at rt for 16 h. Water was added and the reaction mixture was stirred for 10 min, filtered over phase separator and the solvent removed under reduced pressure. The residue was purified by basic prep HPLC to give the title compound. LC-MS (1): IR = 1 .198 min; [M+H]+: 514.4.
Example 1.406 to Example 1.408: were synthesized using ((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1 .170. LC-MS data of Example 1.406 to Example 1.408 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.409 to Example 1.416: were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.263. LC-MS data of Example 1.409 to Example 1.416 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.417 (S)-N-(4,4-Difluorocyclohexyl)-1-((2-(ethyl((RS)-1-methoxypropan-2-yl)amino)-6- methylpyridin-3-yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: was synthesized using (S)-1-((2-chloro-6- methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and rac-N-ethyl-1- methoxypropan-2-amine in analogy to Example 1.163 to give the title compound. LC-MS (1): IR = 1.229 min; [M+H]+: 517.4.
Example 1.418 (RS)-N-(4,4-Difluorocyclohexyl)-3-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)-N-methyloxazolidine-2-carboxamide:
2-Chloro-N-(2-hydroxyethyl)-6-methylpyridine-3-sulfonamide: a soln, of 2-chloro-6-methylpyridine-3-sulfonyl chloride (1.00 g, 4.20 mmol, 1 eq) in DCM (15 mL) was added to a mixture of ethanolamine (0.256 mL, 4.20 mmol, 1 eq) and DIPEA (0.863 mL, 5.04 mmol, 1.2 eq) in DCM (15 mL) at rt. The mixture was stirred for 45 min, and the solvents were removed under reduced pressure. The residue was purified by FC (DCM to MeOH/DCM 1 :9) to give the title compound. LC-MS (2): IR = 0.53 min; [M+H]+: 251.18.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-2-vinyloxazolidine: a mixture of 2-chloro-N-(2-hydroxyethyl)-6- methylpyridine-3-sulfonamide (400 mg, 1.60 mmol, 1 eq), acrolein diethyl acetal (623 mg, 4.79 mmol, 3 eq), pyridinium p-toluenesulfonate (122 mg, 0.479 mmol, 0.3 eq) and molecular sieve (4A, 400 mg) in DME (8 mL) was stirred to reflux for 2.5 h. The mixture was allowed to cool to rt, EtOAc (25 mL) was added, and the mixture was filtered. The filtrate was washed with aq. 5% NaHCOa (1x) and brine (1x). The org. layer was dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to Hept I EtOAc 6:4) to give the title compound. LC-MS (2): IR = 0.82 min; [M+H]+: 289.09. 3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)oxazolidine-2-carbaldehyde: OsC>4 (2.5 wt. % in tBuOH, 2.85 g, 0.281 mmol, 0.3 eq) was added to a mixture of 3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-2-vinyloxazolidine (270 mg, 0.935 mmol, 1 eq), 2,6-dimethylpyridine (0.227 mL, 1.87 mmol, 2 eq) and NMO (226 mg, 1.87 mmol, 2 eq) in THF (7 mL) and water (1 mL) at 0 °C. The mixture was stirred for 5 h while warming up to rt. Aq. sat. Na2SOa was added, and the mixture was stirred for 5 min. The mixture was extracted with EtOAc (3x). The combined org. layers were dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was diluted in a mixture of THF (12 mL) and water (3 mL). NalC (808 mg, 3.74 mmol, 4 eq) was added, and the mixture was stirred at rt for 1.5 h. The mixture was extracted with EtOAc. The org. layer was dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to Hept I EtOAc 9:1) to give the title compound.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)oxazolidine-2-carboxylic acid: to a mixture of rac-3-((2-chloro-6- methylpyridin-3-yl)sulfonyl)oxazolidine-2-carbaldehyde (150 mg, 0.516 mmol, 1 eq) and 2-methyl-2-butene (2.3 mL, 20,6 mmol, 40 eq) in THF (5 mL) and tBuOH (5 mL) was added a soln, of N32HPO4 H2O (431 mg, 3.1 mmol, 6 eq) and NaCIO2 (350 mg, 3.1 mmol, 6 eq) in water (2 mL). The mixture was stirred at rt for 35 min. The mixture was extracted with EtOAc. The combined org. layers were washed with brine, dried over Na2SO4, filtered, and the solvents were removed under reduced pressure to give the title compound, which was used without further purification.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methyloxazolidine-2- carboxamide: a mixture of rac-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)oxazolidine-2-carboxylic acid (87 mg, ca 0.269 mmol, ca 1 eq), 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (50 mg, 0.269 mmol, 1 eq), DIPEA (0.138 mL, 0.808 mmol, 3 eq) and HATU (139 mg, 0.323 mmol, 1.2 eq) in DMF (1.5 mL) was stirred at rt for 24 h. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): tp = 0.91 min; [M+H]+: 438.11.
(RS)-N-(4,4-Difluorocyclohexyl)-3-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methyloxazolidine-2-carboxamide: a mixture of rac-3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methyloxazolidine-2-carboxamide (23 mg, 0.053 mmol, 1 eq) and (3S, 5S)-3,5- dimethylmorpholine (95 mg, 0.81 mmol, 15 eq) in TMP (0.3 mL) was stirred at 140 °C for 8 days. The mixture was allowed to cool to rt. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.172 min; [M+H]+: 517.3.
Example 1.419 (RS)-N-(4,4-Difluorocyclohexyl)-3-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)-N-methyl-1,3-oxazinane-2-carboxamide:
2-Chloro-N-(3-hydroxypropyl)-6-methylpyridine-3-sulfonamide: a soln, of 2-chloro-6-methy I py ridine-3-su Ifony I chloride (1.00 g, 4.20 mmol, 1 eq) in DOM (15 mL) was added to a mixture of 3-amino-1 -propanol (0.328 mL, 4.20 mmol, 1 eq) and DIPEA (0.863 mL, 5.04 mmol, 1.2 eq) in DOM (15 mL) at rt. The mixture was stirred for 10 min, and the solvents were removed under reduced pressure. The residue was purified by FC (DCM to DCM I MeOH 9:1 ) to give the title compound. LC-MS (2): IR = 0.56 min; [M+H]+: 265.19.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-2-vinyl-1,3-oxazinane: a mixture of 2-chloro-N-(3-hydroxypropyl)-6- methylpyridine-3-sulfonamide (400 mg, 1.51 mmol, 1 eq), acrolein diethyl acetal (590 mg, 4.53 mmol, 3 eq), pyridinium p-toluenesulfonate (115 mg, 0.453 mmol, 0.3 eq) and molecular sieve (4A, 400 mg) in DME (8 mL) was stirred to reflux for 2.5 h. The mixture was allowed to cool to rt, EtOAc (25 mL) was added, and the mixture was filtered. The filtrate was washed with aq. 5% NaHCOa (1x) and brine (1x). The org. layer was dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to Hept I EtOAc 6:4) to give the title compound. LC-MS (2): IR = 0.85 min; [M+H]+: 303.06.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-1,3-oxazinane-2-carbaldehyde: OsO4 (2.5 wt. % in tBuOH, 2.22 g, 0.218 mmol, 0.3 eq) was added to a mixture of 3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-2-vinyl-1,3-oxazinane (220 mg, 0.727 mmol, 1 eq), 2,6-dimethylpyridine (0.176 mL, 1.45 mmol, 2 eq) and NMO (176 mg, 1.45 mmol, 2 eq) in THF (7 mL) and water (1 mL) at 0 °C. The mixture was stirred for 8 h while warming up to rt. Aq. sat. Na2SO3 was added, and the mixture was stirred for 5 min. The mixture was extracted with EtOAc (3x). The combined org. layers were dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was diluted in a mixture of THF (12 mL) and water (3 mL). NalO4 (628 mg, 2.91 mmol, 4 eq) was added, and the mixture was stirred at rt for 0.5 h. The mixture was extracted with EtOAc. The org. layer was dried over Na2SO4, filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 0.54 min; [M+H]+: 305.01.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-1,3-oxazinane-2-carboxylic acid: to a mixture of 3-((2-chloro-6- methylpyridin-3-yl)sulfonyl)-1 ,3-oxazinane-2-carbaldehyde (157 mg, 0.516 mmol, 1 eq) and 2-methyl-2-butene (2.3 mL, 20,6 mmol, 40 eq) in THF (5 mL) and tBuOH (5 mL) was added a soln, of N32HPO4 H2O (431 mg, 3.1 mmol, 6 eq) and NaCIO2 (350 mg, 3.1 mmol, 6 eq) in water (2 mL). The mixture was stirred at rt for 45 min. The mixture was extracted with EtOAc (2x). The combined org. layers were washed with brine, dried over Na2SO4, filtered, and the solvents were removed under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): IR = 0.64 min; [M+H]+: 321.05.
3-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methyl-1,3-oxazinane-2- carboxamide: a mixture of 3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-1 ,3-oxazinane-2-carboxylic acid (91 mg, ca 0.269 mmol, ca 1 eq), 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (70 mg, 0.377 mmol, 1.3 eq), DIPEA (0.138 mL, 0.808 mmol, 3 eq) and HATU (139 mg, 0.323 mmol, 1.2 eq) in DMF (1.5 mL) was stirred at rt for 24h. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.96 min; [M+H]+: 452.14.
(RS)-N-(4,4-Difluorocyclohexyl)-3-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methyl-1,3-oxazinane-2-carboxamide: a mixture of 3-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)-N-methyl-1,3-oxazinane-2-carboxamide (24 mg, 0.053 mmol, 1 eq) and (3S, 5S)-3,5- dimethylmorpholine (95 mg, 0.81 mmol, 15 eq) in TMP (0.3 mL) was stirred at 140 °C for 8 days. The mixture was allowed to cool to rt. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): tR = 1.252 min; [M+H]+: 531.3.
Example 1.420 to Example 1.428: were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.263. LC-MS data of Example 1.420 to Example 1.428 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.429 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (1,1-dioxo- hexahydro-1X6-thiopyran-4-yl)-amide: a mixture of ((2'-fluoro-5-methyl-[1 , 1 '-biphenyl]-2-yl)sulfonyl)-L-proline (15 mg, 0.041 mmol, 1 eq), 4-aminotetrahydro-2H-pyrane 1 , 1 -dioxide hydrochloride (8.6 mg, 0.45 mmol, 1.1 eq), DIPEA (0.021 mL, 0.124 mmol, 3 eq) and HATU (31 mg, 0.083 mmol, 2 eq) in DMF (1 mL) was stirred at rt overnight. DCM and aq. sat. NaHCOa were added, and the mixture was separated a phase separator (Isolute®). The org. layer was evaporated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC- MS (1): tR = 0.979 min; [M+H]+: 495.2. Example 1.430 to Example 1.431 : were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.263. LC-MS data of Example 1.430 to Example 1.431 are listed in the table below. The LC-MS conditions used were LC-MS (1). Example 1.432 to Example 1.433: were synthesized according to the procedures described herein before using ((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of Example 1.432 to Example 1.433 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.434 to Example 1.435: were synthesized according to the procedures described herein before using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of Example 1.434 to Example 1.435 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.436 (S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (1,1-dioxo- hexahydro-1X6-thiopyran-4-yl)-N-methyl-amide: a mixture of ((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)-L- proline (15 mg, 0.041 mmol, 1 eq), 4-(methylamino)tetrahydro-2H-thiopyran 1 ,1 -dioxide hydrochloride (9.5 mg, 0.45 mmol, 1.1 eq), DIPEA (0.021 mL, 0.124 mmol, 3 eq) and HATU (31 mg, 0.083 mmol, 2 eq) in DMF (1 mL) was stirred at rt overnight. The mixture was partitioned between DCM and aq. sat. NaHCOa, and the phases were separated through a phase separator (Isolute®). The org. layer was evaporated under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1.018 min; [M+H]+: 509.2.
Examples 1.437 and 1.438 (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]- pyrrolidine-2-carboxylic acid ((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide and (S)-1-[2-((3S,5S)- 3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid ((2S,4S,6R)-2,6- dimethyl-tetrahydro-pyran-4-yl)-amide: the mixture of stereoisomers from Example 1.409 was separated by chiral SFC (SFC 2 method) to give (S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]- py rrolidi ne-2-carboxy lie acid ((2R,4R, 6S)-2,6-dimethyl-tetrahydro-py ran-4-y l)-amide (first eluting diastereomer) and (S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid ((2S,4S,6R)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide (second eluting diastereomer). The absolute stereochemistry was arbitrarily attributed. (S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3- sulfonyl]-pyrrolidine-2-carboxylic acid ((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide: LC-MS (1): IR = 1.086 min; [M+H]+: 495.3. (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine- 2-carboxylic acid ((2S,4S,6R)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide: IR = 1.064 min; [M+H]+: 495.4.
Example 1.439 (S)-N-((1R*,3S*)-3-Cyanocyclopentyl)-1-((4-methyl-2-((S)-2-methylpiperidin-1- yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide:
(S)-N-((1S*,3R*)-3-Cyanocyclopentyl)-1-((2-fluoro-4-methylphenyl)sulfonyl)pyrrolidine-2-carboxamide: a mixture of ((2-fluoro-4-methylphenyl)sulfonyl)-L-proline (104 mg, 0.355 mmol, 1 eq), (1 R, 3S)-rel-3- aminocyclopentane-1 -carbonitrile hydrochloride (60.3 mg, 0.391 mmol, 1.1 eq), DIPEA (0.183 mL, 1.06 mmol, 3 eq) and HATU (270 mg, 0.71 mmol, 2 eq) in DMF (3 mL) was stirred at rt overnight. The mixture was partitioned between DCM and aq. sat. NaHCOa, and the phases were separated through a phase separator. The org. layer was evaporated under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 0.84 min; [M+H]+: 380.29.
(S)-N-((1R*,3S*)-3-Cyanocyclopentyl)-1-((4-methyl-2-((S)-2-methylpiperidin-1- yl)phenyl)sulfonyl)pyrrolidine-2-carboxamide: a mixture of (2S)-N-(3-cyanocyclopentyl)-1-((2-fluoro-4- methylphenyl)sulfonyl)pyrrolidine-2-carboxamide (40 mg, 0.105 mmol, 1 eq), (S)-methylpiperidine (86 mg, 0.84 mmol, 8 eq) in THP (0.288 mL) was stirred at 140 °C overnight. The mixture was allowed to cool to rt. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 1.088 min; [M+H]+: 459.3.
Example 1.440 3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (1,1-difluoro- spiro[2.5]oct-6-yl)-amide: 2'-Fluoro-N-(2-hydroxyethyl)-5-methyl-[1,1'-biphenyl]-2-sulfonamide: a soln, of 2'-fluoro-5-methyl-[1 , T- biphenyl]-2-sulfonyl chloride (155 mg, 0.472 mmol, 0.24 eq) in THF (2 mL) was added to a soln, of ethanolamine (0.12 mL, 2.0 mmol, 1 eq) and EtaN (0.10 mL, 0.71 mmol, 0.36 eq) in THF (10 mL) at rt. The mixture was stirred overnight, and the solvents were removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR = 0.02 min; [M+H]+: 310.11.
3-((2'-Fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-2-vinyloxazolidine: a mixture of 2'-fluoro-N-(2- hydroxyethyl)-5-methyl-[1 , 1 '-biphenyl]-2-sulfonamide (130 mg, 0.42 mmol, 1 eq), acrolein diethyl acetal (173 mg, 1.26 mmol, 3 eq), pyridinium p-toluenesulfonate (32 mg, 0.126 mmol, 0.3 eq) and molecular sieve (4 A, 250 mg) in 1 ,2-dichloroethane (4 mL) was stirred to reflux for 2 h. The mixture was allowed to cool to rt, EtOAc (15 mL) was added, and the mixture was filtered. The filtrate was washed with aq. 5% NaHCOa and brine. The org. layer was dried over NaaSCH filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 1.02 min; [M+H]+: 348.23.
1-(3-((2'-Fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)oxazolidin-2-yl)ethane-1,2-diol: OsO4 (2.5 wt. % in tBuOH, 0.88 mL, 0.087 mmol, 0.3 eq) was added to a mixture of 3-((2'-fluoro-5-methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-
2-vinyloxazolidine (100 mg, 0.288 mmol, 1 eq), 2,6-dimethylpyridine (0.070 mL, 0.57 mmol, 2 eq) and NMO (70 mg, 0.57 mmol, 2 eq) in THF (1 .7 mL) and water (0.25 mL) at 0 °C. The mixture was stirred for 1 .5 h while warming up to rt. Aq. sat. NaaSOa was added, and the mixture was stirred for 5 min. The mixture was extracted with EtOAc (3x). The combined org. layers were dried over MgSO4, filtered, and the solvents were removed under reduced pressure to yield the title compound, which was used in the next step without further purification. LC-MS (2): IR = 0.80 min; [M+H]+: 382.23.
3-((2'-Fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfonyl)oxazolidine-2-carbaldehyde: 1-(3-((2'-fluoro-5-methyl-
[1 , 1 '-biphenyl]-2-yl)sulfonyl)oxazolidin-2-yl)ethane-1 ,2-diol (110 mg, ca 0.288 mol, ca 1 eq) was diluted in a mixture of THF (3 mL) and water (0.75 mL). NalO4 (246 mg, 1.15 mmol, 4 eq) was added, and the mixture was stirred at rt overnight. The mixture was extracted with EtOAc, and the org. layer was washed with brine. The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure to give the title compound, which was used without further purification. LC-MS (2): IR = 0.79 min; [M+H]+: 350.18.
3-((2'-Fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)oxazolidine-2-carboxylic acid: to a mixture of 3-((2'-fluoro- 5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)oxazolidine-2-carbaldehyde (101 mg, ca 0.288 mmol, ca 1 eq) and 2-methyl- 2-butene (1.28 mL, 11.5 mmol, 40 eq) in THF (3 mL) and tBuOH (3 mL) was added a soln, of N32HPO4 H2O (241 mg, 1.73 mmol, 6 eq) and NaCIO2 (195 mg, 1.73 mmol, 6 eq) in water (1.5 mL). The mixture was stirred at rt for 3 days. The mixture was extracted with EtOAc (2x). The combined org. layers were washed with brine, dried over MgSO4, filtered, and the solvents were removed under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): IR = 0.87 min; [M+H]+: 366.19. 3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (1,1-difluoro-spiro[2.5]oct-6-yl)- amide: a mixture of 3-((2'-fluoro-5-methyl-[1 , T-biphenyl]-2-yl)sulfonyl)oxazolidine-2-carboxylic acid (23 mg, 0.063 mmol, 1 eq), 1 , 1-difluorospiro[2.5]octan-6-amine hydrochloride (14.4 mg, 0.19 mmol, 1.1 eq), DIPEA (0.033 mL, 0.19 mmol, 3 eq) and HATU (48 mg, 0.13 mmol, 2 eq) in DMF (1 mL) was stirred at rt overnight. The residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1 .245 min; [M+H]+: 509.2.
Example 1.441 (S)-1-((1S,5R)-6-Methyl-2-3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl-pyridine-3-sulfonyl)-pyrrolidine- 2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: was synthesized using (S)-1-((2-chloro-6- methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and 3-oxa-8- azabicyclo[3.2.1]octane hydrochloride in analogy to Example 1.163 to give the title compound. LC-MS (1): IR = 1.191 min; [M+H]+: 513.3. tert-Butyl (6,6-dimethyltetrahydro-2H-pyran-3-yl)carbamate: (6,6-dimethyltetrahydro-2H-pyran-3-yl)amine (400 mg, 3.1 mmol, 1 eq) was dissolved in DCM (20.0 mL) and the mixture was cooled to 0 °C, followed by addition of DIPEA (2.12 mL, 12.4 mmol, 4 eq) and BOC2O (2027 mg, 9.29 mmol, 3 eq). The mixture was stirred at 0 °C for 30 min, and allowed to warm up to rt overnight. The reaction mixture was washed with aq. 1 M HCI and with aq. sat. NaHCOa, and the org. layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound LC-MS (2): IR= 0.85 min; [M+H]+: 230.32. tert-Butyl (6,6-dimethyltetrahydro-2H-pyran-3-yl)(methyl)carbamate: in a round-bottom two neck flask under N2 atmosphere, NaH (55-65% in mineral oil, 155 mg, ca 4.05 mmol, ca 1.5 eq) was suspended in DMF (2.00 mL) and was stirred at 0 °C under N2. tert-Butyl (6,6-dimethyltetrahydro-2H-pyran-3-yl)carbamate (617 mg, 2.69 mmol, 1 eq) in DMF (1 .00 mL) was added dropwise and the reaction mixture was stirred at 0 °C under N2 for 40 min. CH3I (0.338 mL, 5.38 mmol, 2 eq) was added and the reaction mixture was stirred at rt for 16 h. The mixture was cooled again to 0 °C and NaH (55-65% in mineral oil, 65 mg, ca 1.70 mmol, ca 0.6 eq) was added; after 30 min, CH3I (0.16 mL, 2.68 mmol, 1 eq) was added. After 48 h at rt, water was slowly added at 0 °C and the reaction mixture was extracted twice with EtOAc (10 mL). The org. layer was washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to 100% EtOAc) to give the title compound. LC-MS (2): tR= 0.94 min; [M+H]+: 244.38.
N,6,6-Trimethyltetrahydro-2H-pyran-3-amine hydrochloride: tert-butyl (6,6-dimethyltetrahydro-2H-pyran-3- yl)(methyl)carbamate (420 mg, 1.73 mmol, 1 eq) was dissolved in DCM (10.0 mL) and the mixture was cooled to 0 °C. HCI (4M in dioxane, 8 mL, 34.5 mmol, 20 eq) was added at 0 °C and the mixture was stirred at 0 °C for 10 min, then at rt overnight. The solvent was removed under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): IR= 0.33 min; [M+H]+: 144.39.
Example 1.442 (S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-6,6- dimethyltetrahydro-2H-pyran-3-yl)-N-methylpyrrolidine-2-carboxamide: was synthesized in analogy to Example 1.263 using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-L-proline and N,6,6- trimethyltetrahydro-2H-pyran-3-amine hydrochloride to give the title compound. LC-MS (1): tR = 1.149 min; [M+H]+: 509.4.
Example 1.443 to Example 1.447: were synthesized using 3-((2'-fluoro-5-methyl-[1 , -biphenyl]-2- yl)sulfonyl)oxazolidine-2-carboxylic acid and the appropriate amine or amine salt in analogy to Example 1.440. LC- MS data of Example 1.443 to Example 1.447 are listed in the table below. The LC-MS conditions used were LC- MS (1).
Example 1.448 to Example 1.449: were synthesized according to the procedures described herein before using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt. LC-MS data of Example 1.448 to Example 1.449 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 1.450 (RS)-3-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-6,6- dimethyltetrahydro-2H-pyran-3-yl)-N-methyloxazolidine-2-carboxamide: (3S,5S)-4-(2-(Benzylthio)-5-methylphenyl)-3,5-dimethylmorpholine: to a soln, of (3S,5S)-4-(2-bromo-5- methylphenyl)-3,5-dimethylmorpholine (100 mg, 0.352 mmol, 1 eq) in THF (5 mL) at -78 °C, was added dropwise n-BuLi (1.6M in hexanes, 0.26 mL, 0.42 mmol, 1.2 eq) and the solution was stirred for 15 min at -78 °C before the addition of a soln, of benzyl disulfide (133 mg, 0.528 mmol) in THF (1 mL). The reaction mixture was stirred at -78 °C for 5 min. The cooling bath was removed and the reaction mixture was warmed to rt, partitioned between DCM and water, and filtered through a separation cartridge. The solvent was removed under reduced pressure. The residue was purified by FC (Hept to Hept I EtOAc 9: 1) followed by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 1.14 min; [M+H]+: 328.19.
2-((3R,5R)-3,5-Dimethylmorpholino)-4-methylbenzenesulfonyl chloride: a soln, of (3S,5S)-4-(2-(benzylthio)-5- methylphenyl)-3,5-dimethylmorpholine (50 mg, 0.153 mmol, 1 eq) in THF (1 mL), AcOH (0.25 mL) and H2O (0.5 mL) was cooled to 0 °C. 1 ,3-Dichloro-5,5-dimethylhydantoin was added portionwise. The reaction mixture was stirred to 0 °C for 15 min. DCM (10 mL) was added, and the mixture was washed with aq. sat. NaHCOa (5 mL) and brine (5 mL). The layers were separated by a phase separator. The org. layer was concentrated under reduced pressure to give the title compound which was used without further purification.
3-((2-((3R,5R)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)oxazolidine-2-carboxylic acid: was synthesized in analogy to Example 1.440 using 2-((3R,5R)-3,5-dimethylmorpholino)-4-methylbenzenesulfonyl chloride and ethanolamine to give the title compound as a white solid. LC-MS (2): tR= 0.84 min; [M+H]+: 385.21.
(RS)-3-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-6,6-dimethyltetrahydro-2H- pyran-3-yl)-N-methyloxazolidine-2-carboxamide: was synthesized using N,6,6-trimethyltetrahydro-2H-pyran-3- amine hydrochloride and 3-((2-((3R,5R)-3,5-dimethylmorpholino)-4-methylphenyl)sulfonyl)oxazolidine-2-carboxylic acid in analogy to Example 1.440 to give the title compound as a white solid. LC-MS (2): tR= 1.02 min; [M+H]+: 510.25.
Example 1.451 to Example 1.453: were synthesized in analogy to Example 1.452 using 3-((2-((3R,5R)-3,5- dimethylmorpholino)-4-methylphenyl)sulfonyl)oxazolidine-2-carboxylic acid and the appropriate amine or amine salt. LC-MS data of Example 1.453 to Example 1.455 are listed in the table below.
Example 1.454 to Example 1.467: were synthesized as described herein before using the appropriate carboxylic acid and the appropriate amine or amine salt. LC-MS data of Example 1.454 to Example 1.467 are listed in the table below.
Example 1.468 (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((6-methyl-2-((1S*,2S*)-2- methylcyclopropyl)pyridin-3-yl)sulfonyl)pyrrolidine-2-carboxamide:
2-Bromo-6-methylpyridine-3-sulfonyl chloride: SOCI2 (3.86 mL, 0.0524 mol, 10 eq) was added dropwise over 10 min to water (25 mL) at -10 °C. The reaction mixture was stirred for 45 min at -10 °C. CuCI (18.7 mg, 0.183 mmol, 0.035 eq) was added and the soln, was stirred at -10 °C for 15 min. Fluoroboric acid (50% in water, 0.968 mL, 7.86 mmol, 1.5 eq) was added dropwise to a soln, of 3-amino-2-bromo-6-picoline (1.00 g, 5.24 mmol, 1 eq) in MeCN (6 mL) at 0 °C. The suspension was stirred for 10 min and tert-butyl nitrite (1.04 mL, 7.86 mol, 1.5 eq) was added. The resulting clear orange soln, was stirred at 0 °C for 15 min and then added to the above prepared soln. The yellow suspension was stirred maintaining the temperature between -7 to 0 °C. The suspension was filtered and the filter cake was washed with cold water and dried at 40 °C under reduced pressure to give the title compound which was used as such in the next step without further purification.
(S)-1-((2-Bromo-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide: was synthesized in analogy to Example 1.98 using 2-bromo-6-methylpyridine-3-sulfonyl chloride and (S)-N-(4, 4-difluorocyclohexy l)-N-methy Ipy rrolidine-2-carboxamide to give the title compound as a white solid. LC-MS (2): tR= 0.92 min; [M+H]+: 480.05. (S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-((6-methyl-2-((1S*,2S*)-2-methylcyclopropyl)pyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide: a microwave tube was charged with (S)-1 -((2-bromo-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (10 mg, 0.0208 mmol, 1 eq), K2CO3 (8.63 mg, 0.0625 mmol, 3 eq), Pd(PPh3)4 (2.43 mg, 0.00208 mmol, 0.1 eq) and 4,4,5,5-tetramethyl-2-[(1 S* 2S*)- 2-methylcyclopropyl]-1 ,3,2-dioxaborolane (8.0 mg, 0.042 mmol, 2 eq). A mixture of dioxane/water 4: 1 (0.2 mL) was added and the suspension was stirred at 100 °C for 90 h. The reaction mixture was cooled to rt and diluted with DCM and water. The layers were separated and the org. layer was dried over MgSC , filtered, and the solvent removed under reduced pressure. The residue was purified by basic prep. HPLC to give the title compound. LC- MS (1): tR= 1.241 min; [M+H]+: 456.3. Example 1.469 (S)-N-(4,4-Difluorocyclohexyl)-1-((2-((1S*,2S*)-2-ethylcyclopropyl)-6-methylpyridin-3- yl)sulfonyl)-N-methylpyrrolidine-2-carboxamide: was synthesized using (S)-1-((2-Bromo-6-methylpyridin-3- yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide and 2-[(1 R*,2R*)-2-ethylcyclopropyl]- 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane in analogy to Example 1.471 to give the title compound as a white solid. LC-MS (1): tR= 1.311 min; [M+H]+: 470.4. Example 1.470 to Example 1.477: were synthesized using ((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin- 3-yl)sulfonyl)-L-proline and the appropriate amine or amine salt in analogy to Example 1.177. LC-MS data of Example 1 .470 to Example 1 .477 are listed in the table below.
Methods for the preparation of sulfoniminamides (SIA) compounds (Examples 2.x)
Example 2.1 (2S)-N-(4,4-difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,r-biphen-2- yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2'-Fluoro-5-methyl-[1,r-biphenyl]-2-thiol: 2'-fluoro-5-methyl-[1 , T-biphenyl]-2-amine hydrochloride (200 mg, 0.841 mmol, 1 eq) was suspended in aq. 2M HCI (3.5 ml), then NaNC>2 (70.4 mg, 1.01 mmol, 1.2 eq) was added at once. The mixture was stirred at rt for 30 min until all material was solubilized. The resulting soln, was added dropwise to a soln, of K2CO3 (698 mg, 5.05 mmol, 6 eq) and potassium ethyl xanthogenate (281 mg, 1.68 mmol, 2 eq) in water (5 mL) at 45 °C over 15 min. After the addition was complete, the reaction was stirred another 30 minutes at 45 °C. After cooling to rt, the reaction was diluted with EtOAc and washed with water. The org. layer was dried over MgSC , filtered, and the solvent evaporated under reduced pressure. The intermediate was taken up in aq. 1 M KOH (5 mL) and stirred at 70 °C overnight. After cooling to rt, the reaction was acidified with aq. 1 M HCI and extracted with EtOAc. The org. layer was washed with water, dried over MgSO4, filtered, evaporated under reduced pressure to give the title compound as a brown oil which was used as such in the next step without further purification.
Methyl 2'-fluoro-5-methyl-[1,r-biphenyl]-2-sulfinate: NBS (364 mg, 2.02 mmol, 2.102 eq) was added portionwise to a stirred soln, of 2'-fluoro-5-methyl-[1 , T-biphenyl]-2-thiol (210 mg, 0.962 mmol, 1 eq) in DCM/MeOH 1 :1 (5.6 mL). The reaction was stirred for 1.5 h. The reaction was diluted with DOM and washed once with aq. sat. NaHCOa and once with water. The org. layer was dried over MgSO^ filtered, and evaporated under reduced pressure. The residue was purified by FC (Hept to Hept I EtOAc 7:3) to give the title compound. LC-MS (2): IR = 0.95 min; [M+H]+: 265.26.
2'-Fluoro-N,5-dimethyl-[1,r-biphenyl]-2-sulfinamide: at O°, n-BuLi (1.6M in hexanes, 0.236 mL, 0.378 mmol, 2 eq) was added to a stirred soln, of methylamine (2M in THF, 0.152 mL, 0.303 mmol, 1.6 eq) in THF (0.95 mL). After stirring for 10 minutes, a solution of methyl 2'-fluoro-5-methyl-[1 , T-biphenyl]-2-sulfinate (50.0 mg, 0.189 mmol, 1 eq) in THF (0.95 mL) was added dropwise. The mixture was stirred for 10 min at 0 °C. Water was added and the mixture was diluted with DCM and filtered through a phase separator. The solvent was removed under reduced pressure and the residue was purified by FC (Hept to Hept I EtOAc 6:4) to give the title compound. LC-MS (2): IR = 0.85 min; [M+H]+: 264.29.
(2S)-N-(4,4-difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,1'-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide: f-BuOCI (29 mg, 0.267 mmol, 2.2 eq) was added to a stirred soln, of 2'-fluoro-N,5-dimethyl-[1 ,1 '-biphenyl]-2-sulfinamide (32 mg, 0.122 mmol, 1 eq) in DCM (0.5 ml) at rt. The reaction was stirred for 10 min, then a soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (32.9 mg, 0.134 mmol, 1.1 eq) and TEA (0.0339 mL, 0.243 mmol, 2 eq) in DCM (0.5 ml) was added and stirring was continued for 30 min. The solvent was removed under reduced pressure and the residue was purified by basic prep. HPLC to give the title compound. LC-MS (1): IR = 1 .119 min; [M+H]+: 508.3.
Example 2.2 to Example 2.12: were synthesized using methyl 2'-fluoro-5-methyl-[1, T-biphenyl]-2-sulfinate the appropriate amine in analogy to Example 2.1. LC-MS data of Example 2.2 to Example 2.12 are listed in the table below. sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2'-Fluoro-5-methyl-[1 J'-biphenyl]-2-sulfinamide: in a round-bottom double neck flask under N2, to a soln, of methyl 2'-fluoro-5-methyl-[1 , 1'-biphenyl]-2-sulfinate (17 mg, 0.0621 mmol, 1 eq) in THF (0.13 mL) was added LHMDS (1.0 M in THF, 0.090 mL, 0.093 mmol, 1.5 eq) at -78 °C over 5 min. The reaction mixture was stirred for 30 min, then it was allowed to warm up to rt. Aq. sat. NH4CI (1 mL) was added and the reaction mixture was stirred for 30 min. Water and EtOAc were added to the reaction mixture. The mixture was extracted three times with EtOAc. The combined org. layers were dried over MgSC , filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR = 0.80 min; [M+H]+: 250.27. tert-Butyl ((2'-fluoro-5-methyl-[1,1'-biphenyl]-2-yl)sulfinyl)- X2-azanecarboxylate: in a round-bottom double neck flask under N2, to a soln, of 2'-fluoro-5-methy l-[1 , 1 '-bi pheny l]-2-sulf I namide (15 mg, 0.0602 mmol, 1 eq) in THF (0.27 mL) was added LHMDS (1.0 M in THF, 0.126 mL, 0.126 mmol, 2.1 eq) at O °C over 5 min. A soln, of BOC2O (0.0207 mL, 0.0902 mmol, 1.5 eq) in THF (5mL) was added dropwise. The reaction mixture was stirred for 20 min at 0 °C, then the ice bath was removed and the reaction mixture was stirred for 1 h at rt. Aq. sat. NaHCOa was added and the mixture was extracted with EtOAc. The org. layer was washed with water, dried over MgSO4, filtered, and the solvent evaporated under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): IR = 0.99 min; [M-CH3]+: 335.18. tert-Butyl (((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2'-fluoro-5-methyl-[1,r- biphenyl]-2-yl)(oxo)-k6-sulfaneylidene)carbamate: to a soln, of tert-butyl ((2'-fluoro-5-methyl-[1 ,1 '-biphenyl]-2- yl)sulfinyl)- 2-azanecarboxylate (19.3 mg, 0.0552 mmol, 1 eq) in DCM (1.0 mL) at to 0 °C was added f-BuOCI (8.99 mg, 0.0828 mmol, 1.5 eq). The reaction mixture was stirred for 10 min at the same temperature. A soln, of (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (15.6 mg, 0.0552 mmol, 1 eq) and TEA (0.0307 mL, 0.221 mmol, 4 eq) in DCM (0.2 mL) was added to the reaction mixture and stirred for 15 min at rt. The residue was dissolved with DMF and was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR = 1.14 and 1.15 min ; [M+H]+: 594.03.
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(2'-fluoro-5-methyl-[1,r-biphen-2-yl])-sulfonimidoyl}- pyrrolidine}-2-carboxamide : to a soln, of tert-butyl (((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin- 1 -yl)(2'-fluoro-5-methyl-[1 , 1 '-biphenyl]-2-yl)(oxo)-X6-sulfaneylidene)carbamate (mixture of 2 stereoisomers) (37 mg, 0.062 mmol, 1 eq) in CH3CN (1.06 mL) was added iodotrimethylsilane (0.0183 mL, 0.125 mmol, 2 eq) at rt and the reaction mixture was stirred for 30 minutes. The reaction mixture was diluted with aq. 25% NH3 and DMF. The resulting soln, was purified by basic prep, to give the title compound. LC-MS (1): tR = 1.156 min ; [M+H]+: 494.3.
Example 2.14 (2S)-N-(4,4-Difluorocyclohexyl)-N-methyl-{1-{N-(bicyclo[1.1.1]pentan-1-yl)-(2'-fluoro-5- methyl-[1,r-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using bicyclo[1.1.1]pentan-1 -amine hydrochloride in analogy to Example 2.1 to give the title compound as a white solid. LC-MS (1): tR = 1.442 min; [M+H]+: 560.3.
Example 2.15 (2S)-N-(1,1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,1'- biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
(S)-N-(1,1-Difluorospiro[2.3]hexan-5-yl)-N-methylpyrrolidine-2-carboxamide: in a round-bottom flask, a soln, of 1 , 1-difluoro-N-methylspiro[2.3]hexan-5-amine hydrochloride (300 mg, 1.63 mmol, 1 eq), HATU (683 mg, 1.8 mmol, 1.1 eq), and Fmoc-Pro-OH (606 mg, 1.8 mmol, 1.1 eq) in DMF (3.22 mL, 41.5 mmol, 25.42 eq) and DIPEA (1.12 mL, 6.53 mmol, 4 eq) was stirred overnight at rt. DBU (0.488 mL, 3.27 mmol, 2 eq) was added and the soln, was stirred for 5 min at rt. The reaction mixture was diluted with water and the resulting soln, was purified by basic prep. HPLC to give the title compound. LC-MS (2): t = 0.53 min; [M+H]+: 245.23.
(2S)-N-(1,1-difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,r-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using (S)-N-(1, 1-difluorospiro[2.3]hexan-5-yl)-N- methylpyrrolidine-2-carboxamide and 2'-fluoro-N,5-dimethyl-[1,T-biphenyl]-2-sulfinamide in analogy to Example 2.13 to give the title compound. LC-MS (1): IR = 1.154 min; [M+H]+: 506.3.
Example 2.16 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,T- biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: (S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide: was synthesized in analogy to Example 2.15 using 1 , 1 -difluorospiro[2.5]octan-6-amine hydrochloride to give the title compound. LC-MS (2): tR = 0.60 min; [M+H]+: 273.26.
(2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1,1'-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using 2'-fluoro-N,5-dimethyl-[1 , T-biphenyl]-2- sulfinamide and (S)-N-(1 , 1 -Difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.15 to give the title compound. LC-MS (1): tR = 1.156 min; [M+H]+: 534.4.
Example 2.17 (2S)-N-(1,1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl- [1 '-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
(S)-N-Cyclopropyl-2'-fluoro-5-methyl-[1,r-biphenyl]-2-sulfinamide: was synthesized using methyl 2'-fluoro-5- methyl-[1 JT-biphenyl]-2-sulfinate and cyclopropylamine to give the title compound in analogy to Example 2.1. LC- MS (2): tR = 0.94 min; [M+H]+: 289.96.
(2S)-N-(1,1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl-[1,r-biphen-2- yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using (S)-N-cyclopropyl-2'-fluoro-5-methyl- [1 , T-biphenyl]-2-sulfinamide and (S)-N-(1 , 1-difluorospiro[2.3]hexan-5-yl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.15 to give the title compound. LC-MS (1): t = 1.301 min; [M+H]+: 532.3.
Example 2.18 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl- [1 '-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using (S)-N-cyclopropyl-2'- fluoro-5-methyl-[1 , -biphenyl]-2-sulfinamide and (S)-N-(1 ,1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2- carboxamide in analogy to Example 2.15 to give the title compound. LC-MS (1): t = 1.349 min; [M+H]+: 560.4.
Example 2.19 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl-4- methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2-Cyclohexyl-4-methylbenzenethiol: NaNO2 (171 mg, 2.45 mmol, 1.1 eq) was added to a stirred soln, of 2- cyclohexy l-4-methy I anil ine (469 mg, 2.23 mmol, 1 eq) in aq. 1 M HCI (9 mL) and CH3CN (3 mL) at 0 °C. The reaction was stirred at 0 °C for 10 min and added to a stirred soln, of K2CO3 (770 mg, 5.57 mmol, 2.5 eq) and potassium ethyl xanthogenate (410 mg, 2.45 mmol, 1.1 eq) in water (8.3 mL) at 70 °C within 5 min. The reaction was stirred for another 30 min at 80 °C. After cooling to rt, the reaction was diluted with Et20 and washed twice with water. The org. layer was dried over MgSO4, evaporated, and dried under reduced pressure. The residue was dissolved in 1 M KOH in EtOH (11.1 mL, 11.1 mmol, 5 eq) and stirred at rt overnight. The volatiles were removed under reduced pressure, and the residue dissolved in EtOAc and washed once with aq. sat. NH4CI and once with water. The org. layer was dried over MgSO4, evaporated, and dried under reduced pressure to give the title compound which was used as such in the next step without further purification. LC-MS (2): IR= 1.13 min; [M+H]+: not seen. Methyl 2-cyclohexyl-4-methylbenzenesulfinate: at rt, 2-cyclohexyl-4-methylbenzenethiol (483 mg, 2.34 mmol, 1 eq) was dissolved in DCM/MeOH 1 :1 (11.7 mL), then NBS (884 mg, 4.91 mmol, 2.1 eq) was added. The reaction was stirred for 5 min. The reaction was diluted with EtOAc and washed with aq. sat. NaHCOa and water. The org. layer was dried over MgSC and evaporated under reduced pressure. The residue was purified by FC (Hept to Hept / EtOAc 7:3) to give the title compound. LC-MS (2): IR = 1.05 min; [M+H]+: 253.18.
2-Cyclohexyl-N,4-dimethylbenzenesulfinamide: at 0 °C, n-BuLi (1.6M in hexanes, 2.55 mL, 4.08 mmol, 2 eq) was added dropwise to a stirred suspension of MeNHa (2.0 M in THF, 1.53 mL, 3.06 mmol, 1.5 eq) in THF (5 mL). After stirring for 15 min at 0 °C, a soln, of methyl 2-cyclohexyl-4-methylbenzenesulfinate (515 mg, 2.04 mmol, 1 eq) in THF (5 mL) was added dropwise. The mixture was stirred another 2 h at 0 °C then. Water was added to the reaction mixture, which was then extracted with EtOAc. The org. layer was washed with water, dried over MgSO4 and evaporated under reduced pressure. The residue was purified by FC (DOM I MeOH 9.5:0.5) to give the title compound. LC-MS (2): IR= 0.97 min; [M+H]+: 252.33.
(2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl-4-methylphenyl)- sulfonimidoyl}-pyrrolidine}-2-carboxamide and (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(S)- N-(methyl)-(2-cyclohexyl-4-methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide : at rt, f-BuOCI (22 mg, 0.203 mmol, 1.7 eq) was added to a stirred soln, of 2-cyclohexyl-N,4-dimethylbenzenesulfinamide (30 mg, 0.119 mmol, 1 eq) in DOM (1 mL). After stirring for 20 minutes, this soln, was added to the stirred soln, of (S)-N-(1, 1- difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide (32.1 mg, 0.119 mmol, 1 eq) and DIPEA (0.0613 mL, 0.358 mmol, 3 eq) in DOM (1 mL). The reaction was stirred for 30 min at rt. The volatiles were removed under reduced pressure. The residue was dissolved in DMF and purified by basic prep. HPLC followed by FC (DCM to DCM/MeOH 9.5:05) to give ((S)-1-((S)-2-cyclohexyl-N,4-dimethylphenylsulfonimidoyl)-N-(1,1- difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2 -carboxamide (first eluting diastereomer) and (S)-1-((R)-2- cyclohexyl-N,4-dimethylphenylsulfonimidoyl)-N-(1,1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2- carboxamide (second eluting diastereomer). (S)-1-((S)-2-cyclohexyl-N,4-dimethylphenylsulfonimidoyl)-N-(1,1- difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2 -carboxamide: LC-MS (2): IR = 0.97 min; [M+H]+: 522.27. (S)-1- ((R)-2-cyclohexyl-N,4-dimethylphenylsulfonimidoyl)-N-(1,1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2- carboxamide: LC-MS (2): IR = 0.96 min; [M+H]+: 522.27.
Example 2.20 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5,6-dimethyl- [1,r-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2'-Fluoro-2,3-dimethyl-6-nitro-1,r-biphenyl: 2-bromo-3,4-dimethyl-1-nitrobenzene (695 mg, 1.87 mmol, 1 eq), 2-fluorophenylboronic acid (321 mg, 2.25 mmol, 1.2 eq), K3PO4 (1062 mg, 5 mmol, 2.67 eq) and Pd(PPha)4 (219 mg, 0.187 mmol, 0.1 eq) were dissolved in degassed DME/water 4:1 (7 mL) and the resulting mixture was stirred at 85 °C for 4.5 h. The reaction mixture was filtered through a Celite® pad and washed with EtOAc. The solvent was removed under reduced pressure and the residue was purified by FC (Hept to Hept I EtOAc 9.5:0.5) to give the title compound. LC-MS (2): IR = 1.03 min; [M+H]+: 240.78
2'-Fluoro-5,6-dimethyl-[1 J'-biphenyl]-2-amine: a round-bottom flask was charged with 2'-fluoro-2,3-dimethy I-6- nitro-1 ,1 '-biphenyl (360 mg, 1.47 mmol, 1 eq) and Fe (powder, 410 mg, 7.34 mmol, 5 eq). The material was dissolved with EtOH (9.6 mL), then aq. sat. NH4CI (5 mL) was added. The reaction mixture was stirred at 70 °C for 2 h. The reaction mixture was filtered through Celite® and washed with EtOH. The filtrate was concentrated, taken up in DOM and washed with aq. sat. NaHCOa. The aq. layer was extracted twice more with DOM. The combined org. layers were dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR = 0.72 min; [M+H]+: 216.23.
2'-Fluoro-5,6-dimethyl-[1 ,1 '-biphenyl]-2-thiol : at rt, 2'-fluoro-5,6-dimethyl-[1 , T-biphenyl]-2-amine (188 mg, 0.349 mmol, 1 eq) was suspended in aq. 1 M HOI (1.4 mL, 1.4 mmol, 4 eq), then NaNOa (141 mg, 2.02 mmol, 1.2 eq) was added at once. The mixture was stirred at rt for 30 min and was then added to a soln, of K2CO3 (121 mg, 0.873 mmol, 2.5 eq) and potassium ethyl xanthogenate (64.2 mg, 0.384 mmol, 1.1 eq) in water (1.31 mL, 72.6 mmol, 207.9 eq) and stirred at 45 °C for 45 min. After cooling to rt, the reaction mixture was diluted with EtOAc and washed with water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was taken up in 1 M KOH in EtOH (12 mL, 12 mmol, 5 eq) and stirred for 2 h. The reaction mixture was concentrated under reduced pressure, neutralized with aq. 1 M HOI, and extracted with EtOAc. The combined org. layers were dried over MgSO4, filtered, and concentrated under reduced pressure to give the title compound, which was used as such in the next step without further purification.
Methyl 2'-fluoro-5,6-dimethyl-[1,1'-biphenyl]-2-sulfinate: was synthesized using 2'-fluoro-5,6-dimethyl-[1 , T- biphenyl]-2-thiol in analogy to Example 2.19 to give the title compound. LC-MS (2): IR= 0.99 min; [M+H]+: 279.18.
2,-Fluoro-N,5,6-trimethyl-[1,1'-biphenyl]-2-sulfinamide: was synthesized using methyl 2'-fluoro-5,6-dimethyl- [1 , 1 '-biphenyl]-2-sulfinate and methylamine in analogy to Example 2.19 to give the title compound. LC-MS (2): IR= 0.89 min; [M+H]+: 278.18.
(2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5,6-dimethyl-[1,r-biphen-2- yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using methyl 2'-fluoro-5,6-dimethyl-[1 ,T- biphenyl]-2-sulfinate and (S)-N-(1 , 1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.19 to give the title compound. LC-MS (1): IR= 1.136 min; [M+H]+: 548.4.
Example 2.21 (2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{-N-(methyl)-(2'-fluoro-5,6-dimethyl-[1,r- biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized in analogy to Example 2.20 using methyl 2'-fl uoro-5,6-dimethy l-[1 , 1 '-bi pheny l]-2-sulfi nate and (S)-N-(4, 4-d if I uorocy clohexy I )-N-methy Ipy rrolid I ne-2- carboxamide to give the title compound. LC-MS (1): IR = 1 .095 min; [M+H]+: 522.4. Example 2.22 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl- [1J'-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2',6'-Difluoro-5-methyl-2-nitro-1 , 1 '-biphenyl : in a microwave vial, 3-iodo-4-nitrotoluene 97% (314 mg, 1 .16 mmol, 1 eq) and 2,6-difluorophenylboronic acid (201 mg, 1.27 mmol, 1.1 eq) were dissolved in dioxane (11.6 mL) and aq. 1 M K3PO4 (5.79 mL, 5.79 mmol, 5 eq). XPhos Pd G2 (91 .2 mg, 0.0579 mmol, 0.05 eq) was added and the reaction mixture was stirred at 80 °C overnight. The reaction mixture was diluted with water and extracted with EtOAc. The org. layer was dried over MgSC>4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9: 1) to give the title compound. LC-MS (2): IR = 1.01 min; [M+H]+: not seen.
2',6'-Difluoro-5-methyl-[1,r-biphenyl]-2-amine: in a round-bottom flask, 2',6'-difluoro-5-methyl-2-nitro-1 , T- biphenyl (46.7 mg, 0.188 mmol, 1 eq) and Fe (powder, 52.4 mg, 0.938 mmol, 5 eq) in EtOH (1.23 mL, 21.1 mmol, 112.3 eq) and aq. sat. NH4CI (5 mL) were stirred at 70 °C for 2 h. The reaction mixture was filtered through Celite® and washed with EtOH. The filtrate was concentrated under reduced pressure. The residue was dissolved in DOM and washed with aq. sat. NaHCOa. The aq. layer was extracted twice with DOM. The combined org. layers were dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound, which was used as such in the next step without further purification. LC-MS (2): IR = 0.78 min; [M+H]+: 220.20.
2',6'-Difluoro-5-methyl-[1 ,1'-biphenyl]-2-thiol: at rt, 2',6'-difluoro-5-methyl-[1 , T-biphenyl]-2-amine (37 mg, 0.169 mmol, 1 eq) was suspended in aq. 1 M HOI (0.675 mL, 0.675 mmol, 4 eq), then NaNOa (12.9 mg, 0.186 mmol, 1.2 eq) was added at once. The mixture was stirred at rt for 30 min and was then added to a soln, of K2CO3 (58.3 mg, 0.422 mmol, 2.5 eq) and potassium ethyl xanthogenate (31 mg, 0.186 mmol, 1 .1 eq) in water (0.632 mL, 35.1 mmol, 208 eq), and stirred at 45 °C for 45 min. After cooling to rt, the reaction mixture was diluted with EtOAc and washed with water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was taken up in 1 M KOH in EtOH (0.844 mL, 0.844 mmol, 5 eq) and stirred for 2 h. The reaction mixture was concentrated under reduced pressure, neutralized with aq. 1 M HOI, and extracted with EtOAc. The combined org. layers were dried over MgSO4, filtered, and concentrated under reduced pressure to give the title, which was used as such in the next step without further purification. LC-MS (2): IR = 1 .24 min; [M+H]+: not seen.
Methyl 2,,6'-difluoro-5-methyl-[1,1'-biphenyl]-2-sulfinate: was synthesized using 2',6'-difluoro-5-methyl-[1,T- biphenyl]-2-thiol in analogy to Example 2.19 to give the title compound. LC-MS (2): IR= 0.96 min; [M+H]+: 283.13.
2',6'-Difluoro-N,5-dimethyl-[1 , 1'-biphenyl]-2-sulfinamide: was synthesized using methyl 2',6'-difluoro-5-methyl- [1 , 1 '-biphenyl]-2-sulfinate and methylamine in analogy to Example 2.19 to give the title compound. LC-MS (2): IR= 0.87 min; [M+H]+: 282.17.
(2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1,r-biphen-2- yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using 2',6'-difluoro-N,5-dimethyl-[1 , T- biphenyl]-2-sulfinamide and (S)-N-(1 , 1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.19 to give the title compound. LC-MS (1): IR = 1.223 min; [M+H]+: 552.4.
Example 2.23 (2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1,1'- biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using 2',6'-difluoro-N,5-dimethyl- [1 , 1 '-biphenyl]-2-sulfinamide and (S)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.22 to give the title compound. LC-MS (1): IR = 1.156 min; [M+H]+: 526.3.
Example 2.24 (2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-(3-chloropyridin-2-yl)-4- methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide:
2-lodo-4-methylbenzenethiol: at 0 °C, NaNO2 (1224 mg, 17.6 mmol, 1.1 eq) was added to a stirred soln, of 2- iodo-4-methylaniline (3720 mg, 16 mmol, 1 eq) in aq. 1 M HCI (64 mL). After stirring for 10 min, the resulting yellow soln, was added to a stirred soln, of potassium ethyl xanthogenate (2.93 g, 17.6 mmol, 1.1 eq) and K2CO3 (5515 mg, 39.9 mmol, 2.5 eq) in water (60 mL) at 70 °C within 5 min. After stirring for 1 h at 70 °C, the mixture was allowed to cool to rt. The reaction mixture was diluted with Et20 and washed twice with water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was dissolved in 1 M KOH in EtOH (79.8 mL, 79.8 mmol, 5 eq) and stirred at 50 °C for 30 min. The reaction was cooled to rt and about 70% of the EtOH was evaporated under reduced pressure. The suspension was diluted with EtOAc and washed with aq. sat. NH4CI and a small amount of water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): IR= 1.00 min; [M+H]+: not seen.
Methyl 2-iodo-4-methylbenzenesulfinate: at rt, 2-iodo-4-methylbenzenethiol (3.900 mg, 15.6 mmol, 1 eq) was dissolved in DCM/MeOH 1 : 1 (80 mL), then NBS (5.90 g, 32.8 mmol, 2.1 eq) was added. The reaction was quenched with aq. sat. NaHCOa and extracted with EtOAc. The org. layer was washed with water, dried over MgSO4, and the solvent evaporated under reduced pressure. The residue was purified by FC (DOM to DCM/MeOH 9.5:0.5) to give the title compound. LC-MS (2): IR= 0.91 min; [M+H]+: 296.93.
2-lodo-4-methylbenzenesulfinamide: in a round-bottom double-neck flask at -78 °C and under a N2 atmosphere, LHMDS 1.0 M in THF (2.03 mL, 2.03 mmol, 1.2 eq) was added dropwise to a stirred soln, of methyl 2-iodo-4- methylbenzenesulfinate (500 mg, 1 .69 mmol, 1 eq) while maintaining a temperature below -70 °C. The mixture was stirred at -78 °C for 1 h. LHMDS 1.0 M in THF (2.03 mL, 2.03 mmol, 1.2 eq) was added again at -78 °C and the reaction was stirred for 20 min. LHMDS 1.0 M in THF (2.03 mL, 2.03 mmol, 1.2 eq) was added again and the reaction was stirred another hour while allowing to warm up to 0 °C. The reaction mixture was quenched with aq. sat. NH4CI and extracted with EtOAc. The org. layer was washed with water, dried over MgSO4 and evaporated under reduced pressure. The residue was purified by FC (DOM to DCM/MeOH 9.5:0.5) to give the title compound. LC-MS (2): tR= 0.70 min; [M+H]+: 282.05. tert-Butyl ((2-iodo-4-methylphenyl)sulfinyl)carbamate: at O °C under argon, LHMDS 1.0 M in THF (14.2 mL, 14.2 mmol, 2 eq) was added dropwise to a stirred soln, of 2-iodo-4-methylbenzenesulfinamide (2.00 g, 7.11 mmol, 1 eq) in THF (65 mL) while maintaining the temperature below 5 °C. The brown suspension was stirred at 0 °C for 45 min, then a soln, of BOC2O (1 .65 g, 7.47 mmol, 1 .05 eq) in THF (6 mL) was added dropwise. The resulting brown soln, was stirred at 0 °C for 1 h. The reaction was quenched with aq. sat. NaHCOa and extracted with EtOAc. The org. layer was washed with water, dried over MgSCh, filtered, and the solvent removed under reduced pressure. The residue was purified by FC (DCM to DCM/MeOH 9.5:0.5) to give the title compound. LC-MS (2): IR= 0.85 min; [M+H]+: 381.98. tert-Butyl ((R)-((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4- methylphenyl)(oxo)- 6-sulfaneylidene)carbamate and tert-butyl ((S)-((S)-2-((4,4- difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)-A,6-sulfaneylidene) carbamate: at rt, f-BuOCI (740 mg, 6.82 mmol, 1.3 eq) was added to a stirrred soln, of tert-butyl ((2-iodo-4- ethylphenyl)sulfinyl)carbamate (2.00 g, 5.25 mmol, 1 eq) in DCM (60 mL). After stirring for 15 min, a soln, of (S)-N- (4,4-difluorocyclohexyl)-N-methylpyrrolidine-2-carboxamide (1.71 g, 5.77 mmol, 1.1 eq) and EtaN (2.19 mL, 15.7 mmol, 3 eq) in DCM (33 mL) was added and stirring was continued for 30 min. The reaction was diluted with EtOAc and washed with aq. 0.1 M HCI, aq. sat. NaHCOa and water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 2:8) to give and tert-butyl ((R)-((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)- 7T- sulfaneylidene)carbamate (first eluting diasteromer) and tert-butyl ((S)-((S)-2-((4,4- difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)- X6-sulfaneylidene)carbamate (second eluting diatereomer). LC-MS (2), first eluting diastereomer: IR= 1.08 min; [M+H]+: 626.09. LC-MS (2), second eluting diastereomer: tR= 1.10 min; [M+H]+: 626.07. tert-Butyl ((R)-(2-(3-chloropyridin-2-yl)-4-methylphenyl)((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl) pyrrolidin-1-yl)(oxo)-X6-sulfaneylidene)carbamate: at rt, tert-butyl ((R)-((S)-2-((4,4- difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)- X6-sulfaneylidene)carbamate (150 mg, 0.24 mmol, 1 eq), Cui (4.57 mg, 0.024 mmol, 0.1 eq) and LICI (20.3 mg, 0.48 mmol, 2 eq) were charged into a microwave tube. The tube was then purged with N2 and Pd(PPha)4 (27.7 mg, 0.024 mmol, 0.1 eq) was added, followed by toluene (1.2 ml) and 3-chloro-2-(tributylstannyl)pyridine (0.102 mL, 0.288 mmol, 1.2 eq). The vial was sealed and stirred at 120 °C overnight. The reaction mixture was cooled to rt and the solvent removed under reduced pressure. The crude was taken up in MeCN/H2O and filtered over a 0.45 pm syringe filter. The soln, was purified by basic prep. HPLC to give the title compound. LC-MS (2): IR= 1.05 min; [M+H]+: 611.20.
(S)-1-((R)-2-(3-Chloropyridin-2-yl)-4-methylphenylsulfonimidoyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide: at rt, tert-butyl ((R)-(2-(3-chloropyridin-2-yl)-4-methylphenyl)((S)-2-((4,4- difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1 -yl)(oxo)- 6-sulfaneylidene)carbamate (46.5 mg, 0.0761 mmol, 1 eq) was dissolved in MeCN (1 mL), then iodotrimethylsilane (0.0223 mL, 0.152 mmol, 2 eq) was added and the soln, was stirred for 5 min. The reaction was diluted with EtOAc and washed with aq. sat. NaHCOa and water. The org. layer was dried over MgSC , filtered, and the solvent removed under reduced pressure to give the title compound. LC-MS (2): IR= 0.86 min; [M+H]+: 511.27.
(2S)-N-(4,4-difluorocyclohexyl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-(3-chloropyridin-2-yl)-4-methylphenyl)- sulfonimidoyl}-pyrrolidine}-2-carboxamide : at -60 °C under argon, NaH (ca 55% in mineral oil, 5.13 mg, ca 0.128 mmol, ca 2 eq) was added to a stirred soln, of (S)-1-((R)-2-(3-chloropyridin-2-yl)-4- methylphenylsulfonimidoyl)-N-(4,4-difluorocyclohexyl)-N-methylpy rrolidine-2-carboxamide (32.8 mg, 0.0642 mmol, 1 eq) in DMF (1 mL). After stirring for 20 min, Mel (0.020 mL, 0.32 mmol, 5 eq) was added. The cooling bath was removed and the mixture was allowed to reach rt. After 1 h, few drops of water were added and the obtained soln, was directly purified by basic prep. HPLC to give the title compound. LC-MS (1): IR= 0.986 min; [M+H]+: 525.4.
Example 2.25 to Example 2.26: were synthesized using the appropriate amide in analogy to Example 2.24. LC- MS data of Example 2.25 to Example 2.26 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 2.27 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-(3-fluoropyridin-2- yl)-4-methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: tert-Butyl ((R)-((S)-2-((1,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4- methylphenyl)(oxo)- 6-sulfaneylidene)carbamate and tert-Butyl ((S)-((S)-2-((1,1-difluorospiro[2.5]octan-6- yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)-A,6-sulfaneylidene)carbamate: were synthesized using (S)-N-(1 , 1 -difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide and tert-butyl (S)-((2- iodo-4-methylphenyl)sulfinyl)carbamate in analogy to Example 2.24. The residue was purified by FC (Hept to Hept/EA 2:8) to give tert-Butyl ((R)-((S)-2-((1,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2- iodo-4-methylphenyl)(oxo)-X6-sulfaneylidene)carbamate (first eluting diastereomer) and tert-Butyl ((S)-((S)-2-((1, 1- difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)-X6- sulfaneylidene)carbamate (second eluting diastereomer). First eluting diartereomer: LC-MS (2): IR= 1.12 min; [M+H]+: 652.21. Second eluting diastereomer: LC-MS (2): IR= 1.13 min; [M+H]+: 652.21. (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-(3-fluoropyridin-2-yl)-4- methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using tert-butyl ((R)-((S)-2-((1,1- difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)-X6- sulfaneylidene)carbamate and 3-fluoro-2-(tributylstannyl)pyridine in analogy to Example 2.24 to give the title compound. LC-MS (1): IR= 1.031 min; [M+H]+: 535.4.
Example 2.28 (2S)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(S)-N-(methyl)-(2-(3-fluoropyridin-2- yl)-4-methylphenyl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using tert-butyl ((S)-((S)-2- ((1 ,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(2-iodo-4-methylphenyl)(oxo)-X6- sulfaneylidene)carbamate in analogy to Example 2.27 to give the title compound. LC-MS (2): IR= 0.89 min; [M+H]+: 535.29.
Example 2.29 to Example 2.30: were synthesized in analogy to Example 2.24 using the appropriate amide. LC- MS data of Example 2.29 to Example 2.30 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 2.31 (S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(R)-N-(methyl)-(6-methyl-2-((S)-2- methylpyrrolidin-1-yl)pyridine)-3-sulfonimidoyl}-pyrrolidine}-2-carboxamide: tert-Butyl ((2-chloro-6-methylpyridin-3-yl)sulfinyl)carbamate: at -78 °C under N2 atmosphere, n-BuLi (1.6 M in hexanes, 8.44 mL, 13.5 mmol, 1.1 eq) was added dropwise to a stirred soln, of 5-bromo-6-chloro-2-picoline (2.61 g, 12.3 mmol, 1 eq) in THF (50 mL). After the addition, the soln, was stirred at -78 °C for 30 min. A soln, of N- sulfinyl-tert-butylcarbamate (2.00 g, 12.3 mmol, 1 eq) in THF (10 mL) was added dropwise (exothermic). Stirring was continued at -78 °C for 1 h. The reaction mixture was quenched with water and extracted with EtOAc. The org. layer was washed with water, dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was purified twice by FC (DCM to DCM/MeOH 9.5:0.5) to give the title compound. LC-MS (2): IR= 0.79 min; [M+H]+: 291.17. tert-Butyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1- yl)(oxo)-X6-sulfaneylidene)carbamate: at rt, f-BuOCI (582 mg, 5.36 mmol, 2.2 eq) was added to a stirred soln, of tert-butyl ((2-chloro-6-methylpyridin-3-yl)sulfinyl)carbamate (885 mg, 2.43 mmol, 1 eq) in DCM (23 mL). After stirring for 15 min, a soln, of (S)-N-(4, 4-difl uorocyclohexyl)-N-methyl pyrrol idine-2-carboxamide (795 mg, 2.68 mmol, 1.1 eq) and EtaN (1.02 mL, 7.3 mmol, 3 eq) in DCM (20 mL) was added and stirring was continued for 30 min. The reaction was diluted with EtOAc and washed with aq. 0.1 M HCI, aq. sat. NaHCOa and water. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. The residue was purified by FC (DCM to DCM/MeOH 9.5:0.5) and basic prep. HPLC to give the title compound. LC-MS (2): IR= 0.99 min; [M+H]+: 535.31. tert-Butyl (((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(6-methyl-2-((S)-2-methyl pyrrolidin-1-yl)pyridin-3-yl)(oxo)- X6-sulfaneylidene)carbamate: a mixture of tert-butyl ((2-chloro-6- methylpyridin-3-yl)((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene) carbamate (20 mg, 0.0374 mmol, 1 eq) and (S)-(+)-2-methylpyrrolidine (0.0212 mL, 0.187 mmol, 5.005 eq) in TMP (0.0644 mL, 0.374 mmol, 10 eq) was stirred at 150 °C overnight. The mixture was diluted with DMF and purified by basic prep. HPLC to give the title compound as a mixture of diastereomers. LC-MS (2): IR= 0.96 and 1.05 min; [M+H]+: 584.29.
(2S)-N-(4,4-Difluorocyclohexyl)-N-methyl-1-(6-methyl-2-((S)-2-methylpyrrolidin-1-yl)pyridine-3- sulfonimidoyl)pyrrolidine-2-carboxamide: at rt, tert-butyl (((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl) pyrrolidin-1 -yl)(6-methyl-2-((S)-2-methylpyrrolidin-1-yl)pyridin-3-yl)(oxo)- X6-sulfaneylidene) carbamate (42 mg, 0.0719 mmol, 1 eq) was dissolved in dioxane (1 mL), then HCI (4M in dioxane, 0.36 mL, 1.44 mmol, 20 eq) was added and the mixture was stirred overnight. The mixture was evaporated under reduced pressure to give the title compound which was used as such in the next step without further purification in the next step. LC-MS (2): IR= 0.81 min; [M+H]+: 484.25.
(S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(R)-N-(methyl)-(6-methyl-2-((S)-2-methylpyrrolidin-1-yl) pyridine)-3-sulfonimidoyl}-pyrrolidine}-2-carboxamide and (S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1- {(R)-N-(methyl)-(6-methyl-2-((R)-2-methylpyrrolidin-1-yl)pyridine)-3-sulfonimidoyl}-pyrrolidine}-2- carboxamide: at -60 °C under argon, NaH (ca 55% in mineral oil, 3.6 mg, ca 0.0901 mmol, ca 3.003 eq) was added to a stirred soln, of (2S)-N-(4,4-difluorocyclohexyl)-N-methyl-1-(6-methyl-2-((S)-2-methylpyrrolidin-1- yl)pyridine-3-sulfonimidoyl)pyrrolidine-2-carboxamide (15.6 mg, 0.03 mmol, 1 eq) in DMF (0.70 mL). After stirring for 5 minutes, Mel (0.0075 mL, 0.12 mmol, 4 eq) was added and the soln, was allowed to warm to rt within ca 1 h. The reaction was quenched with a few drops of water and was directly purified by basic prep. HPLC to give (S)-N- (4,4-difluorocyclohexyl)-1-((R)-N,6-dimethyl-2-((S)-2-methylpyrrolidin-1-yl)pyridine-3-sulfonimidoyl)-N- methylpyrrolidine-2-carboxamide and (S)-N-(4,4-difluorocyclohexyl)-1-((S)-N,6-dimethyl-2-((S)-2-methylpyrrolidin- 1-yl)pyridine-3-sulfonimidoyl)-N-methylpyrrolidine-2-carboxamide. (S)-N-(4,4-Difluorocyclohexyl)-1-((R)-N,6- dimethyl-2-((S)-2-methylpyrrolidin-1-yl)pyridine-3-sulfonimidoyl)-N-methylpyrrolidine-2-carboxamide: LC-MS (2): IR= 0.83 min; [M+H]+: 498.18. (S)-N-(4,4-Difluorocyclohexyl)-1-((R)-N,6-dimethyl-2-((S)-2-methylpyrrolidin-1- yl)pyridine-3-sulfonimidoyl)-N-methylpyrrolidine-2-carboxamide: LC-MS (2): IR= 0.889 min; [M+H]+: 498.18. Example 2.32 (2S)-N-((3R,6s)-1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl- 6-methyl-pyridin-3-yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: tert-Butyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((1,1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl) pyrrolidin-1-yl)(oxo)-X6-sulfaneylidene)carbamate: was synthesized in analogy to Example 2.31 using tert-butyl ((2-chloro-6-methylpyridin-3-yl)sulfinyl)carbamate and (S)-N-(1 , 1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine- 2-carboxamide to give the title compound. LC-MS (2): IR= 1.02 and 1.03 min; [M+H]+: 461.09. tert-Butyl ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3R,6s)-1,1-difluorospiro[2.5]octan-6-yl)(methyl) carbamoyl)pyrrolidin-1-yl)(oxo)-A,6-sulfaneylidene)carbamate: was obtained by chiral SFC separation of tertbutyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((1 , 1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1- yl)(oxo)- X6-sulfaneylidene)carbamate (SFC 4 method) to give ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3R,6s)- 1 , 1 -difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene)carbamate (first eluting diastereomer), ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3S,6r)-1 , 1-difluorospiro[2.5]octan-6-yl)(methyl) carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene)carbamate (second eluting diastereomer), ((S)-(2-chloro-6- methylpyridin-3-yl)((S)-2-(((3R,6s)-1 , 1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- 7T- sulfaneylidene)carbamate (third eluting diastereomer) and ((S)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3S,6r)-1,1- difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene)carbamate (fourth eluting diastereomer). The absolute stereochemistry of the spirocycle was arbitrarily attributed. tert-Butyl ((R)-(2-cyclohexyl-6-methylpyridin-3-yl)((S)-2-(((3R,6s)-1,1-difluorospiro[2.5]octan-6-yl)(methyl) carbamoyl)pyrrolidin-1-yl)(oxo)-A,6-sulfaneylidene)carbamate: in a double-neck round-bottom flask and under N2 atmosphere, XPhos Pd G2 (5.6 mg, 0.00356 mmol, 0.1 eq) was added to a soln, of tert-butyl ((R)-(2-chloro-6- methylpyridin-3-yl)((S)-2-(((3R,6s)-1 , 1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- 7T- sulfaneylidene)carbamate (30 mg, 0.054 mmol, 1 eq) in THF (1 mL). 0.5 M cyclohexylzinc bromide in THF (0.0170 mL, 0.0712 mmol, 2 eq) was added and the mixture was stirred at 90 °C for 3 h. The reaction mixture was cooled to rt and purified by basic prep. HPLC to give the title compound. LC-MS (2): IR= 1.17 min; [M+H]+: 609.15.
(S)-1-((R)-2-Cyclohexyl-6-methylpyridine-3-sulfonimidoyl)-N-((3R,6s)-1,1-difluorospiro[2.5]octan-6-yl)-N- methylpyrrolidine-2-carboxamide: was synthesized using tert-butyl ((R)-(2-cyclohexyl-6-methylpyridin-3-yl)((S)- 2-(((3R,6s)-1 , 1-difluorospiro[2.5]octan-6-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)-X6-sulfaneylidene)carbamate in analogy to Example 2.31 to give the title compound. LC-MS (2): IR= 0.96 min; [M+H]+: 509.33.
(2S)-N-((3R,6s)-1,1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl-6-methyl- pyridin-3-yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using (S)-1-((R)-2-cyclohexyl-6- methylpyridine-3-sulfonimidoyl)-N-((3R,6s)-1 , 1-difluorospiro[2.5]octan-6-yl)-N-methylpyrrolidine-2-carboxamide in analogy to Example 2.31 to give the title compound. LC-MS (1): IR= 1.346 min; [M+H]+: 523.4. Example 2.33 (2S)-N-((3R,5s)-1,1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{(R)-N-methyl-(2-cyclohexyl-6- methyl-pyridin-3-yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: tert-Butyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((1,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl) pyrrolidin-1-yl)(oxo)-X6-sulfaneylidene)carbamate: was synthesized in analogy to Example 2.32 using (S)-N- (1, 1-difluorospiro[2.3]hexan-5-yl)-N-methylpyrrolidine-2-carboxamide and tert-butyl ((2-chloro-6-methylpyridin-3- y l)sulfi ny l)carbamate to give the title compound. LC-MS (2): IR= 0.99 min; [M+H]+: 533.21 . tert-Butyl ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3R,5s)-1,1-difluorospiro[2.3]hexan-5-yl)(methyl) carbamoyl)pyrrolidin-1-yl)(oxo)-A,6-sulfaneylidene)carbamate: was obtained by chiral SFC separation of tertbutyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((1,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl)pyrrolidin-1- yl)(oxo)- X6-sulfaneylidene)carbamate (SFC 5 method) to give tert-butyl ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2- (((3R,5s)-1 ,1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)-X6-sulfaneylidene)carbamate (first eluting diatereoisomer), tert-butyl ((R)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3S,5r)-1 ,1- difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene)carbamate (second eluting diatereoisomer), tert-butyl ((S)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3R,5s)-1 ,1 -difluorospiro[2.3]hexan-5- yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- X6-sulfaneylidene)carbamate (third eluting diastereomer) and tert-butyl ((S)-(2-chloro-6-methylpyridin-3-yl)((S)-2-(((3S,5r)-1 , 1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl)pyrrolidin-1- yl)(oxo)- X6-sulfaneylidene)carbamate (fourth eluting diastereomer). The absolute stereochemistry of the spirocycle was arbitrarily attributed.
(2S)-N-((3R,5s)-1,1-difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{(R)-N-methyl-(2-cyclohexyl-6-methyl- pyridin-3-yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide: was synthesized using tert-butyl ((R)-(2-chloro-6- methylpyridin-3-yl)((S)-2-(((3R,5s)-1 , 1-difluorospiro[2.3]hexan-5-yl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)- /?- sulfaneylidene)carbamate in analogy to Example 2.32 to give the title compound. LC-MS (1): IR= 1.271 min; [M+H]+: 495.4.
Example 2.34 to Example 2.36: were synthesized according to the procedures described herein before using tertbutyl ((2-chloro-6-methylpyridin-3-yl)((S)-2-((4,4-difluorocyclohexyl)(methyl)carbamoyl)pyrrolidin-1-yl)(oxo)-X6- sulfaneylidene)carbamate and the appropriate amine. LC-MS data of Example 2.34 to Example 2.36 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Methods for the preparation of sulfone compounds (Examples 3.x)
Example 3.1 rac-(1 R,2S)-N-(4,4-Difluorocyclohexyl)-2-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N- methylcyclohexane-1-carboxamide:
Methyl 2-((2-bromo-4-methylphenyl)thio)cyclohexane-1-carboxylate (mixture of 4 stereoisomers): a mixture of 2-bromo-4-methyl-benzenethiol (1.07 g, 5.00 mmol, 1 eq) and methyl 1-cyclohexene-1 -carboxylate (1.36 mL, 10.0 mmol, 2 eq) in piperidine (5 mL) was stirred at 70 °C for 34 h. The mixture was allowed to cool to rt and partitioned between aq. 1 M HCI (50 mL) and EtOAc (50 mL). The layers were separated. The aq. layer was extracted with EtOAc (2 x 50 mL). The comb. org. layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 95:5) to give the title compound. Rf (Hept/EtOAc 9:1)= 0.34. LC-MS (2): tR= 1.12 min; [M+H]+: 343.13.
Methyl 2-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)thio)cyclohexane-1-carboxylate (mixture of 4 stereoisomers): to a degassed soln, of methyl 2-((2-bromo-4-methylphenyl)thio)cyclohexane-1 -carboxylate (mixture of 4 stereoisomers) (172 mg, 0.5 mmol, 1 eq), 2-fluorophenylboronic acid (143 mg, 1 mmol, 2 eq), and Na2CO3 (160 mg, 1.5 mmol, 3 eq) in dioxane/water 4: 1 (5 mL), Pd(dppf)Cl2CH2Cl2 (40.8 mg, 0.05 mmol, 0.1 eq) was added. The mixture was stirred at 70 °C for 1.5 h. The reaction mixture was allowed to cool to rt, and diluted with EtOAc (20 mL) and water (20 mL). The layers were separated and the aq. phase was extracted with EtOAc (2 x 20 mL). The comb. org. phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9: 1) to give the title compound. Rf (Hept/EtOAc 9:1)= 0.29. LC-MS (2): tR= 1.16 min; [M+H]+: 359.19.
Methyl 2-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)cyclohexane-1-carboxylate (mixture of 4 stereoisomers): to an ice-cooled suspension of methyl 2-((2'-fluoro-5-methyl-[1 , 1 '-biphenyl]-2-yl)thio)cyclohexane- 1 -carboxylate (mixture of 4 stereoisomers) (168 mg, 0.469 mmol, 1 eq) and NaHCOa (118 mg, 1.41 mmol, 3 eq) in DOM (5 mL), 3-chloroperbenzoic acid (315 mg, 1 .41 mmol, 3 eq) was added portionwise. The reaction mixture was stirred at 0 °C for 3 h. The reaction mixture was diluted with aq. 1 N NaOH and DOM. The layers were separated. The aq. layer was extracted with DCM. The comb. org. layers were dried over MgSC , filtered, and concentrated under reduced pressure to give the title compound. The product was used without further purification in the next step. LC-MS (2): tR= 1.07 min; [M+H]+: 391.14. rac-(1 R,2S)-2-((2'-Fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)cyclohexane-1-carboxylic acid: to a mixture of methyl 2-((2'-fluoro-5-methyl-[1,T-biphenyl]-2-yl)sulfonyl)cyclohexane-1 -carboxylate (mixture of 4 stereoisomers) (173 mg, 0.443 mmol, 1 eq) in THF (3 mL) and H2O (3 mL), LiOH H2O (186 mg, 4.43 mmol, 10 eq) was added. The mixture was stirred at 50 °C for 8 h and further at rt for 12 h. The mixture was partitioned between EtOAc and water. The layers were separated. The aq. layer was acidified to pH ~3 with aq. 1 M HCI and extracted with DCM. The combined org. phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 0.95 min; [M+H]+: 337.13. rac-(1 R,2S)-N-(4,4-Difluorocyclohexyl)-2-((2'-fluoro-5-methyl-[1,r-biphenyl]-2-yl)sulfonyl)-N-methyl cyclohexane-1-carboxamide: to a soln. of rac-(1 R,2S)-2-((2'-fluoro-5-methyl-[1 ,T-biphenyl]-2- yl)sulfonyl)cyclohexane-1 -carboxy lie acid (37.6 mg, 0.1 mmol, 1 eq.) in DMF (1 mL), DIPEA (0.0685 mL, 0.4 mmol, 4 eq) and HATU (49.4 mg, 0.13 mmol, 1.3 eq) were added in sequence. 4,4-Difluoro-N-methylcyclohexan-1-amine (18.6 mg, 0.1 mmol, 1 eq) was added and the mixture was stirred at rt for 18 h. The mixture was purified by acidic prep. HPLC to give the title compound. LC-MS (1): tR= 1.316 min; [M+H]+: 508.2.
Example 3.2 (1S,2R)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide: the racemic mixture of rac-(1 R,2S)-N-(4,4-difluorocyclohexyl)-2-((2'-fluoro-5- methyl-[1 ,1 '-biphenyl]-2-yl)sulfonyl)-N-methylcyclohexane-1 -carboxamide (24 mg) was separated by chiral SFC (SFC 3 method) to give (1 R,2S)-2-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide (first eluting enantiomer) and (1 S,2R)-2-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)- cyclohexanecarboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide (second eluting enantiomer). (1 R,2S)-2-(2'- Fluoro-5-methyl-biphenyl-2-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: LC-MS (2): tR= 1.12 min; [M+H]+: 508.26. (1 S,2R)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide: LC-MS (1): tR= 1.316 min; [M+H]+: 508.2.
Example 3.3 (1 RS,2SR)-N-(4,4-Difluorocyclohexyl)-2-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl) sulfonyl)cyclopentane-1-carboxamide:
N-(4,4-Difluorocyclohexyl)cyclopent-1-ene-1-carboxamide: a soln, of 4,4-difluorocyclohexan-1-amine (250 mg, 1.79 mmol, 1 eq), cyclopent-1 -ene-1 -carboxylic acid (308 mg, 2.69 mmol, 1.5 eq), HATU (1023 mg, 2.69 mmol, 1.5 eq) and und DIPEA (3.09 mL, 17.9 mmol, 10eq) in DMF (5 mL) was stirred at rt for 72 h. The soln, was purified by acidic prep HPLC to give the title compound. LC-MS (2): tR= 0.81 min; [M+H]+: 230.25.
(1RS,2SR)-2-((2-Chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)cyclopentane-1- carboxamide: N-(4,4-difluorocyclohexyl)cyclopent-1 -ene-1 -carboxamide (280 mg, 1.22 mmol, 1 eq), 2-chloro-6- methylpyridine-3-sulfonyl chloride (727 mg, 3.05 mmol, 2.5 eq), tris(trimethylsilyl)silane (0.833 mL, 2.44 mmol, 2 eq) und tris(2-phenylpyridine)iridium (84.6 mg, 0.122 mmol, 0.1 eq) were dissolved in degassed CH3CN (5 mL) and the soln, was stirred at rt under blue LED irradiation for 2 h. The mixture was concentrated under reduced pressure and the residue the residue purified by acidic prep. HPLC to give the title compound (cis/trans mixture). LC-MS (1): tR= 0.84 min; [M+H]+: 421.07.
(1RS,2SR)-N-(4,4-Difluorocyclohexyl)-2-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)cyclopentane-1-carboxamide: (1 RS,2SR)-2-((2-chloro-6-methylpyridin-3-yl)sulfonyl)-N-(4,4- difluorocyclohexyl)cyclopentane-1 -carboxamide (8 mg, 0.0043 mmol, 1 eq) and DIPEA (1 JLLL, 0.0086 mmol, 2eq) were dissolved in TMP (3 .L) and stirred at 130 °C during 48 h. The soln, was cooled to rt, partitioned between DCM and water and filtered through a phase separator. The solvent was removed under reduced pressure and the residue was purified by prep HPLC to give the title compound. LC-MS (1): tR= 1.303 min; [M+H]+: 472.2.
Example 3.4 (1R*,2S*)-N-(4,4-Difluorocyclohexyl)-2-((2-((3S,5S)-3,5-dimethylmorpholino)-4- methylphenyl)sulfonyl)cyclopentane-1 -carboxamide :
(3S,5S)-4-(2-(Benzylthio)-5-methylphenyl)-3,5-dimethylmorpholine: to a soln, of (3S,5S)-4-(2-bromo-5- methylphenyl)-3,5-dimethylmorpholine (100 mg, 0.352 mmol, 1 eq) in THF (5 mL) at -78 °C, was added dropwise n-BuLi (1.6 M in hexanes, 0.26 mL, 0.422 mmol, 1.2 eq) and the soln, was stirred for 15 min at -78 °C before the addition of a soln, of benzyl disulfide (133 mg, 0.528 mmol) in THF (1 mL). The reaction mixture was stirred at -78 °C for 5 min. The cooling bath was removed and the reaction mixture was allowed to reach rt and was partitioned between DCM and water and filtered through a separation cartridge. The solvent was removed under reduced pressure. The residue was purified by FC (Hept to Hept/EtOAc 9: 1) followed by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 1.14 min; [M+H]+: 328.19.
2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylbenzenethiol: AICI3 (34.6 mg, 0.26 mmol, 1.7 eq) was suspended in benzene (2 mL). A soln, of (3S,5S)-4-(2-(benzylthio)-5-methylphenyl)-3,5-dimethylmorpholine (50 mg, 0.153 mmol, 1 eq) in benzene (1 mL) was added dropwise. The reaction mixture was stirred during 1 h at rt and AICI3 (34.6 mg, 0.26 mmol, 1.7 eq) was added again and the reaction was stirred for 30 min at rt and then at 50 °C during 20 min. The reaction mixture was cooled down to rt, diluted with water and extracted with EtOAc. The org. layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound, which was used without further purification in the next step. LC-MS (2): tR= 1.02 min; [M+H]+: 238.18.
Methyl 2-((2-((3S,5S)-3,5-dimethylmorpholino)-4-methylphenyl)thio)cyclopentane-1-carboxylate (mixture of 4 stereoisomers): was synthesized using 2-((3S,5S)-3,5-dimethylmorpholino)-4-methylbenzenethiol and methyl cyclopent-1-ene-1-carboxylate in analogy to Example 3.1 to give the title compound. LC-MS (2): tR= 1.13 min; [M+H]+: 364.22. Methyl 2-((2-((3S,5S)-3,5-dimethylmorpholino)-4-methylphenyl)sulfonyl)cyclopentane-1-carboxylate (mixture of 4 stereoisomers): was synthesized using methyl 2-((2-((3S,5S)-3,5-dimethylmorpholino)-4- methylphenyl)thio)cyclopentane-1 -carboxylate in analogy to Example 3.1 to give the title compound. LC-MS (2): tR= 1.01 and 1.03 min; [M+H]+: 396.18.
(1R*,2S*)-2-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)cyclopentane-1-carboxylic acid: was synthesized in analogy to Example 3.1 using methyl 2-((2-((3S,5S)-3,5-dimethylmorpholino)-4- methylphenyl)sulfonyl)cyclopentane-1 -carboxylate to give the title compound. LC-MS (2): tR= 0.87 and 0.91 min; [M+H]+: 382.18.
(1R*,2S*)-N-(4,4-Difluorocyclohexyl)-2-((2-((3S,5S)-3,5-dimethylmorpholino)-4-methylphenyl)sulfonyl) cyclopentane-1-carboxamide: was synthesized in analogy to Example 3.1 using (1R*,2S*))-2-((2-((3S,5S)-3,5- dimethylmorpholino)-4-methylphenyl)sulfonyl)cyclopentane-1 -carboxylic acid and 4,4-difluorocyclohexan-1-amine to give the title compound. LC-MS (1): tR= 1.217 min; [M+H]+: 499.2.
Example 3.5 to Example 3.7: were synthesized following the procedures described herein before using the appropriate sulfone and the appropriate amine or amine salt. LC-MS data of Example 3.5 to Example 3.7 are listed in the table below. The LC-MS conditions used were LC-MS (1).
Example 3.8 rac-(1 R,2S)-N-(4,4-Difluorocyclohexyl)-N-methyl-2-((5-methyl-2'-(methylthio)-[1,T-biphenyl]-2- yl)sulfonyl)cyclohexane-1-carboxamide:
Methyl 2-((2-bromo-4-methylphenyl)sulfonyl)cyclohexane-1-carboxylate (mixture of 4 stereoisomers): to an ice-cooled suspension of methyl 2-((2-bromo-4-methylphenyl)thio)cyclohexane-1 -carboxylate (5.44 g, 15.8 mmol, 1 eq) and NaHCOa (4.01 g, 47.5 mmol, 3 eq) in DCM (165 mL), 3-chloroperbenzoic acid (1.13 g, 1.41 mmol, 3 eq) was added portionwise. The reaction mixture was stirred at 0 °C for 2.5 h. The reaction mixture was diluted with aq. 1 M NaOH and DCM. The layers were separated and the aq. layer was extracted with DCM. The combined org. layers were dried over MgSO4, filtered, and the solvent removed under reduced pressure to give the title compound. LC-MS (2): tR= 0.96 min; [M+H]+: 375.17. rac-(1 R,2S)-2-((2-Bromo-4-methylphenyl)sulfonyl)cyclohexane-1-carboxylic acid: to a mixture of methyl 2- ((2-bromo-4-methylphenyl)sulfonyl)cyclohexane-1 -carboxylate (5.90 g, 15.7 mmol, 1 eq) in THF (106 mL) and H2O (106 mL), LiOH monohydrate (2.64 g, 62.9 mmol, 4 eq) was added. The mixture was stirred at rt for 2 d. The mixture was partitioned between DCM and water. The aq. layer was acidified to pH 3 with aq. 1 M HCI and extracted with DCM. The combined org. layers were dried over MgSC , filtered, and the solvent removed under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 0.84 min; [M+H]+: 361 .06. rac-(1 R,2S)-2-((2-Bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylcyclohexane-1- carboxamide: rac-(1 R,2S)-2-((2-bromo-4-methylphenyl)sulfonyl)cyclohexane-1 -carboxylic acid (5.70 g, 15.8 mmol, 1 eq) was dissolved in DMF (200 mL). DIPEA (9.50 mL, 55.2 mmol, 3.5 eq), HATU (8398 mg, 22.1 mmol, 1.4 eq) and 4,4-difluoro-N-methylcyclohexan-1-amine hydrochloride (2960 mg, 15.9 mmol, 1.011 eq) were added. The mixture was stirred at rt overnight. The reaction mixture was diluted with water and extracted with EtOAc. The org. layer was washed with water and brine. The combined org. layers were dried over MgSC , filtered, and the solvent removed under reduced pressure. The residue was purified by FC and acidic prep. HPLC to give the title compound. LC-MS (2): tR= 1.02 min; [M+H]+: 494.06. rac-(1 R,2S)-N-(4,4-Difluorocyclohexyl)-N-methyl-2-((5-methyl-2'-(methylthio)-[1,r-biphenyl]-2-yl)sulfonyl) cyclohexane-1-carboxamide: was synthesized in analogy to Example 3.1 using 2-(methylthio)phenylboronic acid and rac-(1 R,2S)-2-((2-bromo-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylcyclohexane-1- carboxamide to give the title compound. LC-MS (1): tR= 1.370 min; [M+H]+: 536.4.
Example 3.9 (1R*,2S*)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-2-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3- yl)sulfonyl)cyclopentane-1-carboxamide: rac-(1 R,2S)-2-((2-Fluoro-6-methylpyridin-3-yl)thio)cyclopentane-1-carboxylic acid: in a microwave vial under a N2 atmosphere, 2-fluoro-3-iodo-6-methylpyridine (755 mg, 3.19 mmol, 1 eq) and rac-(1 R,2S)-2- mercaptocyclopentane-1-carboxylic acid (540 mg, 3.51 mmol, 1.102 eq) were dissolved in dioxane (10.4 mL, 121 mmol, 38.1 eq). XantPhos (380 mg, 0.637 mmol, 0.2 eq) and DIPEA (1.06 mL, 6.21 mmol, 1.95 eq) were added and the vial purged with a flux of N2 for 10 min. Pd(OAc)2 (73 mg, 0.319 mmol, 0.1 eq) was added. The reaction was sealed and stirred at 80 °C overnight. The mixture was filtered through a Whatmann filter and concentrated under reduced pressure. The residue was purified by acidic prep. HPLC to give the title compound. LC-MS (2): tR= 0.81 min; [M+H]+: 256.19. rac-(1 R,2S)-2-((2-Fluoro-6-methylpyridin-3-yl)sulfonyl)cyclopentane-1-carboxylic acid: to an ice-cooled suspension of rac-(1 R,2S)-2-((2-fluoro-6-methylpyridin-3-yl)thio)cyclopentane-1 -carboxylic acid (1670 mg, 6.54 mmol, 1 eq) and NaHCOa (1653 mg, 19.6 mmol, 3 eq) in DCM (150 mL), MCPBA (3.67 g, 16.4 mmol, 2.5 eq) was added portionwise. The reaction mixture was stirred at 0 °C for 4 h. The solvent was removed under reduced pressure. The residue was purified by acidic prep HPLC to give the title compound. LC-MS (2): tR= 0.68 min; [M+H]+: 288.16. (1R*,2S*)-N-(1,1-Difluorospiro[2.5]octan-6-yl)-2-((2-fluoro-6-methylpyridin-3-yl)sulfonyl)cyclopentane-1- carboxamide: rac-(1R,2S)-2-((2-fluoro-6-methylpyridin-3-yl)sulfonyl)cyclopentane-1 -carboxylic acid (70 mg, 0.244 mmol, 1 eq) was dissolved in DMF (2 mL). DIPEA (0.147 mL, 0.853 mmol, 3.5 eq), HATU (102 mg, 0.268 mmol, 1.1 eq) and 1 , 1-difluorospiro[2.5]octan-6-amine hydrochloride (55.8 mg, 0.268 mmol, 1.1 eq) were added at rt and the mixture was stirred for 17 h. The soln, was purified by basic prep. HPLC to give the title compound. LC-MS (2): tR= 0.92 min; [M+H]+: 431.16.
(1R*,2S*)-2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-cyclopentanecarboxylic acid (1,1- difluoro-spiro[2.5]oct-6-yl)-amide: a son. of (1R*,2S*)-N-(1,1-difluorospiro[2.5]octan-6-yl)-2-((2-fluoro-6- methylpyridin-3-yl)sulfonyl)cyclopentane-1-carboxamide (45 mg, 0.104 mmol, 1 eq) and DIPEA 98% (0.0387 mL, 0.313 mmol, 3 eq) in THP (0.0881 mL, 0.522 mmol, 5 eq) was heated in a sealed microwave vial at 75 °C for 17 h.
The soln, was cooled to rt and purified by basic prep. HPLC to give the title compound. LC-MS (1): tR= 1.405 min; [M+H]+: 498.4.
Example 3.10 to Example 3.24: were synthesized following the procedures described herein before using the appropriate amines or amine salts and the appropriate sulfone. LC-MS data of Example 3.10 to Example 3.24 are listed in the table below.
Il-Biological assays
IP1 accumulation assay
Agonistic activity on the human orexin-2 receptor (hOX2R) have been measured for each Example compound using an intracellular inositol-1 -phosphate (IP1) accumulation assay (IP-One Gq assay kit, Cisbio) according to manufacturer's instructions with following modifications:
Human embryonic kidney 293 (HEK293) cells expressing the human Orexin-2 receptor (hOX2R), are grown in culture medium DMEM (Thermo Fisher Scientific) containing 500 mg/ml geneticin, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heat inactivated fetal bovine serum (FBS) (Thermo Fisher Scientific). Cells are allowed to grow to 80% confluence at 37°C in 5% CO2. On the day of the assay, cells are washed with PBS (Thermo Fisher Scientific) and harvested using cell dissociation buffer (Thermo Fisher Scientific). After counting, cells are pelleted by centrifugation at 120 g for 5 min and resuspended in Hank's buffered saline soln, supplemented with 20 mM HEPES, 0.375 g/L sodium-bicarbonate, 0.05 M lithium chloride and adjusted to pH 7.4 (hereafter called Stimulation buffer). The cells are seeded at 25'000 cells/well into 384-well white HIBase small volume plates (Greiner Bio-One). Agonist example compounds are dissolved in DMSO as 10 mM stock soln., serially diluted in DMSO and further diluted to 4-times their final concentration in Stimulation buffer supplemented with 0.2% bovine serum albumin (BSA). Human Orexin-A peptide (OxA) is prepared as 1 mM stock soln, in H2O, diluted to 4-times its final concentration in Stimulation buffer supplemented with 0.2% BSA.
Dilution series of agonist example compounds and OxA are added to the seeded cells and IP1 accumulation is allowed for 5.5 h at 37°C in 5% CO2. The assay is terminated by addition of lysis buffer containing IP1 -detection reagents according to the kit's instructions. After 1 h lysis at rt, Homogeneous Time Resolved Fluorescence (HTRF) is acquired at wavelengths of 665 nm and 620 nm following excitation at 337 nm using a PHERAstar FSX plate reader (BMG Labtech).
Analysis
Measured HTRF ratios 665 nm/620 nm are exported using the PHERAstar® acquisition software (BMG Labtech). Analysis is performed in IC50 Studio software (Idorsia Pharmaceuticals ltd.) so that HTRF data is normalized to the responses obtained with 0.5% DMSO and 200 nM OxA, representing 0% and 100% responses, respectively. Potency (EC50) and efficacy (Emax) values are calculated for each example compound using non-linear regression analysis with a 4-parameter curve fitting. Note: alternatively, potency and efficacy calculations can be achieved using commercially available software such as Prism 7.0 (GraphPad).
EC50 value corresponds to the compound concentration that activates 50% of the maximum response obtained with 200 nM OxA and Emax corresponds to the maximum response compared to the maximum response obtained with 200 nM OxA.
The calculated EC50 and efficacy Emax values may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art. EC50 and Emax values from several measurements are given as median values.
Agonistic activities of example compounds on hOX2R are displayed in Table 1.
Table 1

Claims

Claims
1 . A compound of the Formula (I) wherein
Ring B is a 6-membered aromatic ring, wherein independently:
• in said Ring B X1 represents N or CRB2, wherein RB2 represents hydrogen, halogen, or (Ci-3)alkyl, and X2 represents CH; or X1 represents CH and X2 represents N; and
• RB1 represents hydrogen, (Ci-3)alkyl, (Ci-3)alkoxy, halogen, (C2-4)alkenyl, monocyclic (C3-6)cycloalkyl, or (Ci-3)fluoroalkyl; and
• RB3 represents: OR01, wherein R01 represents (C2-5)alkyl that is substituted with zero, one or two (Ci)fluoroalkyl; wherein R01 contains a total of at least 3 carbon atoms; NRN1RN2, wherein independently:
■ RN1 represents:
• hydrogen; or
• (Ci-3)alkyl; and
■ RN2 represents:
• (C2-5)alkyl; wherein said (C2-5)alkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci)fluoroalkyl, (C3-5)cycloalkyl, and (Ci-3)alkoxy; or
• monocyclic (Cs-sjcycloalkyl, wherein said monocyclic (C^cycloalkyl is unsubstituted or mono-substituted with (Ci-3)alkyl; or ■ RN1 and RN2 together with the nitrogen to which they are attached form a 5- to 7-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom; wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl, (Ci-2)fluoroalkyl, and (Ci-3)alkoxy-(Ci-3)alkyl; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring oxygen atom; or a saturated or mono-unsaturated monocyclic (Cs-zjcycloalkyl; wherein said (C4-6)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently (Ci-3)alkyl or halogen; or a saturated or mono-unsaturated bridged bicyclic (C6-8)cycloalkyl;or phenyl or 5- or 6-membered heteroaryl comprising one to three ring heteroatoms independently selected from N, 0, and S; wherein said phenyl or 5- or 6-membered heteroaryl is independently unsubstituted, or mono-, or di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: halogen, (Ci-3)alkyl, (C3-6)cycloalkyl, (Ci-3)alkoxy, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, and cyano; and
X3 represents 0 or NRN3, wherein RN3 represents hydrogen, (Ci-3)alkyl, (C3-6)cycloalkyl, a 4- or 5-membered saturated monocyclic heterocycle comprising one ring oxygen atom, a 5-membered saturated bridged bicyclic cycloalkyl, phenyl, or pyridinyl; and
X4 represents CH or N such that: when X4 represents CH, Ring A represents a monocyclic (Cs-ejcycloalkan-diyl; or when X4 represents N, Ring A represents:
• a 4- to 7-membered saturated monocyclic heterocycloal kan-diy I comprising X4, and zero or one further ring heteroatom selected from 0 or S; wherein said saturated heterocycloalkan-diyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl, halogen, (Ci-3)alkoxy, (Ci-3)alkylidene, and oxo; or
• a 4- to 6-membered mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring N atom; wherein the double bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4; wherein said mono-unsaturated heterocycloalkan-diyl is unsubstituted, or monosubstituted with (Ci-3)alkyl; or a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom; wherein said bicyclic heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci-3)alkyl or di-substituted with fluoro; and
R1 represents: hydrogen; or (Ci-3)alkyl; wherein said (Ci-3)alkyl is unsubstituted, or mono-substituted with (Ci-3)alkoxy; and
R2 represents: (Ci-6)alkyl; wherein said (Ci^alkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from halogen or (Ci-3)alkoxy; or -(CH2)q-Cy1; wherein q is 0 or 1 and Cy1 represents a saturated monocyclic (CsjJcycloalkyl; wherein said monocyclic (C3-7)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl, halogen, (Ci-3)alkyl, (Ci^)alkoxy, cyano, and hydroxy; or -(CH2)n-Cy2; wherein n is 0 or 1 and Cy2 represents a 4- to 7-membered saturated or mono-unsaturated monocyclic heterocycle comprising one ring heteroatomic group selected from -O-, -(SO2)-, -S(O)(NH)-, or -S(O)(NCH3)-; wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)fluoroalkyl, halogen, (Ci^)alkyl, and (Ci-3)alkoxy; or -(CH2)m-Cy3; wherein m is 0 or 1 and Cy3 represents a saturated spiro, fused, or bridged bicyclic (C5- 8)cycloalkyl; wherein said bicyclic (C^cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from halogen or (Ci-3)alkyl; or a 7-membered saturated spiro or bridged bicyclic heterocycle comprising one ring oxygen atom; or
R1 and R2 together with the nitrogen to which they are attached form:
• a 5- or 6-membered saturated monocyclic heterocycle comprising said nitrogen atom, and zero or one additional ring heteroatom selected from 0 or S; wherein said 5- or 6-membered heterocycle is unsubstituted, or mono-, di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: hydroxy, (Ci-3)fluoroalkyl, halogen, (Ci-3)alkyl, (Ci-3)alkyl-(Ci^)alkoxy, ethynyl, and (Ci-3)alkoxy; or
• a 7- to 11-membered saturated spiro bicyclic heterocycle comprising said nitrogen atom, and zero, one or two additional ring 0 atoms; wherein said heterocycle is unsubstituted or mono-substituted with hydroxy; or • an 8- to 10-membered saturated or mono-unsaturated fused bicyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atom; or
• a 7- to 9-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom, and zero additional ring heteroatoms, or one or two additional ring 0 atoms, or one additional ring S atom; wherein said 7- to 9-membered bridged heterocycle is unsubstituted, or mono-, di- or tri-substituted; wherein the substituents are independently selected from the group consisting of: hydroxy, halogen, (Ci-3)alkyl, and (Ci-3)alkoxy; or
• a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms; with the exception of the following compounds: 1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-piperidinecarboxamide (CAS no. 2174271-82-8); 1 -([1,1'-biphenyl]-2-ylsulfonyl)-N-methyl-2-piperidinecarboxamide (CAS no. 2421462-12-4); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-2-pyrrolidinecarboxamide (CAS no. 1956132-61-8); 1-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 1951549-56-6); 1 -([1,1'-biphenyl]-2-ylsulfonyl)-N,N-dimethyl-2-pyrrolidinecarboxamide (CAS no. 2180339-78-8); N-cyclopropyl-1 -[[2-(5-isoxazolyl)phenyl]sulfonyl]-2-pyrrolidinecarboxamide (CAS no. 1957026-44-6); 1-([1,T-biphenyl]-2-ylsulfonyl)-N-propyl-2-pyrrolidinecarboxamide (CAS no. 1101182-03-9); 1-[(4-ethoxy-3-pyridinyl)sulfonyl]-2-(methoxymethyl)-N-methyl-2-pyrrolidinecarboxamide (CAS no. 2223951-41-3); N, N-diethyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 1444098-57-0); N-(1, 1-dimethylethyl)-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinecarboxamide (CAS no. 2175321- 07-8); N-cyclopropyl-3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-4-thiazolidinecarboxamide (CAS no. 1953618- 16-0); 3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-N-methyl-N-(1-methylethyl)-4-thiazolidinecarboxamide (CAS no. 2174321-10-7); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-cyclopropyl-N-methyl-4-thiazolidinecarboxamide (CAS no. 1315694-49- 5); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(2-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1315666-22-8); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(cyclopropylmethyl)-4-thiazolidinecarboxamide (CAS no. 1316038-32-0); 3-([1 ,1'-biphenyl]-2-ylsulfonyl)-N-(1-methylpropyl)-4-thiazolidinecarboxamide (CAS no. 1316017-19-2); [3-[[2-(5-isoxazolyl)phenyl]sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 1948116-54-8); [1-([1,1'-biphenyl]-2-ylsulfonyl)-2-piperidinyl]-1 -pyrrolidinylmethanone (CAS no. 1277333-36-4); [3-([1,T-biphenyl]-2-ylsulfonyl)-4-thiazolidinyl]-4-thiomorpholinylmethanone (CAS no. 1259167-90-2); [(2S,4R)-1-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-fluoro-2-pyrrolidinyl]-4-morpholinylmethanone (CAS no. 1941933-69-2); [3-[(4-ethoxy-3-pyridinyl)sulfonyl]-4-thiazolidinyl]-1 -pyrrolidinylmethanone (CAS no. 2174528-45-9); and [1 -[(4-ethoxy-3-pyridinyl)sulfonyl]-2-pyrrolidinyl]-4-thiomorpholinylmethanone (CAS no. 1945338-12-4).
2. A compound of Formula (I) according to claim 1, wherein X1 represents N or CRB2, wherein RB2 represents hydrogen, halogen, or (Ci-3)alkyl, and X2 represents CH; or a pharmaceutically acceptable salt thereof.
3. A compound of Formula (I) according to claim 1 or 2, wherein RB1 represents (Ci-3)alkyl or (Ci)fluoroalkyl; or a pharmaceutically acceptable salt thereof.
4. A compound of Formula (I) according to any one of claims 1 to 3, wherein RB3 represents: NRN1RN2, wherein independently:
■ RN1 represents (Ci-3)alkyl; and
■ RN2 represents (C^alkyl; or
■ RN1 and RN2 together with the nitrogen to which they are attached form a heterocycle selected from pyrrolidinyl, piperidinyl, or morpholinyl; wherein said heterocycle is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from (Ci-3)alkyl or (Ci. 2)fluoroalkyl; or a mono-unsaturated monocyclic (CsjJcycloalkyl; or a mono-unsaturated bridged bicyclic (Cz)cycloalkyl; or phenyl; wherein said phenyl is mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen, (Ci-3)alkyl, and (Ci-3)alkoxy; or 5- or 6-membered heteroaryl selected from isothiazolyl or pyridinyl; wherein said 5- or 6-membered heteroaryl is mono- or di-substituted; wherein the substituents are independently selected from halogen or (Ci-3)alkyl; or a pharmaceutically acceptable salt thereof.
5. A compound of Formula (I) according to any one of claims 1 to 4, wherein X4 represents N and Ring A represents:
• a 5- to 7-membered saturated monocyclic heterocycloal kan-diy I comprising X4, and zero or one further ring heteroatom selected from 0 or S; wherein said heterocycloalkan-diyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: (Ci-3)alkyl, halogen, (Ci-3)alkoxy, and (Ci-3)alkylidene; or
• a 5-membered mono-unsaturated monocyclic heterocycloalkan-diyl comprising X4 and zero or one further ring N atom; wherein the double bond of said mono-unsaturated heterocycloalkan-diyl does not contain X4; wherein said mono-unsaturated heterocycloalkan-diyl is unsubstituted, or monosubstituted with (Ci-3)alkyl; or
• a 6- to 8-membered saturated spiro, fused, or bridged bicyclic heterocycloalkan-diyl comprising X4, and zero or one ring oxygen atom; wherein said bicyclic heterocycloalkan-diyl is unsubstituted, or mono-substituted with (Ci-3)alkyl; or a pharmaceutically acceptable salt thereof.
6. A compound of Formula (I) according to any one of claims 1 to 5, wherein R1 represents hydrogen; methyl or ethyl; or a pharmaceutically acceptable salt thereof.
7. A compound of Formula (I) according to any one of claims 1 to 6, wherein R2 represents: -(CH2)q-Cy1; wherein q is 0 and Cy1 represents a saturated monocyclic (CsjJcycloalkyl; wherein said monocyclic (C3-z)cycloalkyl is unsubstituted, or mono- or di-substituted; wherein the substituents are independently selected from the group consisting of: halogen, (Ci^alkyl, (Ci-3)alkoxy, and cyano; or -(CH2)n-Cy2; wherein n is 0 and Cy2 represents a 4- to 7-membered saturated monocyclic heterocycle comprising one ring heteroatomic group selected from -0- or -(SO2)-; wherein said heterocycle is mono- or di-substituted; wherein the substituents are independently selected from halogen or (Ci-3)alkyl; or -(CH2)m-Cy3; wherein m is 0 and Cy3 represents a saturated spiro, fused, or bridged bicyclic (Cs-sjcycloalkyl; wherein said bicyclic (Cs-sjcycloalkyl is unsubstituted or di-substituted with halogen; or a 7-membered saturated bridged bicyclic heterocycle comprising one ring oxygen atom; or a pharmaceutically acceptable salt thereof.
8. A compound of Formula (I) according to any one of claims 1 to 6, wherein R1 and R2 together with the nitrogen to which they are attached form:
• an 8-membered saturated spiro bicyclic heterocycle comprising said nitrogen atom; or
• a 7- to 8-membered saturated bridged bicyclic heterocycle comprising said nitrogen atom; wherein said 7- to 8-membered bridged heterocycle is unsubstituted, or mono-substituted with (Ci-3)alkoxy; or
• a 10-membered saturated bridged tricyclic heterocycle comprising said nitrogen atom, and zero or one additional ring 0 atoms; or a pharmaceutically acceptable salt thereof.
9. A compound of Formula (I) according to any one of claims 1 to 8, selected from the group consisting of: {(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-((1 S,3R,5R)-3-methoxy-8-aza- bicy clo [3.2.1 ]oct-8-yl)-methanone;
{(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-(2-oxa-6-aza- tricy clo [3.3.1 .13,7]dec-6-yl)-methanone;
{(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}-((1 S,3R,5R)-3- methoxy-8-aza-bicyclo[3.2.1]oct-8-yl)-methanone; (2R*,4R*)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(2S,4S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-methyl-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(1R,2S)-2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-amide;
(1S,2R)-2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4-difluoro- cyclohexyl)-amide
5-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-aza-spiro[2.4]heptane-6-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
5-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-aza-spiro[2.4]heptane-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
3-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-oxazolidine-2-carboxylic acid (1, 1-difluoro-spiro[2.5]oct-6-yl)-N-methyl- amide;
2-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-5-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methyl-2-aza-bicyclo[2.1.1]hexane-1-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-azepane-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide; 1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4,4-dimethyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-N-(Cyclopentylmethyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-methyl-[1, T-biphenyl]-2-yl)sulfonyl)-N-(methyl-d3)pyrrolidine-2- carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'-fluoro-6'-methoxy-5-methyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-6'-methoxy-5-methyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5-(methyl-d3)-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide; (S)-N-(4,4-Difluorocyclohexyl)-1-(((Sa)-2'-fluoro-5J6-dimethyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-((SR)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1-((2-(ethyl(isopropyl)amino)-4-methylphenyl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Dimethylcyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Dimethylcyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((RS)-3,3-Difluorocyclopentyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((RS)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1-((2-(ethyl(isopropyl)amino)-4- methylphenyl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((1R*,3S*)-3-Cyanocyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((4-methyl-2-((S)-2-methylpiperidin-1-yl)phenyl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((2-(ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)pyrrolidine-2- carboxamide;
(S)-N-((1 R*, 3S*)-3-Cyanocyclopentyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N- methylpyrrolidine-2-carboxamide;
(S)-N-((1R* 3S*)-3-Cyanocyclopentyl)-1-((2'-fluoro-5-methyl-[1 , -biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(S)-N-((1R*,3R*)-3-Cyanocyclohexyl)-1-((2-((3S,5S)-3,5-dimethylmorpholino)-6-methylpyridin-3- yl)sulfonyl)pyrrolidine-2-carboxamide;
(S)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-[6-Methyl-2-((1 S,2R)-2-methyl-cyclohexyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[6-Methyl-2-(2-methyl-cyclohex-1-enyl)-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(4-methyl-isothiazol-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 , 1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide; (S)-1-[4-Methyl-2-(3-methyl-pyrazin-2-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro-spiro[2.5]oct- 6-yl)-N-methyl-amide;
(S)-1-[4-Methyl-2-(2-methyl-pyridin-3-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-trifluoromethyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid spiro[3.3]hept-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid spiro[2.4]hept-1- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(tetrahydro- pyran-4-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(4-methyl- cyclohexyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl-(2-methyl- tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cyclohexyl-N-methyl- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cycloheptylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[4.1.0]hept-3- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[3.1.0]hex-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[2.2.1]hept-2- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicyclo[1 .1 .1]pent-1- ylamide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (bicyclo[4.1 ,0]hept-3- yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (bicyclo[2.2.1]hept-2- ylmethyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (7-oxa- bicy clo [2.2.1 ] hept-2-y l)-amide ;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4-methyl-cyclohexyl)- amide; (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4-methoxy- cyclohexyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-trifluoromethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-methyl-cyclohexyl)- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-methoxy-tetrahydro- pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3-difluoromethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-dimethyl- cyclopentyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-dimethyl- cyclobutyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (3,3-difluoro- cyclobutylmethyl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2-cyano-cyclopentyl)- amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6-dimethyl- tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,2-dimethyl- tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 R,2R,4S)- bicy clo [2.2.1 ] hept-2-y I amide ;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.5]oct-6-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.5]oct-6-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.4]hept-5-yl)-amide; (S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.3]hex-5-yl)-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro- spiro[2.3]hex-5-yl)-N-methyl-amide;
(S)-1-[2-(Ethyl-isopropyl-amino)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6-dimethyl-tetrahydro- pyran-4-yl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(Cyclopropyl-ethyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-[2-(5-Ethyl-pyrazol-1-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-[2-(3-Fluoro-pyridin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-(3-Fluoro-pyrazin-2-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (1 ,1-difluoro-spiro[2.5]oct- 6-yl)-N-methyl-amide;
(S)-1-[2-(2,6-Difluoro-phenyl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl- spiro[2.5]oct-6-yl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid methyl- (2-methyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid cyclohexyl-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicy clo [4.1 .0]hept-3-ylamide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid bicy clo [4.1 .0]hept-3-yl-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- dimethyl-cyclohexyl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-amide; (S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (2,2- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.5]oct-6-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.5]oct-6-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.4]hept-5-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.3]hex-5-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (1,1- difluoro-spiro[2.3]hex-5-yl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid
((2S,4S,6R)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid
((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-amide;
(S)-1-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-4-methyl-benzenesulfonyl]-pyrrolidine-2-carboxylic acid (2,6- dimethyl-tetrahydro-pyran-4-yl)-N-methyl-amide;
(S)-1-[2-((2R,5S)-2,5-Dimethyl-pyrrolidin-1-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-(6'-Methyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-(5,2'-Dimethyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide; (S)-1-(2-tert-Butylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-lsopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Diisopropylamino-6-methyl-pyridine-3-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Cyclohexyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2-Cyclohex-1-enyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Cyclohept-1-enyl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N- methyl-amide;
(S)-1-(2-Bicyclo[2.2.1]hept-2-en-2-yl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(S)-1-(2-Azepan-1-yl-4-methyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Methoxy-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-ethyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (1,1 -dioxo-hexahydro-1 l6-thiopyran-4- yl)-N-methyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methylene-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2,5-dihydro-1 H-pyrrole-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(S)-1-(2',6'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2',5'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-(2',4'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide; (S)-1-(2',3'-Difluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(S)-1-((S)-2,6'-Dimethyl-3,4,5,6-tetrahydro-2H-[1 ,4']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((S)-2,6'-Dimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl-amide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-spiro[2.5]octan-4-yl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-3-methyltetrahydrofuran-3-yl)pyrrolidine- 2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S*,3S*)-3-methoxycyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S*,2R*)-2-methylcyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,3S*)-3-methoxycyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R* 3S*)-3-fluorocyclopentyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,3R*)-3-hydroxycyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-isopropylcyclopropyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-hydroxycyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2R*)-2-methylcyclohexyl)pyrrolidine-2- carboxamide;
(S)-1-((2-(Ethyl(isopropyl)amino)-6-methylpyridin-3-yl)sulfonyl)-N-(((RS)-3-methyltetrahydrofuran-3- yl)methyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((RS)-sec-Butoxy)-6-methylpyridin-3-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((SR)-2,2-dimethyltetrahydro-2H- pyran-4-yl)pyrrolidine-2-carboxamide; (S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-spiro[2.4]heptan-5- yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((RS)-6,6-dimethyltetrahydro-2H- pyran-3-yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((2R,4SR,6S)-2,6-dimethyltetrahydro- 2H-pyran-4-yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((2R,4SR,6S)-2,6-dimethyltetrahydro-
2H-pyran-4-yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R,2S)-2- methoxycyclopentyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 S,2R)-2- methoxycyclopentyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2-methoxycyclopentyl)-N- methylpyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2- methoxycyclohexyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-6-methylpyridin-3-yl)sulfonyl)-N-((1 R*,2S*)-2- hydroxycyclohexyl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-2,2-dimethyltetrahydro-2H-pyran-4- yl)pyrrolidine-2-carboxamide;
(S)-1-((2-((3S,5S)-3,5-Dimethylmorpholino)-4-methylphenyl)sulfonyl)-N-((RS)-2,2-dimethyltetrahydro-2H-pyran-4- yl)-N-methylpyrrolidine-2-carboxamide;
(S)-1-(((Sa)-2'-Chloro-5,6'-dimethyl-[1, 1'-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(S)-1-(((Ra)-2'-Chloro-5,6'-dimethyl-[1, 1'-biphenyl]-2-yl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N-methylpyrrolidine-2- carboxamide;
(R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-4-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-thiazolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)-N-methyl- amide;
(7-Aza-bicyclo[2.2.1]hept-7-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone;
(6-Aza-spiro[2.5]oct-6-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone; (6-Aza-spiro[2.5]oct-6-yl)-{(S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin- 2-yl}-methanone;
(2S,5S)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-5-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-4-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2 -carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-1-[2-(Ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-4-fluoro-pyrrolidine-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(25.45)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methyl-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(25.45)-1-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-4-methoxy-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(2S,4R)-4-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(2S)-N-(Bicyclo[4.1.0]heptan-3-yl)-1-((2'-fluoro-5-methyl-[1 , -biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{(2'-fluoro-5-methyl-[1,T-biphen-2-yl])-sulfonimidoyl}-pyrrolidine}-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2'-fluoro-5J6'-dimethyl-[1 , -biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-N-(methyl)-{1-{N-(methyl)-(6-methyl-2-((S)-2-methylpiperidin-1-yl)pyridin-3-yl)- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(4,4-Difluorocyclohexyl)-1-((2-(2,4-difluoropyridin-3-yl)-4-methylphenyl)sulfonyl)-N-methylpyrrolidine-2- carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2'-fluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl-[1 , T-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{N-(methyl)-(2',6'-difluoro-5-methyl-[1 , 1 '-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-N-(1 , 1-Difluorospiro[2.3]hexan-5-yl)-N-(methyl)-{1-{N-(cyclopropyl)-(2'-fluoro-5-methyl-[1 ,1 '-biphen-2-yl])- sulfonimidoyl}-pyrrolidine}-2-carboxamide; (2S)-N-((3R,6s)-1 , 1-Difluorospiro[2.5]octan-6-yl)-N-(methyl)-{1-{(R)-N-(methyl)-(2-cyclohexyl-6-methyl-pyridin-3- yl)-sulfonimidoyl}-pyrrolidine}-2-carboxamide;
(2S)-1-((2-(2-Chloro-4-methylpyridin-3-yl)-4-methylphenyl)sulfonyl)-N-(4,4-difluorocyclohexyl)-N- methylpyrrolidine-2-carboxamide;
(2R,3S)-3-Fluoro-1-(2'-fluoro-5-methyl-biphenyl-2-sulfonyl)-pyrrolidine-2-carboxylic acid (4,4-difluoro-cyclohexyl)- N-methyl-amide;
(2-Aza-tricyclo[3.3.1 .13,7]dec-2-yl)-{(S)-1-[2-(ethyl-isopropyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidin-2-yl}- methanone;
(2-Aza-tricyclo[3.3.1 .13,7]dec-2-yl)-{(S)-1-[2-((3S,5S)-3,5-dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]- pyrrolidin-2-yl}-methanone;
(1S,3S,5S)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(1S,2S,5R)-3-(4-Methyl-2-piperidin-1-yl-benzenesulfonyl)-3-aza-bicyclo[3.1 ,0]hexane-2-carboxylic acid (4,4- difluoro-cyclohexyl)-N-methyl-amide;
(1S,2S,5R)-3-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-3-aza-bicyclo[3.1 ,0]hexane-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
(1S,2R)-2-[2-((3S,5S)-3,5-Dimethyl-morpholin-4-yl)-6-methyl-pyridine-3-sulfonyl]-cyclohexanecarboxylic acid (4,4- difluoro-cyclohexyl)-amide;
(1S,2R)-2-((2S,6S)-2,6,6'-Trimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-3'-sulfonyl)-cyclohexanecarboxylic acid (4,4-difluoro-cyclohexyl)-amide;
(1RS,2SR)-N-(4,4-Difluorocyclohexyl)-2-((2-((2S,6S)-2,6-dimethylpiperidin-1-yl)-6-methylpyridin-3- yl)sulfonyl)cyclopentane-1-carboxamide;
(1R,3S,4S)-2-(2'-Fluoro-5-methyl-biphenyl-2-sulfonyl)-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide;
((S)-1-[2-(lsopropyl-methyl-amino)-6-methyl-pyridine-3-sulfonyl]-pyrrolidine-2-carboxylic acid (4,4-difluoro- cyclohexyl)-N-methyl-amide; and
(S)-N-(4,4-Difluorocyclohexyl)-1-(((Ra)-2'-fluoro-5J6-dimethyl-[1 ,T-biphenyl]-2-yl)sulfonyl)-N-methylpyrrolidine-2- carboxamide; or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising, as active principle, one or more compounds according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
11 . A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.
12. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in improving wakefulness.
13. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof:
• for use in the treatment of hypersomnia including narcolepsy, narcolepsy associated with inherited disorders; narcolepsy associated with tumors, narcolepsy associated with head trauma, idiopathic hypersomnia, or Kleine-Levin syndrome;
• for use in improving symptoms of excessive daytime sleepiness (EDS) including: improving symptoms of EDS in subjects having a circadian rhythm sleep-wake disorder; improving symptoms of EDS due to or associated with a medical disorder, wherein said medical disorder is especially an objective sleep disturbance, obesity, diabetes, a neurodegenerative disorder, an auto-immune disorder, a psychiatric disorder, or insufficient sleep syndrome; improving symptoms of EDS due to a medication or substance;
• for use in the treatment of fatigue; or
• for use in the treatment of eating disorders, obesity, neuropsychiatric disorders, pain, inflammation, or cognitive impairments associated with diminished wakefulness.
14. Use of a compound of Formula (I) as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, in the preparation of a medicament for improving wakefulness.
15. A method for improving wakefulness comprising administering to a subject in need thereof an effective amount of a compound of Formula (I) as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof.
PCT/EP2025/061059 2024-04-24 2025-04-23 Aryl sulfone and sulfanone derivatives as orexin receptor modulators Pending WO2025224168A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2024/061255 2024-04-24
EP2024061255 2024-04-24

Publications (1)

Publication Number Publication Date
WO2025224168A1 true WO2025224168A1 (en) 2025-10-30

Family

ID=95558874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/061059 Pending WO2025224168A1 (en) 2024-04-24 2025-04-23 Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Country Status (1)

Country Link
WO (1) WO2025224168A1 (en)

Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469984A2 (en) 1990-07-31 1992-02-05 Sanofi N-sulfonyl-indoline derivatives, their preparation and pharmaceutical compositions containing them
WO1997018194A1 (en) 1995-11-13 1997-05-22 Hoechst Aktiengesellschaft CYCLIC AND HETEROCYCLIC N-SUBSTITUTED α-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO2000004892A2 (en) 1998-07-21 2000-02-03 Warner-Lambert Company Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US20010056184A1 (en) 2000-05-12 2001-12-27 Atsushi Noda Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
WO2002051838A1 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
US20030130506A1 (en) 1995-12-08 2003-07-10 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
WO2004004733A1 (en) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
WO2004085403A1 (en) 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2005030728A1 (en) 2003-09-27 2005-04-07 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases
WO2005097162A2 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2006124387A (en) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods associated with the use thereof
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
WO2008026149A1 (en) 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
WO2008081399A2 (en) 2006-12-28 2008-07-10 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
WO2008139416A1 (en) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd 2-cyclopropyl-thiazole derivatives
WO2009004584A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
WO2009022311A2 (en) 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives as orexin antagonists
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
WO2009104155A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009133522A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
WO2009150614A1 (en) 2008-06-11 2009-12-17 Actelion Pharmaceuticals Ltd Tetrazole compounds as orexin receptor antagonists
WO2009156951A2 (en) 2008-06-25 2009-12-30 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010007027A1 (en) 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010131192A2 (en) 2009-05-12 2010-11-18 Actelion Pharmaceuticals Ltd Novel oxazolidinone derivatives
WO2010131191A1 (en) 2009-05-12 2010-11-18 Actelion Pharmaceuticals Ltd Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
WO2012025877A1 (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2013020440A1 (en) 2011-08-09 2013-02-14 上海医药集团股份有限公司 Amide derivate, and preparation method therefor, pharmaceutical composition and use thereof
US20140051700A1 (en) 2008-06-04 2014-02-20 University Of Texas, Board Of Regents Small-molecule agonists for type-2 orexin receptor
WO2014098098A1 (en) 2012-12-18 2014-06-26 味の素株式会社 Heterocyclic amide derivative, and medicine containing same
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2016133160A1 (en) 2015-02-19 2016-08-25 国立大学法人筑波大学 Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2018164191A1 (en) 2017-03-08 2018-09-13 武田薬品工業株式会社 Substituted pyrrolidine compound and use thereof
WO2018164192A1 (en) 2017-03-08 2018-09-13 武田薬品工業株式会社 Substituted pyrrolidine compound and use thereof
WO2019027003A1 (en) 2017-08-03 2019-02-07 武田薬品工業株式会社 Heterocyclic compound and application thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2019117148A1 (en) 2017-12-12 2019-06-20 国立大学法人 筑波大学 Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
WO2019191327A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Ox2r compounds
WO2020004537A1 (en) 2018-06-29 2020-01-02 武田薬品工業株式会社 Heterocyclic compound and use thereof
WO2020122093A1 (en) 2018-12-12 2020-06-18 武田薬品工業株式会社 Heterocyclic compound
WO2020122092A1 (en) 2018-12-12 2020-06-18 武田薬品工業株式会社 Heterocyclic compound
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021065893A1 (en) 2019-09-30 2021-04-08 国立大学法人 筑波大学 Tetralin derivative or pharmaceutically acceptable acid addition salt thereof
US20210155636A1 (en) 2019-11-25 2021-05-27 Alkermes, Inc. Substituted Macrocyclic Compounds and Related Methods of Treatment
WO2021106975A1 (en) 2019-11-27 2021-06-03 武田薬品工業株式会社 Heterocyclic compound
WO2021107023A1 (en) 2019-11-27 2021-06-03 大日本住友製薬株式会社 Cycloalkyl urea derivative
US20210385345A1 (en) 2017-08-18 2021-12-09 Kyocera Document Solutions Inc. Image reading apparatus and method for controlling image reading apparatus

Patent Citations (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469984A2 (en) 1990-07-31 1992-02-05 Sanofi N-sulfonyl-indoline derivatives, their preparation and pharmaceutical compositions containing them
WO1997018194A1 (en) 1995-11-13 1997-05-22 Hoechst Aktiengesellschaft CYCLIC AND HETEROCYCLIC N-SUBSTITUTED α-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US20030130506A1 (en) 1995-12-08 2003-07-10 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
WO2000004892A2 (en) 1998-07-21 2000-02-03 Warner-Lambert Company Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US20010056184A1 (en) 2000-05-12 2001-12-27 Atsushi Noda Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
WO2002051838A1 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
WO2004004733A1 (en) 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
WO2004085403A1 (en) 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2005030728A1 (en) 2003-09-27 2005-04-07 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2005097162A2 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
JP2006124387A (en) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods associated with the use thereof
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
WO2008026149A1 (en) 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
WO2008081399A2 (en) 2006-12-28 2008-07-10 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
WO2008139416A1 (en) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd 2-cyclopropyl-thiazole derivatives
WO2009004584A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
WO2009022311A2 (en) 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives as orexin antagonists
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
WO2009104155A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009133522A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
US20140051700A1 (en) 2008-06-04 2014-02-20 University Of Texas, Board Of Regents Small-molecule agonists for type-2 orexin receptor
WO2009150614A1 (en) 2008-06-11 2009-12-17 Actelion Pharmaceuticals Ltd Tetrazole compounds as orexin receptor antagonists
WO2009156951A2 (en) 2008-06-25 2009-12-30 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010007027A1 (en) 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010131192A2 (en) 2009-05-12 2010-11-18 Actelion Pharmaceuticals Ltd Novel oxazolidinone derivatives
WO2010131191A1 (en) 2009-05-12 2010-11-18 Actelion Pharmaceuticals Ltd Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
WO2012025877A1 (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2013020440A1 (en) 2011-08-09 2013-02-14 上海医药集团股份有限公司 Amide derivate, and preparation method therefor, pharmaceutical composition and use thereof
CN102952059A (en) * 2011-08-09 2013-03-06 上海医药集团股份有限公司 Amide derivative and preparation method thereof, medicine composition and application
WO2014098098A1 (en) 2012-12-18 2014-06-26 味の素株式会社 Heterocyclic amide derivative, and medicine containing same
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2016133160A1 (en) 2015-02-19 2016-08-25 国立大学法人筑波大学 Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2018164191A1 (en) 2017-03-08 2018-09-13 武田薬品工業株式会社 Substituted pyrrolidine compound and use thereof
WO2018164192A1 (en) 2017-03-08 2018-09-13 武田薬品工業株式会社 Substituted pyrrolidine compound and use thereof
WO2019027003A1 (en) 2017-08-03 2019-02-07 武田薬品工業株式会社 Heterocyclic compound and application thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US20210385345A1 (en) 2017-08-18 2021-12-09 Kyocera Document Solutions Inc. Image reading apparatus and method for controlling image reading apparatus
WO2019117148A1 (en) 2017-12-12 2019-06-20 国立大学法人 筑波大学 Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
US20210078955A1 (en) 2017-12-12 2021-03-18 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
WO2019191327A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Ox2r compounds
WO2020004537A1 (en) 2018-06-29 2020-01-02 武田薬品工業株式会社 Heterocyclic compound and use thereof
US20210198240A1 (en) 2018-06-29 2021-07-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020122093A1 (en) 2018-12-12 2020-06-18 武田薬品工業株式会社 Heterocyclic compound
WO2020122092A1 (en) 2018-12-12 2020-06-18 武田薬品工業株式会社 Heterocyclic compound
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021065893A1 (en) 2019-09-30 2021-04-08 国立大学法人 筑波大学 Tetralin derivative or pharmaceutically acceptable acid addition salt thereof
US20210155636A1 (en) 2019-11-25 2021-05-27 Alkermes, Inc. Substituted Macrocyclic Compounds and Related Methods of Treatment
WO2021106975A1 (en) 2019-11-27 2021-06-03 武田薬品工業株式会社 Heterocyclic compound
WO2021107023A1 (en) 2019-11-27 2021-06-03 大日本住友製薬株式会社 Cycloalkyl urea derivative

Non-Patent Citations (107)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts. Properties, Selection and Use.", 2008, WILEY-VCH
"Pharmaceutical Salts and Co-crystals", 2012, RSC PUBLISHING
ADAMANTIDIS AR ET AL.: "Neural substrates of awakening probed with optogenetic control of hypocretin neurons", NATURE., vol. 450, no. 7168, 2007, pages 420 - 4, XP037798575, DOI: 10.1038/nature06310
ANGEW.CHEM.INT.ED., vol. 59, 2020, pages 11620 - 11626
BARAVKAR SET: "Synthesis and anticancer activity of conformationally constrained Smac mimetics containing pseudo β turns", TETRAHEDRON LETTERS, vol. 59, no. 38, 2018, pages 3473 - 3476, XP093210566, DOI: 10.1016/j.tetlet.2018.08.016
BARDSEN K ET AL.: "Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjogren's syndrome", J NEUROINFLAMMATION., vol. 16, no. 1, 2019, pages 102
BARLOESE M ET AL.: "Reduced CSF hypocretin-1 levels are associated with cluster headache", CEPHALALGIA., vol. 35, no. 10, 2015, pages 869 - 76
BASSETTI C. ET AL., EUR J NEUROL., vol. 00, 2021, pages 1 - 16
BAUMANN CR ET AL.: "Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury", NEUROLOGY., vol. 65, no. 1, 2005, pages 147 - 9
BENARROCH EE ET AL.: "Involvement of hypocretin neurons in multiple system atrophy", ACTA NEUROPATHOL., vol. 113, no. 1, 2007, pages 75 - 80, XP019460273, DOI: 10.1007/s00401-006-0150-0
BLOUIN AM ET AL.: "Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction", NAT COMMUN., vol. 4, 2013, pages 1547
BRUNDIN L ET AL.: "Orexin and psychiatric symptoms in suicide attempters", J AFFECT DISORD., vol. 100, no. 1-3, 2007, pages 259 - 63, XP022097576, DOI: 10.1016/j.jad.2006.10.019
BRUNDIN LET: "Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder", EUR NEUROPSYCHOPHARMACOL., vol. 17, no. 9, 2007, pages 573 - 9, XP022163638, DOI: 10.1016/j.euroneuro.2007.01.005
BUSQUETS X ET AL.: "Decreased plasma levels of orexin-A in sleep apnea", RESPIRATION., vol. 71, no. 6, 2004, pages 575 - 9
CALVA CB ET AL.: "Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats", FRONT AGING NEUROSCI., vol. 11, 2019, pages 362
CALVA CB ET AL.: "Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction", BRAIN RES., vol. 1731, 2020, pages 145921
CHAMJANGALI A: "Modelling of cytotoxicity data (CC ) of anti-HIV 1-[5-chlorophenyl)sulfonyl]-1H-pyrrole derivatives using calculated molecular descriptors and levenberg-marquardt artificial neural network", CHEMICAL BIOLOGY AND DRUG DESIGN, vol. 73, no. 4, 2009, pages 456 - 465
CHEMELLI RM ET AL.: "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation", CELL, vol. 98, no. 4, 1999, pages 437 - 51, XP002175980, DOI: 10.1016/S0092-8674(00)81973-X
CHIEFFI SET: "Orexin System: The Key for a Healthy Life", FRONT PHYSIOL., vol. 8, 2017, pages 357
COCCURELLO R: "Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing", BEHAV BRAIN RES., vol. 372, 2019, pages 112041, XP085742344, DOI: 10.1016/j.bbr.2019.112041
DAHMEN N ET AL.: "Increased frequency of migraine in narcoleptic patients: a confirmatory study", CEPHALALGIA., vol. 23, no. 1, 2003, pages 14 - 9
DAUVILLIERS Y ET AL.: "Narcolepsy and Other Central Hypersomnias", CONTINUUM (MINNEAP MINN)., vol. 23, 2017, pages 4
DE LECEA L: "Hypocretins and the neurobiology of sleep-wake mechanisms", PROG BRAIN RES., vol. 198, 2012, pages 15 - 24
DEADWYLER SA ET AL.: "Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates", J NEUROSCI., vol. 27, no. 52, 2007, pages 14239 - 47
DIANO S ET AL.: "Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets", ENDOCRINOLOGY., vol. 144, no. 9, 2003, pages 3774 - 8
EDLOW BL ET AL.: "Neuroanatomic connectivity of the human ascending arousal system critical to consciousness and its disorders", J NEUROPATHOL EXP NEUROL., vol. 71, no. 6, 2012, pages 531 - 46
FERNANDEZ-MENDOZA J ET AL.: "Natural history of excessive daytime sleepiness: role of obesity, weight loss, depression, and sleep propensity", SLEEP., vol. 38, no. 3, 2015, pages 351 - 60
FRONCZEK R ET AL.: "Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease", BRAIN., vol. 131, no. 1, 2008, pages 88
FRONCZEK R ET AL.: "Hypocretin (orexin) loss in Alzheimer's disease", NEUROBIOL AGING., vol. 33, no. 8, 2012, pages 1642 - 50
FRONCZEK R ET AL.: "Hypocretin (orexin) loss in Parkinson's disease", BRAIN., vol. 130, no. 6, 2007, pages 1577 - 85, XP055118150, DOI: 10.1093/brain/awm090
FRONCZEK R ET AL.: "The orexin/hypocretin system in neuropsychiatric disorders: Relation to signs and symptoms", HANDB CLIN NEUROL., vol. 180, 2021, pages 343 - 358
GANDHI KD ET AL.: "Excessive Daytime Sleepiness: A Clinical Review", MAYO CLIN PROC., vol. 96, no. 5, 2021, pages 1288 - 1301
GOTTER AL ET AL.: "The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold", BMC NEUROSCI., vol. 14, 2013, pages 90, XP021158646, DOI: 10.1186/1471-2202-14-90
GROSSBERG AJ ET AL.: "Inflammation-induced lethargy is mediated by suppression of orexin neuron activity", J NEUROSCI., vol. 31, no. 31, 2011, pages 11376 - 86
HUANG ZL ET AL.: "Arousal effect of orexin A depends on activation of the histaminergic system", PROC NATL ACAD SCI U S A., vol. 98, no. 17, 2001, pages 9965 - 70
INUTSUKA A ET AL.: "The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions", FRONT ENDOCRINOL (LAUSANNE)., vol. 4, 2013, pages 18
JAEGER LB ET AL.: "Effects of orexin-A on memory processing", PEPTIDES., vol. 23, no. 9, 2002, pages 1683 - 8
JANG SH ET AL.: "The Relation Between Loss of Consciousness, Severity of Traumatic Brain Injury, and Injury of Ascending Reticular Activating System in Patients With Traumatic Brain Injury", AM J PHYS MED REHABIL., vol. 98, no. 12, 2019, pages 1067 - 1071
JIA X ET AL.: "Arousal effects of orexin A on acute alcohol intoxication-induced coma in rats", NEUROPHARMACOLOGY., vol. 62, no. 2, 2012, pages 775 - 83, XP028445237, DOI: 10.1016/j.neuropharm.2011.08.047
KANBAYASHI T ET AL.: "Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications", ARCH NEUROL., vol. 66, no. 12, 2009, pages 1563 - 6
KANBAYASHI T ET AL.: "The pathophysiologic basis of secondary narcolepsy and hypersomnia", CURR NEUROL NEUROSCI REP., vol. 11, no. 2, 2011, pages 235 - 41
KANG X ET AL.: "Research progress on the mechanism of orexin in pain regulation in different brain regions", OPEN LIFE SCI., vol. 16, no. 1, 2021, pages 46 - 52
KASANUKI K ET AL.: "Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies", NEUROSCI LETT., vol. 569, 2014, pages 68 - 73, XP028658055, DOI: 10.1016/j.neulet.2014.03.020
KELZ MB ET AL.: "An essential role for orexins in emergence from general anesthesia", PROC NATL ACAD SCI U S A., vol. 105, no. 4, 2008, pages 1309 - 14
KHAIRUDDIN S ET AL.: "Dysregulation of the orexinergic system: A potential neuropeptide target in depression", NEUROSCI BIOBEHAV REV., vol. 118, 2020, pages 384 - 396, XP086407467, DOI: 10.1016/j.neubiorev.2020.07.040
KOENIG MA ET AL.: "Intraventricular orexin-A improves arousal and early EEG entropy in rats after cardiac arrest", BRAIN RES., vol. 1255, 2009, pages 153 - 61, XP025926392, DOI: 10.1016/j.brainres.2008.11.102
KUSHIKATA T ET AL.: "Orexinergic neurons and barbiturate anesthesia", NEUROSCIENCE., vol. 121, no. 4, 2003, pages 855 - 63
LATIFI B ET AL.: "Sleep-Wake Cycling and Energy Conservation: Role of Hypocretin and the Lateral Hypothalamus in Dynamic State-Dependent Resource Optimization", FRONT NEUROL., vol. 9, 2018, pages 790
LECEA L ET AL.: "The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity", PROC NATL ACAD SCI U S A., vol. 95, no. 1, 1998, pages 322 - 7, XP002105411, DOI: 10.1073/pnas.95.1.322
LEE MG ET AL.: "Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle", J NEUROSCI., vol. 25, no. 28, 2005, pages 6716 - 20
LI T ET AL.: "Orexin A alleviates neuroinflammation via OXR2/CaMKKbeta/AMPK signaling pathway after ICH in mice", J NEUROINFLAMMATION., vol. 17, no. 1, 2020, pages 187
LIN L ET AL.: "The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene", CELL., vol. 98, no. 3, 1999, pages 365 - 76, XP002153571, DOI: 10.1016/S0092-8674(00)81965-0
LRUKAYAMA-TOMOBE Y ET AL.: "Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models", PROC NATL ACAD SCI U S A., vol. 114, no. 22, 2017, pages 5731 - 5736
LUTTER M ET AL.: "Orexin signaling mediates the antidepressant-like effect of calorie restriction", J NEUROSCI., vol. 28, no. 12, 2008, pages 3071 - 5, XP055668736, DOI: 10.1523/JNEUROSCI.5584-07.2008
MAHLER SV ET AL.: "Motivational activation: a unifying hypothesis of orexin/hypocretin function", NAT NEUROSCI., vol. 17, no. 10, 2014, pages 1298 - 303
MASKI K. ET AL., J CLIN SLEEP MED., vol. 17, no. 9, 2021, pages 1881 - 1893
MATTMANN M ET AL., IDENTIFICATION OF (R)-N-(4-(4-METHOXYPHENYL)THIAZOL-2-YL)-1-TOSYLPIPERIDINE-2-CARBOXAMIDE, ML277, AS A NOVEL, POTENT AND SELECTIVE K 7.1 (KCNQ1) POTASSIUM CHANNEL ACTIVATOR, vol. 22, no. 18, 2012, pages 5936 - 5941
MIEDA M ET AL.: "Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice", PROC NATL ACAD SCI U S A., vol. 101, no. 13, 2004, pages 4649 - 54
MISHIMA T ET AL.: "Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy", PARKINSONISM RELAT DISORD., vol. 42, 2017, pages 85 - 89, XP085234166, DOI: 10.1016/j.parkreldis.2017.06.003
MODI HR ET AL.: "Intranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation", PLOS ONE., vol. 12, no. 9, 2017, pages 0182707
MODIRROUSTA M ET AL.: "Orexin and MCH neurons express c-Fos differently after sleep deprivation vs. recovery and bear different adrenergic receptors", EUR J NEUROSCI., vol. 21, no. 10, 2005, pages 2807 - 16, XP071863885, DOI: 10.1111/j.1460-9568.2005.04104.x
MOHAMMADI S ET AL.: "Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis", SLEEP MED., vol. 81, 2021, pages 268 - 284, XP086553122, DOI: 10.1016/j.sleep.2021.02.040
NAKAMURA A ET AL.: "Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice", J APPL PHYSIOL, vol. 102, no. 1, 1985, pages 241 - 8
NISHINO S ET AL.: "CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies", NEUROLOGY., vol. 61, no. 6, 2003, pages 823 - 5
NISHINO SET: "Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system", SLEEP MED REV., vol. 9, no. 4, 2005, pages 269 - 310
NIXON JP ET AL.: "Sleep disorders, obesity, and aging: the role of orexin", AGEING RES REV., vol. 20, 2015, pages 63 - 73
NOCJAR C ET AL.: "The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus", NEUROSCIENCE., vol. 218, 2012, pages 138 - 53, XP028401594, DOI: 10.1016/j.neuroscience.2012.05.033
O'DONNELL JC ET AL.: "Challenges and demand for modeling disorders of consciousness following traumatic brain injury", NEUROSCI BIOBEHAV REV., vol. 98, 2019, pages 336 - 346, XP085617091, DOI: 10.1016/j.neubiorev.2018.12.015
OGAWA Y ET AL.: "Peripherally administered orexin improves survival of mice with endotoxin shock", ELIFE., vol. 5, 2016
OVEREEM SET: "Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis", NEUROLOGY., vol. 62, no. 1, 2004, pages 138 - 40
PEREZ-LEIGHTON CE ET AL.: "Behavioral responses to orexin, orexin receptor gene expression, and spontaneous physical activity contribute to individual sensitivity to obesity", AM J PHYSIOL ENDOCRINOL METAB., vol. 303, no. 7, 2012, pages 865 - 74
PETERSEN A ET AL.: "Orexin loss in Huntington's disease", HUM MOL GENET., vol. 14, no. 1, 2005, pages 39 - 47
PEYRON C ET AL.: "A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains", NAT MED., vol. 6, no. 9, 2000, pages 991 - 7, XP002941810, DOI: 10.1038/79690
PEYRON C ET AL.: "Neurons containing hypocretin (orexin) project to multiple neuronal systems", J NEUROSCI., vol. 18, no. 23, 1998, pages 9996 - 10015, XP002300928
PIPER DC ET AL.: "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats", EUR J NEUROSCI., vol. 12, no. 2, 2000, pages 726 - 30, XP009080867, DOI: 10.1046/j.1460-9568.2000.00919.x
RAGNO R ET AL.: "Design, Molecular Modeling, Synthesis, and Anti-HIV-1 Activity of New Indolyl Aryl Sulfones. Novel Derivatives of the Indole-2-carboxamide", J. MED. CHEM., vol. 49, 2006, pages 3172 - 3184
RAGNO R ET AL.: "Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones. Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non-Nucleoside Binding Site and Design of Highly Active N-(2-Hydroxyethyl)carboxamide and N-(2-Hydroxyethyl)carbohydrazide Derivatives", J. MED. CHEM., vol. 48, 2005, pages 213 - 223, XP002415706, DOI: 10.1021/jm040854k
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
S. T. CHEUNGN. L. BENOITON, CAN. J. CHEMISTRY, vol. 55, no. 1375325-64-6, 1977, pages 506
SAKURAI T ET AL.: "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", CELL, vol. 92, no. 5, 1998, pages 1,696
SAKURAI T: "The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness", NAT REV NEUROSCI., vol. 8, no. 3, 2007, pages 171 - 81
SALOMON RM ET AL.: "Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects", BIOL PSYCHIATRY., vol. 54, no. 2, 2003, pages 96 - 104
SASAKI K ET AL.: "Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice", PLOS ONE., vol. 6, no. 5, 2011, pages 20360
SATEIA MJ: "Chest.", vol. 146, 2014, article "International classification of sleep disorders-third edition: highlights and modifications", pages: 1387 - 1394
SCAMMELL TE ET AL.: "Neural Circuitry of Wakefulness and Sleep", NEURON., vol. 93, no. 4, 2017, pages 747 - 765, XP029931487, DOI: 10.1016/j.neuron.2017.01.014
SEGAL B ET AL.: "Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome", ARTHRITIS RHEUM., vol. 59, no. 12, 2008, pages 1780 - 7
SILVESTRI R ET AL.: "Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations: Synthesis and SAR Studies", J. MED. CHEM., vol. 46, 2003, pages 2482 - 2493, XP002415707, DOI: 10.1021/jm0211063
SLEEP NEUROLOGY, pages 989 - 1004
STATON CD ET AL.: "Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression", NEUROPHARMACOLOGY., vol. 143, 2018, pages 79 - 94, XP085545032, DOI: 10.1016/j.neuropharm.2018.09.016
T.W. GREENEP.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
TAHERI SET: "Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats", NEUROREPORT., vol. 12, no. 3, 2001, pages 459 - 64
THANNICKAL TC ET AL.: "Reduced number of hypocretin neurons in human narcolepsy", NEURON., vol. 27, no. 3, 2000, pages 469 - 74
VIJAYADAS K ET AL.: "An unusual conformational similarity of two peptide folds featuring sulfonamide and carboxamide on the backbone", CHEMICAL COMMUNICATIONS, vol. 48, no. 78, 2012, pages 9747 - 9749
VIJAYADAS K ET AL.: "Reversal of H-bonding direction by N-sulfonation in a synthetic reverse-turn peptide motif", ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 13, no. 10, 2015, pages 3064 - 3069
WANG W ET AL.: "Orexin: a potential role in the process of obstructive sleep apnea", PEPTIDES., vol. 42, 2013, pages 48 - 54, XP028535819, DOI: 10.1016/j.peptides.2013.01.001
WATANABE S ET AL.: "Persistent pain and stress activate pain-inhibitory orexin pathways", NEUROREPORT., vol. 16, no. 1, 2005, pages 5 - 8
WILLIE JT ET AL.: "Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice", J NEUROTRAUMA., vol. 29, no. 10, 2012, pages 1908 - 21
WILLIE JT ET AL.: "Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes", NEURON., vol. 38, no. 5, 2003, pages 715 - 30
XU H ET AL.: "Development of indoles an anti-HIV-1 inhibitors", CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 18, 2009, pages 2120 - 2148
YAMANAKA A ET AL.: "Hypothalamic orexin neurons regulate arousal according to energy balance in mice", NEURON., vol. 38, no. 5, 2003, pages 701 - 13, XP055149050, DOI: 10.1016/S0896-6273(03)00331-3
YANG L ET AL.: "Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice", J NEUROSCI., vol. 33, no. 12, 2013, pages 5275 - 84
YUKITAKE H ET AL.: "TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice", PHARMACOL BIOCHEM BEHAV., vol. 187, 2019, pages 172794, XP085903575, DOI: 10.1016/j.pbb.2019.172794
ZAJO KN ET AL.: "Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons", PSYCHOPHARMACOLOGY (BERL)., vol. 233, no. 4, 2016, pages 639 - 47, XP035867210, DOI: 10.1007/s00213-015-4139-z
ZEITZER JM ET AL.: "Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness", J NEUROSCI., vol. 23, no. 8, 2003, pages 3555 - 60
ZHANG LN ET AL.: "Orexin-A facilitates emergence from propofol anesthesia in the rat", ANESTH ANALG., vol. 115, no. 4, 2012, pages 789 - 96
ZHANG LN ET AL.: "Orexin-A facilitates emergence of the rat from isoflurane anesthesia via mediation of the basal forebrain", NEUROPEPTIDES., vol. 58, 2016, pages 7 - 14, XP029685572, DOI: 10.1016/j.npep.2016.02.003
ZHANG SET: "Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy", J PHYSIOL., vol. 581, no. 2, 2007, pages 649 - 63

Similar Documents

Publication Publication Date Title
JP6560436B2 (en) 1,3,4-oxadiazolesulfonamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same
TWI418557B (en) Azole carboxamide compounds or salts thereof
AU2023202086A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
TWI822803B (en) Pharmaceutical compounds
AU2018361249B2 (en) Aminoimidazopyridazines as kinase inhibitors
CN107949384A (en) muscarinic agonists
CN107949558A (en) muscarinic agonists
KR20070009699A (en) Proline derivatives and their use as dipeptidyl peptidase-IV inhibitors
TW201625625A (en) Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors
RS64551B9 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
TW201211053A (en) Spiro compound and drug for activating adiponectin receptor
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
WO2024049977A1 (en) Substituted indole compounds and methods of use thereof
EP3676261B1 (en) Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN102282138A (en) Inhibitors of diacylglycerol acyltransferase
TW201805277A (en) Aminopyridine derivatives and their use as selective ALK-2 inhibitors
CA3166597A1 (en) Muscarinic receptor 4 antagonists and methods of use
CA2805427A1 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EA037264B1 (en) Heterocyclic sulfonamide derivative and medicament containing same
TW201625608A (en) Substituted 2,4,5,6-tetrahydropyrrolo[3,4-C]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-C]pyridine compounds as GLYT1 inhibitors
KR102512201B1 (en) Aliphatic prolinamide derivatives
WO2025224168A1 (en) Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CA3030220A1 (en) Inhibitors of tryptophan 2,3-dioxygenase
KR102595723B1 (en) Heterocyclic Prolinamide Derivatives
EP2408767B1 (en) Amide derivatives as neuropeptide y5 receptor ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25721837

Country of ref document: EP

Kind code of ref document: A1